"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2004/0105470 A1,157-307-511-544-334,2004-06-03,2004,US 71348203 A,2003-11-14,US 71348203 A;;US 31969702 P,2002-11-15,Method for reducing non-linearities in a laser communication system,"
   A system including a laser and a semiconductor optical amplifier (SOA) and a method of generating a dithered laser light with substantially constant amplitude with this system. The laser drive current is modulated to generate a modulated laser light with optical linewidth dithering. The modulated laser light is coupled into the SOA. The SOA drive current is modulated approximately 180 out of phase with the laser drive current to generate the dithered laser light with substantially constant amplitude. 
",BOND AARON,BOND AARON,CYOPTICS ACQUISITION CORP (2007-04-02);;APOGEE PHOTONICS INC (2005-07-11);;T-NETWORKS INC (2003-11-13),https://lens.org/157-307-511-544-334,Patent Application,yes,2,13,1,1,0,H04B10/564;;H04B10/564;;H01S5/0427;;H01S5/0427;;H01S5/062;;H01S5/062;;H01S5/06233;;H01S5/06233;;H01S5/0652;;H01S5/0652;;H01S5/06817;;H01S5/06817;;H01S5/10;;H01S5/10;;H01S5/50;;H01S5/50;;H04B10/2537;;H04B10/2537,H01S3/10;;H01S5/042;;H01S5/062;;H01S5/068;;H01S5/10;;H01S5/50;;H04B10/155;;H04B10/18,372/26,0,0,,,,DISCONTINUED
2,CA,A1,CA 2331992 A1,028-095-081-687-482,2001-07-28,2001,CA 2331992 A,2001-01-22,US 49375800 A,2000-01-28,HIGH SPEED SEMICONDUCTOR PHOTODETECTOR,"The invention is a semiconductor avalanche photodetector (10) including an essentially undoped multiplication layer (14); a thin, undoped light absorbi ng layer (16); and a doped waveguide layer (17) which is separate from the light absorbing layer and is capable of coupling incident light into the light absorbing layer. (Fig. 1)",LUCENT TECHNOLOGIES INC,BOND AARON EUGENE,,https://lens.org/028-095-081-687-482,Patent Application,no,0,0,9,9,0,H01L31/1075;;H01L31/1075,H01L27/14;;H01L31/107,,0,0,,,,DISCONTINUED
3,EP,A2,EP 1132974 A2,197-323-114-550-408,2001-09-12,2001,EP 01300532 A,2001-01-22,US 49375800 A,2000-01-28,High speed semiconductor photodetector,"The invention is a semiconductor avalanche photodetector (10) including an essentially undoped multiplication layer (14); a thin, undoped light absorbing layer (16); and a doped waveguide layer (17) which is separate from the light absorbing layer and is capable of coupling incident light into the light absorbing layer.",AGERE SYST OPTOELECTRONICS,BOND AARON EUGENE,,https://lens.org/197-323-114-550-408,Patent Application,yes,0,3,9,9,0,H01L31/1075;;H01L31/1075,H01L27/14;;H01L31/107,,0,0,,,,DISCONTINUED
4,US,B1,US 6417528 B1,142-213-629-773-739,2002-07-09,2002,US 49375800 A,2000-01-28,US 49375800 A,2000-01-28,High speed semiconductor photodetector,"
    The invention is a semiconductor avalanche photodetector including an essentially undoped multiplication layer; a thin, undoped light absorbing layer; and a doped waveguide layer which is separate from the light absorbing layer and is capable of coupling incident light into the light absorbing layer. 
",AGERE SYST GUARDIAN CORP,BOND AARON EUGENE,AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-08-04);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;LUCENT TECHNOLOGIES INC (2000-01-28);;AGERE SYSTEMS OPTOELECTRONICS GUARDIAN CORP (2001-01-31),https://lens.org/142-213-629-773-739,Granted Patent,yes,6,8,9,9,0,H01L31/1075;;H01L31/1075,H01L27/14;;H01L31/107,257/186;;257/199;;257/91;;257/184,1,1,126-079-657-190-00X,10.1109/22.414580,"Traveling-Wave Photodetectors for High Power, Large-Bandwidth Applications, IEEE Transactions On Microwave Theory And Techniques, vol. 43, No. 9, Sep. 1995.",EXPIRED
5,EP,A3,EP 1132974 A3,193-528-003-886-99X,2005-10-19,2005,EP 01300532 A,2001-01-22,US 49375800 A,2000-01-28,High speed semiconductor photodetector,"The invention is a semiconductor avalanche photodetector (10) including an essentially undoped multiplication layer (14); a thin, undoped light absorbing layer (16); and a doped waveguide layer (17) which is separate from the light absorbing layer and is capable of coupling incident light into the light absorbing layer.",AGERE SYST OPTOELECTRONICS,BOND AARON EUGENE,,https://lens.org/193-528-003-886-99X,Search Report,yes,0,0,9,9,0,H01L31/1075;;H01L31/1075,H01L27/14;;H01L31/107,,3,0,,,"PATENT ABSTRACTS OF JAPAN vol. 2000, no. 04 31 August 2000 (2000-08-31);;PATENT ABSTRACTS OF JAPAN vol. 1997, no. 11 28 November 1997 (1997-11-28);;PATENT ABSTRACTS OF JAPAN vol. 1996, no. 06 28 June 1996 (1996-06-28)",DISCONTINUED
6,US,A1,US 2002/0195616 A1,115-803-978-408-01X,2002-12-26,2002,US 11522602 A,2002-04-03,US 11522602 A;;US 49375800 A,2000-01-28,High speed semiconductor photodetector,"
   The invention is a semiconductor avalanche photodetector including an essentially undoped multiplication layer; a thin, undoped light absorbing layer; and a doped waveguide layer which is separate from the light absorbing layer and is capable of coupling incident light into the light absorbing layer. 
",BOND AARON EUGENE,BOND AARON EUGENE,AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-08-04);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09),https://lens.org/115-803-978-408-01X,Patent Application,yes,1,19,9,9,0,H01L31/1075;;H01L31/1075,H01L27/14;;H01L31/107,257/186,0,0,,,,EXPIRED
7,JP,A,JP 2001284633 A,048-604-335-594-613,2001-10-12,2001,JP 2001019497 A,2001-01-29,US 49375800 A,2000-01-28,SEMICONDUCTOR AVALANCHE PHOTODETECTOR,"PROBLEM TO BE SOLVED: To provide a photodetector capable of providing a device operable at a high speed by accelerating the movement of electrons or holes. SOLUTION: This semiconductor avalanche photodetector is provided with an undoped multiplication layer (14), a thin undoped light absorbing layer (16) and a doped waveguide layer (17) which is separate from the light absorbing layer for coupling incident light into the light absorbing layer.",LUCENT TECHNOLOGIES INC,BOND AARON EUGENE,,https://lens.org/048-604-335-594-613,Patent Application,no,1,2,9,9,0,H01L31/1075;;H01L31/1075,H01L27/14;;H01L31/107,,0,0,,,,EXPIRED
8,US,B2,US 6858463 B2,119-026-015-482-710,2005-02-22,2005,US 11522602 A,2002-04-03,US 11522602 A;;US 49375800 A,2000-01-28,High speed semiconductor photodetector,"The invention is a semiconductor avalanche photodetector including an essentially undoped multiplication layer; a thin, undoped light absorbing layer; and a doped waveguide layer which is separate from the light absorbing layer and is capable of coupling incident light into the light absorbing layer.",AGERE SYSTEMS INC,BOND AARON EUGENE,AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-08-04);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09),https://lens.org/119-026-015-482-710,Granted Patent,yes,12,10,9,9,0,H01L31/1075;;H01L31/1075,H01L27/14;;H01L31/107,438/82;;257/40;;257/79;;257/80;;257/89,1,1,126-079-657-190-00X,10.1109/22.414580,"Vincent M. Hietala, Allen Vawter, T.M. Brennan, B.E. Hammoius, ""Traveling Wave Photodetectors for High-Power, Large Bandwidth Applications"" IEEE Transactions on Microwave Theory and Techniques, vol. 43, No. 9, Sep. 1995.",EXPIRED
9,US,B1,US 6388331 B1,087-631-588-571-40X,2002-05-14,2002,US 50575000 A,2000-02-16,US 50575000 A,2000-02-16,Bond pad having reduced capacitance and method for reducing capacitance of a bond pad,"
    A bond pad having reduced capacitance is disclosed which is useful in fabricating integrated circuit and communications devices. The bond pad is disposed within a select bond pad area and comprises a ribbon of conductive material within the select pad area and a two-phased region of air and conductive material. Also, at least one interconnect area is disposed within the bond pad area. The ribbon is coupled to the two-phased region, and the interconnect is coupled to the ribbon and to the device. Inclusion of air within the bond pad structure reduces the capacitance of the device, while the surface area of the bonding pad is maintained to at least substantially retain the adhesive properties of the pad. 
",AGERE SYST GUARDIAN CORP,BOND AARON EUGENE;;FOCHT MARLIN WILBERT,AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-08-04);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;LUCENT TECHNOLOGIES INC (2000-07-07),https://lens.org/087-631-588-571-40X,Granted Patent,yes,6,8,1,1,0,H01L23/5222;;H01L2224/0401;;H01L2924/01006;;H01L2924/01013;;H01L2924/01079;;H01L2924/14;;H01L2924/19041;;H01L2924/30105;;H01L2924/01033;;H01L24/05;;H01L2224/04042;;H01L24/02;;H01L2924/01013;;H01L23/5222;;H01L2924/14;;H01L2224/0401;;H01L2924/19041;;H01L2924/30105;;H01L2924/01006;;H01L2924/01079;;H01L2924/01033,H01L23/485;;H01L23/522,257/773;;257/786;;257/781;;257/784;;257/758;;257/734,0,0,,,,EXPIRED
10,US,B1,US 9676373 B1,166-494-927-325-605,2017-06-13,2017,US 201414533621 A,2014-11-05,US 201414533621 A;;US 201361962653 P;;US 201461939350 P,2013-11-13,Decontainment and containment trailer and roll-off system,"The present invention comprises a trailer unit and or a roll-off trailer unit that converts when deployed into a washing and decontamination pad and may include a first section and two or more wings that unfold to provide a platform that is capable of having vehicles and other equipment driven and or wheeled into position on the platform and may also provide a containment system that traps wastewater, contaminates and so forth.",BOND CLINT AARON;;COCHRAN MICHAEL JAMES,BOND CLINT AARON;;COCHRAN MICHAEL JAMES,,https://lens.org/166-494-927-325-605,Granted Patent,yes,13,2,1,1,0,B60S3/00;;B08B17/025;;B60P3/14;;B60S3/04;;B60P3/42;;B60P3/14;;B60S3/00;;B08B17/025,B60P3/14;;B60P3/42;;B60S3/04,,0,0,,,,ACTIVE
11,US,B2,US 6987908 B2,123-384-231-629-873,2006-01-17,2006,US 16791502 A,2002-06-11,US 16791502 A;;US 31495101 P,2001-08-24,Grating dispersion compensator and method of manufacture,"A grating dispersion compensator (GDC), including: a substrate; a dielectric grating layer; a planar waveguide; and a passivation layer. The dielectric grating layer may be formed on the substrate and includes a variation in refractive index. This variation in refractive index defines a grating period. The grating period may vary along the longitudinal axis of the GDC according to a predetermined function. A selected center wavelength and dispersion curve may be created. The chirp of the grating period may be controlled by current, voltage, temperature, or pressure. The planar waveguide is formed on the dielectric grating layer and includes an input/output (I/O) surface normal to the longitudinal axis of the planar waveguide. The passivation layer is formed on the planar waveguide. Alternatively, a GDC may be formed with the dielectric grating layer on top of the planar waveguide rather then beneath it.",NETWORKS INC T,BOND AARON;;JAMBUNATHAN RAM;;FRATESCHI NEWTON C,CYOPTICS INC (2000-04-18);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-01-06);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;BROADCOM INTERNATIONAL PTE. LTD (2020-08-26);;CYOPTICS ACQUISITION CORP (2007-04-02);;APOGEE PHOTONICS INC (2005-07-11);;T-NETWORKS INC (2002-06-08),https://lens.org/123-384-231-629-873,Granted Patent,yes,18,77,4,4,0,G02B6/12007;;G02B6/29325;;G02B6/29394;;G02B6/29395;;G02B6/29398;;G02B2006/12107;;G02B6/12007;;G02B6/29395;;G02B6/29394;;G02B6/29398;;G02B2006/12107;;G02B6/29325,G02B6/34;;G02B6/12,385/37;;385/123,0,0,,,,EXPIRED
12,US,A1,US 2004/0027634 A1,193-097-129-538-980,2004-02-12,2004,US 63508003 A,2003-08-06,US 63508003 A;;US 21828902 A;;US 31478901 P;;US 33516601 P,2001-08-24,Method of stabilizing electro-absorption modulators (EAM's) performance by maintaining constant absorption with the use of integrated tap couplers and method of manufacture,"
   An exemplary monolithic stabilized monolithic transmissive active optical device, such as an electroabsorption modulator (EAM), a variable optical attenuator (VOA), or a semiconductor optical amplifier (SOA), with an output optical tap, is formed from: a substrate; a waveguide layer; a semiconductor layer. The waveguide layer is coupled to the substrate and includes an active medium, which interacts with a predetermined wavelength of light, and is responsive to an electric signal. The electric signal is applied between the substrate and the semiconductor layer. The waveguide layer includes an output optical tap section and an active section adjacent to the output optical tap section. These sections include portions of the active medium. Further embodiments of the present invention incorporate temperature as well as bias control to improve performance of exemplary monolithic transmissive active optical devices. 
",BOND AARON;;ANDERSEN JOHN KAI;;JAMBUNATHAN RAM,BOND AARON;;ANDERSEN JOHN KAI;;JAMBUNATHAN RAM,CYOPTICS INC (2000-04-18);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-01-06);;CYOPTICS ACQUISITION CORP (2007-04-02);;APOGEE PHOTONICS INC (2005-07-11),https://lens.org/193-097-129-538-980,Patent Application,yes,4,11,4,4,0,G02F1/025;;G02F1/025;;G02F1/0123;;G02F1/0123;;G02F2203/05;;G02F2203/05,G02F1/01;;G02F1/025,35924,0,0,,,,EXPIRED
13,US,B2,US 6844212 B2,009-376-677-485-189,2005-01-18,2005,US 84374304 A,2004-05-12,US 84374304 A;;US 16791502 A;;US 31495101 P,2001-08-24,Grating dispersion compensator and method of manufacture,"A grating dispersion compensator (GDC), including: a substrate; a dielectric grating layer; a planar waveguide; and a passivation layer; is disclosed. The dielectric grating layer may be formed on the substrate and includes a variation in refractive index. This variation in refractive index defines a grating period. The grating period may vary along the longitudinal axis of the GDC according to a predetermined function. A selected center wavelength and dispersion curve may be created. The chirp of the grating period may be controlled by current, voltage, temperature, or pressure. The planar waveguide is formed on the dielectric grating layer and includes an input/output (I/O) surface normal to the longitudinal axis of the planar waveguide. The passivation layer is formed on the planar waveguide. Alternatively, a GDC may be formed with the dielectric grating layer on top of the planar waveguide rather than beneath it.",NETWORKS INC T,BOND AARON;;JAMBUNATHAN RAM;;FRATESCHI NEWTON C,CYOPTICS INC (2000-04-18);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-01-06);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;BROADCOM INTERNATIONAL PTE. LTD (2020-08-26);;CYOPTICS ACQUISITION CORP (2007-04-02);;APOGEE PHOTONICS INC (2005-07-11),https://lens.org/009-376-677-485-189,Granted Patent,yes,12,77,4,4,0,G02B6/12007;;G02B6/29325;;G02B6/29394;;G02B6/29395;;G02B6/29398;;G02B2006/12107;;G02B6/12007;;G02B6/29395;;G02B6/29394;;G02B6/29398;;G02B2006/12107;;G02B6/29325,G02B6/12;;G02B6/34,438/31;;438/32,0,0,,,,EXPIRED
14,US,A1,US 2003/0142895 A1,118-314-369-452-287,2003-07-31,2003,US 5692902 A,2002-01-25,US 5692902 A,2002-01-25,Method of fabricating a monolithic expanded beam mode electroabsorption modulator,"
   A monolithic single pass expanded beam mode active optical device includes: a substrate; a waveguide layer coupled to the top surface of the substrate; a semiconductor layer coupled to the waveguide layer; first and second electrodes for receiving an electric signal coupled to the substrate and the semiconductor layer, respectively. The waveguide layer includes a plurality of sublayers, forming a quantum well structure, which is responsive to the electric signal. The waveguide layer has three sections, two expansion/contraction sections and an active section, which extends between and adjacent to the two expansion/contraction sections. The thickness of at least one of the plurality of sublayers varies within the expansion/contraction portions of the quantum well structure. Possible interactions of the active region with the light include: absorption in the case of an electro-absorptive modulator and optical gain. 
",BOND AARON;;JAMBUNATHAN RAM;;CHOI WON JIN,BOND AARON;;JAMBUNATHAN RAM;;CHOI WON JIN,CYOPTICS INC (2000-04-18);;HEWLETT-PACKARD COMPANY (2002-01-08);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-01-06);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;BROADCOM INTERNATIONAL PTE. LTD (2020-08-26);;CYOPTICS ACQUISITION CORP (2007-04-02);;APOGEE PHOTONICS INC (2005-07-11);;T-NETWORKS INC (2002-01-24),https://lens.org/118-314-369-452-287,Patent Application,yes,7,10,4,4,0,B82Y20/00;;G02F1/01708;;B82Y20/00;;G02F1/01708,G02F1/017,385/2;;X385 4;;385/15;;385/14;;385/131;;359/344,0,0,,,,EXPIRED
15,US,B2,US 6661556 B2,193-245-747-900-811,2003-12-09,2003,US 21828902 A,2002-08-14,US 21828902 A;;US 31478901 P;;US 33516601 P,2001-08-24,Stabilizing electro-absorption modulators (EAM's) performance by maintaining constant absorption with the use of integrated tap couplers,"
    An exemplary monolithic stabilized monolithic transmissive active optical device, such as an electroabsorption modulator (EAM), a variable optical attenuator (VOA), or a semiconductor optical amplifier (SOA), with an output optical tap, includes: a substrate; a waveguide layer; a semiconductor layer. The waveguide layer is coupled to the substrate and includes an active medium, which interacts with a predetermined wavelength of light, and is responsive to an electric signal. The electric signal is applied between the substrate and the semiconductor layer. The waveguide layer includes an output optical tap section and an active section adjacent to the output optical tap section. These sections include portions of the active medium. Further embodiments of the present invention incorporate temperature as well as bias control to improve performance of exemplary monolithic transmissive active optical devices. Additional embodiments include exemplary methods of manufacture and methods of operation. 
",NETWORKS INC T,BOND AARON;;ANDERSEN JOHN KAI;;JAMBUNATHAN RAM,CYOPTICS INC (2000-04-18);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-01-06);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;BROADCOM INTERNATIONAL PTE. LTD (2020-08-26);;CYOPTICS ACQUISITION CORP (2007-04-02);;APOGEE PHOTONICS INC (2005-07-11);;T-NETWORKS INC (2002-08-12),https://lens.org/193-245-747-900-811,Granted Patent,yes,6,17,4,4,0,G02F1/025;;G02F1/025;;G02F1/0123;;G02F1/0123;;G02F2203/05;;G02F2203/05,G02F1/01;;G02F1/025,359/245;;359/248;;385/2;;257/189,0,0,,,,EXPIRED
16,US,A1,US 2003/0043448 A1,127-330-956-578-403,2003-03-06,2003,US 21828902 A,2002-08-14,US 21828902 A;;US 31478901 P;;US 33516601 P,2001-08-24,Stabilizing electro-absorption modulators (EAM's) performance by maintaining constant absorption with the use of integrated tap couplers,"
   An exemplary monolithic stabilized monolithic transmissive active optical device, such as an electroabsorption modulator (EAM), a variable optical attenuator (VOA), or a semiconductor optical amplifier (SOA), with an output optical tap, includes: a substrate; a waveguide layer; a semiconductor layer. The waveguide layer is coupled to the substrate and includes an active medium, which interacts with a predetermined wavelength of light, and is responsive to an electric signal. The electric signal is applied between the substrate and the semiconductor layer. The waveguide layer includes an output optical tap section and an active section adjacent to the output optical tap section. These sections include portions of the active medium. Further embodiments of the present invention incorporate temperature as well as bias control to improve performance of exemplary monolithic transmissive active optical devices. Additional embodiments include exemplary methods of manufacture and methods of operation. 
",BOND AARON;;ANDERSEN JOHN KAI;;JAMBUNATHAN RAM,BOND AARON;;ANDERSEN JOHN KAI;;JAMBUNATHAN RAM,CYOPTICS INC (2000-04-18);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-01-06);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;BROADCOM INTERNATIONAL PTE. LTD (2020-08-26);;CYOPTICS ACQUISITION CORP (2007-04-02);;APOGEE PHOTONICS INC (2005-07-11);;T-NETWORKS INC (2002-08-12),https://lens.org/127-330-956-578-403,Patent Application,yes,0,11,4,4,0,G02F1/025;;G02F1/025;;G02F1/0123;;G02F1/0123;;G02F2203/05;;G02F2203/05,G02F1/01;;G02F1/025,359/248;;385/3,0,0,,,,EXPIRED
17,US,A1,US 2004/0258339 A1,130-591-525-314-362,2004-12-23,2004,US 89569904 A,2004-07-21,US 89569904 A;;US 5692902 A,2002-01-25,Method of fabricating a monolithic expanded beam mode electroabsorption modulator,"
   A method of manufacturing a monolithic expanded beam mode electroabsorption modulator including a waveguide layer with a two expansion/contraction sections and an electroabsorption section arranged along a longitudinal axis. At least one patterned growth retarding layer is formed on the top surface of a substrate. The waveguide layer is formed on a portion of the top surface of the substrate by selective area growth and has an index of refraction different from the substrate. An electroabsorption portion of the waveguide layer has a thickness which is greater than thicknesses in its other portions. The semiconductor layer is formed on the waveguide layer and includes an index of refraction different from the waveguide. The waveguide and semiconductor layers are defined and etched to form the expansion/contraction and electroabsorption sections of the waveguide layer. Electrical contacts are formed, one electrically coupled to the substrate and another electrically coupled to the semiconductor layer. 
",BOND AARON;;JAMBUNATHAN RAM;;CHOI WON JIN,BOND AARON;;JAMBUNATHAN RAM;;CHOI WON JIN,CYOPTICS INC (2000-04-18);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-01-06);;CYOPTICS ACQUISITION CORP (2007-04-02);;APOGEE PHOTONICS INC (2005-07-11),https://lens.org/130-591-525-314-362,Patent Application,yes,9,0,4,4,0,B82Y20/00;;G02F1/01708;;B82Y20/00;;G02F1/01708,G02F1/017,385/1,0,0,,,,EXPIRED
18,US,A1,US 2004/0208446 A1,133-327-651-810-013,2004-10-21,2004,US 84374304 A,2004-05-12,US 84374304 A;;US 16791502 A;;US 31495101 P,2001-08-24,Grating dispersion compensator and method of manufacture,"
   A grating dispersion compensator (GDC), including: a substrate; a dielectric grating layer; a planar waveguide; and a passivation layer; is disclosed. The dielectric grating layer may be formed on the substrate and includes a variation in refractive index. This variation in refractive index defines a grating period. The grating period may vary along the longitudinal axis of the GDC according to a predetermined function. A selected center wavelength and dispersion curve may be created. The chirp of the grating period may be controlled by current, voltage, temperature, or pressure. The planar waveguide is formed on the dielectric grating layer and includes an input/output (I/O) surface normal to the longitudinal axis of the planar waveguide. The passivation layer is formed on the planar waveguide. Alternatively, a GDC may be formed with the dielectric grating layer on top of the planar waveguide rather than beneath it. 
",BOND AARON;;JAMBUNATHAN RAM;;FRATESCHI NEWTON C.,BOND AARON;;JAMBUNATHAN RAM;;FRATESCHI NEWTON C,CYOPTICS INC (2000-04-18);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-01-06);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;BROADCOM INTERNATIONAL PTE. LTD (2020-08-26);;CYOPTICS ACQUISITION CORP (2007-04-02);;APOGEE PHOTONICS INC (2005-07-11),https://lens.org/133-327-651-810-013,Patent Application,yes,12,76,4,4,0,G02B6/12007;;G02B6/29325;;G02B6/29394;;G02B6/29395;;G02B6/29398;;G02B2006/12107;;G02B6/12007;;G02B6/29395;;G02B6/29394;;G02B6/29398;;G02B2006/12107;;G02B6/29325,G02B6/12;;G02B6/34,385/37,0,0,,,,EXPIRED
19,US,A1,US 2003/0039442 A1,127-648-649-935-140,2003-02-27,2003,US 16791502 A,2002-06-11,US 16791502 A;;US 31495101 P,2001-08-24,Grating dispersion compensator and method of manufacture,"
   A grating dispersion compensator (GDC), including: a substrate; a dielectric grating layer; a planar waveguide; and a passivation layer; is disclosed. The dielectric grating layer may be formed on the substrate and includes a variation in refractive index. This variation in refractive index defines a grating period. The grating period may vary along the longitudinal axis of the GDC according to a predetermined function. A selected center wavelength and dispersion curve may be created. The chirp of the grating period may be controlled by current, voltage, temperature, or pressure. The planar waveguide is formed on the dielectric grating layer and includes an input/output (I/O) surface normal to the longitudinal axis of the planar waveguide. The passivation layer is formed on the planar waveguide. Alternatively, a GDC may be formed with the dielectric grating layer on top of the planar waveguide rather than beneath it. 
",BOND AARON;;JAMBUNATHAN RAM;;FRATESCH NEWTON C.,BOND AARON;;JAMBUNATHAN RAM;;FRATESCH NEWTON C,CYOPTICS INC (2000-04-18);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-01-06);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;BROADCOM INTERNATIONAL PTE. LTD (2020-08-26);;CYOPTICS ACQUISITION CORP (2007-04-02);;APOGEE PHOTONICS INC (2005-07-11);;T-NETWORKS INC (2002-06-08),https://lens.org/127-648-649-935-140,Patent Application,yes,18,91,4,4,0,G02B6/12007;;G02B6/29325;;G02B6/29394;;G02B6/29395;;G02B6/29398;;G02B2006/12107;;G02B6/12007;;G02B6/29395;;G02B6/29394;;G02B6/29398;;G02B2006/12107;;G02B6/29325,G02B6/12;;G02B6/34,385/37;;X385 4;;385/13,0,0,,,,EXPIRED
20,US,B2,US 6844954 B2,139-609-412-234-745,2005-01-18,2005,US 63508003 A,2003-08-06,US 63508003 A;;US 21828902 A;;US 31478901 P;;US 33516601 P,2001-08-24,Method of stabilizing electro-absorption modulators (EAM's) performance by maintaining constant absorption with the use of intergrated tap couplers and method of manufacture,"An exemplary monolithic stabilized monolithic transmissive active optical device, such as an electroabsorption modulator (EAM), a variable optical attenuator (VOA), or a semiconductor optical amplifier (SOA), with an output optical tap, is formed from: a substrate; a waveguide layer; a semiconductor layer. The waveguide layer is coupled to the substrate and includes an active medium, which interacts with a predetermined wavelength of light, and is responsive to an electric signal. The electric signal is applied between the substrate and the semiconductor layer. The waveguide layer includes an output optical tap section and an active section adjacent to the output optical tap section. These sections include portions of the active medium. Further embodiments of the present invention incorporate temperature as well as bias control to improve performance of exemplary monolithic transmissive active optical devices.",NETWORKS INC T,BOND AARON;;ANDERSON JOHN KAI;;JAMBUNATHAN RAM,CYOPTICS INC (2000-04-18);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-01-06);;CYOPTICS ACQUISITION CORP (2007-04-02);;APOGEE PHOTONICS INC (2005-07-11),https://lens.org/139-609-412-234-745,Granted Patent,yes,4,3,4,4,0,G02F1/025;;G02F1/025;;G02F1/0123;;G02F1/0123;;G02F2203/05;;G02F2203/05,G02F1/01;;G02F1/025,359/240;;359/245;;359/248;;385/2,0,0,,,,EXPIRED
21,US,A1,US 2005/0018732 A1,182-192-592-941-989,2005-01-27,2005,US 74149403 A,2003-12-19,US 74149403 A;;US 43462902 P,2002-12-19,"Uncooled and high temperature long reach transmitters, and high power short reach transmitters","A method for improving the reliability of an uncooled long reach optical transmitter operating substantially at a predetermined output power. The uncooled long reach optical transmitter in this method includes a laser, an SOA and a modulator. The laser is operated to produce a reduced power laser beam, thereby improving the laser reliability. The SOA bias current is controlled so that the SOA amplifies the reduced power laser beam to substantially maintain the predetermined output power. The SOA is sufficiently long to provide this amplification, while maintaining a reduced current density within the SOA, thereby improving the SOA reliability. Small signal chirp parameters are measured for two bias voltages of the modulator. A linear function of the modulator bias voltage versus temperature is determined. The modulator bias voltage as a function of temperature is adjusted to maintain a constant dispersion penalty for data transmission.",BOND AARON;;FRATESCHI NEWTON C.;;ZHANG JIAMING,BOND AARON;;FRATESCHI NEWTON C;;ZHANG JIAMING,CYOPTICS ACQUISITION CORP (2007-04-02);;APOGEE PHOTONICS INC (2005-07-11);;T-NETWORKS INC (2004-10-03),https://lens.org/182-192-592-941-989,Patent Application,yes,3,46,1,1,0,H01S5/005;;H01S5/0064;;H01S5/0085;;H01S5/0265;;H01S5/12;;H01S5/4006;;Y02E10/548;;H01S5/4006;;H01S5/005;;H01S5/12;;H01S5/0265;;H01S5/0064;;H01S5/0085,H01L31/075;;H01S5/00;;H01S5/026;;H01S5/12;;H01S5/40,372 5;;257/458,0,0,,,,DISCONTINUED
22,US,B2,US 6804421 B2,002-041-900-032-547,2004-10-12,2004,US 5692902 A,2002-01-25,US 5692902 A,2002-01-25,Monolithic expanded beam mode electroabsorption modulator,"
    A monolithic single pass expanded beam mode active optical device includes: a substrate; a waveguide layer coupled to the top surface of the substrate; a semiconductor layer coupled to the waveguide layer; first and second electrodes for receiving an electric signal coupled to the substrate and the semiconductor layer, respectively. The waveguide layer includes a plurality of sublayers, forming a quantum well structure, which is responsive to the electric signal. The waveguide layer has three sections, two expansion/contraction sections and an active section, which extends between and adjacent to the two expansion/contraction sections. The thickness of at least one of the plurality of sublayers varies within the expansion/contraction portions of the quantum well structure. Possible interactions of the active region with the light include: absorption in the case of an electro-absorptive modulator and optical gain. 
",NETWORKS INC T,BOND AARON;;JAMBUNATHAN RAM;;CHOI WON JIN,CYOPTICS INC (2000-04-18);;HEWLETT-PACKARD COMPANY (2002-01-08);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-01-06);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;BROADCOM INTERNATIONAL PTE. LTD (2020-08-26);;CYOPTICS ACQUISITION CORP (2007-04-02);;APOGEE PHOTONICS INC (2005-07-11);;T-NETWORKS INC (2002-01-24),https://lens.org/002-041-900-032-547,Granted Patent,yes,7,3,4,4,0,B82Y20/00;;G02F1/01708;;B82Y20/00;;G02F1/01708,G02F1/017,385/2;;385/20;;359/344,0,0,,,,EXPIRED
23,US,B2,US 6862376 B2,110-944-590-330-68X,2005-03-01,2005,US 89569904 A,2004-07-21,US 89569904 A;;US 5692902 A,2002-01-25,Method of fabricating a monolithic expanded beam mode electroabsorption modulator,"A method of manufacturing a monolithic expanded beam mode electroabsorption modulator including a waveguide layer with a two expansion/contraction sections and an electroabsorption section arranged along a longitudinal axis. At least one patterned growth retarding layer is formed on the top surface of a substrate. The waveguide layer is formed on a portion of the top surface of the substrate by selective area growth and has an index of refraction different from the substrate. An electroabsorption portion of the waveguide layer has a thickness which is greater than thicknesses in its other portions. The semiconductor layer is formed on the waveguide layer and includes an index of refraction different from the waveguide. The waveguide and semiconductor layers are defined and etched to form the expansion/contraction and electroabsorption sections of the waveguide layer. Electrical contacts are formed, one electrically coupled to the substrate and another electrically coupled to the semiconductor layer.",NETWORKS INC T,BOND AARON;;JAMBUNATHAN RAM;;CHOI WON JIN,CYOPTICS INC (2000-04-18);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-01-06);;CYOPTICS ACQUISITION CORP (2007-04-02);;APOGEE PHOTONICS INC (2005-07-11),https://lens.org/110-944-590-330-68X,Granted Patent,yes,8,2,4,4,0,B82Y20/00;;G02F1/01708;;B82Y20/00;;G02F1/01708,G02F1/017,385/1;;385/2;;385/131;;438/31,0,0,,,,EXPIRED
24,US,B1,US 6376272 B1,113-531-703-362-738,2002-04-23,2002,US 58842700 A,2000-06-06,US 58842700 A,2000-06-06,InA1As etch stop layer for precise semiconductor waveguide fabrication,"
    A semiconductor waveguide device and method for forming the same provide an InAlAs film as an etch stop layer. The InAlAs film does not etch in the CH _{ 4 } /H _{ 2 } etch chemistry used to produce the device using reactive ion etching techniques. The etching process etches the waveguide layer and cladding layer or layers formed above the InAlAs layer, and exposes the InAlAs etch stop film to produce a waveguide device having desired physical characteristics. 
",LUCENT TECHNOLOGIES INC,BOND AARON EUGENE;;OUGAZZADEN ABDALLAH;;SHTENGEL GLEB E,ALCATEL-LUCENT USA INC (2000-05-04);;PROVENANCE ASSET GROUP LLC (2017-09-12);;RPX CORPORATION (2021-11-29),https://lens.org/113-531-703-362-738,Granted Patent,yes,1,12,1,1,0,G02B6/10;;G02B6/10;;G02B6/122;;G02B6/122;;G02B6/136;;G02B6/136;;G02B2006/12097;;G02B2006/12097;;H01S5/209;;H01S5/209,G02B6/10;;G02B6/12;;G02B6/122;;G02B6/136;;H01S5/20,438/31;;372/45;;385/130,0,0,,,,EXPIRED
25,CO,A2,CO 6940382 A2,190-302-054-293-368,2014-05-09,2014,CO 14086819 A,2014-04-23,US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,Agentes de ligación a vegf/dll4 y usos de los mismos,,ONCOMED PHARM INC,GURNEY AUSTIN;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/190-302-054-293-368,Patent Application,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;C07K16/00;;C12P21/08,,0,0,,,,PENDING
26,ZA,B,ZA 201402890 B,021-631-729-716-285,2015-08-26,2015,ZA 201402890 A,2014-04-22,US 201161538454 P;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,,ONCOMED PHARM INC,BOND CHRISTOPHER JOHN;;SATO AARON KEN;;GURNEY AUSTIN L,,https://lens.org/021-631-729-716-285,Granted Patent,no,0,0,2,82,0,,,,0,0,,,,ACTIVE
27,HU,T2,HU E061002 T2,039-132-075-515-368,2023-04-28,2023,HU E18197338 A,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,,MEREO BIOPHARMA 5 INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/039-132-075-515-368,Amended Patent,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/08,,0,0,,,,PENDING
28,CY,T1,CY 1121148 T1,106-084-186-756-505,2020-05-29,2020,CY 191100077 T,2019-01-21,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;US 2012/0056886 W,2011-09-23,ΠΑΡΑΓΟΝΤΕΣ ΣΥΝΔΕΣΗΣ VEGF/DLL4 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ,"Η παρούσα εφεύρεση αφορά σε παράγοντες σύνδεσης VEGF, παράγοντες σύνδεσης DLL4, διπλά ειδικούς παράγοντες σύνδεσης VEGF/DLL4 και μεθόδους χρήσης των παραγόντων για θεραπεία ασθενειών όπως καρκίνου. Η παρούσα εφεύρεση παρέχει αντισώματα που ειδικώς συνδέουν ανθρώπινο VEGF, αντισώματα που ειδικώς συνδέουν ανθρώπινο DLL4 και διπλά ειδικά αντισώματα που ειδικώς συνδέουν ανθρώπινο VEGF ή/και ανθρώπινο DLL4. Η παρούσα εφεύρεση περαιτέρω παρέχει μεθόδους χρήσης των παραγόντων για να παρεμποδίζεται ανάπτυξη όγκου. Επίσης περιγραφόμενες είναι μέθοδοι θεραπείας καρκίνου που περιλαμβάνουν χορήγηση θεραπευτικώς αποτελεσματικής ποσότητας ενός παράγοντα ή αντισώματος της παρούσας εφεύρεσης σε έναν ασθενή που έχει όγκο ή καρκίνο.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/106-084-186-756-505,Granted Patent,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/08,,0,0,,,,ACTIVE
29,SI,T1,SI 3485903 T1,104-153-453-153-842,2023-02-28,2023,SI 201232019 T,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;EP 18197338 A,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,,MEREO BIOPHARMA 5 INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/104-153-453-153-842,Granted Patent,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/00,,0,0,,,,ACTIVE
30,WO,A1,WO 2014/047179 A1,041-144-428-775-561,2014-03-27,2014,US 2013/0060404 W,2013-09-18,US 201261703191 P;;US 201361874741 P,2012-09-19,METHOD AND SYSTEM FOR ENHANCED IMAGING VISUALIZATION OF DEEP BRAIN ANATOMY USING INFUSION,"Provided is a method and system for delivering a diagnostic agent to a site in the brain of a subject for imaging at least a portion of the brain site on a medical imaging system. The method and system includes a catheter device with associated lumens having diagnostic agent ports for delivering the diagnostic agent (e.g., infusate) through the lumens and advancing the diagnostic agent so as to exit out from the lumens to at least a portion of the brain site and while sealing a portion of the brain site thereby preventing the exited diagnostic agent from travelling proximally beyond the sealing location, and at the same time imaging at least a portion of the brain site during at least a portion of the sealing duration so that the brain site can be visualized on a medical imaging system. The diagnostic agent (infusate) is able to highlight borders and internal patterns of the deep structures of the brain thereby enabling direct targeting. Ultimately this leads to reduced complications, enhanced therapy, and the elimination of the need for awake surgery. The method and system provides the capability heretofore not possible to visualize the small, often indistinct regions, which will greatly improve clinical outcomes with therapeutic interventions.",UNIV VIRGINIA PATENT FOUND;;ELIAS WILLIAM J;;BOND AARON E;;GILLIES GEORGE T,ELIAS WILLIAM J;;BOND AARON E;;GILLIES GEORGE T,,https://lens.org/041-144-428-775-561,Patent Application,yes,6,12,5,5,0,A61M25/10;;A61B5/0042;;A61B5/055;;A61M25/007;;A61M25/0127;;A61M25/1002;;A61M31/005;;A61M2025/0042;;A61M2025/105;;A61M2025/1052;;A61M2025/1093;;G01R33/285;;A61B6/032;;A61B6/12;;A61B6/481;;A61B6/501;;A61M25/10;;A61B5/0042;;A61B5/055;;A61M25/007;;A61M25/0127;;A61M25/1002;;A61M31/005;;A61M2025/0042;;A61M2025/105;;A61M2025/1052;;A61M2025/1093;;G01R33/285;;A61B6/032;;A61B6/12;;A61B6/481;;A61B6/501;;A61M5/007;;A61M25/0026;;A61M2025/0037;;A61N1/36139,A61M25/10,,0,0,,,,PENDING
31,BR,A2,BR 112014007035 A2,130-982-728-244-606,2017-04-11,2017,BR 112014007035 A,2012-09-24,US 2012/0056886 W;;US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,agentes de ligação a vegf/dll4 e usos dos mesmos,,ONCOMED PHARM INC,AARON KEN SATO;;AUSTIN L GURNEY;;CHRISTOPHER JOHN BOND,,https://lens.org/130-982-728-244-606,Patent Application,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,C07K16/00;;A61K39/00;;C12P21/08,,0,0,,,,ACTIVE
32,SG,A,SG 11201400870W A,158-955-961-977-809,2014-04-28,2014,SG 11201400870W A,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,,ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/158-955-961-977-809,Unknown,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;C07K16/00;;C12P21/08,,0,0,,,,PENDING
33,US,B2,US 9879084 B2,017-338-863-441-879,2018-01-30,2018,US 201715401543 A,2017-01-09,US 201715401543 A;;US 201615163301 A;;US 201414476582 A;;US 201213625417 A;;US 201261692978 P;;US 201261597409 P;;US 201161538454 P,2011-09-23,Modified immunoglobulin molecules that specifically bind human VEGF and DLL4,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,MEREO BIOPHARMA 5 INC (2012-12-11),https://lens.org/017-338-863-441-879,Granted Patent,yes,276,7,76,82,80,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/395;;A61K39/00;;C07K16/00;;C07K16/22;;C07K16/28;;C12P21/08,,327,242,084-085-138-348-898;;006-049-213-810-548;;042-535-804-056-355;;164-216-761-918-204;;070-614-370-694-544;;016-251-721-517-200;;021-197-916-777-658;;115-778-640-766-918;;020-327-681-254-735;;000-913-948-188-914;;015-807-813-009-849;;126-923-418-365-467;;043-293-799-149-190;;003-984-734-905-938;;037-480-189-672-490;;018-597-551-636-944;;059-703-624-598-226;;005-112-559-456-657;;053-851-713-620-401;;006-553-734-546-212;;003-849-961-384-35X;;105-316-874-895-908;;031-901-495-166-515;;061-397-752-245-555;;004-522-738-863-341;;016-291-551-264-744;;001-779-867-387-972;;032-443-032-575-719;;049-134-753-209-354;;061-518-684-585-221;;099-532-412-433-785;;078-200-031-570-847;;100-371-416-663-157;;029-611-134-469-353;;027-845-339-272-06X;;133-610-790-984-99X;;016-270-419-085-156;;079-109-121-457-433;;025-070-183-573-259;;015-506-336-131-104;;037-809-048-883-498;;048-319-205-023-297;;007-837-250-546-989;;027-519-986-651-310;;018-320-647-455-556;;056-188-962-943-86X;;101-575-504-070-651;;073-702-812-203-896;;091-232-484-240-784;;138-876-315-756-795;;054-283-410-011-338;;060-684-120-299-26X;;112-241-917-646-013;;009-062-652-854-847;;090-306-007-122-585;;095-500-970-877-346;;027-306-913-195-466;;068-271-687-772-412;;129-005-046-068-395;;106-254-156-307-214;;032-048-398-057-385;;002-209-250-502-039;;003-711-275-433-72X;;035-232-534-898-963;;149-834-701-635-194;;035-067-471-486-809;;038-442-198-715-21X;;110-500-797-458-579;;072-351-640-594-174;;068-352-608-171-550;;065-608-090-342-50X;;005-119-615-003-591;;067-111-531-425-423;;065-542-021-501-547;;061-958-083-948-364;;164-451-236-197-939;;042-041-573-268-106;;016-512-212-388-570;;087-726-883-167-698;;008-498-336-394-659;;031-100-076-670-370;;032-071-991-081-664;;087-191-128-287-209;;089-486-878-211-546;;075-221-017-149-582;;077-495-150-106-187;;092-634-627-505-478;;089-633-612-001-004;;136-835-589-937-16X;;002-723-775-902-029;;017-328-222-500-841;;085-727-974-637-837;;023-378-335-265-81X;;033-368-627-556-233;;008-844-599-921-544;;099-964-134-794-845;;021-745-342-029-670;;006-574-964-805-278;;046-013-436-890-449;;015-623-518-697-144;;068-238-957-669-243;;014-119-439-143-988;;104-212-297-137-759;;054-531-591-081-65X;;022-883-652-460-089;;085-528-415-223-353;;056-502-337-160-838;;014-785-980-334-859;;004-425-043-791-551;;029-657-616-636-736;;004-602-847-993-84X;;056-289-930-116-029;;054-277-945-870-664;;044-312-778-204-450;;024-810-152-282-074;;085-249-110-169-470;;128-376-920-124-813;;066-699-026-742-579;;086-164-247-322-732;;043-453-890-807-326;;024-298-462-228-882;;095-334-545-560-259;;024-561-324-817-879;;062-547-748-254-237;;010-916-105-450-247;;020-855-322-534-259;;024-042-571-208-910;;032-607-776-688-407;;113-146-142-749-076;;041-945-536-319-424;;113-146-142-749-076;;108-327-398-058-238;;052-515-652-666-158;;092-881-815-515-655;;020-636-405-917-503;;048-208-171-994-922;;117-775-899-628-564;;039-118-196-658-356;;058-205-097-704-518;;018-709-667-787-457;;096-836-261-967-31X;;077-108-010-423-006;;030-607-398-087-475;;006-454-751-452-062;;071-717-719-996-536;;033-073-320-277-143;;108-821-214-937-013;;011-745-980-251-775;;048-103-697-044-146;;065-287-969-992-103;;127-754-934-722-768;;085-593-346-327-896;;033-658-808-499-907;;006-798-173-804-888;;000-185-481-899-567;;008-268-944-751-345;;000-935-046-673-192;;028-156-483-654-882;;015-239-659-590-870;;069-144-826-896-138;;027-020-473-411-693;;102-675-067-390-626;;016-014-793-014-160;;041-596-561-800-698;;100-984-968-676-329;;020-564-002-939-564;;042-204-626-457-327;;089-635-536-661-885;;027-477-313-726-928;;094-311-434-287-343;;090-714-216-170-949;;081-098-206-476-749;;026-048-786-530-595;;049-192-915-761-746;;072-064-906-772-096;;061-751-917-222-159;;043-558-136-070-327;;107-303-389-554-878;;064-792-093-706-002;;058-211-492-859-131;;091-347-675-692-644;;093-067-181-692-392;;063-640-832-834-034;;000-438-864-132-323;;036-379-137-455-723;;000-438-864-132-323;;175-243-588-850-607;;080-191-903-791-47X;;013-642-802-665-79X;;047-364-936-221-939;;085-729-060-237-502;;016-658-224-490-240;;037-711-371-585-567;;047-025-555-564-763;;011-910-096-463-060;;026-145-110-279-358;;008-266-889-199-914;;006-257-463-053-048;;125-269-916-334-305;;002-219-259-764-94X;;031-063-853-127-197;;022-375-749-274-329;;051-940-176-386-905;;067-279-783-581-616;;008-479-069-316-491;;049-991-770-424-933;;091-582-771-406-994;;053-665-131-053-807;;045-094-249-115-990;;069-495-502-499-501;;091-114-424-339-46X;;016-314-653-579-682;;052-795-433-555-537;;009-188-067-200-010;;037-589-218-577-038;;083-606-989-843-197;;047-462-962-275-331;;119-515-479-159-88X;;008-411-420-307-533;;013-142-717-038-23X;;006-124-137-496-346;;003-711-929-171-854;;049-491-181-937-297;;025-046-032-214-179;;035-236-318-471-090;;060-472-079-666-376;;028-960-308-516-850;;066-407-919-450-381;;150-651-615-448-193;;078-077-493-330-521;;091-051-926-686-546;;018-146-170-889-398;;064-048-827-826-930;;035-275-453-395-352;;012-005-224-634-423;;059-212-558-154-670;;132-484-526-820-872;;020-239-636-647-054;;022-648-069-840-113;;155-710-259-787-090;;025-331-205-864-51X;;000-740-232-876-831,10.1073/pnas.0530291100;;pmc153034;;12629218;;12496471;;10.4161/cbt.1.5.159;;10.1200/jco.2007.14.7116;;18316791;;10.1126/science.284.5415.770;;10221902;;15288256;;10.1016/j.semcancer.2004.04.010;;10.1073/pnas.91.9.3809;;pmc43671;;8170992;;15549094;;10.1038/nature03100;;17363584;;10.1158/0008-5472.can-06-4158;;pmc2118717;;10.1084/jem.20061442;;17261636;;10.1158/1538-7445.am2012-lb-196;;10.1158/1538-7445.am2011-2834;;10.1158/1538-7445.am2013-4330;;9041643;;pmc2143633;;10.1002/pro.5560060217;;10.4049/jimmunol.147.1.86;;2051030;;9212098;;10.1038/nm0797-730;;10.1038/nrm2009;;16921404;;pmc154142;;10.1186/bcr559;;12631384;;10.1126/science.3925553;;3925553;;10586066;;10.4049/jimmunol.163.12.6694;;8424945;;10.1021/bi00055a024;;1699952;;pmc2116333;;10.1083/jcb.111.5.2129;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;10.1023/a:1009512414430;;11467450;;11905803;;10.1038/35101072;;19436303;;10.1038/sj.bjc.6605061;;pmc2695695;;1512548;;10.1084/jem.176.3.855;;pmc2119366;;10.1006/jmbi.1999.3192;;10543973;;pmc4790121;;19487335;;10.1634/theoncologist.2008-0272;;10.1016/0022-2836(87)90412-8;;3681981;;10.1016/0022-2836(85)90137-8;;4093982;;10385321;;10.1038/9872;;10.1158/0008-5472.can-06-3126;;16990346;;10.1016/j.modgep.2004.05.004;;15533827;;7516563;;10.1016/s0923-2494(94)80039-1;;10.1158/1535-7163.targ-13-b78;;10.1073/pnas.0703478104;;pmc1891215;;17548814;;15790776;;10.1634/stemcells.2004-0205;;10.2210/pdb1fc1/pdb;;7236608;;10.2210/pdb1fc2/pdb;;10.1021/bi00512a001;;20046569;;pmc2715180;;10.4161/mabs.1.1.7347;;pmc1064073;;10.1186/bcr920;;15535842;;10.1182/blood.v100.6.2046.h81802002046_2046_2055;;12200365;;2045660;;10.1016/0022-1759(91)90189-m;;15466159;;pmc529534;;10.1101/gad.1239004;;10.1093/annonc/mdv050.18;;1831692;;10.1016/0092-8674(91)90111-b;;pmc2671578;;10.1038/nm1712;;18297084;;pmc397852;;10.1073/pnas.82.11.3688;;3159018;;10.1007/s12015-007-0023-5;;17873349;;17440163;;10.1093/jnci/djk133;;10.1158/0008-5472.can-10-2817;;21193546;;17709001;;10.1016/s0962-8924(97)01161-6;;15959516;;10.1038/nature03589;;17533181;;10.1161/circulationaha.106.675462;;10.1073/pnas.040337597;;pmc15970;;10688880;;10.1073/pnas.0407290101;;15520367;;pmc524697;;3023699;;pmc255246;;10.1128/jvi.61.1.218-220.1987;;8620493;;10.1093/jnci/djm148;;17728207;;10.1200/jco.2014.32.3_suppl.279;;10.1007/s10555-005-5865-1;;15785879;;10.1073/pnas.101138098;;pmc33218;;11344278;;17611219;;10.1242/dev.004184;;10.1200/jco.2008.20.9114;;19433683;;10.4049/jimmunol.152.11.5368;;8189055;;pmc3177777;;10.1186/2045-824x-3-18;;21831306;;10.1158/0008-5472.can-05-4226;;16951162;;15520185;;10.1158/0008-5472.can-04-1813;;10.1182/blood.v95.5.1616.005k31_1616_1625;;10688816;;14986825;;10.1046/j.1399-0004.2003.00194.x;;10.1016/j.mvr.2007.06.006;;17692341;;8654676;;10.1042/bst0231035;;10.1016/0022-2836(92)90639-2;;1507232;;17259973;;10.1038/nature05571;;10.1016/j.exphem.2007.05.014;;17637499;;3044339;;10.1016/s0959-8049(14)70292-8;;19664991;;10.1016/j.stem.2009.05.019;;17556669;;10.1161/01.res.0000266408.42939.e4;;16770536;;10.1007/s10555-006-8504-6;;12177445;;10.1073/pnas.172398299;;pmc123267;;16989900;;10.1016/j.molimm.2006.08.001;;10.1016/0022-2836(92)90894-p;;1404359;;15170211;;10.1038/ni1080;;pmc2361628;;10.1038/sj.bjc.6602719;;16136053;;10.1016/s0022-1759(97)00172-5;;9461335;;10.1016/0958-1669(94)90053-1;;7765176;;10.1158/1078-0432.ccr-08-2740;;19509175;;6933450;;pmc349762;;10.1073/pnas.77.7.4030;;15563463;;10.1074/jbc.m406788200;;12615665;;10.1161/01.atv.0000060892.81529.8f;;10.1093/annonc/mdn713;;19150949;;7897213;;10.4049/jimmunol.154.7.3310;;10.1126/science.1222879;;pmc3577348;;22653731;;10.1016/s0161-5890(98)00095-9;;10199394;;7566092;;10.1038/377355a0;;10805736;;pmc85741;;10.1128/mcb.20.11.3928-3941.2000;;10.1101/gad.6.3.345;;1372276;;10.1038/321522a0;;3713831;;10.1073/pnas.172398399;;pmc123268;;12177446;;389741;;10.1016/0378-1119(79)90029-5;;10556249;;10.1093/protein/12.10.879;;10.1007/bf02893458;;15188021;;10.4049/jimmunol.148.5.1547;;1531669;;pmc529533;;10.1101/gad.1239204;;15466160;;10837027;;pmc316662;;10.1101/gad.14.11.1343;;10.1073/pnas.081615298;;11274374;;pmc31881;;7509044;;10.1038/367645a0;;10.1038/sj.leu.2403288;;14990974;;10.1016/s0161-5890(98)00109-6;;10369421;;10.1038/sj.onc.1203703;;10918578;;16291593;;10.1182/blood-2005-08-3329;;16023591;;10.1016/j.ccr.2005.06.013;;10.1038/nm.2021;;19855400;;pmc2780347;;10.1158/0008-5472.can-06-0191;;16618717;;10.1161/01.res.0000258174.77370.2c;;17234965;;10.1186/bcr1021;;15987436;;pmc1143566;;10.1096/fj.05-4880fje;;16571776;;12482957;;pmc140667;;10.1128/mcb.23.1.14-25.2003;;10.1073/pnas.0611206104;;pmc1805530;;17296940;;23750318;;10.2217/cns.12.36;;pmc3673744;;25700513;;10.1126/science.1261093;;pmc4445638;;10.1006/jmbi.1996.0548;;8876650;;1873503;;10.3233/hab-1991-2302;;10.1046/j.1432-0436.2001.690207.x;;11798067;;10.1038/nbt0792-779;;1368267;;1748994;;10.1016/0022-2836(91)90498-u;;10.1210/en.2007-0477;;17916635;;pmc2734500;;pmc3491453;;23019585;;10.1073/pnas.1206400109;;10.1016/s0959-8049(12)72395-x;;10.1158/1535-7163.targ-13-a71;;10.1016/s0959-8049(12)72395-x;;10.1200/jco.2014.32.15_suppl.2544;;10.1038/nbt0798-677;;9661204;;10528225;;10.1002/(sici)1097-4652(199912)181:3<393::aid-jcp3>3.0.co;2-6;;16489059;;10.1158/1078-0432.ccr-05-2570;;15319485;;10.1093/toxsci/kfh254;;10.1038/305537a0;;6137772;;1560176;;10.1016/0165-022x(92)90051-b;;10.1016/s0952-7915(97)80138-0;;9099790;;9039255;;10.1016/s0092-8674(00)81867-x;;10.1146/annurev.cb.11.110195.000343;;10.1146/annurev.cellbio.11.1.35;;8689561;;10.1353/dem.2000.0009;;11086575;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;12133727;;10.1016/s1367-5931(02)00346-0;;10.1038/sj.onc.1206758;;14528285;;17605027;;10.1007/s00418-007-0306-6;;10.1038/nature05355;;17183313;;10.1073/pnas.051624498;;pmc30615;;11248040;;pmc390431;;10.1073/pnas.82.14.4592;;3927286;;10.3109/14017431.2010.511256;;20799913;;pmc1698634;;17028337;;10.1534/genetics.106.061630;;10.3892/ijmm.14.5.779;;15492845;;10.1158/0008-5472.can-05-1208;;16204037;;10.1097/01.moh.0000143965.90813.70;;15548998;;8642337;;10.1084/jem.183.5.2283;;pmc2192581;;19154719;;pmc8114544;;10.1016/j.devcel.2008.12.009;;10.1093/glycob/cwi007;;15496501;;15288259;;10.1016/j.semcancer.2004.04.013;;10.4049/jimmunol.150.3.880;;8423344;;8360482;;10.4049/jimmunol.151.5.2623;;15781650;;10.1158/0008-5472.can-04-1890;;11072240;;10.1002/1097-0215(20001201)88:5<726::aid-ijc7>3.0.co;2-h;;10.1006/excr.2000.5034;;11035934;;16697642;;10.1016/j.tcb.2006.04.003;;10.1038/35102167;;11689955;;10.1038/nature05313;;17183323;;3127726;;10.1038/332323a0;;8898201;;10.1016/s0092-8674(00)81368-9;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;17822956;;10.1016/j.molmed.2007.07.002;;pmc1134670;;15330757;;10.1042/bj20041022;;10.1182/blood-2006-12-063933;;pmc1885521;;17311993;;10.1016/0378-1119(95)00821-7;;8647439;;18392005;;10.1038/nbt0408-366c;;pmc2119072;;10.1084/jem.175.1.217;;1346155;;12814948;;10.1111/j.1749-6632.2003.tb03219.x;;10.1073/pnas.95.11.6157;;pmc27609;;9600934;;17308088;;10.1158/0008-5472.can-06-3311;;10837024;;10.1101/gad.14.11.1313;;pmc316657;;17259972;;10.1038/nature05577;;10.1093/jnci/djp280;;pmc2758310;;19738166;;7688398;;10.4049/jimmunol.151.4.2296;;10631780;;10.1016/s0167-7799(99)01398-0;;10.1016/s1359-6349(10)71927-3;;25324140;;10.1158/1078-0432.ccr-14-1373;;10.1016/s1359-6349(10)71927-3;;7544153;;10.1002/(sici)1097-0215(20000601)86:5<652::aid-ijc8>3.3.co;2-m;;10797286;;10.1002/(sici)1097-0215(20000601)86:5<652::aid-ijc8>3.0.co;2-v;;10.1158/1538-7445.am2015-255;;388229;;10.1038/282039a0;;10.1016/j.exphem.2005.12.016;;16569589;;pmc2394258;;12865906;;10.1038/sj.bjc.6601107;;10.1016/0076-6879(86)21019-8;;3724461;;10.3892/ijo.17.6.1131;;11078798;;8747303;;10.1291/hypres.18.259;;8139658;;10.1038/368150a0;;0008139658;;10.1186/1471-5945-2-7;;pmc111189;;11978185;;15293563;;10.1532/ijh97.04065;;17457300;;10.1038/nrc2130;;14754405;;10.2174/1381612043453603;;pmc453097;;1834458;;10.1002/j.1460-2075.1991.tb04932.x;;1675655;;10.4049/jimmunol.147.1.60;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;9576833;;10.1006/dbio.1998.8863;;10.1016/j.molmed.2005.09.008;;16214417;;11107116;;10.1002/1096-911x(20001201)35:6<554::aid-mpo13>3.0.co;2-r;;10.1016/s1081-1206(10)62794-9;;9723555;;9630891;;10.1038/nbt0396-309;;10.1126/science.2451287;;2451287;;10.1007/978-1-61779-968-6_2;;22886243;;9166828;;10.1182/blood.v89.11.3919;;10.1016/s1054-3589(08)60931-x;;8504061;;10.1038/nm754;;12185362;;10.1126/science.1102160;;15472075;;12509463;;10.1128/mcb.23.2.655-664.2003;;pmc151540;;10.1182/blood-2005-03-1000;;16219802;;pmc1895896;;10.1016/j.febslet.2006.03.024;;16574107;;10.1016/s1359-6349(08)72532-1;;17934452;;10.1038/nbt1345;;10556035;;10.1006/jmbi.1999.3141;;10.1074/jbc.m505569200;;15994325;;10.1038/nature08751;;20147986;;10.1182/blood.v98.13.3793;;11739188;;10.4049/jimmunol.155.4.1994;;7636250;;10.1158/0008-5472.sabcs-09-5071;;10.1158/1538-7445.am2013-3725;;22952347;;10.1158/1078-0432.ccr-12-0736;;10.1158/1538-7445.am2014-207;;10.1158/1538-7445.am2012-3357;;10.1158/1538-7445.am2014-1898;;10.1093/oxfordjournals.jbchem.a002832;;11134954;;10.1073/pnas.92.14.6414;;pmc41528;;7604005;;10.1038/nrd984;;12509759;;10.1016/s0022-1759(00)00339-2;;11223065;;10.1093/protein/gzn047;;18790793;;pmc2759461;;10.1016/j.tibtech.2004.03.006;;10.1016/s0167-7799(04)00080-0;;15109810;;pmc1302257;;10.1016/s0006-3495(02)73929-5;;12202384;;21803743;;10.1158/0008-5472.can-11-1704;;10.1074/jbc.m500815200;;15757893;;10.1016/j.coi.2008.06.012;;18656541;;15680154;;10.1016/j.jim.2004.11.005;;10835110;;10.1093/protein/13.5.361,"Al-Hajj, M., et al., “Prospective Identification of Tumorigenic Breast Cancer Cells,” Proceedings of the National Academy of Sciences 100(7):3983-3988, The National Academy of Sciences, United States (2003).;;Allenspach, E.J., et al., “Notch Signaling in Cancer,” Cancer Biology Therapy 1(5):466-476, Informa UK Limited, United Kingdom (2002).;;Amado, R.G., et al., “Wild-Type KRAS is Required for Panitumumab Efficacy in Patients with Metastatic Colorectal Cancer,” Journal of Clinical Oncology 26(10):1626-1634, American Society of Clinical Oncology, United States (2008).;;Artavanis-Tsakonas, S., et al., “Notch Signaling: Cell Fate Control and Signal Integration in Development,” Science 284(5415):770-776, American Association for the Advancement of Science, United States (1999).;;Axelson, H., “Notch Signaling and Cancer: Emerging Complexity,” Seminars in Cancer Biology 14(5):317-319, Academic Press, England (2004).;;Barbas, C.F. 3rd., et al., “In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity,” Proceedings of the National Academy of Sciences 91(9):3809-3813, National Academy of Sciences, United States (1994).;;Beachy, P.A., et al., “Tissue Repair and Stem Cell Renewal in Carcinogenesis,” Nature 432(7015):324-331, Nature Publishing Group, England (2004).;;Bellavia, D., et al, “Constitutive Activation of NF-κB and T-cell Leukemia/lymphoma in Notch3 Transgenic Mice,” The EMBO Journal 19(13):3337-3348, European Molecular Biology Organization, Germany (2000).;;Benvenuti, S., et al., “Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies,” Cancer Research 67(6):2643-2648, American Association for Cancer Research, United States (2007).;;Besseyrias, V., et al., “Hierarchy of Notch-Delta interactions promoting T cell lineage commitment and maturation,” The Journal of Experimental Medicine 204(2)331-343, The Rockefeller University Press, United States (2007).;;Beviglia, L., et al., “Anti-DLL4 reduces tumor growth and tumorigenicity in B-RAF V600E melanomas including those with acquired resistance to B-RAF inhibitors,” AACR 103rd Annual Meeting, Mar. 31-Apr. 4, 2012, Abstract LB-196, 1 page (2012).;;Beviglia, L., et al., “Anti-DLL4 Treatment Inhibits Melanoma Tumor Growth, Recurrence, Metastases and Reduces Frequency of Cancer Stem Cells in a Clinically Relevant Tumor Model in NOD/SCID Mice,” Cancer Research 71(8 Suppl.):Abstract 2834, AACR 102nd Annual Meeting 2011, Apr. 2-6, 2011.;;Beviglia, L., et al., “In vivo evaluation of anti-tumor activity by an anti-VEGF and anti-DLL4 bispecific antibody in a humanized model of skin graft,” AACR 104th Annual Meeting 2013, Abstract 4330, Apr. 6-10, 1 page (2013).;;Bloom, J.W., et al., “Intrachain disulfide bond in the core hinge region of human IgG4,” Protein Science 6(2):407-415, John Wiley & Sons, Inc., United States (1997).;;Boerner, P., et al., “Production of Antigen-specific Human Monoclonal Antibodies from in Vitro-primed Human Splenocytes,” Journal of Immunology 147(1):86-95, The American Association of Immunologists, United States (1991).;;Bonnet, D. and Dick, J.E., “Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell,” Nature Medicine 3(7):730-737, Nature Publishing Company, United States (1997).;;Bray, S.J., “Notch signalling: a simple pathway becomes complex,” Nature Reviews Molecular Cell Biology 7(9):678-689, Nature Publishing Group, United States (2006).;;Brennan, K. and Brown, A.M., “Is there a Role for Notch Signalling in Human Breast Cancer?,” Breast Cancer Research 5(2):69-75, BioMed Central Ltd., United Kingdom (2003).;;Brennan, M., et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments,” Science 229(4708):81-83, American Association for the Advancement of Science, United States (1985).;;Brorson, K., et al., “Mutational Analysis of Avidity and Fine Specificity of Anti-Levan Antibodies,” Journal of Immunology 163(12):6694-6701, American Association of Immunologists, United States (1999).;;Brummell, D.A., et al., “Probing the Combining Site of an Anti-Carbohydrate Antibody by Saturation-Mutagenesis: Role of the Heavy-Chain CDR3 Residues,” Biochemistry 32(4):1180-1187, American Chemical Society, United States (1993).;;Burgess, W.H., et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,” The Journal of Cell Biology 111(5Pt1):2129-2138, The Rockefeller University Press, United States (1990).;;Burks, E.A., et al., “In vitro Scanning Saturation Mutagenesis of an Antibody Binding Pocket,” Proceedings of the National Academy of Sciences USA 94(2):412-417, National Academy of Sciences, United States (1997).;;Callahan, R. and Raafat, A., “Notch Signaling in Mammary Gland Tumorigenesi,” Journal of Mammary Gland Biology and Neoplasia 6(1):23-36, Kluwer Academic/Plenum Publishers, United States (2001).;;Carter, P., “Improving the efficacy of antibody-based cancer therapies,” Nature Reviews Cancer 1(2):118-129, Nature Publishing Group, United States (2001).;;Chartier, C., et al., “The Hippo Signaling Pathway Mediates BMP Inhibition of Cancer Stem Cells,” 2015 AACR Annual meeting, Apr. 18-22, Abstract 2322, 1 page (2015).;;Chau, I. and Cunningham, D., “Treatment in advanced colorectal cancer: what, when and how?,” British Journal of Cancer 100(11):1704-1719, Nature Publishing Group, United States (2009).;;Chen, C., et al., “Generation and Analysis of Random Point Mutations in an Antibody CDR2 Sequence: Many Mutated Antibodies Lose their Ability to Bind Antigen,” The Journal of Experimental Medicine 176(3):855-866, Rockefeller University Press, United States (1992).;;Chen, Y., et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen,” Journal of Molecular Biology 293(4):865-881, Academic Press, England (1999).;;Chi, A.S., et al., “Angiogenesis as a Therapeutic Target in Malignant Gliomas,” Oncologist 14(6):621-636, AlphaMed Press, United States (2009).;;Chothia, C. and Leek, A.M., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” Journal of Molecular Biology 196(4):901-917, Elsevier Science, United States (1987).;;Chothia, C., et al., “Domain association in immunoglobulin molecules. The packing of variable domains,” Journal of Molecular Biology 186(3):651-663, Elsevier Science, England (1985).;;Chowdhury, P.S. and Pastan, I., “Improving Antibody Affinity by Mimicking Somatic Hypermutation in vitro,” Nature Biotechnology 17(6):568-572, Nature Publishing Group, United States (1999).;;Clarke, M.F., et al., “Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells,” Cancer Research 66(19):9339-9344, American Association for Cancer Research, United States (2006).;;Claxton, S. and Fruttiger, M., “Periodic Delta-like 4 expression in developing retinal arteries,” Gene Expression Pattern 5:123-127, Elsevier B.V., Netherlands (2004).;;Cole, S.P.C., et al., “The EBV-Hybridoma Technique and Its Application to Human Lung Cancer,” Monoclonal Antibodies and Cancer Therapy, 77-96, Proceedings of the Roche-UCLA Symposium, United States (1985).;;Colman, P.M., “Effects of Amino Acid Sequence Changes on Antibody-antigen Interactions,” Research in Immunology 145(1):33-36, Elsevier, France (1994).;;Cubillo, A., et al, “A Ph1b Study of Demcizumab (DEM, anti-DLL4) with Gemcitabine (GEM) in Patients with 1st Line Locally Advanced or Metastatic Pancreatic Cancer,” AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 19-23, 2013, Poster (2013), 8 pages.;;Cubillo, A., et al., “A Phase Ib study of demcizumab (DEM, anti-DLL4) with gemcitabine (GEM) in patients with first line locally advanced or metastatic pancreatic cancer,” Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 19-23, 2013, Abstract B78, 2 pages (2013).;;Dalerba, P., et al., “Phenotypic characterization of human colorectal cancer stern cells,” Proceedings of the National Academy of Sciences 104(24):10158-10163, National Academy of Sciences, United States (2007).;;Dando, J.S., et al., “Notch/Delta4 interaction in human embryonic liver CD34+ CD38-cells: positive influence on BFU-E production and LTC-IC potential maintenance,” Stem Cells 23(4):550-560, John Wiley & Sons, Inc., United States (2005).;;Deisenhofer, J., “Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution,” Biochemistry 20(9):2361-2370, American Chemical Society, United States (1981).;;Deonarain, M.P., et al., “Antibodies Targeting Cancer Stem Cells: A New Paradigm in Immunotherapy?,” mAbs 1(1):12-25,Taylor & Francis, United States (2009).;;Dixit, R., “Cardiovascular Safety of Biologics: Challenges and Opportunities,” Medimmune, Safety Pharmacology Society, Annular Meeting Speakers Presentations (Oct. 3, 2012).;;Dontu, G., et al., “Role of Notch Signaling in Cell-Fate Determination of Human Mammary Stem/progenitor Cells,” Breast Cancer Research 6(6):R605-R615, BioMed Central, England (2004).;;Dorsch, M., et al., “Ectopic expression of Delta4 impairs hematopoietic development and leads to lymphoproliferative disease,” Blood 100(6):2046-2055, American Society of Hematology, United States (2002).;;Dreher, M.L., et al., “Colony assays for antibody fragments expressed in bacteria,” Journal of Immunological Methods 139(2):197-205, Elsevier Science, United States (1991).;;Duarte, A., et al., “Dosage-sensitive requirement for mouse Dll4 in artery development,” Genes & Development 18(20):2474-2478, Cold Spring Harbor Laboratory Press, United States (2004).;;Dupont, J. “Anti-Angiogenic Agents and Cardiovascular Effects: Implications for Clinical Development in Cancer,” presentation given in Barcelona, Spain on Nov. 4, 2011, 16 pages.;;Dupont, J., et al., “A Phase 1b Study of Anti-DLL4 (Delta-Like Ligand 4) Antibody Demcizumab (DEM) with Pemetrexed (PEM) and Carboplatin (CARBO) in Patients with 1st-Line Non-Squamous NSCLC,” 2015 European Lung Cancer Conference (ELCC), Geneva, Switzerland, Apr. 15-18, Abstract 114, 2 pages (2015).;;Ellisen, L.W., et al., “TAN-1, the Human Homolog of the Drosophila Notch Gene, Is Broken by Chromosomal Translocations in T Lymphoblastic Neoplasms,” Cell 66(4):649-661, Elsevier Science, United States (1991).;;Engin,F., et al., “Dimorphic effects of Notch signaling in bone homeostasis,” Nature Medicine 14(3):299-305, Nature Publishing Group, United States (2008).;;English language translation of Oishi, H., et al., “Novel therapeutic strategy for pancreatic cancer targeting Notch signaling pathway,” Proceedings of the Japanese Cancer Association 65:311-312, Japan (2006).;;English language translation of “Tumor-angiogenesis suppression therapy targeting the Notch signaling pathway,” Suizo (Pancreas) 21(3):249, Japan (2006).;;Eppstein, D.A., et al., “Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor,” Proceedings of the National Academy of Sciences 82(11):3688-3692, National Academy of Sciences, United States (1985).;;European Search Report for EP Application No. EP10824244.7, Munich, Germany, dated Feb. 18, 2013, 6 pages.;;Farnie, G. and Clarke, R.B., “Mammary stem cells and breast cancer—role of Notch signalling,” Stem Cell Reviews and Reports 3(2):169-175, Humana Press, United States (2007).;;Farnie, G., et al., “Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways,” Journal of the National Cancer Institute 99(8):616-627, Oxford University Press, United Kingdom (2007).;;Fischer, M., et al., “Anti-DLL4 Inhibits Growth and Reduces Tumor-Initiating Cell Frequency in Colorectal Tumors with Oncogenic KRAS Mutations,” Cancer Research 71(5):1520-1525, American Association for Cancer Research, United States (2011).;;Fleming, R.J., et al., “The NOTCH receptor and its ligands,” Trends in Cell Biology 7(11):437-441, Elsevier Science Ltd., The Netherlands (1997).;;Fre, S., et al., “Notch Signals Control the Fate of Immature Progenitor Cells in the Intestine,” Nature 435(7044):964-968, Nature Publishing Group, United States (2005).;;Fung, E., et al., “Delta-like 4 induces notch signaling in macrophages: implications for inflammation,” Circulation 115(23):2948-2956, American Heart Association, Inc., United States (2007).;;Gagnon, M.L., et al., “Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: in vivo expression and antitumor activity,” Proceedings of the National Academy of Sciences 97(6):2573-2578, National Academy of Sciences, United States (2000).;;Gale, N.W., et al., “Haploinsufficiency of Delta-like 4 Ligand Results in Embryonic Lethality due to Major Defects in arterial and Vascular Development,” Proceedings of the National Academy of Sciences 101(45):15949-15954, National Academy of Sciences, United States (2004).;;Gallahan, D., et al., “A new common integration region (int-3) for mouse mammary tumor virus on mouse chromosome 17,” Journal of Virology 61(1):218-220, American Society for Microbiology, United States (1987).;;Gallahan, D., et al., “Expression of a TruncatedInt3Gene in Developing Secretory Mammary Epithelium Specifically Retards Lobular Differentiation Resulting in Turnorigenesis.” Cancer Research 56(8):1775-1785, American Association for Cancer Research, United States (1996).;;Garber, K., “Notch emerges as new cancer drug target,” Journal of the National Cancer Institute 99(17):1284-1285, Oxford University Press, United States (2007).;;Gracian, A.C., et al., “A phase 1b study of the anticancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) with or without paclitaxel protein bound particles (nab-paclitaxel) in patients with pancreatic cancer,” 2014 Gastrointestinal Cancers Symposium, Abstract 279, 2 pages (2014).;;Gray-Schopfer, V.C., et al., “The Role of B-RAF in Melanoma,” Cancer Metastasis Reviews 24(1):165-183, Springer Science + Business Media, Inc., Netherlands (2005).;;Gridley, T., “Notch Signaling During Vascular Development,” Proceedings of the National Academy of Sciences 98(10):5377-5378, National Academy of Sciences, United States (2001).;;Gridley, T. “Notch signaling in vascular development and physiology,” Development 134(15):2709-2718, (2007).;;Gronberg, B.H., et al., “Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared with Gemcitabine Plus Carboplatin as First-line Chemotherapy in Advanced Non-small-cell Lung Cancer,” Journal of Clinical Oncology 27(19):3217-3224, American Society of Clinical Oncology, United States (2009).;;Gruber, M., et al., “Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed inEscherichia coli,” The Journal of Immunology 152(11):5368-5374, The American Association of Immunologists, Inc., United States (1994).;;Gurney, A. and Hoey, T., “Anti-DLL4, a Cancer Therapeutic with Multiple Mechanisms of Action,” Vascular Cell 3, 4 pages, BioMed Central, United States (2011).;;Hainaud, P., et al., “The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions,” Cancer Research 66(17):8501-8510, American Association for Cancer Research, United States (2006).;;Hallahan, A.R., et al., “The SmoA1 Mouse Mod& Reveals that Notch Signaling is Critical for the Growth and Survival of Sonic Hedgehog-Induced Medulloblastomas,” Cancer Research 64(21):7794-7800, American Association for Cancer Research, United States (2004).;;Han, W., et al., “A soluble form of human Delta-like-1 inhibits differentiation of hematopoietic progenitor cells,” Blood 95(5):1616-1625, The American Society of Hematology, United States (2000).;;Harlow, E. and Lane, D., eds., “immunoassays,” in Antibodies: A Laboratory Manual, 14:553-612, Cold Spring Harbor Laboratory, United States (1988).;;Harper, J.A., et al., “Notch Signaling in Development and Disease,” Clinical Genetics 64(6):461-472, Blackwell Publishing, United States (2003).;;Harrington, L.S., et al., “Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells,” Microvascular Research 75(2):144-154, Elsevier Science, United States (2008).;;Harris, W.J., “Production of Humanized Monoclonal Antibodies for in vivo Imaging and Therapy,” Biochemical Society Transactions 23(4):1035-1038, Portland Press on the Behalf of the Biochemical Society, England (1995).;;Hawkins, R.E., et al., “Selection of phage antibodies by binding affinity. Mimicking affinity maturation,” Journal of Molecular Biology 226(3):889-896, Elsevier Science, United States (1992).;;Hellström, M., et al., “Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis.” Nature 445(7129):776-780, Nature Publishing Group, United States (2007).;;Henning, K., et al., “mNotch1 signaling and erythropoietin cooperate in erythroid differentiation of multipotent progenitor cells and upregulate beta-globin,” Experimental Hematology 35(9):1321-1332, Elsevier Science, United States (2007).;;Hermentin, P. and Seiler, F.R., “Investigations with Monoclonal Antibody Drug (Anthracycline) Conjugates,” Behring Institute Research Communications 82:197-215, Behringwerke Ag, Germany (1988).;;Hidalgo, M., et al., “A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxvel in Patients with Pancreatic Cancer,” European Society for Medical Oncology 2014 Congress, Sep. 17 and Sep. 28, Poster 616PD, 1 page (2014).;;Hidalgo, M., et al., “A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, Anti-DLL4) and Gemcitabine (GEM) with or without Paclitaxel Protein Bound Particles (Nab-Paclitaxel) in pts with Pancreatic Cancer,” 2015 ASCO Annual Meeting, Abstract 4118, 3 pages (2015).;;Hidalgo, M., et al., “Pre-Clinical and Clinical Activity of Anti-DLL4 (Demcizumab) in Combination with Gemcitabine Pius nab-Paclitaxel in Pancreatic Cancer,” 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Preclinical Models Poster Session, Abstract 166, 2 pages (Nov. 2014).;;Hoey, T., et al., “DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency,” Cell Stem Cell 5(2)168-177, Elsevier Science, United States (2009).;;Hofmann, J.J. and Iruela-Arispe, M.L., “Notch signaling in blood vessels: who is talking to whom about what?,” Circulation Research 100(11):1556-1568, American Heart Association, Inc., United States (2007).;;Holash, J., et al., “Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents,” Cancer Metastasis Rev 25:243-252, Dordrecht, Netherlands (2006).;;Holash, J., et al., “VEGF-Trap: A VEGF Blocker with Potent Antitumor Effects,” Proceedings of the National Academy of Sciences USA 99(17):11393-11398, National Academy of Sciences, United States (2002).;;Holm, P., et al., “Functional Mapping and Single Chain Construction of the Anti-Cytokeratin 8 Monoclonal Antibody TS1,” Molecular Immunology 44(6):1075-1084, Pergamon Press, England (2007).;;Hoogenboom, H.R. and Winter, G., “By-Passing Immunisation. Human Antibodies from Synthetic Repertoires of Germline VH Gene Segments Rearranged in vitro,” Journal of Molecular Biology 227(2):381-388, Elsevier, England (1992).;;Hope, K.J., et al., “Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in selfrenewal capacity,” Nature Immunology 5(7):738-743, Nature Publishing Group,United States (2004).;;Hopfer, O.,et al., “The Notch Pathway in Ovarian Carcinomas and Adenomas,” British Journal of Cancer 93(6):709-718, Nature Publishing Group on behalf of Cancer Research UK, England (2005).;;Humphreys, D.P., et al., “Formation of dimeric Fabs in Escherichia coli: effect of hinge size and isotype, presence of interchain disulphide bond, Fab′ expression levels, tail piece sequences and growth conditions,” Journal of Immunological Methods 209(2):193-202, Elsevier Science, Netherlands (1997).;;Hurle, M.R. and Gross, M., “Protein engineering techniques for antibody humanization,” Current Opinion in Biotechnology 5(4):428-433, (1994).;;Hurwitz, H.I., et al., “Phase I Trial of Pazopanib in Patients with Advanced Cancer,” Clinical Cancer Research 5(12):4220-4227, American Association for Cancer Research, United States (2009).;;Hwang, K.J., et al., “Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study,” Proceedings of the National Academy of Sciences 77(7):4030-4034, National Academy of Sciences, United States (1980).;;International Preliminary Report on Patentability and Written Opinion for International Application No. PCT/US2010/53064, International Searching Authority, dated Feb. 14, 2011, 7 pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2013/065015, The International Bureau of WIPO, Switzerland, dated Apr. 22, 2014, 17 pages.;;International Search Report for International Application No. PCT/US16/53316, ISA/US, Alexandria, Virginia, dated Feb. 21, 2017, 7 pages.;;International Search Report for International Application No. PCT/US2010/53064, dated Feb. 14, 2011, 3 pages.;;International Search Report for International Application No. PCT/US2015/024251, ISA/US, Alexandria, Virginia, United States, dated Jul. 16, 2015, 4 pages.;;International Search Report for International Patent Application No. PCT/US11/60773, International Searching Authority, Alexandria, Virginia, United States, dated Mar. 26, 2012, 3 pages.;;International Search Report for International Patent Application No. PCT/US2007/020889, United States Patent and Trademark Office, United States, dated Apr. 9, 2008, 5 pages.;;International Search Report with the Written Opinion of the International Searching Authority for International application No. PCT/US10/32625, United States Patent and Trademark Office, United States, dated Dec. 17, 2010, 11 pages.;;International Search Report with the Written Opinion of the International Searching Authority for International application No. PCT/US12/56886, United States Patent and Trademark Office, United States, dated Feb. 28, 2013, 8 pages.;;International Search Report with the Written Opinion of the International Searching Authority for International application No. PCT/US15/58327, United States Patent and Trademark Office, United States, dated May 19, 2016, 12 pages.;;International Search Report with Written Opinion for International Application No. PCT/US2010/58511, International Searching Authority, United States, dated Mar. 3, 2011, 9 pages.;;Ishiko, E., et al., “Notch signals inhibit the development of erythroid/megakaryocytic cells by suppressing GATA-1 activity through the induction of HES1,” The Journal of Biological Chemistry 280(6):4929-4939, American Society for Biochemistry and Molecular Biology, United States (2005).;;Iso, T., et al., “Notch Signaling in Vascular Development,” Arteriosclerosis, Thrombosis, and Vascular Biology 23(4):543-553, American Heart Association, Inc., United States (2003).;;Izzedine, H., et al., “Management of Hypertension in Angiogenesis Inhibitor-Treated Patients,” Annals of Oncology 20(5):807-815, Oxford University Press, England (2009).;;Jackson, Jr., et al., “In vitro antibody maturation. improvement of a high affinity, neutralizing antibody against IL-1 beta,” The Journal of Immunology 154(7):3310-3319, The American Association of lmmunologists, Inc., United States (1995).;;Janda, C.Y., “Structural Basis of Wnt Recognition by Frizzled,” Science 337(6090):59-64, American Association for the Advancement of Science, United States (2012).;;Janeway, Jr., et al., “Immunobiology, the immune System in Health and Disease,” Edition 4:579-581, Current Biology Publications (1999).;;Jang, Y.J., et al., “The Structural Basis for DNA Binding by an Anti-DNA Autoantibody,” Molecular Immunology 35(18):1207-1217, Pergamon Press, England (1998).;;Jarriault, S., et al., “Signalling Downstream of Activated Mammalian Notch,” Nature 377(6547):355-358, Nature Publishing Group, United States (1995).;;Jeffries, S. and Capobianco, A.J., “Neoplastic transformation by Notch requires nuclear localization,” Molecular and Cellular Biology 20(11):3928-3941, American Society for Microbiology, United States (2000).;;Jhappan, C., et al., “Expression of an Activated Notch-Related int-3 Transgene Interferes with Cell Differentiation and Induces Neoplastic Transformation in Mammary and Salivary Glands,” Genes & Development 6(3):345-355, Cold Spring Harbor Laboratory Press, United States (1992).;;Jimeno, A., et al., “Phase 1 study of REGN421 (R)/SAR153192, a fully-hurnan delta-like ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumors,” ASCO University 2013 ASCO Annual Meeting accessed at http://meetinglibrary.asco.org/content/113836-132, 2 pages.;;Jones, P.T., et al., “Replacing the Complementarity-Determining Regions in a Human Antibody with those from a Mouse,” Nature 321(6069):522-525, Nature Publishing Group, England (1986).;;Kim, E.S., et al., “Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma,” Proceedings of the National Academy of Sciences 99(17):11399-11404, National Academy of Sciences, United States (2002).;;Kingsman, A.J., et al., “Replication in Saccharomyces cerevisiae of Plasmid pBR313 Carrying DNA from the Yeast Trpl Region,” Gene 7(2):141-152, Elsevier/North-Holland Biomedical Press, Netherlands (1979).;;Kobayashi, H., et al., “Tryptophan H33 Plays an important Role in Pyrimidine (6-4) Pyrimidone Photoproduct Binding by a High-Affinity Antibody,” Protein Engineering Design and Selection 12(10):879-884, Oxford University Press, United States (1999).;;Kopper, L. and Hajdu, M., “Tumor Stem Cells,” Pathology and Oncology Research 10(2):69-73, Aranyl Lajos Foundation, Hungary (2004).;;Kostelny, S.A., et al., “Formation of a Bispecific Antibody by the Use of Leucine Zippers,” The Journal of Immunology 148(5):1547-1553, American Association of Immunologists, United States (1992).;;Krebs, L.T., et al., “Haploinsufficient Lethality and Formation of Arteriovenous Malformations in Notch Pathway Mutants,” Genes & Development 18(20):2469-2473, Cold Spring Harbor Laboratory Press, United States (2004).;;Krebs, L.T., et al., “Notch Signaling is Essential for Vascular Morphogenesis in Mice,” Genes & Development 14(11):1343-1352, Cold Spring Harbor Laboratory Press, United States (2000).;;Kuo, C.J., et al., “Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer,” Proceedings of the National Academy of Sciences 98(8):4605-4610, National Academy of Sciences, United States (2001).;;Lapidot, T., et al., “A Cell Initiating Human Acute Myeloid Leukaemia After Transplantation Into SCID Mice,” Nature 367(6464):645-648, Nature Publishing Group, United States (1994).;;Lauret, E., et al., “Membrane-Bound Delta-4 Notch Ligand Reduces the Proliferative Activity of Primitive Human Hematopoietic, CD34+CD38low Cells while Maintaining their LTC-IC Potential,” Leukemia 18(4):788-797, Nature Publishing Group, United States (2006).;;Lazar, E., et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,” Molecular and Cellular Biology 8(3):1247-1252, American Society for Microbiology, United States (1988).;;Lee, H.S., et al., “Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions,” Molecular Immunology 36(1):61-71, Elsevier Science Ltd., Netherlands (1999).;;Leethanakul, C., et al., “Distinct Pattern of Expression of Differentiation and Growth-Related Genes in Squamous Cell Carcinomas of the Head and Neck Revealed by the Use of Laser Capture Microdissection and cDNA Arrays,” Oncogene 19(28):3220-3224, Nature Publishing Group, United States (2000).;;Lenihan, D.J., “How is cardiac toxicity defined and what impact does this have on cancer outcome or drug development,” PowerPoint Presentation from the DIA Meeting, 42 slides (2011).;;Leong, K.G. and Karsan, A., “Recent Insights into the Role of Notch Signaling in Tumorigenesis,” Blood 107(6):2223-2233, The American Society of Hematology, United States (2006).;;Li, J.L. and Harris A.L., “Notch Signaling from Tumor Cells: A New Mechanism of Angiogenesis,” Cancer Cell 8(1):pp. 1-3, Cell Press, United States (2005).;;Li, X., et al., “Notch3 Signaling is Required for the Development of Pulmonary Arterial Hypertension,” Nature Medicine 15(11)1289-1297, Nature Publishing Company, United States (2009).;;Lievre, A., et al., “KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer,” Cancer Research 66(8):3992-3995, American Association for Cancer Research, United States (2006).;;Limbourg, A., et al., “Notch ligand Delta-like 1 is essential for postnatal arteriogenesis,” Circulation Research 100(3):363-371, American Heart Association, Inc., United States (2007).;;Liu, S., et al., “Mammary stem cells, self-renewal pathways, and carcinogenesis,” Breast Cancer Research 7(3):86-95, BioMed Central, England (2005).;;Liu, Z.J., et al., “Inhibition of endothelial cell proliferation by Notch 1 signaling is mediated by reprocessing MAPK and P14K/Akt pathways and requires MAML1,” Federation of American Societies for Experimental Biology 20:E201-E210, American Society for Experimental Biology, United States (2006).;;Liu, Z.J., et al., “Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis,” Molecular and Cellular Biology 23(1):14-25, American Society for Microbiology, United States (2003).;;Lobov, I.B., et al., “Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting,” Proceedings of the National Academy of Sciences 104(9):3219-3224, National Academy of Sciences, United States (2007).;;Lu, K.V., and Bergers G., “Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma,” CNS Oncology 2(1):49-65, Future Medicine, Inc., United States (2013).;;Luca, V.C., et al., “Structural basis for Notch1 engagement of Delta-like 4,” Science, 347(6224):847-853, American Association for the Advancement of Science, United States (2015).;;MacCallum, R.M., et al., “Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography,” Journal of Molecular Biology 262(5):732-745, Elsevier, England (1996).;;Maeda, H., et al., “Construction of Reshaped Human Antibodies with HIV-Neutralizing Activity,” Human Antibodies and Hybridomas 2(3):124-134, Butterworth-Heinemann, United Kingdom (1991).;;Mailhos, C., et al., “Delta4, an Endothelial Specific Notch Ligand Expressed at Sites of Physiological and Tumor Angiogenesis,” Differentiation 69:135-144, Elsevier, England (2001).;;Marks, J.D., et al., “By-Passing immunization: Building High Affinity Human Antibodies by Chain Shuffling,” Biotechnology 10(7):779-783, Nature Publishing Company, United States (1992).;;Marks, J.D., et al., “By-passing immunization. Human Antibodies from V-Gene Libraries Displayed on Phage,” Journal of Molecular Biology 222(3):581-597, Academic Press Limited, United States (1991).;;Mazella, J., et al., “Expression of Delta-like protein 4 in the human endometrium,” Endocrinology 149(1):15-19, Association for the Study of Internal Secretions, United States (2008). et al.",ACTIVE
34,BR,B1,BR 112014007035 B1,081-029-670-997-944,2021-05-04,2021,BR 112014007035 A,2012-09-24,US 2012/0056886 W;;US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,"anticorpos biespecíficos que se ligam a vegf/dll4, composição farmacêutica e célula procariótica, fúngica ou de levedura que compreende os mesmos, moléculas de polinucleotídeo, vetor, usos terapêuticos e método para a produção de um anticorpo","agentes de ligação a vegf/dll4 e usos dos mesmos. a presente invenção refere-se a agentes de ligação ao vegf, agentes de ligação ao dll4, agentes de ligação biespecíficos a vegfidll4 e métodos de utilização dos agentes para o tratamento de doenças tal como câncer. a presente invenção fornece anticorpos que se ligam especificamente ao vegf humano, anticorpos que se ligam especificamente ao dll4 humano e anticorpos biespecíficos que se ligam especificamente ao vegf humano e/ou ao dll4 humano. a presente invenção fornece ainda métodos de utilização dos agentes para inibir o crescimento de tumor. são também descritos métodos de tratamento de câncer que compreendem a administração de uma quantidade terapeuticamente eficiente de um agente ou um anticorpo da presente invenção a um paciente que possui um tumor ou um câncer.",ONCOMED PHARM INC,AARON KEN SATO;;AUSTIN L GURNEY;;CHRISTOPHER JOHN BOND,,https://lens.org/081-029-670-997-944,Granted Patent,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,C07K16/00;;A61K39/00;;C12P21/08,,0,0,,,,ACTIVE
35,US,A1,US 2018/0305449 A1,104-766-543-620-178,2018-10-25,2018,US 201715847335 A,2017-12-19,US 201715847335 A;;US 201715401543 A;;US 201615163301 A;;US 201414476582 A;;US 201213625417 A;;US 201261692978 P;;US 201261597409 P;;US 201161538454 P,2011-09-23,VEGF/DLL4 Binding Agents and Uses Thereof,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,MEREO BIOPHARMA 5 INC (2012-12-11),https://lens.org/104-766-543-620-178,Patent Application,yes,0,0,76,82,80,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,C07K16/28;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K45/00;;A61K45/06;;C07K16/18;;C07K16/22;;C07K16/30,,2,2,014-113-432-888-031;;045-942-104-775-903,12218124;;10.4049/jimmunol.169.6.3076;;12850000;;10.1016/s0006-291x(03)01131-8,De Pascalis et al. (2002). J. Immunol. 169:3076-3084.;;Casset et al. (2003). Biochem. and Biophys. Res. Comm. 307:198-205.,ACTIVE
36,CL,A1,CL 2014000725 A1,156-739-526-824-454,2014-09-05,2014,CL 2014000725 A,2014-03-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,Anticuerpo biespecifico que se liga especificamente a vegf humano y dll4 humano; anticuerpo que se liga especificamente a vegf humano; anticuerpo que se liga especificamente a dll4 humano; molecula de polinucleotido que lo codifica; vector; celula; metodo de produccion; composicion farmaceutica que los comprende; y sus usos para tratar cancer.,,ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/156-739-526-824-454,Patent Application,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,C07K16/22;;A61K39/395;;A61P35/00;;C07K16/28;;C12N15/13,,0,0,,,,PENDING
37,AU,B2,AU 2015/268749 B2,164-006-220-396-583,2017-05-25,2017,AU 2015/268749 A,2015-12-16,AU 2015/268749 A;;AU 2013/201095 A;;US 201261692978 P;;US 201161538454 P;;US 201261597409 P;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 binding agents and uses thereof,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGiF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/164-006-220-396-583,Granted Patent,no,2,0,4,82,0,,C07K16/00;;A61K39/00;;C12P21/08,,0,0,,,,ACTIVE
38,US,A1,US 2015/0238685 A1,181-244-663-400-06X,2015-08-27,2015,US 201314429592 A,2013-09-18,US 201314429592 A;;US 201261703191 P;;US 201361874741 P;;US 2013/0060404 W,2012-09-19,Method and System for Enhanced Imaging Visualization of Deep Brain Anatomy Using Infusion,"Provided is a method and system for delivering a diagnostic agent to a site in the brain of a subject for imaging at least a portion of the brain site on a medical imaging system. The method and system includes a catheter device with associated lumens having diagnostic agent ports for delivering the diagnostic agent (e.g., infusate) through the lumens and advancing the diagnostic agent so as to exit out from the lumens to at least a portion of the brain site and while sealing a portion of the brain site thereby preventing the exited diagnostic agent from travelling proximally beyond the sealing location, and at the same time imaging at least a portion of the brain site during at least a portion of the sealing duration so that the brain site can be visualized on a medical imaging system. The diagnostic agent (infusate) is able to highlight borders and internal patterns of the deep structures of the brain thereby enabling direct targeting. Ultimately this leads to reduced complications, enhanced therapy, and the elimination of the need for awake surgery. The method and system provides the capability heretofore not possible to visualize the small, often indistinct regions, which will greatly improve clinical outcomes with therapeutic interventions.",ELIAS WILLIAM J;;BOND AARON E;;GILLIES GEORGE T;;UNIV VIRGINIA PATENT FOUND,ELIAS WILLIAM J;;BOND AARON E;;GILLIES GEORGE T,UNIVERSITY OF VIRGINIA PATENT FOUNDATION (2013-12-03);;UNIVERSITY OF VIRGINIA (2013-10-13),https://lens.org/181-244-663-400-06X,Patent Application,yes,4,20,5,5,0,A61M25/10;;A61B5/0042;;A61B5/055;;A61M25/007;;A61M25/0127;;A61M25/1002;;A61M31/005;;A61M2025/0042;;A61M2025/105;;A61M2025/1052;;A61M2025/1093;;G01R33/285;;A61B6/032;;A61B6/12;;A61B6/481;;A61B6/501;;A61M25/10;;A61B5/0042;;A61B5/055;;A61M25/007;;A61M25/0127;;A61M25/1002;;A61M31/005;;A61M2025/0042;;A61M2025/105;;A61M2025/1052;;A61M2025/1093;;G01R33/285;;A61B6/032;;A61B6/12;;A61B6/481;;A61B6/501;;A61M5/007;;A61M25/0026;;A61M2025/0037;;A61N1/36139,A61B5/055;;A61M5/00;;A61M25/00;;A61M25/10;;A61N1/36,,0,0,,,,ACTIVE
39,US,A1,US 2019/0070356 A1,196-898-582-529-352,2019-03-07,2019,US 201816181498 A,2018-11-06,US 201816181498 A;;US 2013/0060404 W;;US 201361874741 P;;US 201261703191 P,2012-09-19,Method and System for Enhanced Imaging Visualization of Deep Brain Anatomy Using Infusion,"Provided is a method and system for delivering a diagnostic agent to a site in the brain of a subject for imaging at least a portion of the brain site on a medical imaging system. The method and system includes a catheter device with associated lumens having diagnostic agent ports for delivering the diagnostic agent (e.g., infusate) through the lumens and advancing the diagnostic agent so as to exit out from the lumens to at least a portion of the brain site and while sealing a portion of the brain site thereby preventing the exited diagnostic agent from travelling proximally beyond the sealing location, and at the same time imaging at least a portion of the brain site during at least a portion of the sealing duration so that the brain site can be visualized on a medical imaging system. The diagnostic agent (infusate) is able to highlight borders and internal patterns of the deep structures of the brain thereby enabling direct targeting. Ultimately this leads to reduced complications, enhanced therapy, and the elimination of the need for awake surgery. The method and system provides the capability heretofore not possible to visualize the small, often indistinct regions, which will greatly improve clinical outcomes with therapeutic interventions.",UNIV VIRGINIA PATENT FOUNDATION,ELIAS WILLIAM J;;BOND AARON E;;GILLIES GEORGE T,UNIVERSITY OF VIRGINIA PATENT FOUNDATION (2013-12-03);;UNIVERSITY OF VIRGINIA (2013-10-13),https://lens.org/196-898-582-529-352,Patent Application,yes,0,4,5,5,0,A61M25/10;;A61B5/0042;;A61B5/055;;A61M25/007;;A61M25/0127;;A61M25/1002;;A61M31/005;;A61M2025/0042;;A61M2025/105;;A61M2025/1052;;A61M2025/1093;;G01R33/285;;A61B6/032;;A61B6/12;;A61B6/481;;A61B6/501;;A61M25/10;;A61B5/0042;;A61B5/055;;A61M25/007;;A61M25/0127;;A61M25/1002;;A61M31/005;;A61M2025/0042;;A61M2025/105;;A61M2025/1052;;A61M2025/1093;;G01R33/285;;A61B6/032;;A61B6/12;;A61B6/481;;A61B6/501;;A61M5/007;;A61M25/0026;;A61M2025/0037;;A61N1/36139,A61M5/00;;A61B5/00;;A61B5/055;;A61B6/00;;A61B6/03;;A61B6/12;;A61M25/00;;A61M25/01;;A61M25/10;;A61M31/00;;A61N1/36;;G01R33/28,,0,0,,,,ACTIVE
40,EA,B1,EA 029958 B1,066-072-226-488-49X,2018-06-29,2018,EA 201490622 A,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;US 2012/0056886 W,2011-09-23,ANTIBODIES THAT BIND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)/DELTA-LIKE 4 LIGAND (DLL4) AND USE THEREOF,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using said agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/066-072-226-488-49X,Granted Patent,no,6,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;C07K16/00;;C12P21/08,,0,0,,,,ACTIVE
41,US,B2,US 9574009 B2,085-684-728-280-53X,2017-02-21,2017,US 201615163301 A,2016-05-24,US 201615163301 A;;US 201414476582 A;;US 201213625417 A;;US 201261692978 P;;US 201261597409 P;;US 201161538454 P,2011-09-23,Polynucleotides encoding VEGF/DLL4 binding agents,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,MEREO BIOPHARMA 5 INC (2012-12-11),https://lens.org/085-684-728-280-53X,Granted Patent,yes,99,8,76,82,80,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,C12N5/10;;A61K39/00;;C07K16/22;;C07K16/24;;C07K16/30,,99,87,084-085-138-348-898;;006-049-213-810-548;;042-535-804-056-355;;164-216-761-918-204;;070-614-370-694-544;;016-251-721-517-200;;021-197-916-777-658;;013-783-671-147-94X;;115-778-640-766-918;;020-327-681-254-735;;000-913-948-188-914;;015-807-813-009-849;;126-923-418-365-467;;043-293-799-149-190;;003-984-734-905-938;;037-480-189-672-490;;018-597-551-636-944;;059-703-624-598-226;;005-112-559-456-657;;053-851-713-620-401;;006-553-734-546-212;;003-849-961-384-35X;;105-316-874-895-908;;031-901-495-166-515;;061-397-752-245-555;;004-522-738-863-341;;001-779-867-387-972;;032-443-032-575-719;;049-134-753-209-354;;061-518-684-585-221;;099-532-412-433-785;;078-200-031-570-847;;100-371-416-663-157;;029-611-134-469-353;;027-845-339-272-06X;;133-610-790-984-99X;;016-270-419-085-156;;079-109-121-457-433;;025-070-183-573-259;;015-506-336-131-104;;037-809-048-883-498;;048-319-205-023-297;;007-837-250-546-989;;027-519-986-651-310;;018-320-647-455-556;;056-188-962-943-86X;;101-575-504-070-651;;073-702-812-203-896;;091-232-484-240-784;;138-876-315-756-795;;054-283-410-011-338;;060-684-120-299-26X;;112-241-917-646-013;;009-062-652-854-847;;090-306-007-122-585;;095-500-970-877-346;;027-306-913-195-466;;068-271-687-772-412;;129-005-046-068-395;;106-254-156-307-214;;032-048-398-057-385;;002-209-250-502-039;;003-711-275-433-72X;;035-232-534-898-963;;149-834-701-635-194;;035-067-471-486-809;;038-442-198-715-21X;;110-500-797-458-579;;072-351-640-594-174;;068-352-608-171-550;;065-608-090-342-50X;;005-119-615-003-591;;067-111-531-425-423;;065-542-021-501-547;;061-958-083-948-364;;164-451-236-197-939;;042-041-573-268-106;;016-512-212-388-570;;087-726-883-167-698;;008-498-336-394-659;;031-100-076-670-370;;032-071-991-081-664;;087-191-128-287-209;;089-486-878-211-546;;075-221-017-149-582;;077-495-150-106-187;;092-634-627-505-478,10.1073/pnas.0530291100;;pmc153034;;12629218;;12496471;;10.4161/cbt.1.5.159;;10.1200/jco.2007.14.7116;;18316791;;10.1126/science.284.5415.770;;10221902;;15288256;;10.1016/j.semcancer.2004.04.010;;10.1073/pnas.91.9.3809;;pmc43671;;8170992;;15549094;;10.1038/nature03100;;10880446;;pmc313949;;10.1093/emboj/19.13.3337;;17363584;;10.1158/0008-5472.can-06-4158;;pmc2118717;;10.1084/jem.20061442;;17261636;;10.1158/1538-7445.am2012-lb-196;;10.1158/1538-7445.am2011-2834;;10.1158/1538-7445.am2013-4330;;9041643;;pmc2143633;;10.1002/pro.5560060217;;10.4049/jimmunol.147.1.86;;2051030;;9212098;;10.1038/nm0797-730;;10.1038/nrm2009;;16921404;;pmc154142;;10.1186/bcr559;;12631384;;10.1126/science.3925553;;3925553;;10586066;;10.4049/jimmunol.163.12.6694;;8424945;;10.1021/bi00055a024;;1699952;;pmc2116333;;10.1083/jcb.111.5.2129;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;10.1023/a:1009512414430;;11467450;;11905803;;10.1038/35101072;;19436303;;10.1038/sj.bjc.6605061;;pmc2695695;;10.1006/jmbi.1999.3192;;10543973;;pmc4790121;;19487335;;10.1634/theoncologist.2008-0272;;10.1016/0022-2836(87)90412-8;;3681981;;10.1016/0022-2836(85)90137-8;;4093982;;10385321;;10.1038/9872;;10.1158/0008-5472.can-06-3126;;16990346;;10.1016/j.modgep.2004.05.004;;15533827;;7516563;;10.1016/s0923-2494(94)80039-1;;10.1158/1535-7163.targ-13-b78;;10.1073/pnas.0703478104;;pmc1891215;;17548814;;15790776;;10.1634/stemcells.2004-0205;;10.2210/pdb1fc1/pdb;;7236608;;10.2210/pdb1fc2/pdb;;10.1021/bi00512a001;;20046569;;pmc2715180;;10.4161/mabs.1.1.7347;;pmc1064073;;10.1186/bcr920;;15535842;;10.1182/blood.v100.6.2046.h81802002046_2046_2055;;12200365;;2045660;;10.1016/0022-1759(91)90189-m;;15466159;;pmc529534;;10.1101/gad.1239004;;10.1093/annonc/mdv050.18;;1831692;;10.1016/0092-8674(91)90111-b;;pmc2671578;;10.1038/nm1712;;18297084;;pmc397852;;10.1073/pnas.82.11.3688;;3159018;;10.1007/s12015-007-0023-5;;17873349;;17440163;;10.1093/jnci/djk133;;10.1158/0008-5472.can-10-2817;;21193546;;17709001;;10.1016/s0962-8924(97)01161-6;;15959516;;10.1038/nature03589;;17533181;;10.1161/circulationaha.106.675462;;10.1073/pnas.040337597;;pmc15970;;10688880;;10.1073/pnas.0407290101;;15520367;;pmc524697;;3023699;;pmc255246;;10.1128/jvi.61.1.218-220.1987;;8620493;;10.1093/jnci/djm148;;17728207;;10.1200/jco.2014.32.3_suppl.279;;10.1007/s10555-005-5865-1;;15785879;;10.1073/pnas.101138098;;pmc33218;;11344278;;17611219;;10.1242/dev.004184;;10.1200/jco.2008.20.9114;;19433683;;10.4049/jimmunol.152.11.5368;;8189055;;pmc3177777;;10.1186/2045-824x-3-18;;21831306;;10.1158/0008-5472.can-05-4226;;16951162;;15520185;;10.1158/0008-5472.can-04-1813;;10.1182/blood.v95.5.1616.005k31_1616_1625;;10688816;;14986825;;10.1046/j.1399-0004.2003.00194.x;;10.1016/j.mvr.2007.06.006;;17692341;;8654676;;10.1042/bst0231035;;10.1016/0022-2836(92)90639-2;;1507232;;17259973;;10.1038/nature05571;;10.1016/j.exphem.2007.05.014;;17637499;;3044339;;10.1016/s0959-8049(14)70292-8;;19664991;;10.1016/j.stem.2009.05.019;;17556669;;10.1161/01.res.0000266408.42939.e4;;16770536;;10.1007/s10555-006-8504-6;;12177445;;10.1073/pnas.172398299;;pmc123267;;16989900;;10.1016/j.molimm.2006.08.001;;10.1016/0022-2836(92)90894-p;;1404359;;15170211;;10.1038/ni1080;;pmc2361628;;10.1038/sj.bjc.6602719;;16136053;;10.1016/s0022-1759(97)00172-5;;9461335;;10.1016/0958-1669(94)90053-1;;7765176;;10.1158/1078-0432.ccr-08-2740;;19509175,"Al-Hajj, M., et al., ""Prospective Identification of Tumorigenic Breast Cancer Cells,"" Proceedings of the National Academy of Sciences 100(7):3983-3988, The National Academy of Sciences, United States (2003).;;Allenspach, E.J., et al., ""Notch Signaling in Cancer,"" Cancer Biology Therapy 1(5):466-476, Informa UK Limited, United Kingdom (2002).;;Amado, R.G., et al., ""Wild-Type KRAS is Required for Panitumumab Efficacy in Patients with Metastatic Colorectal Cancer,""Journal of Clinical Oncology 26(10):1626-1634, American Society of Clinical Oncology, United States (2008).;;Artavanis-Tsakonas, S., et al., ""Notch Signaling: Cell Fate Control and Signal Integration in Development,"" Science 284(5415):770-776, American Association for the Advancement of Science, United States (1999).;;Axelson, H., ""Notch Signaling and Cance: Emerging Complexity,"" Seminars in Cancer Biology 14(5):317-319, Academic Press, England (2004).;;Barbas, C.F. 3rd., et al., ""In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity,"" Proceedings of the National Academy of Sciences 91(9):3809-3813, National Academy of Sciences, United States (1994).;;Beachy, P.A., et al., ""Tissue Repair and Stem Cell Renewal in Carcinogenesis,"" Nature 432(7015):324-331, Nature Publishing Group, England (2004).;;Bellavia, D., et al., ""Constitutive Activation of NF-kappaB and T-cell Leukemia/lymphoma in Notch3 Transgenic Mice,"" The EMBO Journal 19(13):3337-3348, European Molecular Biology Organization, Germany (2000).;;Benvenuti, S., et al., ""Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies,"" Cancer Research 67(6):2643-2648, American Association for Cancer Research, United States (2007).;;Besseyrias, V., et al., ""Hierarchy of Notch-Delta interactions promoting T cell lineage commitment and maturation,"" The Journal of Experimental Medicine 204(2):331-343, The Rockefeller University Press, United States (2007).;;Beviglia, L., et al., ""Anti-DLL4 reduces tumor growth and tumorigenicity in B-RAF V600E melanomas including those with acquired resistance to B-RAF inhibitors,"" AACR 103rd Annual Meeting 2012, Mar. 31-Apr. 4, Abstract LB-196, 1 page (2012).;;Beviglia, L., et al., ""Anti-DLL4 Treatment Inhibits Melanoma Tumor Growth, Recurrence, Metastases and Reduces Frequency of Cancer Stem Cells in a clinically Relevant Tumor Model in NOD/SCID Mice,"" Cancer Research 71(8 Suppl.):Abstract 2834, AACR 102nd Annual Meeting 2011, Apr. 2-6, 2011.;;Beviglia, L., et al., ""In vivo evaluation of anti-tumor activity by an anti-VEGF and anti-DLL4 bispecific antibody in a humanized model of skin graft,"" AACR 104th Annual Meeting 2013, Abstract 4330, Apr. 6-10, 1 page (2013).;;Bloom, J.W., et al., ""Intrachain disulfide bond in the core hinge region of human IgG4,"" Protein Science 6(2):407-415, John Wiley & Sons, Inc., United States (1997).;;Boerner, P., et al., ""Production of Antigen-specific Human Monoclonal Antibodies from in Vitro-primed Human Splenocytes,"" Journal of Immunology 147(1):86-95, The American Association of Immunologists, United States (1991).;;Bonnet, D. and Dick, J.E., ""Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell,"" Nature Medicine 3(7):730-737, Nature Publishing Company, United States (1997).;;Bray, S.J., ""Notch signalling: a simple pathway becomes complex,"" Nature Reviews Molecular Cell Biology 7(9):678-689, Nature Publishing Group, United States (2006).;;Brennan, K. and Brown, A.M., ""Is there a Role for Notch Signalling in Human Breast Cancer?,"" Breast Cancer Research 5(2):69-75, BioMed Central Ltd., United Kingdom (2003).;;Brennan, M., et al., ""Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments,"" Science 229(4708):81-83, American Association for the Advancement of Science, United States (1985).;;Brorson, K., et al., ""Mutational Analysis of Avidity and Fine Specificity of Anti-Levan Antibodies,"" Journal of Immunology 163(12):6694-6701, American Association of Immunologists, United States (1999).;;Brummell, D.A., et al., ""Probing the Combining Site of an Anti-Carbohydrate Antibody by Saturation-Mutagenesis: Role of the Heavy-Chain CDR3 Residues,"" Biochemistry 32(4):1180-1187, American Chemical Society, United States (1993).;;Burgess, W.H., et al., ""Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,"" The Journal of Cell Biology 111(5Pt1):2129-2138, The Rockefeller University Press, United States (1990).;;Burks, E.A., et al., ""In vitro Scanning Saturation Mutagenesis of an Antibody Binding Pocket,"" Proceedings of the National Academy of Sciences of the United States of America 94(2):412-417, National Academy of Sciences, United States (1997).;;Callahan, R. and Raafat, A., ""Notch Signaling in Mammary Gland Tumorigenesis,"" Journal of Mammary Gland Biology and Neoplasia 6(1):23-36, Kluwer Academic/Plenum Publishers, United States (2001).;;Carter, P., ""Improving the efficacy of antibody-based cancer therapies,"" Nature Reviews Cancer 1(2):118-129, Nature Publishing Group, United States (2001).;;Chartier, C., et al., ""The Hippo Signaling Pathway Mediates BMP Inhibition of Cancer Stem Cells,"" 2015 AACR Annual meeting, Apr. 18-22, Abstract 2322, 1 page (2015).;;Chau, I. and Cunningham, D., ""Treatment in advanced colorectal cancer: what, when and how?,"" British Journal of Cancer 100(11):1704-1719, Nature Publishing Group, United States (2009).;;Chen, Y., et al., ""Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen,"" Journal of Molecular Biology 293(4):865-881, Academic Press, England (1999).;;Chi, A.S., et al., ""Angiogenesis as a Therapeutic Target in Malignant Gliomas,"" Oncologist 14(6):621-636, AlphaMed Press, United States (2009).;;Chothia, C. and Lesk, A.M., ""Canonical structures for the hypervariable regions of immunoglobulins,"" Journal of Molecular Biology 196(4):901-917, Elsevier Science, United States (1987).;;Chothia, C., et al., ""Domain association in immunoglobulin molecules. The packing of variable domains,"" Journal of Molecular Biology 186(3):651-663, Elsevier Science, England (1985).;;Chowdhury, P.S. and Pastan, I., ""Improving Antibody Affinity by Mimicking Somatic Hypermutation in vitro,"" Nature Biotechnology 17(6):568-572, Nature Publishing Group, United States (1999).;;Clarke, M.F., et al., ""Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells,"" Cancer Research 66(19):9339-9344, American Association for Cancer Research, United States (2006).;;Claxton, S. and Fruttiger, M., ""Periodic Delta-like 4 expression in developing retinal arteries,"" Gene Expression Pattern 5:123-127, Elsevier B.V., Netherlands (2004).;;Cole, S.P.C., et al., ""The EBV-Hybridoma Technique and Its Application to Human Lung Cancer,"" Monoclonal Antibodies and Cancer Therapy, 77-96, Proceedings of the Roche-UCLA Symposium, United States (1985).;;Colman, P.M., ""Effects of Amino Acid Sequence Changes on Antibody-antigen Interactions,"" Research in Immunology 145(1):33-36, Elsevier, France (1994).;;Co-pending U.S. Appl. No. 12/497,405 inventors Yan., et al., filed Jul. 2, 2009 (Not Published and Now Abandoned).;;Cubillo, A., et al., ""A Ph1b Study of Demcizumab (DEM, anti-DLL4) with Gemcitabine (GEM) in Patients with 1st Line Locally Advanced or Metastatic Pancreatic Cancer,"" AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 19-23, 2013, Poster (2013), 8 pages.;;Cubillo, A., et al., ""A Phase lb study of demcizumab (DEM, anti-DLL4) with gemcitabine (GEM) in patients with first line locally advanced or metastatic pancreatic cancer,"" Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 19-23, 2013, Abstract B78, 2 pages (2013).;;Dalerba, P., et al., ""Phenotypic characterization of human colorectal cancer stem cells,"" Proceedings of the National Academy of Sciences 104(24):10158-10163, National Academy of Sciences, United States (2007).;;Dando, J.S., et al., ""Notch/Delta4 interaction in human embryonic liver CD34+ CD38-cells: positive influence on BFU-E production and LTC-IC potential maintenance,"" Stem Cells 23(4):550-560, John Wiley & Sons, Inc., United States (2005).;;Deisenhofer, J., ""Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution,"" Biochemistry 20(9):2361-2370, American Chemical Society, United States (1981).;;Deonarain, M.P., et al., ""Antibodies Targeting Cancer Stem Cells: A New Paradigm in Immunotherapy?,"" mAbs 1(1):12-25, Taylor & Francis, United States (2009).;;Dixit, R., ""Cardiovascular Safety of Biologics: Challenges and Opportunities,"" Medimmune, Safety Pharmacology Society, Annular Meeting Speakers Presentations (Oct. 3, 2012).;;Dontu, G., et al., ""Role of Notch Signaling in Cell-Fate Determination of Human Mammary Stem/progenitor Cells,"" Breast Cancer Research 6(6):R605-R615, BioMed Central, England (2004).;;Dorsch, M., et al., ""Ectopic expression of Delta4 impairs hematopoietic development and leads to lymphoproliferative disease,"" Blood 100(6):2046-2055, American Society of Hematology, United States (2002).;;Dreher, M.L., et al., ""Colony assays for antibody fragments expressed in bacteria,"" Journal of Immunological Methods 139(2):197-205, Elsevier Science, United States (1991).;;Duarte, A., et al., ""Dosage-sensitive requirement for mouse Dll4 in artery development,"" Genes & Development 18 (20):2474-2478, Cold Spring Harbor Laboratory Press, United States (2004).;;Dupont, J. ""Anti-Angiogenic Agents and Cardiovascular Effects: Implications for Clinical Development in Cancer,"" presentation given in Barcelona, Spain on Nov. 4, 2011, 16 pages.;;Dupont, J., et al., ""A Phase 1b Study of Anti-DLL4 (Delta-Like Ligand 4) Antibody Demcizumab (DEM) with Pemetrexed (PEM) and Carboplatin (CARBO) in Patients with 1st-Line Non-Squamous NSCLC,"" 2015 European Lung Cancer Conference (ELCC), Geneva, Switzerland, Apr. 15-18, Abstract 114, 2 pages (2015).;;Ellisen, L.W., et al., ""TAN-1, the Human Homolog of the Drosophila notch Gene, Is Broken by Chromosomal Translocations in T Lymphoblastic Neoplasms,"" Cell 66(4):649-661, Elsevier Science, United States (1991).;;Engin,F., et al., ""Dimorphic effects of Notch signaling in bone homeostasis,"" Nature Medicine 14(3):299-305, Nature Publishing Group, United States (2008).;;English language translation of Oishi, H., et al., ""Novel therapeutic strategy for pancreatic cancer targeting Notch signaling pathway,"" Proceedings of the Japanese Cancer Association 65:311-312, Japan (2006).;;English language translation of ""Tumor-angiogenesis suppression therapy targeting the Notch signaling pathway,"" Suizo (Pancreas) 21(3):249, Japan (2006).;;Eppstein, D.A., et al., ""Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor,"" Proceedings of the National Academy of Sciences 82(11):3688-3692, National Academy of Sciences, United States (1985).;;European Search Report for EP Application No. EP10824244.7, Munich, Germany, mailed on Feb. 18, 2013, 6 pages.;;Farnie, G. and Clarke, R.B., ""Mammary stem cells and breast cancer-role of Notch signalling,"" Stem Cell Reviews and Reports 3(2):169-175, Humana Press, United States (2007).;;Farnie, G., et al., ""Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways,"" Journal of the National Cancer Institute 99(8):616-627, Oxford University Press, United Kingdom (2007).;;Fischer, M., et al., ""Anti-DLL4 Inhibits Growth and Reduces Tumor-Initiating Cell Frequency in Colorectal Tumors with Oncogenic KRAS Mutations,"" Cancer Research 71(5):1520-1525, American Association for Cancer Research, United States (2011).;;Fleming, R.J., et al., ""The NOTCH receptor and its ligands,"" Trends in Cell Biology 7(11):437-441, Elsevier Science Ltd., The Netherlands (1997).;;Fre, S., et al., ""Notch Signals Control the Fate of Immature Progenitor Cells in the Intestine,"" Nature 435(7044):964-968, Nature Publishing Group, United States (2005).;;Fung, E., et al., ""Delta-like 4 induces notch signaling in macrophages: implications for inflammation,"" Circulation 115(23):2948-2956, American Heart Association, Inc., United States (2007).;;Gagnon, M.L., et al., ""Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity,"" Proceedings of the National Academy of Sciences 97(6):2573-2578, National Academy of Sciences, United States (2000).;;Gale, N.W., et al., ""Haploinsufficiency of Delta-like 4 Ligand Results in Embryonic Lethality due to Major Defects in arterial and Vascular Development,"" Proceedings of the National Academy of Sciences 101(45):15949-15954, National Academy of Sciences, United States (2004).;;Gallahan, D., et al., ""A new common integration region (int-3) for mouse mammary tumor virus on mouse chromosome 17,"" Journal of Virology 61(1):218-220, American Society for Microbiology, United States (1987).;;Gallahan, D., et al., ""Expression of a Truncated Int3 Gene in Developing Secretory Mammary Epithelium Specifically Retards Lobular Differentiation Resulting in Tumorigenesis,"" Cancer Research 56(8):1775-1785, American Association for Cancer Research, United States (1996).;;Garber, K., ""Notch emerges as new cancer drug target,"" Journal of the National Cancer Institut 99(17):1284-1285, Oxford University Press, United States (2007).;;Gracian, A.C., et al., ""A phase 1b study of the anticancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) with or without paclitaxel protein bound particles (nab-paclitaxel) in patients with pancreatic cancer,"" 2014 Gastrointestinal Cancers Symposium, Abstract 279, 2 pages (2014).;;Gray-Schopfer, V.C., et al., ""The Role of B-RAF in Melanoma,"" Cancer Metastasis Reviews 24(1):165-183, Springer Science + Business Media, Inc., Netherlands (2005).;;Gridley, T., ""Notch Signaling During Vascular Development,"" Proceedings of the National Academy of Sciences 98(10):5377-5378, National Academy of Sciences, United States (2001).;;Gridley, T. ""Notch signaling in vascular development and physiology,"" Development 134(15):2709-2718, (2007).;;Gronberg, B.H., et al., ""Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared with Gemcitabine Plus Carboplatin as First-line Chemotherapy in Advanced Non-small-cell Lung Cancer,"" Journal of Clinical Oncology 27(19):3217-3224, American Society of Clinical Oncology, United States (2009).;;Gruber, M., et al., ""Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed in Escherichia coli,"" The Journal of Immunology 152(11):5368-5374, The American Association of Immunologists, Inc., United States (1994).;;Gurney, A. and Hoey, T., ""Anti-DLL4, a Cancer Therapeutic with Multiple Mechanisms of Action,"" Vascular Cell 3, 4 pages, BioMed Central, United States (2011).;;Hainaud, P., et al., ""The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions,"" Cancer Research 66(17):8501-8510, American Association for Cancer Research, United States (2006).;;Hallahan, A.R., et al., ""The SmoA1 Mouse Model Reveals that Notch Signaling is Critical for the Growth and Survival of Sonic Hedgehog-Induced Medulloblastomas,"" Cancer Research 64(21):7794-7800, American Association for Cancer Research, United States (2004).;;Han, W., et al., ""A soluble form of human Delta-like-1 inhibits differentiation of hematopoietic progenitor cells,"" Blood 95(5):1616-1625, The American Society of Hematology, United States (2000).;;Harlow, E. and Lane, D., eds., ""Immunossays, in Antibodies: A Laboratory Manual,"" 14:553-612, Cold Spring Harbor Laboratory, United States (1988).;;Harper, J.A., et al., ""Notch Signaling in Development and Disease,"" Clinical Genetics 64(6):461-472, Blackwell Publishing, United States (2003).;;Harrington, L.S., et al., ""Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells,"" Microvascular Research 75(2):144-154, Elsevier Science, United States (2008).;;Harris, W.J., ""Production of Humanized Monoclonal Antibodies for in vivo Imaging and Therapy,"" Biochemical Society Transactions 23(4):1035-1038, Portland Press on the Behalf of the Biochemical Society, England (1995).;;Hawkins, R.E., et al., ""Selection of phage antibodies by binding affinity. Mimicking affinity maturation,"" Journal of Molecular Biology 226(3):889-896, Elsevier Science, United States (1992).;;Hellströ, M., et al., ""Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis,"" Nature 445(7129):776-780, Nature Publishing Group, United States (2007).;;Henning, K., et al., ""mNotch1 signaling and erythropoietin cooperate in erythroid differentiation of multipotent progenitor cells and upregulate beta-globin,"" Experimental Hematology 35(9):1321-1332, Elsevier Science, United States (2007).;;Hermentin, P. and Seiler, F.R., ""Investigations with Monoclonal Antibody Drug (Anthracycline) Conjugates,"" Behring Institute Research Communications 82:197-215, Behringwerke Ag, Germany (1988).;;Hidalgo, M., et al., ""A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxvel in Patients with Pancreatic Cancer,"" European Society for Medical Oncology 2014 Congress, Sep. 17 and Sep. 28, Poster 616PD, 1 page (2014).;;Hidalgo, M., et al., ""A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, Anti-DLL4) and Gemcitabine (GEM) with or without Paclitaxel Protein Bound Particles (Nab-Paclitaxel) in pts with Pancreatic Cancer,"" 2015 ASCO Annual Meeting, Abstract 4118, 3 pages (2015).;;Hidalgo, M., et al., ""Pre-Clinical and Clinical Activity of Anti-DLL4 (Demcizumab) in Combination with Gemcitabine Plus nab-Paclitaxel in Pancreatic Cancer,"" 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Preclinical Models Poster Session, Abstract 166, 2 pages (Nov. 2014).;;Hoey, T., et al., ""DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency,"" Cell Stem Cell 5(2):168-177, Elsevier Science, United States (2009).;;Hofmann, J.J. and Iruela-Arispe, M.L., ""Notch signaling in blood vessels: who is talking to whom about what?,"" Circulation Research 100(11):1556-1568, American Heart Association, Inc., United States (2007).;;Holash, J., et al., ""Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents,"" Cancer Metastasis Rev 25:243-252, Dordrecht, Netherlands (2006).;;Holash, J., et al., ""VEGF-Trap: A VEGF Blocker with Potent Antitumor Effects,"" Proceedings of the National Academy of Sciences USA 99(17):11393-11398, National Academy of Sciences, United States (2002).;;Holm, P., et al., ""Functional Mapping and Single Chain Construction of the Anti-Cytokeratin 8 Monoclonal Antibody TS1,"" Molecular Immunology 44(6):1075-1084, Pergamon Press, England (2007).;;Hoogenboom, H.R. and Winter, G., ""By-Passing Immunisation. Human Antibodies from Symthetic Repertoires of Germline VH Gene Segments rearranged in vitro,"" Journal of Molecular Biology 227(2):381-388, Elsevier, England (1992).;;Hope, K.J., et al., ""Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in selfrenewal capacity,"" Nature Immunology 5(7):738-743, Nature Publishing Group,United States (2004).;;Hopfer, O.,et al., ""The Notch Pathway in Ovarian Carcinomas and Adenomas,"" British Journal of Cancer 93(6):709-718, Nature Publishing Group on behalf of Cancer Research UK, England (2005).;;Humphreys, D.P., et al., ""Formation of dimeric Fabs in Escherichia coli: effect of hinge size and isotype, presence of interchain disulphide bond, Fab' expression levels, tail peice sequences and growth conditions,"" Journal of Immunological Methods 209(2):193-202, Elsevier Science, Netherlands (1997).;;Hurle, M.R. and Gross, M., ""Protein engineering techniques for antibody humanization,"" Current Opinion in Biotechnology 5(4):428-433, (1994).;;Hurwitz, H.I., et al., ""Phase I Trial of Pazopanib in Patients with Advanced Cancer,"" Clinical Cancer Research 15(12):4220-4227, American Association for Cancer Research, United States (2009).",ACTIVE
42,US,A1,US 2017/0183406 A1,086-708-427-143-814,2017-06-29,2017,US 201715401543 A,2017-01-09,US 201715401543 A;;US 201615163301 A;;US 201414476582 A;;US 201213625417 A;;US 201261692978 P;;US 201261597409 P;;US 201161538454 P,2011-09-23,VEGF/DLL4 Binding Agents and Uses Thereof,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,MEREO BIOPHARMA 5 INC (2012-12-11),https://lens.org/086-708-427-143-814,Patent Application,yes,0,9,76,82,80,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,C07K16/28;;C07K16/22,,0,0,,,,ACTIVE
43,US,B1,US 7296817 B1,103-261-306-458-98X,2007-11-20,2007,US 94113504 A,2004-09-15,US 94113504 A,2004-09-15,Fifth wheel slide rail stop block,A stop block for preventing over travel of an adjustable fifth wheel hitch assemblies comprising a generally rectangular solid member having a double curve disposed in said member such that a long portion of said member is higher in elevation than a short portion of said member.,FONTAINE INTERNAT,MANN STEVEN WILLIAM;;WOLFE MICHAEL SHANE;;BOND CHRISTOPHER AARON,FONTAINE FIFTH WHEEL COMPANY (2009-07-30);;FONTAINE INTERNATIONAL (2004-12-30),https://lens.org/103-261-306-458-98X,Granted Patent,yes,12,10,1,1,0,B62D53/0814;;B62D53/0814,B62D53/06,280/438.1;;280/407;;280/433,0,0,,,,ACTIVE
44,DK,T3,DK 2758073 T3,138-751-802-620-562,2019-01-14,2019,DK 12833767 T,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;US 2012/0056886 W,2011-09-23,VEGF/DLL4-BINDENDE MIDLER OG ANVENDELSER DERAF,,ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/138-751-802-620-562,Granted Patent,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/08,,0,0,,,,ACTIVE
45,MY,A,MY 188192 A,169-011-499-266-759,2021-11-24,2021,MY PI2014000857 A,2012-09-24,US 2012/0056886 W;;US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/169-011-499-266-759,Granted Patent,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,C07K16/00;;A61K39/00;;A61K39/395;;A61K45/00;;C07K16/18;;C07K16/22;;C07K16/28;;C12P21/08,,0,0,,,,ACTIVE
46,LT,T,LT 3485903 T,005-162-493-282-580,2023-02-27,2023,LT 18197338 T,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,,MEREO BIOPHARMA 5 INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/005-162-493-282-580,Unknown,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K45/06;;A61P35/00;;A61P35/02;;C07K16/00;;C07K16/22;;C07K16/28;;C12P21/08,,0,0,,,,PENDING
47,EP,B1,EP 3485903 B1,049-346-075-032-485,2022-11-16,2022,EP 18197338 A,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;EP 12833767 A;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,,MEREO BIOPHARMA 5 INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,"MEREO BIOPHARMA 5, INC. (2023-03-08);;MEREO BIOPHARMA 5, INC., US (2023-04-17);;MEREO BIOPHARMA 5, INC.; US (2023-02-24);;MEREO BIOPHARMA 5, INC., MOUNTAIN VIEW, US (2023-02-16)",https://lens.org/049-346-075-032-485,Granted Patent,yes,6,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/08,,1,0,,,"SMITH D C ET AL: ""222 A first-in-human, phase I trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem cells (CSC) in patients with advanced solid tumors"", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 8, no. 7, 1 November 2010 (2010-11-01), page 73, XP027497910, ISSN: 1359-6349, DOI: 10.1016/S1359-6349(10)71927-3 [retrieved on 2010-11-01]",ACTIVE
48,US,A1,US 2023/0279101 A1,085-438-263-714-364,2023-09-07,2023,US 202218055642 A,2022-11-15,US 202218055642 A;;US 202016928452 A;;US 201715847335 A;;US 201715401543 A;;US 201615163301 A;;US 201414476582 A;;US 201213625417 A;;US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",MEREO BIOPHARMA 5 INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,MEREO BIOPHARMA 5 INC (2012-12-11),https://lens.org/085-438-263-714-364,Patent Application,yes,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,C07K16/28;;A61K31/4745;;A61K31/7068;;A61K39/00;;A61K39/395;;A61K45/00;;A61K45/06;;C07K16/18;;C07K16/22;;C07K16/30,,0,0,,,,PENDING
49,US,A1,US 2004/0090659 A1,085-640-659-868-617,2004-05-13,2004,US 64748503 A,2003-08-25,US 64748503 A;;US 40555502 P,2002-08-23,Method of tuning wavelength tunable electro-absorption modulators,"
   A method of tuning an electroabsorption modulator (EAM). A reference average power loss factor for light having a reference peak wavelength that is modulated by the EAM is provided. This loss factor is based on operation of the EAM using a reference bias voltage, a reference temperature, and a reference modulation signal which has a predetermined duty cycle. Input light is coupled into the EAM and modulated using a modulation signal which has the same duty cycle as the reference modulation signal. The input power of the input light and the average output power of light emitted from the EAM are measured. These input and average output powers are used to generate an average power loss factor. The average power loss factor is compared to the reference average power loss factor and the bias voltage and/or the temperature of the EAM are adjusted to reduce differences between these loss factors. 
",ZHANG LIYAN;;FRATESCHI NEWTON C.;;ZHANG JIAMING;;BOND AARON,ZHANG LIYAN;;FRATESCHI NEWTON C;;ZHANG JIAMING;;BOND AARON,CYOPTICS INC (2000-04-18);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-01-06);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2023-02-02);;BROADCOM INTERNATIONAL PTE. LTD (2020-08-26);;CYOPTICS ACQUISITION CORP (2007-04-02);;APOGEE PHOTONICS INC (2005-07-11);;T-NETWORKS INC (2003-08-23),https://lens.org/085-640-659-868-617,Patent Application,yes,4,26,2,2,0,G02F1/0123;;G02F1/0123;;G02F1/0157;;G02F1/0157,G02F1/01;;G02F1/015,35924,0,0,,,,EXPIRED
50,CA,A1,CA 2849562 A1,143-471-576-240-282,2013-03-28,2013,CA 2849562 A,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/143-471-576-240-282,Patent Application,no,0,0,76,82,80,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,C07K16/28;;A61K39/00;;C07K16/22;;C07K16/46;;C12N15/13,,0,0,,,,ACTIVE
51,PT,T,PT 2758073 T,178-883-397-331-462,2019-02-01,2019,PT 12833767 T,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,,ONCOMED PHARM INC,AUSTIN L GURNEY;;AARON K SATO;;CHRISTOPHER JOHN BOND,,https://lens.org/178-883-397-331-462,Patent Application,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/08,,0,0,,,,PENDING
52,EP,A1,EP 2758073 A1,027-932-891-447-770,2014-07-30,2014,EP 12833767 A,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,,ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/027-932-891-447-770,Patent Application,yes,0,0,76,82,80,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/08,,0,0,,,,ACTIVE
53,US,B2,US 8858941 B2,037-770-447-537-431,2014-10-14,2014,US 201213625417 A,2012-09-24,US 201213625417 A;;US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,VEGF/DLL4 binding agents and uses thereof,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,MEREO BIOPHARMA 5 INC (2012-12-11),https://lens.org/037-770-447-537-431,Granted Patent,yes,99,28,76,82,80,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/395;;A61K39/00;;A61K45/00;;C07K16/00;;C07K16/18;;C07K16/22;;C07K16/28;;C12P21/08,424/136.1;;424/130.1;;424/133.1;;424/141.1;;424/145.1;;530/387.1;;530/387.3;;530/388.1;;530/388.24,105,97,095-334-545-560-259;;014-113-432-888-031;;045-942-104-775-903;;001-779-867-387-972;;013-142-717-038-23X;;027-477-313-726-928;;021-197-916-777-658;;013-783-671-147-94X;;037-480-189-672-490;;059-703-624-598-226;;087-191-128-287-209;;002-723-775-902-029;;021-745-342-029-670;;014-119-439-143-988;;022-883-652-460-089;;056-502-337-160-838;;029-657-616-636-736;;018-709-667-787-457;;108-821-214-937-013;;085-593-346-327-896;;000-185-481-899-567;;006-798-173-804-888;;028-156-483-654-882;;027-020-473-411-693;;102-675-067-390-626;;089-635-536-661-885;;064-792-093-706-002;;175-243-588-850-607;;080-191-903-791-47X;;047-025-555-564-763;;125-269-916-334-305;;067-279-783-581-616;;008-479-069-316-491;;049-991-770-424-933;;052-795-433-555-537;;049-491-181-937-297;;018-146-170-889-398;;054-283-410-011-338;;037-809-048-883-498;;016-270-419-085-156;;083-606-989-843-197;;014-785-980-334-859;;085-729-060-237-502;;128-376-920-124-813;;035-067-471-486-809;;007-837-250-546-989;;112-241-917-646-013;;090-306-007-122-585;;068-271-687-772-412;;002-209-250-502-039;;068-352-608-171-550;;067-111-531-425-423;;065-542-021-501-547;;136-835-589-937-16X;;008-844-599-921-544;;054-531-591-081-65X;;062-547-748-254-237;;024-042-571-208-910;;127-754-934-722-768;;033-658-808-499-907;;016-014-793-014-160;;081-098-206-476-749;;047-462-962-275-331;;020-327-681-254-735;;056-188-962-943-86X;;058-211-492-859-131;;008-268-944-751-345;;094-311-434-287-343;;042-041-573-268-106;;056-289-930-116-029;;061-751-917-222-159;;018-597-551-636-944;;037-809-048-883-498;;091-232-484-240-784;;090-306-007-122-585;;066-699-026-742-579;;085-249-110-169-470;;015-506-336-131-104;;073-702-812-203-896;;092-881-815-515-655;;007-837-250-546-989;;020-636-405-917-503;;016-512-212-388-570;;024-810-152-282-074;;086-164-247-322-732;;078-200-031-570-847;;048-208-171-994-922;;100-984-968-676-329;;026-145-110-279-358;;091-114-424-339-46X;;009-188-067-200-010;;006-049-213-810-548;;164-216-761-918-204;;070-614-370-694-544;;031-901-495-166-515;;060-684-120-299-26X;;110-500-797-458-579,10.1006/jmbi.1996.0548;;8876650;;12218124;;10.4049/jimmunol.169.6.3076;;12850000;;10.1016/s0006-291x(03)01131-8;;10.1006/jmbi.1999.3192;;10543973;;10556035;;10.1006/jmbi.1999.3141;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;15549094;;10.1038/nature03100;;10880446;;pmc313949;;10.1093/emboj/19.13.3337;;9212098;;10.1038/nm0797-730;;pmc154142;;10.1186/bcr559;;12631384;;15170211;;10.1038/ni1080;;12615665;;10.1161/01.atv.0000060892.81529.8f;;10.1101/gad.6.3.345;;1372276;;10.1007/bf02893458;;15188021;;10837027;;pmc316662;;10.1101/gad.14.11.1343;;7509044;;10.1038/367645a0;;10.1038/sj.onc.1203703;;10918578;;9039255;;10.1016/s0092-8674(00)81867-x;;10.1038/nature05355;;17183313;;10.3892/ijmm.14.5.779;;15492845;;8642337;;10.1084/jem.183.5.2283;;pmc2192581;;10.1097/01.moh.0000143965.90813.70;;15548998;;15288259;;10.1016/j.semcancer.2004.04.013;;15781650;;10.1158/0008-5472.can-04-1890;;11072240;;10.1002/1097-0215(20001201)88:5<726::aid-ijc7>3.0.co;2-h;;8898201;;10.1016/s0092-8674(00)81368-9;;10837024;;10.1101/gad.14.11.1313;;pmc316657;;7544153;;10.1002/(sici)1097-0215(20000601)86:5<652::aid-ijc8>3.3.co;2-m;;10797286;;10.1002/(sici)1097-0215(20000601)86:5<652::aid-ijc8>3.0.co;2-v;;10.3892/ijo.17.6.1131;;11078798;;17457300;;10.1038/nrc2130;;9576833;;10.1006/dbio.1998.8863;;10.1016/j.molmed.2005.09.008;;16214417;;11107116;;10.1002/1096-911x(20001201)35:6<554::aid-mpo13>3.0.co;2-r;;10.1038/nm754;;12185362;;10.1182/blood.v98.13.3793;;11739188;;10.1073/pnas.92.14.6414;;pmc41528;;7604005;;17709001;;10.1016/s0962-8924(97)01161-6;;10.1182/blood.v100.6.2046.h81802002046_2046_2055;;12200365;;15790776;;10.1634/stemcells.2004-0205;;10.1182/blood-2005-03-1000;;16219802;;pmc1895896;;10.1038/sj.leu.2403288;;14990974;;10.1016/j.exphem.2005.12.016;;16569589;;10.1096/fj.05-4880fje;;16571776;;10.1158/0008-5472.can-05-4226;;16951162;;15466159;;pmc529534;;10.1101/gad.1239004;;17533181;;10.1161/circulationaha.106.675462;;10.1073/pnas.0407290101;;15520367;;pmc524697;;10.1093/jnci/djm148;;17728207;;17611219;;10.1242/dev.004184;;10.1016/j.mvr.2007.06.006;;17692341;;17259973;;10.1038/nature05571;;10.1016/j.exphem.2007.05.014;;17637499;;15563463;;10.1074/jbc.m406788200;;7566092;;10.1038/377355a0;;pmc529533;;10.1101/gad.1239204;;15466160;;10.1046/j.1432-0436.2001.690207.x;;11798067;;10.1210/en.2007-0477;;17916635;;pmc2734500;;pmc1698634;;17028337;;10.1534/genetics.106.061630;;10.1158/0008-5472.can-05-1208;;16204037;;10.1006/excr.2000.5034;;11035934;;10.1182/blood-2006-12-063933;;pmc1885521;;17311993;;10.1016/j.febslet.2006.03.024;;16574107;;pmc2118717;;10.1084/jem.20061442;;17261636;;pmc2671578;;10.1038/nm1712;;18297084;;17259972;;10.1038/nature05577;;19154719;;pmc8114544;;10.1016/j.devcel.2008.12.009;;17822956;;10.1016/j.molmed.2007.07.002;;19664991;;10.1016/j.stem.2009.05.019;;16023591;;10.1016/j.ccr.2005.06.013;;12814948;;10.1111/j.1749-6632.2003.tb03219.x;;10.1038/nrm2009;;16921404;;10.1182/blood.v100.6.2046.h81802002046_2046_2055;;12200365;;17440163;;10.1093/jnci/djk133;;10.1073/pnas.0407290101;;15520367;;pmc524697;;12482957;;pmc140667;;10.1128/mcb.23.1.14-25.2003;;10.1186/bcr1021;;15987436;;pmc1143566;;pmc1064073;;10.1186/bcr920;;15535842;;10.1007/s12015-007-0023-5;;17873349;;10528225;;10.1002/(sici)1097-4652(199912)181:3<393::aid-jcp3>3.0.co;2-6;;15466159;;pmc529534;;10.1101/gad.1239004;;16489059;;10.1158/1078-0432.ccr-05-2570;;17556669;;10.1161/01.res.0000266408.42939.e4;;10.1161/01.res.0000258174.77370.2c;;17234965;;10.1073/pnas.0611206104;;pmc1805530;;17296940;;10.1158/0008-5472.can-06-3126;;16990346;;15319485;;10.1093/toxsci/kfh254;;10.1038/35102167;;11689955;;8139658;;10.1038/368150a0;;0008139658;;9166828;;10.1182/blood.v89.11.3919;;10.1126/science.1102160;;15472075;;12496471;;10.4161/cbt.1.5.159;;10.1126/science.284.5415.770;;10221902;;15288256;;10.1016/j.semcancer.2004.04.010;;10.1023/a:1009512414430;;11467450;;15959516;;10.1038/nature03589;;10.1182/blood.v95.5.1616.005k31_1616_1625;;10688816,"MacCallum et al. (1996). J. Mol. Biol. 262:732-745.;;De Pascalis et al. (2002). Journal of Immunology. 169:3076-3084.;;Casset et al. (2003). Biochemical and Biophysical Reseaerch Communications. 307:198-205.;;Chen et al. (1999). J. Mol. biol. 293:865-881.;;Wu et al. (1999). J. Mol. Biol. 294:151-162.;;Rudikoff et al. (1982). PNAS. 79:1979-1983.;;Beachy, P., et al., ""Tissue repair and stem cell renewal in carcinogenesis,"" Nature 432:324-331, Nature Publishing Group, New York, NY, U.S.A. (2004).;;Bellavia, D., et al., ""Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice,"" EMBO J. 19:3337-3348, Oxford University Press, New York, NY U.S.A. (2000).;;Bonnet, D. and Dick, J.E., ""Human acute myeloid leukemia is organized as a hierarachy that originates from a primitive hematopoietic cell,"" Nat. Med. 3:730-737, Nature Publishing Group, New York, NY, U.S.A. (1997).;;Brennan, K. and Brown, A.M.C., ""Is there a role for Notch signalling in human breast cancer?"" Breast Cancer Res. 5:69-75, BioMed Central Ltd, London, UK (2003).;;Hope, K.J., et al., ""Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity,"" Nat. Immunol. 5:738-43, Nature Publishing Group, New York, NY, U.S.A. (2004).;;Iso, T., et al., ""Notch Signaling in Vascular Development,"" Arterioscler. Thromb. Vasc. Biol. 23:543-553, Lippincott Williams & Wilkins, Philadelphia, PA, U.S.A. (2003).;;Jhappan, C., et al., ""Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic and salviary glands,"" Genes & Dev. 6:345-355, Cold Spring Harbor Laboratory Press, Woodbury NY, U.S.A. (1992).;;Kopper, L. and Hajdú, M., ""Tumor Stem Cells,"" Pathol. Oncol. Res. 10:69-73, Arányi Lajos Foundation, Budapest, Hungary (2004).;;Krebs, L.T., et al., ""Notch signaling is essential for vascular morphogenesis in mice,"" Genes & Dev. 14:1343-1352, Cold Spring Harbor Laboratory Press, Woodbury NY, U.S.A. (2000).;;Lapidot, T., et al., ""A cell initiating human acute myeloid leukaemia after transplantation into SCID mice,"" Nature 367:645-648, Nature Publishing Group, New York, NY, U.S.A. (1994).;;Leethanakul, C., et al., ""Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by the use of laser capture microdissection and cDNA arrays,"" Oncogene 19:3220-3224, Nature Publishing Group, New York, NY, U.S.A. (2000).;;Morrison, S.J., et al., ""Regulatory Mechanisms in Stem Cell Biology,"" Cell 88:287-298, Cell Press, St. Louis, MO, U.S.A. (1997).;;Noguera-Troise, I., et al., ""Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis,"" Nature 444:1032-1037, Nature Publishing Group, New York, NY, U.S.A. (2006).;;Parr, C., et al., ""The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer,"" Int. J. Mol. Med. 14:779-786, Spandidos Publications Ltd., Athens, Greece (2004).;;Pear, W.S., et al., ""Exclusive Development of T cell Neoplasms in Mice Transplanted with Bone Marrow Expressing Activated Notch Alleles,"" J. Exp. Med. 183:2283-2291, the Rockefeller University Press, New York, NY, U.S.A. (1996).;;Pear, W.S. and Aster, J.C., ""T cell acute lymphoblastic leukemia/lymphoma: a human cancer commonly associated with aberrant NOTCH1 signaling,"" Curr. Opin. Hematol. 11:426-433, Lippincott Williams & Wilkins, Philadelphia, PA, U.S.A. (2004).;;Politi, K., et al., ""Notch in mammary gland development and breast cancer,"" Semin. Cancer Biol. 14:341-347, Elsevier Inc., Amsterdam, The Netherlands (2004).;;Purow, B.W., et al., ""Expression of Notch-1 and Its Ligands, Delta-Like-1 and Jagged-1, Is Critical for Glioma Cell Survival and Proliferation,"" Cancer Res. 65:2353-2363, BioMed Central Ltd, London, UK (2005).;;Rae, F.K., et al., ""Novel Association of a Diverse Range of Genes with Renal Cell Carcinoma as Identified by Differential Display,"" Int. J. Cancer 88:726-732, Wiley-Liss, Inc., Massachusetts, U.S.A (2000).;;Ridgeway., J., et al., ""Inhibition of Dll4 signaling inhibits tumour growth by deregulating angiogenesis,"" Nature 444:1083-1087, Nature Publishing Group, New York, NY, U.S.A. (2006).;;Robey, E., et al., ""An Activated Form of Notch Influences the Choice between CD4 and CD8 T Cell Lineages,"" Cell 87:483-492, Elsevier Inc., Amsterdam, The Netherlands (1996).;;Shutter, J.R., et al., ""Dll4, a novel Notch ligand expressed in arterial endothelium,"" Genes & Dev. 14:1313-1318, Cold Spring Harbor Laboratory Press, Woodbury NY, U.S.A. (2000).;;Smith, G.H., et al., ""Constitutive Expression of a Truncated INT3 Gene in Mouse Mammary Epithelium Impairs Differentiation and Functional Development,"" Cell Growth Differ. 6:563-577, the American Association for Cancer Research, Philadelphia, PA, U.S.A. (1995).;;Soriano, J.V., at al., ""Expression of an Activated Notch4(int-3) Oncoprotein Disrupts Morphogenesis and Induces an Invasive Phenotype in Mammary Epithelial Cells In Vitro,"" Int. J. Cancer 86:652-659, Wiley-Liss, Inc, Massachusetts, U.S.A (2000).;;Suzuki, T., at al., ""Imbalanced expression of TAN-1 and human Notch4 in endometrial cancers,"" Int. J. Oncol. 17:1131-1139, Spandidos Publications Ltd., Athens, Greece (2000).;;Thurston, G., et al., ""The Delta paradox:DLL4 blockade leads to more tumour vessels but less tumour growth,"" Nature Reviews Cancer 7:327-331, Nature Publishing Group, New York, NY, U.S.A. (2007).;;Uyttendaele, H., et al., ""Notch4 and Wnt-1 Proteins Function to Regulate Branching Morphogenesis of Mammary Epithelial Cells in an Opposing Fashion,"" Dev. Biol. 196:204-217, Elsevier Inc., Amsterdam, The Netherlands (1998).;;Van ES, J.H., and Clevers, H., ""Notch and Wnt inhibitors as potential new drugs for intestinal neoplastic disease,"" Trends Mol. Med. 11:496-502, Elsevier Inc., Amsterdam, The Netherlands (2005).;;Van Limpt, V., et al., ""SAGE Analysis of Neuroblastoma Reveals a High Expression of the Human Homologue of the Drosophila Delta Gene,"" Med. Pediatr. Oncol. 35:554-558, Wiley-Liss, Inc., Massachusetts, U.S.A (2000).;;Weijzen, S., et al., ""Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells,"" Nat. Med. 8:979-986, Nature Publishing Group, New York, NY, U.S.A. (2002).;;Yan, X.-Q., et al., ""A novel Notch ligand, D114, induces T-cell leukemia/lymphoma when overexpressed in mice by retroviral-mediated gene transfer,"" Blood 98:3793-3799, the American Society of Hematology, Washington, DC, U.S.A. (2001).;;Zagouras, P., et al., ""Alterations in Notch signaling in neoplastic lesions of the human cervix,"" PNAS 92:6414-6418, the National Academy of Sciences, Washington, DC, U.S.A. (1995).;;Fleming, R.J. et al., ""The Notch receptor and its ligands,"" Trends in Cell Biol. 7:437-441 (1997).;;Dorsch, M., et al., ""Ectopic expression of Delta4 impairs hematopoietic development and leads to lymphoproliferative disease,"" Blood 100:2046-2055 (2002).;;Dando, J. et al., ""Notch/Delta4 Interaction in Human Embryonic Liver CD34+CD38- Cells: Positive Influence on BGU-E Production in LTC-IC Potential Maintenance,"" Stem Cells 23:550-560 (2005)..;;Williams, C.K., et al., ""Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function,"" Blood 107:931-939 (Feb. 2006).;;Lauret, E. et al., ""Membrane-bound Delta-4 Notch ligand reduces the proliferative activity of primitive human hematopoietic CD34+CD38low cells while maintaining their LTC-IC potential,"" Leukemia 18:788-797 (Feb. 2006).;;Sugimoto, A. et al., ""Delta-4 Notch ligand promotes erythroid differentiation of human umbilical cord blood CD34+ cells,"" Exp. Hematol. 34:424-432 (Apr. 2006).;;Liu, Z-J., et al., ""Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MAPK and P14K/AKT pathways and requires MAML1,"" FASEB J. 20:E201-E210 (May 2006).;;Hainaud, P., et al., ""The Role of the Vascular Endothelial Growth Factor-Delta-like 4 ligand/Notch4-Ephrin B2 Cascade in Tumor Vessel Remodeling and Endothelial Cell Functions,"" Cancer Res. 66:8501-8510 (Sep. 2006).;;Duarte, A., et al., ""Dosage-sensitive requirement for mouse Dll4 in artery development,"" Genes Dev. 18:2474-2478, Cold Spring Harbor, NY U.S.A. (2004).;;Fung, E., et al., ""Delta-like 4 induces notch signaling in macrophages: implications for inflammation,"" Circulation 115:2948-2956, Lippincott Williams & Wilkins, Baltimore, MD U.S.A. (2007).;;Gale, N.W., et al., ""Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development,"" Proc. Natl. Acad. Sci. USA 101:15949-15954, National Academy of Sciences (2004).;;Garber, K., ""Notch Emerges as New Cancer Drug Target,"" JNCI 991284-1285, Oxford University Press (2007).;;Gridley, T., ""Notch signaling in vascular development and physiology,"" Development 134:2709-2718, The Company of Biologists (2007).;;Harrington, L.S., et al., ""Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells,"" Microvasc. Res. 75:144-154, Elsevier, Inc. (2008).;;Hellström, M., et al., ""Dll4 signalling through Notch 1 regulates formation of tip cells during angiogenesis,"" Nature 445:776-780, Nature Publishing Group (2007).;;Henning, K., et al., ""mNotch 1 signaling and erythropoietin cooperate in erythroid differentiation of multipotent progenitor cells and upregulate beta-globin,"" Exp. Hematol. 35:1321-1332, Elsevier, Inc. (2007).;;Ishiko, E., et al., ""Notch Signals Inhibit the Development of Erythroid/Megakaryocytic Cells by Suppressing GATA-1 Activity through Induction of HES1,"" J. Biol. Chem. 280:4929-4939, The American Society for Biochemistry and Molecular Biology, Inc. (2005).;;Jarriault, S., et al., ""Signalling downstream of activated mammalian Notch,"" Nature 377:355-358, Nature Publishing Group (1995).;;Krebs, L.T., et al., ""Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants,"" Genes Dev. 18:2469-2473, Cold Spring Harbor Laboratory Press (2004).;;Mailhos, C., et al., ""Delta4, an endothelial specific Notch ligand expressed at sites of physiological and tumor angiogenesis,"" Differentiation 69:135-144, Blackwell Wissenschafts-Verlag (2001).;;Mazella, J., et al., ""Expression of Delta-Like Protein 4 in the Human Endometrium,"" Endocrinology 149:15-19, The Endocrine Society (2008).;;Parks, A.L., et al., ""Structure-Function Analysis of Delta Trafficking, Receptor Binding and Signaling in Drosophila,"" Genetics 174:1947-1961, The Genetics Society of America (2006).;;Patel, N.S., et al., ""Up-regulation of Delta-like 4 Ligand in Human Tumor Vasculature and the Role of Basal Expression in Endothelial Cell Function,"" Cancer Res. 65:8690-8697, The American Association for Cancer Research (2005).;;Rao, P.K., et al., ""Isolation and Characterization of the Notch Ligand Delta4,"" Cell Res. 260:379-386, Elsevier, Inc. (2000).;;Scehnet, J.S., et al., ""Inhibition of Dll4-mediated sigaling induces proliferation of immature vessels and results in poor tissue perfusion,"" Blood 109:4753-4760, American Society of Hematology (2007).;;Wilson, A. and Radtke, F., ""Multiple functions of Notch signaling in self-renewing organs and cancer,"" FEBS Lett. 580:2860-2868, Elsevier, Inc. (2006).;;Besseyrias, V., et al., ""Hierarchy of Notch-Delta interactions promoting T cell lineage commitment and maturaction,"" J. Exp. Med. 204:331-343, The Rockefeller University Press (2007).;;Engin, F., et al., ""Dimorphic effects of Notch signaling in bone homeostasis,"" Nature Medicine 14:299-305, Nature Publishing Group (2007).;;Siekmann, A.F. and Lawson, N.D., ""Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries,"" Nature 445:781-784, Nautre Publishing Group (2007).;;Phng, L.-K., et al., ""Nrarp Coordinates Endothelial Notch and Wnt Signaling to Control Vessel Density in Angiogenesis,"" Dev. Cell 16:70-82, Elsevier, Inc. (2009).;;Sainson, R.C.A. and Harris, A.L., ""Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis?,"" Trends Mol. Med. 13:389-395, Elsevier, Inc. (2007).;;Hoey, T., et al., ""DLL4 Blockade Inhibits Tumor Growth and Reduces Tumor Initiating Cell Frequency,"" Cell Stem Cell 5(2):168-77, Cell Press (2009).;;Hellström, M., et al., ""Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis,"" Nature 445:776-780, Nature Publishing Group (2007).;;Li, J.-L. and Harris, A.L., ""Notch signaling from tumor cells: A new mechanism of angiogenesis,"" Cancer Cell 8:1-3, Cell Press (2005).;;Shawber, C.J., et al., ""Notch Signaling in Primary Endothelial Cells,"" Ann. N.Y. Acad. Sci. 995:162-170, New York Academy of Sciences (2003).;;Bray, S.J., ""Notch signalling: a simple pathway becomes complex,"" Nature 7:678-689, Nature Publishing Group (2006).;;Dorsch, M., et al.,""Ectopic expression of Delta4 impairs hematopoietic development and leads to lymphoproliferative disease,"" Blood 100:2046-2055, American Society of Hematology (2002).;;Farnie, G., et al., ""Novel Cell Culture Technique for Primary Ductal Carcinoma In Situ: Role of Notch and Epidermal Growth Factor Receptor Signaling Pathways ,"" JNCI 99:616-627, Oxford University Press (2007).;;Gale, N.W., et al., ""Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development,"" PNAS 101 :15949-15954, National Academy of Sciences (2004).;;Liu, Z.-J., et al., ""Regulation of Notch1 and Dll4 by Vascular Endothelial Growth Factor in Arterial Endothelial Cells: Implications for Modulating Arteriogenesis and Angiogenesis,"" Molecular and Cellular Biology 23:14-25, American Society for Microbiology (2003).;;Liu, S., et al., ""Mammary stem cells, self-renewal pathways, and carcinogenesis,"" Breast Cancer Research 7:86-95, BioMed Central Ltd. (2005).;;Dontu, G., et al., ""Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells,"" Breast Cancer Res. 6:R605-R615, BioMed Central Ltd. (2004).;;Farnie, G. and Clarke, R.B., ""Mammary Stem Cells and Breast Cancer-Role of Notch Signalling,"" Stem Cell Rev. 3:169-175, Humana Press (2007).;;Miele, L. and Osborne, B., ""Arbiter of Differentiation and Death: Notch Signaling Meets Apoptosis,"" Journal of Cellular Physiology 181:393-409, Wiley-Liss, Inc. (1999).;;Duarte, A., et al., Dosage-sensitive requirement for mouse Dll4 in artery development, Genes & Dev. 18:2474-2478, Cold Spring Harbor Laboratory Press (2004).;;Miele, L., ""Notch Signaling,"" Cancer Res. 12:1074-1077, American Association for Cancer Research (2006).;;Garber, K., ""Notch Emerges as New Cancer Drug Target,"" JNCI 99:1284-1285, Oxford University Press (2007).;;Hofmann, J.J. and Iruela-Arispe, M.L., ""Notch Signaling in Blood Vessels: Who Is Talking to Whom About What?,"" Circ. Res. 100:1556-1568 American Heart Association, Inc. (2007).;;Limbourg, A., et al., Notch Ligand Delta-Like 1 Is Essential for Postnatal Arteriogenesis, Circ. Res. 100:363-371, American Heart Association, Inc. (2007).;;Lobov, I.B., et al., Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting, PNAS 104:3219-3224, National Academy of Sciences (2007).;;Clarke, M.F., et al., ""Cancer Stem Cells-Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells,"" Cancer Res. 66:9339-9344, American Association for Cancer Research (2006).;;Milano, J., et al., Modulation of Notch Processing by gamma-Secretase Inhibitors Causes Intestinal Goblet Cell Metaplasia and Induction of Genes Known to Specify Gut Secretory Lineage Differentiation, Toxicol Sci 82:341-358, Society of Toxicology (2004).;;Reya, T., et al., ""Stem cells, cancer and cancer stem cells,"" Nature 414:105-111, Nature Publishing Company (2001).;;Tax, F.E., et al., ""Sequence of C. elegans lag-2 reveals a cell-signalling domain shared with Delta and Serrate of Drosophila,"" Nature 368:150-154, Nature Publishing Company (1994).;;Wang, J.C.Y., et al., ""Primitive Human Hematopoeitic Cells Are Enriched in Cord Blood Compared with Adult Bone Marrow or Mobilized Peripheral Blood as Measured by the Quantitative In Vivo SCID-Repopulating Cell Assay,"" Blood 89:3919-3924, The American Society of Hematology (1997).;;Weng, A.P., et al., ""Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia,"" Science 306:269-371, American Association for the Advancement of Science (2004).;;Yen, W.-C., et al., ""Targeting Cancer Stem Cells and Vasculature by a Novel Anti-Dll4 Antibody Inhibits Pancreatic Tumor Growth and Delays Tumor Recurrence,"" presented at the 100th Annual Meeting of the American Association for Cancer Research in Denver, Colorado, on Apr. 18-22, 2009, 1 page.;;Office Action mailed Dec. 26, 2008 in U.S. Appl. No. 11/607,780, inventors Clarke, et al., filed Dec. 1, 2006.;;Office Action mailed Jan. 2, 2009 in U.S. Appl. No. 11/607,780, inventors Clarke, et al., filed Dec. 1, 2006;;Response to Office Action mailed Jan. 2, 2009, sent electronically on Jul. 2, 2009, in U.S. Appl. No. 11/607,780, inventors Clarke, et al., filed Dec. 1, 2006.;;Allenspach, E.J. et al., ""Notch signaling in cancer,"" Cancer Biol Ther. 1(5):466-76, Landes Bioscience, United States (2002).;;Artavanis-Tsakonas, S. et al., ""Notch signaling: cell fate control and signal integration in development,"" Science 284(5415):770-6, American Association Advancement for the Advancement of Science, United States (1999);;Axelson, H., ""Notch signaling and cancer: emerging complexity,"" Semin Cancer Biol. 14(5):317-9, Academic Press, England (2004).;;Callahan, R. and Raafat, A., ""Notch signaling in mammary gland tumorigenesis,"" J Mammary Gland Biol Neoplasia 6(1):23-36, Kluwer Academic/Plenum Publishers, United States (2001).;;U.S. Appl. No. 12/497,405, inventors Yan et al., filed Jul. 2, 2009 (Now Abandoned).;;Fre, S. et al., ""Notch signals control the fate of immature progenitor cells in the intestine,"" Nature 435(7044):964-8, Nature Publishing Group, England (2005).;;Han, W. et al., ""A soluble form of human Delta-like-1 inhibits differentiation of hematopoietic progenitor cells,"" Blood 95(5):1616-25, American Society of Hematology, United States (2000).",ACTIVE
54,US,B2,US 11241526 B2,109-682-308-550-310,2022-02-08,2022,US 201816181498 A,2018-11-06,US 201816181498 A;;US 2013/0060404 W;;US 201361874741 P;;US 201261703191 P,2012-09-19,Method and system for enhanced imaging visualization of deep brain anatomy using infusion,"Provided is a method and system for delivering a diagnostic agent to a site in the brain of a subject for imaging at least a portion of the brain site on a medical imaging system. The method and system includes a catheter device with associated lumens having diagnostic agent ports for delivering the diagnostic agent (e.g., infusate) through the lumens and advancing the diagnostic agent so as to exit out from the lumens to at least a portion of the brain site and while sealing a portion of the brain site thereby preventing the exited diagnostic agent from travelling proximally beyond the sealing location, and at the same time imaging at least a portion of the brain site during at least a portion of the sealing duration so that the brain site can be visualized on a medical imaging system. The diagnostic agent (infusate) is able to highlight borders and internal patterns of the deep structures of the brain thereby enabling direct targeting. Ultimately this leads to reduced complications, enhanced therapy, and the elimination of the need for awake surgery. The method and system provides the capability heretofore not possible to visualize the small, often indistinct regions, which will greatly improve clinical outcomes with therapeutic interventions.",UNIV VIRGINIA PATENT FOUNDATION,ELIAS WILLIAM J;;BOND AARON E;;GILLIES GEORGE T,UNIVERSITY OF VIRGINIA PATENT FOUNDATION (2013-12-03);;UNIVERSITY OF VIRGINIA (2013-10-13),https://lens.org/109-682-308-550-310,Granted Patent,yes,9,0,5,5,0,A61M25/10;;A61B5/0042;;A61B5/055;;A61M25/007;;A61M25/0127;;A61M25/1002;;A61M31/005;;A61M2025/0042;;A61M2025/105;;A61M2025/1052;;A61M2025/1093;;G01R33/285;;A61B6/032;;A61B6/12;;A61B6/481;;A61B6/501;;A61M25/10;;A61B5/0042;;A61B5/055;;A61M25/007;;A61M25/0127;;A61M25/1002;;A61M31/005;;A61M2025/0042;;A61M2025/105;;A61M2025/1052;;A61M2025/1093;;G01R33/285;;A61B6/032;;A61B6/12;;A61B6/481;;A61B6/501;;A61M5/007;;A61M25/0026;;A61M2025/0037;;A61N1/36139,A61M5/00;;A61B5/00;;A61B5/055;;A61B6/00;;A61B6/03;;A61B6/12;;A61M25/00;;A61M25/01;;A61M25/10;;A61M31/00;;A61N1/36;;G01R33/28,,0,0,,,,ACTIVE
55,HR,T1,HR P20190044 T1,135-888-501-931-955,2019-02-22,2019,HR P20190044 T,2019-01-07,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;EP 12833767 A;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,,ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/135-888-501-931-955,Granted Patent,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/08,,0,0,,,,ACTIVE
56,DK,T3,DK 3485903 T3,161-480-953-849-008,2023-02-06,2023,DK 18197338 T,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;EP 12833767 A,2011-09-23,VEGF/DLL4-BINDENDE MIDLER OG ANVENDELSER DERAF,,MEREO BIOPHARMA 5 INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/161-480-953-849-008,Granted Patent,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/08,,0,0,,,,ACTIVE
57,WO,A9,WO 2013/044215 A9,189-767-753-422-012,2014-04-03,2014,US 2012/0056886 W,2012-09-24,US 201261597409 P;;US 201161538454 P;;US 201261692978 P,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/189-767-753-422-012,Search Report,yes,0,1,76,82,80,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;C07K16/00;;C12P21/08,,0,0,,,,PENDING
58,AU,A1,AU 2013/201095 A1,197-534-495-451-04X,2013-04-11,2013,AU 2013/201095 A,2012-09-24,US 201261692978 P;;US 201161538454 P;;US 201261597409 P;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 binding agents and uses thereof,"- 125 The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/197-534-495-451-04X,Patent Application,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00,,0,0,,,,ACTIVE
59,RS,B1,RS 58201 B1,100-593-312-904-642,2019-03-29,2019,RS P20190023 A,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;US 2012/0056886 W;;EP 12833767 A,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,,ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/100-593-312-904-642,Granted Patent,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/08,,0,0,,,,ACTIVE
60,SI,T1,SI 2758073 T1,197-102-030-817-348,2019-02-28,2019,SI 201231484 T,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;US 2012/0056886 W;;EP 12833767 A,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,,ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/197-102-030-817-348,Granted Patent,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/00,,0,0,,,,ACTIVE
61,NI,A,NI 201400024 A,015-733-515-451-568,2014-06-26,2014,NI 201400024 A,2014-03-21,US 201161538454 P;;US 201261692978 P;;US 201261597409 P,2011-09-23,AGENTES DE LIGACIÓN AL FACTOR DE CRECIMIENTO ENDOTELIAL VASCULAR/LIGANDO 4 SIMILAR A DELTA ( VEGF/DLL4) Y USOS DE LOS MISMOS.,"La presente invención se refiere a agentes de ligación a VEGF, agentes de ligación a DLL4, agentes de ligación biespecíficos a VEGF/DLL4, y métodos para usar los agentes para tratar las enfermedades tales como cáncer. La presente invención proporciona anticuerpos que se ligan específicamente a VEGF humano, anticuerpos que se ligan específicamente a DLL4 humano, y anticuerpos biespecíficos que se ligan específicamente a VEGF humano y/o DLL4 humano. La presente invención proporciona además métodos para usar los agentes para inhibir el crecimiento tumoral. También se describen métodos para tratar cáncer que comprenden administrar una cantidad terapéuticamente efectiva de un agente o anticuerpo de la presente invención a un paciente que tiene un tumor o cáncer.",ONCOMED PHARM INC,AUSTIN L GURNEY;;AARON KEN SATO;;CHRISTOPHER JOHN BOND,,https://lens.org/015-733-515-451-568,Granted Patent,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;C07K16/00;;C12P21/08,,0,0,,,,ACTIVE
62,EP,A1,EP 3485903 A1,010-139-662-118-147,2019-05-22,2019,EP 18197338 A,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;EP 12833767 A;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,"MEREO BIOPHARMA 5, INC. (2023-03-08);;MEREO BIOPHARMA 5, INC., US (2023-04-17);;MEREO BIOPHARMA 5, INC.; US (2023-02-24);;MEREO BIOPHARMA 5, INC., MOUNTAIN VIEW, US (2023-02-16)",https://lens.org/010-139-662-118-147,Patent Application,yes,52,0,76,82,80,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/08,,49,36,000-438-864-132-323;;004-602-847-993-84X;;108-821-214-937-013;;042-041-573-268-106;;032-720-983-972-675;;006-574-964-805-278;;042-204-626-457-327;;045-094-249-115-990;;010-916-105-450-247;;016-251-721-517-200;;026-048-786-530-595;;085-727-974-637-837;;005-119-615-003-591;;115-922-065-986-888;;106-753-778-592-300;;030-630-100-818-462;;034-331-211-704-877;;020-855-322-534-259;;053-665-131-053-807;;043-558-136-070-327;;032-071-991-081-664;;020-855-322-534-259;;047-193-486-795-201;;005-112-559-456-657;;031-063-853-127-197;;072-064-906-772-096;;104-212-297-137-759;;035-232-534-898-963;;092-325-088-257-225;;022-375-749-274-329;;033-797-614-829-293;;062-583-333-788-366;;038-527-559-639-375;;001-490-044-769-438;;043-016-539-897-20X;;006-053-610-642-017,10.1016/s1359-6349(10)71927-3;;16291593;;10.1182/blood-2005-08-3329;;10.1038/nature05355;;17183313;;19664991;;10.1016/j.stem.2009.05.019;;10.1006/jmbi.1997.1354;;9367782;;10.1038/321522a0;;3713831;;3127726;;10.1038/332323a0;;10.1126/science.2451287;;2451287;;10.1038/nbt0792-779;;1368267;;10.1073/pnas.91.9.3809;;pmc43671;;8170992;;10.1016/0378-1119(95)00821-7;;8647439;;7897213;;10.4049/jimmunol.154.7.3310;;10.1016/0022-2836(92)90639-2;;1507232;;10557084;;10.1038/sj.onc.1202985;;1172191;;10.1038/256495a0;;10.1038/348552a0;;2247164;;10.1038/352624a0;;1907718;;1748994;;10.1016/0022-2836(91)90498-u;;9630891;;10.1038/nbt0396-309;;10.1073/pnas.95.11.6157;;pmc27609;;9600934;;10.1016/0022-2836(92)90894-p;;1404359;;1748994;;10.1016/0022-2836(91)90498-u;;10.1016/j.jmb.2007.12.018;;18191144;;10.1126/science.3925553;;3925553;;pmc453097;;1834458;;10.1002/j.1460-2075.1991.tb04932.x;;pmc2119072;;10.1084/jem.175.1.217;;1346155;;10.4049/jimmunol.148.5.1547;;1531669;;10.4049/jimmunol.152.11.5368;;8189055;;8844834;;10.1093/protein/9.7.617;;1675655;;10.4049/jimmunol.147.1.60;;2531466;;10.1126/science.2531466;;10.1016/j.copbio.2007.04.010;;17643280;;pmc2242358;;16373474;;10.1110/ps.051817606;;10.1016/j.copbio.2006.10.003;;17055245;;17095910;;10.1097/01.mol.0000252612.21602.e3;;10.1111/j.1742-4658.2008.06438.x;;18435759;;10.1111/j.1742-4658.2008.06439.x;;18435758,"SMITH D C ET AL: ""222 A first-in-human, phase I trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem cells (CSC) in patients with advanced solid tumors"", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 8, no. 7, 1 November 2010 (2010-11-01), pages 73, XP027497910, ISSN: 1359-6349, [retrieved on 20101101], DOI: 10.1016/S1359-6349(10)71927-3;;LEONG ET AL., BLOOD, vol. 107, 2006, pages 2223 - 2233;;NOGUERA-TROISE ET AL., NATURE, vol. 444, 2006, pages 1032 - 1037;;HOEY ET AL., CELL STEM CELL, vol. 5, 2009, pages 168 - 177;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, NATIONAL INSTITUTES OF HEALTH;;AL-LAZIKANI ET AL., J. MOL. BIOL., vol. 273, 1997, pages 927 - 948;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327;;VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536;;MARKS ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 779 - 783;;BARBAS ET AL., PNAS, vol. 91, 1994, pages 3809 - 3813;;SCHIER ET AL., GENE, vol. 169, 1995, pages 147 - 155;;YELTON ET AL., J. IMMUNOL., vol. 155, 1995, pages 1994 - 2004;;JACKSON ET AL., J. IMMUNOL., vol. 154, 1995, pages 3310 - 9;;HAWKINS ET AL., J. MOL. BIOL., vol. 226, 1992, pages 889 - 896;;""Current Protocols in Molecular Biology"", 1994, JOHN WILEY & SONS, INC.;;GAZIT ET AL., ONCOGENE, vol. 18, 1999, pages 5959 - 66;;KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497;;J.W. GODING: ""Monoclonal Antibodies: Principles and Practice"", 1996, ACADEMIC PRESS;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597;;COLE ET AL.: ""Monoclonal Antibodies and Cancer Therapy"", 1985, ALAN R. LISS, pages: 77;;BOEMER ET AL., J. IMMUNOL., vol. 147, 1991, pages 86 - 95;;VAUGHAN ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 309 - 314;;SHEETS ET AL., PNAS, vol. 95, 1998, pages 6157 - 6162;;HOOGENBOOM; WINTER, J. MOL. BIOL., vol. 227, 1991, pages 381;;MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581;;ROTHE ET AL., J. MOL. BIO., vol. 376, 2008, pages 1182 - 1200;;MILLSTEIN ET AL., NATURE, vol. 305, 1983, pages 537 - 539;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81;;SURESH ET AL., METHODS IN ENZYMOL., vol. 121, 1986, pages 120;;TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655 - 3659;;SHALABY ET AL., J. EXP. MED., vol. 175, 1992, pages 217 - 225;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;GRUBER ET AL., J. IMMUNOL., vol. 152, 1994, pages 5368;;RIDGWAY, PROT. ENGIN., vol. 9, 1996, pages 617 - 621;;TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60;;HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281;;""Remington: The Science and Practice of Pharmacy"", 2005, UNIVERSITY OF THE SCIENCES;;ZOELLER ET AL., PNAS, vol. 81, 1984, pages 5662 - 5066;;POUWELS ET AL.: ""Cloning Vectors: A Laboratory Manual"", 1985, ELSEVIER;;SKERRA, CURR. OPIN. BIOTECHNOL., vol. 18, 2007, pages 295 - 304;;HOSSE ET AL., PROTEIN SCIENCE, vol. 15, 2006, pages 14 - 27;;GILL ET AL., CURR. OPIN. BIOTECHNOL., vol. 17, 2006, pages 653 - 658;;NYGREN, FEBS J., vol. 275, 2008, pages 2668 - 76;;SKERRA, FEBS J., vol. 275, 2008, pages 2677 - 83;;""The Chemotherapy Source Book"", 2008, LIPPINCOTT, WILLIAMS & WILKINS;;TAHTIS ET AL., MOL. CANCER THER., vol. 2, 2003, pages 229 - 737",ACTIVE
63,US,A1,US 2015/0098949 A1,030-716-530-465-975,2015-04-09,2015,US 201414476582 A,2014-09-03,US 201414476582 A;;US 201213625417 A;;US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,VEGF/DLL4 Binding Agents and Uses Thereof,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,MEREO BIOPHARMA 5 INC (2012-12-11),https://lens.org/030-716-530-465-975,Patent Application,yes,0,8,76,82,80,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,C07K16/22,424/158.1;;530/389.2;;530/388.23;;530/387.3;;536/23.53,0,0,,,,ACTIVE
64,PL,T3,PL 2758073 T3,032-645-375-233-476,2019-04-30,2019,PL 12833767 T,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;EP 12833767 A;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,,ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/032-645-375-233-476,Patent Application,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/08,,0,0,,,,PENDING
65,PE,A1,PE 20141537 A1,082-455-088-725-562,2014-11-17,2014,PE 2014000407 A,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,AGENTES DE LIGACION AL FACTOR DE CRECIMIENTO ENDOTELIAL VASCULAR/LIGANDO 4 SIMILAR A DELTA (VEGF/DLL4) Y USOS DE LOS MISMOS,"SE REFIERE A UN ANTICUERPO BIESPECIFICO, CARACTERIZADO PORQUE COMPRENDE: a) UN PRIMER SITIO DE LIGACION A ANTIGENO QUE LIGA ESPECIFICAMENTE EL FACTOR DE CRECIMIENTO ENDOTELIAL VASCULAR HUMANO (VEGF), Y b) UN SEGUNDO SITIO DE LIGACION A ANTIGENO QUE LIGA ESPECIFICAMENTE EL LIGANDO 4 SIMILAR A DELTA HUMANO(DLL4). DICHO ANTICUERPO TIENE UNA REGION VARIABLE DE CADENA PESADA QUE TIENE EL 90% DE IDENTIDAD DE LA SECUENCIA SEQ ID NO: 11 Y UNA REGION VARIABLE DE CADENA LIGERA QUE TIENE EL 90% DE IDENTIDAD DE LA SECUENCIA SEQ ID NO: 12. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE ES UTIL PARA EL TRATAMIENTO DE CANCER.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/082-455-088-725-562,Patent Application,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;C07K16/00;;C12P21/08,,0,0,,,,ACTIVE
66,TW,A,TW 201326204 A,126-710-303-136-008,2013-07-01,2013,TW 101134966 A,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,VEGF/DLL4 binding agents and uses thereof,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/126-710-303-136-008,Patent of Addition,no,0,1,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,C07K16/18;;A61K39/395;;A61P35/00;;C07K16/26,,0,0,,,,ACTIVE
67,US,A1,US 2019/0062424 A1,163-594-891-206-899,2019-02-28,2019,US 201816116036 A,2018-08-29,US 201816116036 A;;US 201715847335 A;;US 201715401543 A;;US 201615163301 A;;US 201414476582 A;;US 201213625417 A;;US 201261692978 P;;US 201261597409 P;;US 201161538454 P,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,ONCOMED PHARMACEUTICALS INC (2012-12-11),https://lens.org/163-594-891-206-899,Patent Application,yes,0,0,76,82,80,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,C07K16/28;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K45/00;;A61K45/06;;C07K16/18;;C07K16/22;;C07K16/30,,2,1,045-942-104-775-903,12850000;;10.1016/s0006-291x(03)01131-8,"<span style=""font-family: ""Windows Arial Unicode"";"">De Pascalis et al. (2002). Journal of Immunology. 169:3076-3084.</span>;;Casset et al. (2003). Biochemical and Biophysical Reseaerch Communications. 307:198-205.",DISCONTINUED
68,CN,A,CN 104168914 A,175-082-733-045-045,2014-11-26,2014,CN 201280056471 A,2012-09-24,US 2012/0056886 W;;US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,VEGF/DLL4 binding agents and uses thereof,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/175-082-733-045-045,Patent Application,no,4,2,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;C07K16/00;;C12P21/08,,0,0,,,,ACTIVE
69,AU,A1,AU 2015/268749 A1,018-380-859-824-012,2016-01-21,2016,AU 2015/268749 A,2015-12-16,AU 2015/268749 A;;AU 2013/201095 A;;US 201261692978 P;;US 201161538454 P;;US 201261597409 P;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 binding agents and uses thereof,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGiF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/018-380-859-824-012,Patent Application,no,0,0,4,82,0,,C07K16/00;;A61K39/00;;C12P21/08,,0,0,,,,ACTIVE
70,EP,B1,EP 2758073 B1,040-998-460-026-31X,2018-10-31,2018,EP 12833767 A,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,,ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/040-998-460-026-31X,Granted Patent,yes,11,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/08,,1,0,,,"SMITH D C ET AL: ""222 A first-in-human, phase I trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem cells (CSC) in patients with advanced solid tumors"", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 8, no. 7, 1 November 2010 (2010-11-01), page 73, XP027497910, ISSN: 1359-6349, DOI: 10.1016/S1359-6349(10)71927-3 [retrieved on 2010-11-01]",ACTIVE
71,PL,T3,PL 3485903 T3,134-996-663-182-143,2023-06-12,2023,PL 18197338 T,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,,MEREO BIOPHARMA 5 INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/134-996-663-182-143,Patent Application,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/08,,0,0,,,,PENDING
72,KR,A,KR 20140082719 A,181-384-688-014-944,2014-07-02,2014,KR 20147010688 A,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,,ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/181-384-688-014-944,Patent Application,no,5,1,76,82,160,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,C07K16/46;;A61K39/395;;A61P35/00,,0,0,,,,ACTIVE
73,US,B2,US 11512128 B2,191-891-265-411-576,2022-11-29,2022,US 202016928452 A,2020-07-14,US 202016928452 A;;US 201715847335 A;;US 201715401543 A;;US 201615163301 A;;US 201414476582 A;;US 201213625417 A;;US 201261692978 P;;US 201261597409 P;;US 201161538454 P,2011-09-23,VEGF/DLL4 binding agents and uses thereof,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",MEREO BIOPHARMA 5 INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,MEREO BIOPHARMA 5 INC (2012-12-11),https://lens.org/191-891-265-411-576,Granted Patent,yes,336,1,76,82,80,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/395;;A61K31/4745;;A61K31/7068;;A61K39/00;;A61K45/00;;A61K45/06;;C07K16/18;;C07K16/22;;C07K16/28;;C07K16/30,,347,259,084-085-138-348-898;;006-049-213-810-548;;042-535-804-056-355;;164-216-761-918-204;;070-614-370-694-544;;016-251-721-517-200;;021-197-916-777-658;;115-778-640-766-918;;020-327-681-254-735;;000-913-948-188-914;;015-807-813-009-849;;126-923-418-365-467;;043-293-799-149-190;;003-984-734-905-938;;037-480-189-672-490;;018-597-551-636-944;;059-703-624-598-226;;005-112-559-456-657;;053-851-713-620-401;;006-553-734-546-212;;003-849-961-384-35X;;105-316-874-895-908;;031-901-495-166-515;;061-397-752-245-555;;004-522-738-863-341;;016-291-551-264-744;;001-779-867-387-972;;032-443-032-575-719;;049-134-753-209-354;;061-518-684-585-221;;099-532-412-433-785;;034-331-211-704-877;;078-200-031-570-847;;100-371-416-663-157;;029-611-134-469-353;;027-845-339-272-06X;;133-610-790-984-99X;;016-270-419-085-156;;079-109-121-457-433;;025-070-183-573-259;;015-506-336-131-104;;037-809-048-883-498;;048-319-205-023-297;;007-837-250-546-989;;027-519-986-651-310;;018-320-647-455-556;;056-188-962-943-86X;;101-575-504-070-651;;073-702-812-203-896;;091-232-484-240-784;;138-876-315-756-795;;054-283-410-011-338;;060-684-120-299-26X;;112-241-917-646-013;;009-062-652-854-847;;090-306-007-122-585;;095-500-970-877-346;;027-306-913-195-466;;068-271-687-772-412;;129-005-046-068-395;;106-254-156-307-214;;032-048-398-057-385;;002-209-250-502-039;;003-711-275-433-72X;;035-232-534-898-963;;149-834-701-635-194;;035-067-471-486-809;;038-442-198-715-21X;;110-500-797-458-579;;072-351-640-594-174;;068-352-608-171-550;;065-608-090-342-50X;;005-119-615-003-591;;067-111-531-425-423;;065-542-021-501-547;;061-958-083-948-364;;164-451-236-197-939;;042-041-573-268-106;;016-512-212-388-570;;087-726-883-167-698;;008-498-336-394-659;;031-100-076-670-370;;032-071-991-081-664;;087-191-128-287-209;;089-486-878-211-546;;075-221-017-149-582;;077-495-150-106-187;;092-634-627-505-478;;089-633-612-001-004;;136-835-589-937-16X;;002-723-775-902-029;;017-328-222-500-841;;085-727-974-637-837;;023-378-335-265-81X;;033-368-627-556-233;;008-844-599-921-544;;099-964-134-794-845;;030-922-427-128-310;;021-745-342-029-670;;129-973-531-805-684;;006-574-964-805-278;;046-013-436-890-449;;015-623-518-697-144;;068-238-957-669-243;;106-753-778-592-300;;014-119-439-143-988;;104-212-297-137-759;;054-531-591-081-65X;;022-883-652-460-089;;085-528-415-223-353;;056-502-337-160-838;;014-785-980-334-859;;004-425-043-791-551;;029-657-616-636-736;;004-602-847-993-84X;;056-289-930-116-029;;054-277-945-870-664;;044-312-778-204-450;;024-810-152-282-074;;085-249-110-169-470;;128-376-920-124-813;;066-699-026-742-579;;086-164-247-322-732;;043-453-890-807-326;;024-298-462-228-882;;095-334-545-560-259;;024-561-324-817-879;;062-547-748-254-237;;010-916-105-450-247;;020-855-322-534-259;;024-042-571-208-910;;032-607-776-688-407;;030-630-100-818-462;;113-146-142-749-076;;041-945-536-319-424;;113-146-142-749-076;;108-327-398-058-238;;052-515-652-666-158;;092-881-815-515-655;;020-636-405-917-503;;048-208-171-994-922;;117-775-899-628-564;;039-118-196-658-356;;058-205-097-704-518;;018-709-667-787-457;;096-836-261-967-31X;;077-108-010-423-006;;030-607-398-087-475;;006-454-751-452-062;;071-717-719-996-536;;108-821-214-937-013;;011-745-980-251-775;;048-103-697-044-146;;127-754-934-722-768;;085-593-346-327-896;;033-658-808-499-907;;006-798-173-804-888;;000-185-481-899-567;;008-268-944-751-345;;000-935-046-673-192;;008-151-002-104-508;;033-073-320-277-143;;065-287-969-992-103;;028-156-483-654-882;;015-239-659-590-870;;069-144-826-896-138;;027-020-473-411-693;;024-779-467-240-124;;102-675-067-390-626;;016-014-793-014-160;;041-596-561-800-698;;100-984-968-676-329;;020-564-002-939-564;;042-204-626-457-327;;018-414-301-058-606;;089-635-536-661-885;;027-477-313-726-928;;094-311-434-287-343;;090-714-216-170-949;;081-098-206-476-749;;026-048-786-530-595;;049-192-915-761-746;;072-064-906-772-096;;061-751-917-222-159;;043-558-136-070-327;;107-303-389-554-878;;064-792-093-706-002;;058-211-492-859-131;;091-347-675-692-644;;093-067-181-692-392;;063-640-832-834-034;;000-438-864-132-323;;036-379-137-455-723;;000-438-864-132-323;;175-243-588-850-607;;080-191-903-791-47X;;013-642-802-665-79X;;047-364-936-221-939;;085-729-060-237-502;;016-658-224-490-240;;037-711-371-585-567;;047-025-555-564-763;;011-910-096-463-060;;026-145-110-279-358;;008-266-889-199-914;;006-257-463-053-048;;125-269-916-334-305;;002-219-259-764-94X;;031-063-853-127-197;;022-375-749-274-329;;051-940-176-386-905;;067-279-783-581-616;;008-479-069-316-491;;049-991-770-424-933;;091-582-771-406-994;;053-665-131-053-807;;045-094-249-115-990;;069-495-502-499-501;;091-114-424-339-46X;;016-314-653-579-682;;052-795-433-555-537;;009-188-067-200-010;;037-589-218-577-038;;083-606-989-843-197;;047-462-962-275-331;;119-515-479-159-88X;;008-411-420-307-533;;013-142-717-038-23X;;006-124-137-496-346;;003-711-929-171-854;;049-491-181-937-297;;025-046-032-214-179;;035-236-318-471-090;;060-472-079-666-376;;028-960-308-516-850;;066-407-919-450-381;;150-651-615-448-193;;078-077-493-330-521;;091-051-926-686-546;;018-146-170-889-398;;064-048-827-826-930;;035-275-453-395-352;;012-005-224-634-423;;059-212-558-154-670;;132-484-526-820-872;;020-239-636-647-054;;022-648-069-840-113;;155-710-259-787-090;;025-331-205-864-51X;;000-740-232-876-831;;022-983-639-581-992;;026-365-124-273-808;;014-158-096-594-681;;049-666-882-297-378;;059-476-065-054-670;;082-593-540-788-849;;015-283-465-647-996;;032-117-626-844-978;;022-560-800-296-262,10.1073/pnas.0530291100;;pmc153034;;12629218;;12496471;;10.4161/cbt.1.5.159;;10.1200/jco.2007.14.7116;;18316791;;10.1126/science.284.5415.770;;10221902;;15288256;;10.1016/j.semcancer.2004.04.010;;10.1073/pnas.91.9.3809;;pmc43671;;8170992;;15549094;;10.1038/nature03100;;17363584;;10.1158/0008-5472.can-06-4158;;pmc2118717;;10.1084/jem.20061442;;17261636;;10.1158/1538-7445.am2012-lb-196;;10.1158/1538-7445.am2011-2834;;10.1158/1538-7445.am2013-4330;;9041643;;pmc2143633;;10.1002/pro.5560060217;;10.4049/jimmunol.147.1.86;;2051030;;9212098;;10.1038/nm0797-730;;10.1038/nrm2009;;16921404;;pmc154142;;10.1186/bcr559;;12631384;;10.1126/science.3925553;;3925553;;10586066;;10.4049/jimmunol.163.12.6694;;8424945;;10.1021/bi00055a024;;1699952;;pmc2116333;;10.1083/jcb.111.5.2129;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;10.1023/a:1009512414430;;11467450;;11905803;;10.1038/35101072;;19436303;;10.1038/sj.bjc.6605061;;pmc2695695;;1512548;;10.1084/jem.176.3.855;;pmc2119366;;10.1006/jmbi.1999.3192;;10543973;;pmc4790121;;19487335;;10.1634/theoncologist.2008-0272;;10.1016/0022-2836(87)90412-8;;3681981;;10.1016/0022-2836(85)90137-8;;4093982;;10385321;;10.1038/9872;;10.1038/352624a0;;1907718;;10.1158/0008-5472.can-06-3126;;16990346;;10.1016/j.modgep.2004.05.004;;15533827;;7516563;;10.1016/s0923-2494(94)80039-1;;10.1158/1535-7163.targ-13-b78;;10.1073/pnas.0703478104;;pmc1891215;;17548814;;15790776;;10.1634/stemcells.2004-0205;;10.2210/pdb1fc1/pdb;;7236608;;10.2210/pdb1fc2/pdb;;10.1021/bi00512a001;;20046569;;pmc2715180;;10.4161/mabs.1.1.7347;;pmc1064073;;10.1186/bcr920;;15535842;;10.1182/blood.v100.6.2046.h81802002046_2046_2055;;12200365;;2045660;;10.1016/0022-1759(91)90189-m;;15466159;;pmc529534;;10.1101/gad.1239004;;10.1093/annonc/mdv050.18;;1831692;;10.1016/0092-8674(91)90111-b;;pmc2671578;;10.1038/nm1712;;18297084;;pmc397852;;10.1073/pnas.82.11.3688;;3159018;;10.1007/s12015-007-0023-5;;17873349;;17440163;;10.1093/jnci/djk133;;10.1158/0008-5472.can-10-2817;;21193546;;17709001;;10.1016/s0962-8924(97)01161-6;;15959516;;10.1038/nature03589;;17533181;;10.1161/circulationaha.106.675462;;10.1073/pnas.040337597;;pmc15970;;10688880;;10.1073/pnas.0407290101;;15520367;;pmc524697;;3023699;;pmc255246;;10.1128/jvi.61.1.218-220.1987;;8620493;;10.1093/jnci/djm148;;17728207;;10.1200/jco.2014.32.3_suppl.279;;10.1007/s10555-005-5865-1;;15785879;;10.1073/pnas.101138098;;pmc33218;;11344278;;17611219;;10.1242/dev.004184;;10.1200/jco.2008.20.9114;;19433683;;10.4049/jimmunol.152.11.5368;;8189055;;pmc3177777;;10.1186/2045-824x-3-18;;21831306;;10.1158/0008-5472.can-05-4226;;16951162;;15520185;;10.1158/0008-5472.can-04-1813;;10.1182/blood.v95.5.1616.005k31_1616_1625;;10688816;;14986825;;10.1046/j.1399-0004.2003.00194.x;;10.1016/j.mvr.2007.06.006;;17692341;;8654676;;10.1042/bst0231035;;10.1016/0022-2836(92)90639-2;;1507232;;17259973;;10.1038/nature05571;;10.1016/j.exphem.2007.05.014;;17637499;;3044339;;10.1016/s0959-8049(14)70292-8;;19664991;;10.1016/j.stem.2009.05.019;;17556669;;10.1161/01.res.0000266408.42939.e4;;16770536;;10.1007/s10555-006-8504-6;;12177445;;10.1073/pnas.172398299;;pmc123267;;16989900;;10.1016/j.molimm.2006.08.001;;10.1016/0022-2836(92)90894-p;;1404359;;15170211;;10.1038/ni1080;;pmc2361628;;10.1038/sj.bjc.6602719;;16136053;;10.1016/s0022-1759(97)00172-5;;9461335;;10.1016/0958-1669(94)90053-1;;7765176;;10.1158/1078-0432.ccr-08-2740;;19509175;;6933450;;pmc349762;;10.1073/pnas.77.7.4030;;15563463;;10.1074/jbc.m406788200;;12615665;;10.1161/01.atv.0000060892.81529.8f;;10.1093/annonc/mdn713;;19150949;;7897213;;10.4049/jimmunol.154.7.3310;;10.1126/science.1222879;;pmc3577348;;22653731;;10.1016/s0161-5890(98)00095-9;;10199394;;7566092;;10.1038/377355a0;;10805736;;pmc85741;;10.1128/mcb.20.11.3928-3941.2000;;12568441;;10.3322/canjclin.53.1.5;;10.1101/gad.6.3.345;;1372276;;10.1200/jco.2013.31.15_suppl.2502;;10.1038/321522a0;;3713831;;10.1073/pnas.172398399;;pmc123268;;12177446;;389741;;10.1016/0378-1119(79)90029-5;;10556249;;10.1093/protein/12.10.879;;1172191;;10.1038/256495a0;;10.1007/bf02893458;;15188021;;10.4049/jimmunol.148.5.1547;;1531669;;pmc529533;;10.1101/gad.1239204;;15466160;;10837027;;pmc316662;;10.1101/gad.14.11.1343;;10.1073/pnas.081615298;;11274374;;pmc31881;;7509044;;10.1038/367645a0;;10.1038/sj.leu.2403288;;14990974;;10.1016/s0161-5890(98)00109-6;;10369421;;10.1038/sj.onc.1203703;;10918578;;16291593;;10.1182/blood-2005-08-3329;;16023591;;10.1016/j.ccr.2005.06.013;;10.1038/nm.2021;;19855400;;pmc2780347;;10.1158/0008-5472.can-06-0191;;16618717;;10.1161/01.res.0000258174.77370.2c;;17234965;;10.1186/bcr1021;;15987436;;pmc1143566;;10.1096/fj.05-4880fje;;16571776;;12482957;;pmc140667;;10.1128/mcb.23.1.14-25.2003;;10.1073/pnas.0611206104;;pmc1805530;;17296940;;23750318;;10.2217/cns.12.36;;pmc3673744;;25700513;;10.1126/science.1261093;;pmc4445638;;10.1006/jmbi.1996.0548;;8876650;;1873503;;10.3233/hab-1991-2302;;10.1046/j.1432-0436.2001.690207.x;;11798067;;10.1038/nbt0792-779;;1368267;;1748994;;10.1016/0022-2836(91)90498-u;;10.1210/en.2007-0477;;17916635;;pmc2734500;;pmc3491453;;23019585;;10.1073/pnas.1206400109;;10.1038/348552a0;;2247164;;10.1016/s0959-8049(12)72395-x;;10.1158/1535-7163.targ-13-a71;;10.1016/s0959-8049(12)72395-x;;10.1200/jco.2014.32.15_suppl.2544;;10.1038/nbt0798-677;;9661204;;10528225;;10.1002/(sici)1097-4652(199912)181:3<393::aid-jcp3>3.0.co;2-6;;16489059;;10.1158/1078-0432.ccr-05-2570;;15319485;;10.1093/toxsci/kfh254;;10.1038/305537a0;;6137772;;1560176;;10.1016/0165-022x(92)90051-b;;10.1016/s0952-7915(97)80138-0;;9099790;;9039255;;10.1016/s0092-8674(00)81867-x;;10.1146/annurev.cb.11.110195.000343;;10.1146/annurev.cellbio.11.1.35;;8689561;;10.1353/dem.2000.0009;;11086575;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;12133727;;10.1016/s1367-5931(02)00346-0;;10.1038/sj.onc.1206758;;14528285;;10.1038/nature05355;;17183313;;10.1073/pnas.051624498;;pmc30615;;11248040;;pmc390431;;10.1073/pnas.82.14.4592;;3927286;;pmc1698634;;17028337;;10.1534/genetics.106.061630;;10.3892/ijmm.14.5.779;;15492845;;10.1158/0008-5472.can-05-1208;;16204037;;10.1097/01.moh.0000143965.90813.70;;15548998;;8642337;;10.1084/jem.183.5.2283;;pmc2192581;;19154719;;pmc8114544;;10.1016/j.devcel.2008.12.009;;10.1093/glycob/cwi007;;15496501;;pmc3608722;;10.4049/jimmunol.1202820;;23440416;;17605027;;10.1007/s00418-007-0306-6;;10.3109/14017431.2010.511256;;20799913;;15288259;;10.1016/j.semcancer.2004.04.013;;10.4049/jimmunol.150.3.880;;8423344;;8360482;;10.4049/jimmunol.151.5.2623;;15781650;;10.1158/0008-5472.can-04-1890;;16409162;;10.1146/annurev.med.57.121304.131240;;11072240;;10.1002/1097-0215(20001201)88:5<726::aid-ijc7>3.0.co;2-h;;10.1006/excr.2000.5034;;11035934;;16697642;;10.1016/j.tcb.2006.04.003;;10.1038/35102167;;11689955;;10.1038/nature05313;;17183323;;3127726;;10.1038/332323a0;;18758481;;10.1038/onc.2008.226;;8898201;;10.1016/s0092-8674(00)81368-9;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;17822956;;10.1016/j.molmed.2007.07.002;;pmc1134670;;15330757;;10.1042/bj20041022;;10.1182/blood-2006-12-063933;;pmc1885521;;17311993;;10.1016/0378-1119(95)00821-7;;8647439;;18392005;;10.1038/nbt0408-366c;;pmc2119072;;10.1084/jem.175.1.217;;1346155;;12814948;;10.1111/j.1749-6632.2003.tb03219.x;;10.1073/pnas.95.11.6157;;pmc27609;;9600934;;17308088;;10.1158/0008-5472.can-06-3311;;10837024;;10.1101/gad.14.11.1313;;pmc316657;;17259972;;10.1038/nature05577;;10.1093/jnci/djp280;;pmc2758310;;19738166;;7688398;;10.4049/jimmunol.151.4.2296;;10631780;;10.1016/s0167-7799(99)01398-0;;10.1016/s1359-6349(10)71927-3;;25324140;;10.1158/1078-0432.ccr-14-1373;;10.1016/s1359-6349(10)71927-3;;7544153;;10.1002/(sici)1097-0215(20000601)86:5<652::aid-ijc8>3.3.co;2-m;;10797286;;10.1002/(sici)1097-0215(20000601)86:5<652::aid-ijc8>3.0.co;2-v;;10.1158/1538-7445.am2015-255;;388229;;10.1038/282039a0;;10.1016/j.exphem.2005.12.016;;16569589;;pmc2394258;;12865906;;10.1038/sj.bjc.6601107;;10.1016/0076-6879(86)21019-8;;3724461;;10.3892/ijo.17.6.1131;;11078798;;8747303;;10.1291/hypres.18.259;;8139658;;10.1038/368150a0;;0008139658;;10.1186/1471-5945-2-7;;pmc111189;;11978185;;15293563;;10.1532/ijh97.04065;;17457300;;10.1038/nrc2130;;14754405;;10.2174/1381612043453603;;pmc453097;;1834458;;10.1002/j.1460-2075.1991.tb04932.x;;1675655;;10.4049/jimmunol.147.1.60;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;9576833;;10.1006/dbio.1998.8863;;10.1016/j.molmed.2005.09.008;;16214417;;11107116;;10.1002/1096-911x(20001201)35:6<554::aid-mpo13>3.0.co;2-r;;10.1016/s1081-1206(10)62794-9;;9723555;;9630891;;10.1038/nbt0396-309;;10.1126/science.2451287;;2451287;;10.1007/978-1-61779-968-6_2;;22886243;;9166828;;10.1182/blood.v89.11.3919;;10.1016/s1054-3589(08)60931-x;;8504061;;10.1038/nm754;;12185362;;10.1126/science.1102160;;15472075;;12509463;;10.1128/mcb.23.2.655-664.2003;;pmc151540;;10.1182/blood-2005-03-1000;;16219802;;pmc1895896;;10.1016/j.febslet.2006.03.024;;16574107;;10.1016/s1359-6349(08)72532-1;;17934452;;10.1038/nbt1345;;10556035;;10.1006/jmbi.1999.3141;;10.1074/jbc.m505569200;;15994325;;10.1038/nature08751;;20147986;;10.1182/blood.v98.13.3793;;11739188;;10.4049/jimmunol.155.4.1994;;7636250;;10.1158/0008-5472.sabcs-09-5071;;10.1158/1538-7445.am2013-3725;;22952347;;10.1158/1078-0432.ccr-12-0736;;10.1158/1538-7445.am2014-207;;10.1158/1538-7445.am2012-3357;;10.1158/1538-7445.am2014-1898;;10.1093/oxfordjournals.jbchem.a002832;;11134954;;10.1073/pnas.92.14.6414;;pmc41528;;7604005;;10.1038/nrd984;;12509759;;10.1016/s0022-1759(00)00339-2;;11223065;;10.1093/protein/gzn047;;18790793;;pmc2759461;;10.1016/j.tibtech.2004.03.006;;10.1016/s0167-7799(04)00080-0;;15109810;;pmc1302257;;10.1016/s0006-3495(02)73929-5;;12202384;;21803743;;10.1158/0008-5472.can-11-1704;;10.1074/jbc.m500815200;;15757893;;10.1016/j.coi.2008.06.012;;18656541;;15680154;;10.1016/j.jim.2004.11.005;;10835110;;10.1093/protein/13.5.361;;16527339;;10.1016/j.ygyno.2006.01.030;;20624122;;10.2217/fon.10.62;;10.1182/blood-2010-08-302067;;21498671;;10.1038/scibx.2011.151;;pmc2570514;;18827808;;10.1038/sj.bjc.6604484;;21824400;;pmc3170613;;10.1186/2045-824x-3-17;;10.1158/1078-0432.ccr-07-1393;;18094402;;pmc3174342;;10.1158/0008-5472.can-10-2719;;21795478;;22679110;;10.1158/1535-7163.mct-11-1027,"Al-Hajj, M., et al., “Prospective Identification of Tumorigenic Breast Cancer Cells,” Proceedings of the National Academy of Sciences 100(7):3983-3988, The National Academy of Sciences, United States (2003).;;Allenspach, E.J., et al., “Notch Signaling in Cancer,” Cancer Biology Therapy 1(5):466-476, Landes Biosience, United Kingdom (2002).;;Amado, R.G., et al., “Wild-Type KRAS is Required for Panitumumab Efficacy in Patients with Metastatic Colorectal Cancer,” Journal of Clinical Oncology 26(10):1626-1634, American Society of Clinical Oncology, United States (2008).;;Artavanis-Tsakonas, S., et al., “Notch Signaling: Cell Fate Control and Signal Integration in Development,” Science 284(5415):770-776, American Association for the Advancement of Science, United States (1999).;;Axelson, H., “Notch Signaling and Cancer: Emerging Complexity,” Seminars in Cancer Biology 14(5):317-319, Academic Press, England (2004).;;Barbas, C.F. 3rd., et al., “In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity,” Proceedings of the National Academy of Sciences 91(9):3809-3813, National Academy of Sciences, United States (1994).;;Beachy, P.A., et al., “Tissue Repair and Stem Cell Renewal in Carcinogenesis,” Nature 432(7015):324-331, Nature Publishing Group, England (2004).;;Bellavia, D., et al., “Constitutive Activation of NF-κB and T-cell Leukemia/lymphoma in Notch3 Transgenic Mice,” The EMBO Journal 19(13):3337-3348, European Molecular Biology Organization, Germany (2000).;;Benvenuti, S., et al., “Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies,” Cancer Research 67(6):2643-2648, American Association for Cancer Research, United States (2007).;;Besseyrias, V., et al., “Hierarchy of Notch-Delta interactions promoting T cell lineage commitment and maturation,” The Journal of Experimental Medicine 204(2):331-343, The Rockefeller University Press, United States (2007).;;Beviglia, L., et al., “Anti-DLL4 reduces tumor growth and tumorigenicity in B-RAF V600E melanomas including those with acquired resistance to B-RAF inhibitors,” AACR 103rd Annual Meeting 2012, Mar. 31-Apr. 4, Abstract LB-196, 1 page (2012).;;Beviglia, L., et al., “Anti-DLL4 Treatment Inhibits Melanoma Tumor Growth, Recurrence, Metastases and Reduces Frequency of Cancer Stem Cells in a Clinically Relevant Tumor Model in NOD/SCID Mice,” Cancer Research 71(8 Suppl.):Abstract 2834, AACR 102nd Annual Meeting 2011, Apr. 2-6, 2011.;;Beviglia, L., et al., “In vivo evaluation of anti-tumor activity by an anti-VEGF and anti-DLL4 bispecific antibody in a humanized model of skin graft,” AACR 104th Annual Meeting 2013, Abstract 4330, Apr. 6-10, 1 page (2013).;;Bloom, J.W., et al., “Intrachain Disulfide Bond in the Core Hinge Region of Human IgG4,” Protein Science 6(2):407-415, John Wiley & Sons, Inc., United States (Feb. 1997).;;Boerner, P., et al., “Production of Antigen-specific Human Monoclonal Antibodies from in Vitro-primed Human Splenocytes,” Journal of Immunology 147(1):86-95, The American Association of Immunologists, United States (1991).;;Bonnet, D. and Dick, J.E., “Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell,” Nature Medicine 3(7):730-737, Nature Publishing Company, United States (1997).;;Bray, S.J., “Notch signalling: a simple pathway becomes complex,” Nature Reviews Molecular Cell Biology 7(9):678-689, Nature Publishing Group, United States (2006).;;Brennan, K. and Brown, A.M., “Is there a Role for Notch Signalling in Human Breast Cancer?,” Breast Cancer Research 5(2):69-75, BioMed Central Ltd., United Kingdom (2003).;;Brennan, M., et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments,” Science 229(4708):81-83, American Association for the Advancement of Science, United States (Jul. 1985).;;Brorson, K., et al., “Mutational Analysis of Avidity and Fine Specificity of Anti-Levan Antibodies,” Journal of Immunology 163(12):6694-6701, American Association of Immunologists, United States (1999).;;Brummell, D.A., et al., “Probing the Combining Site of an Anti-Carbohydrate Antibody by Saturation-Mutagenesis: Role of the Heavy-Chain CDR3 Residues,” Biochemistry 32(4):1180-1187, American Chemical Society, United States (1993).;;Burgess, W.H., et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,” The Journal of Cell Biology 111(5Pt1):2129-2138, The Rockefeller University Press, United States (Nov. 1990).;;Burks, E.A., et al., “In vitro Scanning Saturation Mutagenesis of an Antibody Binding Pocket,” Proceedings of the National Academy of Sciences USA 94(2):412-417, Plenum Publishing Corporation , United States (1997).;;Callahan, R. and Raafat, A., “Notch Signaling in Mammary Gland Tumorigenesis,” Journal of Mammary Gland Biology and Neoplasia 6(1):23-36, Kluwer Academic/Plenum Publishers, United States (2001).;;Carter, P., “Improving the efficacy of antibody-based cancer therapies,” Nature Reviews Cancer 1(2):118-129, Nature Publishing Group, United States (2001).;;Chartier, C., et al., “The Hippo Signaling Pathway Mediates BMP Inhibition of Cancer Stem Cells,” 2015 AACR Annual meeting, Apr. 18-22, Abstract 2322, 1 page (2015).;;Chau, I. and Cunningham, D., “Treatment in advanced colorectal cancer: what, when and how?,” British Journal of Cancer 100(11):1704-1719, Nature Publishing Group, United States (2009).;;Chen, C., et al., “Generation and Analysis of Random Point Mutations in an Antibody CDR2 Sequence: Many Mutated Antibodies Lose their Ability to Bind Antigen,” The Journal of Experimental Medicine 176(3):855-866, Rockefeller University Press, United States (1992).;;Chen, Y., et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen,” Journal of Molecular Biology 293(4):865-881, Academic Press, England (Nov. 1999).;;Chi, A.S., et al., “Angiogenesis as a Therapeutic Target in Malignant Gliomas,” Oncologist 14(6):621-636, AlphaMed Press, United States (2009).;;Chothia, C. and Lesk, A.M., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” Journal of Molecular Biology 196(4):901-917, Elsevier Science, United States (Aug. 1987).;;Chothia, C., et al., “Domain association in immunoglobulin molecules. The packing of variable domains,” Journal of Molecular Biology 186(3):651-663, Elsevier Science, England (1985).;;Chowdhury, P.S. and Pastan, I., “Improving Antibody Affinity by Mimicking Somatic Hypermutation in Vitro,” Nature Biotechnology 17(6):568-572, Nature Publishing Group, United States (Jun. 1999).;;Clackson, T., et al., “Making Antibody Fragments using Phage Display Libraries,” Nature 352(6336):624-628, Nature Publishing Group, England (Aug. 1991).;;Clarke, M.F., et al., “Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells,” Cancer Research 66(19):9339-9344, American Association for Cancer Research, United States (2006).;;Claxton, S. and Fruttiger, M., “Periodic Delta-like 4 expression in developing retinal arteries,” Gene Expression Pattern 5:123-127, Elsevier B.V., Netherlands (2004).;;Cole, S.P.C., et al., “The EBV-Hybridoma Technique and Its Application to Human Lung Cancer,” in Monoclonal Antibodies and Cancer Therapy, Reisfeld, R.A. and Sell, S., eds., pp. 77-96, Alan R. Liss, Inc., United States (1985).;;Colman, P.M., “Effects of Amino Acid Sequence Changes on Antibody-antigen Interactions,” Research in Immunology 145(1):33-36, Elsevier, France (Jan. 1994).;;Cubillo, A., et al., “A Ph1b Study of Demcizumab (DEM, anti-DLL4) with Gemcitabine (GEM) in Patients with 1st Line Locally Advanced or Metastatic Pancreatic Cancer,” AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 19-23, 2013, Poster (2013), 8 pages.;;Cubillo, A., et al., “A Phase lb study of demcizumab (DEM, anti-DLL4) with gemcitabine (GEM) in patients with first line locally advanced or metastatic pancreatic cancer,” Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 19-23, 2013, Abstract B78, 2 pages (2013).;;Dalerba, P., et al., “Phenotypic characterization of human colorectal cancer stem cells,” Proceedings of the National Academy of Sciences 104(24):10158-10163, National Academy of Sciences, United States (2007).;;Dando, J.S., et al., “Notch/Delta4 interaction in human embryonic liver CD34+ CD38-cells: positive influence on BFU-E production and LTC-IC potential maintenance,” Stem Cells 23(4):550-560, John Wiley & Sons, Inc., United States (2005).;;Deisenhofer, J., “Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution,” Biochemistry 20(9):2361-2370, American Chemical Society, United States (1981).;;Deonarain, M.P., et al., “Antibodies Targeting Cancer Stem Cells: A New Paradigm in Immunotherapy?,” mAbs 1(1):12-25,Taylor & Francis, United States (2009).;;Dixit, R., “Cardiovascular Safety of Biologics: Challenges and Opportunities,” Medimmune, Safety Pharmacology Society, Annular Meeting Speakers Presentations (Oct. 3, 2012).;;Dontu, G., et al., “Role of Notch Signaling in Cell-Fate Determination of Human Mammary Stem/progenitor Cells,” Breast Cancer Research 6(6):R605-R615, BioMed Central, England (2004).;;Dorsch, M., et al., “Ectopic expression of Delta4 impairs hematopoietic development and leads to lymphoproliferative disease,” Blood 100(6):2046-2055, American Society of Hematology, United States (2002).;;Dreher, M.L., et al., “Colony assays for antibody fragments expressed in bacteria,” Journal of Immunological Methods 139(2):197-205, Elsevier Science, United States (1991).;;Duarte, A., et al., “Dosage-sensitive requirement for mouse Dll4 in artery development,” Genes & Development 18(20):2474-2478, Cold Spring Harbor Laboratory Press, United States (2004).;;Dupont, J. “Anti-Angiogenic Agents and Cardiovascular Effects: Implications for Clinical Development in Cancer,” presentation given in Barcelona, Spain on Nov. 4, 2011, 16 pages.;;Dupont, J., et al., “A Phase 1b Study of Anti-DLL4 (Delta-Like Ligand 4) Antibody Demcizumab (DEM) with Pemetrexed (PEM) and Carboplatin (CARBO) in Patients with 1st-Line Non-Squamous NSCLC,” 2015 European Lung Cancer Conference (ELCC), Geneva, Switzerland, Apr. 15-18, Abstract 114, 2 pages (2015).;;Ellisen, L.W., et al., “TAN-1, the Human Homolog of the Drosophila Notch Gene is Broken by Chromosomal Translocations in T Lymphoblastic neoplasm,” Cell 66(4):649-661, Cell Press, United States (1991).;;Engin,F., et al., “Dimorphic effects of Notch signaling in bone homeostasis,” Nature Medicine 14(3):299-305, Nature Publishing Group, United States (2008).;;English language translation of Oishi, H., et al., “Novel therapeutic strategy for pancreatic cancer targeting Notch signaling pathway,” Proceedings of the Japanese Cancer Association 65:311-312, Japan (2006).;;English language translation of “Tumor-angiogenesis suppression therapy targeting the Notch signaling pathway,” Suizo (Pancreas) 21(3):249, Japan (2006).;;Eppstein, D.A., et al., “Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor,” Proceedings of the National Academy of Sciences 82(11):3688-3692, National Academy of Sciences, United States (1985).;;European Search Report for EP Application No. EP10824244.7, Munich, Germany, dated Feb. 18, 2013, 6 pages.;;Farnie, G. and Clarke, R.B., “Mammary stem cells and breast cancer—role of Notch signalling,” Stem Cell Reviews and Reports 3(2):169-175, Humana Press, United States (2007).;;Farnie, G., et al., “Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways,” Journal of the National Cancer Institute 99(8):616-627, Oxford University Press, United Kingdom (2007).;;Fischer, M., et al., “Anti-DLL4 Inhibits Growth and Reduces Tumor-Initiating Cell Frequency in Colorectal Tumors with Oncogenic KRAS Mutations,” Cancer Research 71(5):1520-1525, American Association for Cancer Research, United States (2011).;;Fleming, R.J., et al., “The NOTCH receptor and its ligands,” Trends in Cell Biology 7(11):437-441, Elsevier Science Ltd., The Netherlands (1997).;;Fre, S., et al., “Notch Signals Control the Fate of Immature Progenitor Cells in the Intestine,” Nature 435(7044):964-968, Nature Publishing Group, United States (2005).;;Fung, E., et al., “Delta-like 4 induces notch signaling in macrophages: implications for inflammation,” Circulation 115(23):2948-2956, American Heart Association, Inc., United States (2007).;;Gagnon, M.L., et al., “Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity,” Proceedings of the National Academy of Sciences 97(6):2573-2578, National Academy of Sciences, United States (2000).;;Gale, N.W., et al., “Haploinsufficiency of Delta-like 4 Ligand Results in Embryonic Lethality due to Major Defects in arterial and Vascular Development,” Proceedings of the National Academy of Sciences 101(45):15949-15954, National Academy of Sciences, United States (2004).;;Gallahan, D., et al., “A new common integration region (int-3) for mouse mammary tumor virus on mouse chromosome 17,” Journal of Virology 61(1):218-220, American Society for Microbiology, United States (1987).;;Gallahan, D., et al., “Expression of a Truncated Int3 Gene in Developing Secretory Mammary Epithelium Specifically Retards Lobular Differentiation Resulting in Tumorigenesis,” Cancer Research 56(8):1775-1785, American Association for Cancer Research, United States (1996).;;Garber, K., “Notch Emerges as New Cancer Drug Target,” Journal of the national Cancer Institute 99(17):1284-1285, Oxford University Press, United States (2007).;;Goding, J.W., “Production of Monoclonal Antibodies,” in Monoclonal Antibodies: Principles and Practice, 2nd ed., pp. 59-103, Academic Press Inc., London (1986).;;Gracian, A.C., et al., “A phase 1b study of the anticancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) with or without paclitaxel protein bound particles (nab-paclitaxel) in patients with pancreatic cancer,” 2014 Gastrointestinal Cancers Symposium, Abstract 279, 2 pages (2014).;;Gray-Schopfer, V.C., et al., “The Role of B-RAF in Melanoma,” Cancer Metastasis Reviews 24(1):165-183, Springer Science + Business Media, Inc., Netherlands (2005).;;Gridley, T., “Notch Signaling During Vascular Development,” Proceedings of the National Academy of Sciences 98(10):5377-5378, National Academy of Sciences, United States (2001).;;Gridley, T. “Notch signaling in vascular development and physiology,” Development 134(15):2709-2718, (2007).;;Gronberg, B.H., et al., “Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared with Gemcitabine Plus Carboplatin as First-line Chemotherapy in Advanced Non-small-cell Lung Cancer,” Journal of Clinical Oncology 27(19):3217-3224, American Society of Clinical Oncology, United States (2009).;;Gruber, M., et al., “Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed in Escherichia coli,” The Journal of Immunology 152(11):5368-5374, The American Association of Immunologists, Inc., United States (1994).;;Gurney, A. and Hoey, T., “Anti-DLL4, a Cancer Therapeutic with Multiple Mechanisms of Action,” Vascular Cell 3, 4 pages, BioMed Central, United States (2011).;;Hainaud, P., et al., “The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions,” Cancer Research 66(17):8501-8510, American Association for Cancer Research, United States (2006).;;Hallahan, A.R., et al., “The SmoA1 Mouse Model Reveals that Notch Signaling is Critical for the Growth and Survival of Sonic Hedgehog-Induced Medulloblastomas,” Cancer Research 64(21):7794-7800, American Association for Cancer Research, United States (2004).;;Han, W., et al., “A soluble form of human Delta-like-1 inhibits differentiation of hematopoietic progenitor cells,” Blood 95(5):1616-1625, The American Society of Hematology, United States (2000).;;Harlow, E. and Lane, D., eds., “Immunoassays,” in Antibodies: A Laboratory Manual, 14:553-612, Cold Spring Harbor Laboratory, United States (1988).;;Harper, J.A., et al., “Notch Signaling in Development and Disease,” Clinical Genetics 64(6):461-472, Blackwell Publishing, United States (2003).;;Harrington, L.S., et al., “Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells,” Microvascular Research 75(2):144-154, Elsevier Science, United States (2008).;;Harris, W.J., “Production of Humanized Monoclonal Antibodies for in vivo Imaging and Therapy,” Biochemical Society Transactions 23(4):1035-1038, Portland Press on the Behalf of the Biochemical Society, England (1995).;;Hawkins, R.E., et al., “Selection of phage antibodies by binding affinity. Mimicking affinity maturation,” Journal of Molecular Biology 226(3):889-896, Elsevier Science, United States (1992).;;Hellström, M., et al., “Dll4 signalling through Notchl regulates formation of tip cells during angiogenesis,” Nature 445(7129):776-780, Nature Publishing Group, United States (2007).;;Henning, K., et al., “mNotch1 signaling and erythropoietin cooperate in erythroid differentiation of multipotent progenitor cells and upregulate beta-globin,” Experimental Hematology 35(9):1321-1332, Elsevier Science, United States (2007).;;Hermentin, P. and Seiler, F.R., “Investigations with Monoclonal Antibody Drug (Anthracycline) Conjugates,” Behring Institute Research Communications 82:197-215, Behringwerke Ag, Germany (1988).;;Hidalgo, M., et al., “A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxvel in Patients with Pancreatic Cancer,” European Society for Medical Oncology 2014 Congress, Sep. 17 and Sep. 28, Poster 616PD, 1 page (2014).;;Hidalgo, M., et al., “A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, Anti-DLL4) and Gemcitabine (GEM) with or without Paclitaxel Protein Bound Particles (Nab-Paclitaxel) in pts with Pancreatic Cancer,” 2015 ASCO Annual Meeting, Abstract 4118, 3 pages (2015).;;Hidalgo, M., et al., “Pre-Clinical and Clinical Activity of Anti-DLL4 (Demcizumab) in Combination with Gemcitabine Plus nab-Paclitaxel in Pancreatic Cancer,” 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Preclinical Models Poster Session, Abstract 166, 2 pages (Nov. 2014).;;Hoey, T., et al., “DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency,” Cell Stem Cell 5(2):168-177, Elsevier Science, United States (2009).;;Hofmann, J.J. and Iruela-Arispe, M.L., “Notch signaling in blood vessels: who is talking to whom about what?,” Circulation Research 100(11):1556-1568, American Heart Association, Inc., United States (2007).;;Holash, J., et al., “Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents,” Cancer Metastasis Rev 25:243-252, Dordrecht, Netherlands (2006).;;Holash, J., et al., “VEGF-Trap: A VEGF Blocker with Potent Antitumor Effects,” Proceedings of the National Academy of Sciences USA 99(17):11393-11398, National Academy of Sciences, United States (2002).;;Holm, P., et al., “Functional Mapping and Single Chain Construction of the Anti-cytokeratin 8 Monoclonal Antibody TS1,” Molecular Immunology 44(6):1075-1084, Pergamon Press, England (Feb. 2007).;;Hoogenboom, H.R. and Winter, G., “By-Passing Immunisation. Human Antibodies from Synthetic Repertoires of Germline VH Gene Segments Rearranged in vitro,” Journal of Molecular Biology 227(2):381-388, Elsevier, England (1992).;;Hope, K.J., et al., “Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in selfrenewal capacity,” Nature Immunology 5(7):738-743, Nature Publishing Group,United States (2004).;;Hopfer, O., et al., “The Notch Pathway in Ovarian Carcinomas and Adenomas,” British Journal of Cancer 93(6):709-718, Nature Publishing Group on behalf of Cancer Research UK, England (2005).;;Humphreys, D.P., et al., “Formation of dimeric Fabs in Escherichia coli: effect of hinge size and isotype, presence of interchain disulphide bond, Fab′ expression levels, tail piece sequences and growth conditions,” Journal of Immunological Methods 209(2):193-202, Elsevier Science, Netherlands (1997).;;Hurle, M.R. and Gross, M., “Protein engineering techniques for antibody humanization,” Current Opinion in Biotechnology 5(4):428-433, (1994).;;Hurwitz, H.I., et al., “Phase I Trial of Pazopanib in Patients with Advanced Cancer,” Clinical Cancer Research 15(12):4220-4227, American Association for Cancer Research, United States (2009).;;Hwang, K.J., et al., “Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study,” Proceedings of the National Academy of Sciences 77(7):4030-4034, National Academy of Sciences, United States (1980).;;International Preliminary Report on Patentability and Written Opinion for International Application No. PCT/US2010/53064, International Searching Authority, dated Feb. 14, 2011, 7 pages.;;International Preliminary Report on Patentability for Application No. PCT/US2016/053316, International Searching Authority, dated Apr. 5, 2018, 11 pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2013/065015, The International Bureau of WIPO, Switzerland, dated Apr. 22, 2014, 17 pages.;;International Search Report for International Application No. PCT/US16/53316, ISA/US, Alexandria, Virginia, dated Feb. 21, 2017, 7 pages.;;International Search Report for International Application No. PCT/US2010/53064, dated Feb. 14, 2011, 3 Pages.;;International Search Report for International Application No. PCT/US2015/024251, ISA/US, Alexandria, Virginia, United States, dated Jul. 16, 2015, 4 pages.;;International Search Report for International Patent Application No. PCT/US11/60773, International Searching Authority, Alexandria, Virginia, United States, dated Mar. 26, 2012, 3 pages.;;International Search Report for International Patent Application No. PCT/US2007/020889, United States Patent and Trademark Office, United States, dated Apr. 9, 2008, 5 pages.;;International Search Report with the Written Opinion of the International Searching Authority for International application No. PCT/US10/32625, United States Patent and Trademark Office, United States, dated Dec. 17, 2010, 11 pages.;;International Search Report with the Written Opinion of the International Searching Authority for International application No. PCT/US12/56886, United States Patent and Trademark Office, United States, dated Feb. 28, 2013, 8 pages.;;International Search Report with the Written Opinion of the International Searching Authority for International application No. PCT/US15/58327, United States Patent and Trademark Office, United States, dated May 19, 2016, 12 pages.;;International Search Report with Written Opinion for International Application No. PCT/US2010/58511, International Searching Authority, United States, dated Mar. 3, 2011, 9 pages.;;Ishiko, E., et al., “Notch signals inhibit the development of erythroid/megakaryocytic cells by suppressing GATA-1 activity through the induction of HES1,” The Journal of Biological Chemistry 280(6):4929-4939, American Society for Biochemistry and Molecular Biology, United States (2005).;;Iso, T., et al., “Notch Signaling in Vascular Development,” Arteriosclerosis, Thrombosis, and Vascular Biology 23(4):543-553, American Heart Association, Inc., United States (2003).;;Izzedine, H., et al., “Management of Hypertension In Angiogenesis Inhibitor-Treated Patients,” Annals of Oncology 20(5):807-815, Oxford University Press, England (2009).;;Jackson, J.R., et al., “In vitro antibody maturation. Improvement of a high affinity, neutralizing antibody against IL-1 beta,” The Journal of Immunology 154(7):3310-3319, The American Association of Immunologists, Inc., United States (1995).;;Janda, C.Y., “Structural Basis of Wnt Recognition by Frizzled,” Science 337(6090):59-64, American Association for the Advancement of Science, United States (2012).;;Janeway, Jr., et al., “Immunobiology, The Immune System in Health and Disease,” Edition 4:579-581, Current Biology Publications (1999).;;Jang, Y.-J., et al., “The Structural Basis for DNA Binding by an Anti-DNA Autoantibody,” Molecular Immunology 35(18):1207-1217, Pergamon Press, England (1998).;;Jarriault, S., et al., “Signalling Downstream of Activated Mammalian Notch,” Nature 377(6547):355-358, Nature Publishing Group, United States (1995).;;Jeffries, S. and Capobianco, A.J., “Neoplastic transformation by Notch requires nuclear localization,” Molecular and Cellular Biology 20(11):3928-3941, American Society for Microbiology, United States (2000).;;Jemal, A., et al., “Cancer Statistics, 2003,” CA—A Cancer Journal for Clinicians 53(1):05-26, American Cancer Society, United States (2003).;;Jhappan, C., et al., “Expression of an Activated Notch-Related int-3 Transgene Interferes with Cell Differentiation and Induces Neoplastic Transformation in Mammary and Salivary Glands,” Genes & Development 6(3):345-355, Cold Spring Harbor Laboratory Press, United States (1992).;;Jimeno, A., et al., “Phase 1 study of REGN421 (R)/SAR153192, a fully-human delta-like ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumors,” ASCO University 2013 ASCO Annual Meeting accessed at http://meetinglibrary.asco.org/content/113836-132, 2 pages.;;Jones, P.T., et al., “Replacing the Complementarity-determining Regions in a Human Antibody with those from a Mouse,” Nature 321(6069):522-525, Nature Publishing Group, England (May 1986).;;Kim, E.S., et al., “Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma,” Proceedings of the National Academy of Sciences 99(17):11399-11404, National Academy of Sciences, United States (2002).;;Kingsman, A.J., et al., “Replication in Saccharomyces cerevisiae of Plasmid pBR313 Carrying DNA from the Yeast Trpl Region,” Gene 7(2):141-152, Elsevier/North-Holland Biomedical Press, Netherlands (Oct. 1979).;;Kobayashi, H., et al., “Tryptophan H33 Plays an Important Role in Pyrimidine (6-4) Pyrimidone Photoproduct Binding by a High-Affinity Antibody,” Protein Engineering Design and Selection 12(10):879-884, Oxford University Press, United States (1999).;;Kohler, G. and Milstein, C., “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,” Nature 256(5517):495-497, Macmillan Journals Ltd., England (Aug. 1975).;;Kopper, L. and Hajdu, M., “Tumor Stem Cells,” Pathology Oncology Research 10(2):69-73, Aranyl Lajos Foundation, Hungary (2004).;;Kostelny, S.A., et al., “Formation of a Bispecific Antibody by the Use of Leucine Zippers,” The Journal of Immunology 148(5):1547-1553, American Association of Immunologists, United States (Mar. 1992).;;Krebs, L.T., et al., “Haploinsufficient Lethality and Formation of Arteriovenous Malformations in Notch Pathway Mutants,” Genes & Development 18(20):2469-2473, Cold Spring Harbor Laboratory Press, United States (2004).;;Krebs, L.T., et al., “Notch Signaling is Essential for Vascular Morphogenesis in Mice,” Genes & Development 14(11):1343-1352, Cold Spring Harbor Laboratory Press, United States (2000).;;Kuo, C.J., et al., “Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer,” Proceedings of the National Academy of Sciences 98(8):4605-4610, National Academy of Sciences, United States (2001).;;Lapidot, T., et al., “A Cell Initiating Human Acute Myeloid Leukaemia After Transplantation Into SCID Mice,” Nature 367(6464):645-648, Nature Publishing Group, United States (1994).;;Lauret, E., et al., “Membrane-Bound Delta-4 Notch Ligand Reduces the Proliferative Activity of Primitive Human Hematopoietic CD34+CD38low Cells while Maintaining their LTC-IC Potential,” Leukemia 18(4):788-797, Nature Publishing Group, United States (2006).;;Lazar, E., et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,” Molecular and Cellular Biology 8(3):1247-1252, American Society for Microbiology, United States (Mar. 1988).;;Lee, H.S., et al., “Generation and Characterization of a Novel Single-gene-encoded Single-chain Immunoglobulin Molecule with Antigen Binding Activity and Effector Functions,” Molecular Immunology 36(1):61-71, Elsevier Science Ltd., Netherlands (Jan. 1999).;;Leethanakul, C., et al., “Distinct Pattern of Expression of Differentiation and Growth-Related Genes in Squamous Cell Carcinomas of the Head and Neck Revealed By the Use of Laser Capture Microdissection and cDNA Arrays,” Oncogene 19(28):3220-3224, Nature Publishing Group, United States (2000).;;Lenihan, D.J., “How is cardiac toxicity defined and what impact does this have on cancer outcome or drug development,” PowerPoint Presentation from the DIA Meeting, 42 slides (2011).;;Leong, K.G. and Karsan, A., “Recent Insights into the Role of Notch Signaling in Tumorigenesis,” Blood 107(6):2223-2233, The American Society of Hematology, United States (2006).;;Li, J.L. and Harris A.L., “Notch Signaling from Tumor Cells: A New Mechanism of Angiogenesis,” Cancer Cell 8(1):pp. 1-3, Cell Press, United States (2005).;;Li, X., et al., “Notch3 Signaling is Required for the Development of Pulmonary Arterial Hypertension,” Nature Medicine 15(11):1289-1297, Nature Publishing Company, United States (2009).;;Lievre, A., et al., “KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer,” Cancer Research 66(8):3992-3995, American Association for Cancer Research, United States (2006).;;Limbourg, A., et al., “Notch ligand Delta-like 1 is essential for postnatal arteriogenesis,” Circulation Research 100(3):363-371, American Heart Association, Inc., United States (2007).;;Liu, S., et al., “Mammary stem cells, self-renewal pathways, and carcinogenesis,” Breast Cancer Research 7(3):86-95, BioMed Central, England (2005).;;Liu, Z.J., et al., “Inhibition of endothelial cell proliferation by Notch 1 signaling is mediated by represessing MAPK and P14K/Akt pathways and requires MAML1,” Federation of American Societies for Experimental Biology 20:E201-E210, American Society for Experimental Biology, United States (2006).;;Liu, Z.J., et al., “Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis,” Molecular and Cellular Biology 23(1):14-25, American Society for Microbiology, United States (2003).;;Lobov, I.B., et al., “Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting,” Proceedings of the National Academy of Sciences 104(9):3219-3224, National Academy of Sciences, United States (2007).;;Lu, K.V., and Bergers, G., “Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma,” CNS Oncology 2(1):49-65, Future Medicine, Inc., United States (2013).;;Luca, V.C., et al., “Structural basis for Notch1 engagement of Delta-like 4,” Science, 347(6224):847-853, American Association for the Advancement of Science, United States (2015).;;Maccallum, R.M., et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography,” Journal of Molecular Biology 262(5):732-745, Academic Press, England (Oct. 1996). et al.",ACTIVE
74,TW,B,TW I583699 B,006-569-211-322-806,2017-05-21,2017,TW 101134966 A,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,Vegf/dll4 binding agents and uses thereof,,ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/006-569-211-322-806,Granted Patent,no,1,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,,,0,0,,,,ACTIVE
75,US,A1,US 2013/0164295 A1,015-137-488-756-84X,2013-06-27,2013,US 201213625417 A,2012-09-24,US 201213625417 A;;US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,VEGF/DLL4 Binding Agents and Uses Thereof,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC;;ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,MEREO BIOPHARMA 5 INC (2012-12-11),https://lens.org/015-137-488-756-84X,Patent Application,yes,0,22,76,82,80,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,C07K16/22;;A61K39/395;;A61K45/00;;C07K16/18,424/136.1;;530/389.2;;530/388.23;;530/387.3;;435/328;;536/23.53;;435/320.1;;435/69.6,6,6,095-334-545-560-259;;014-113-432-888-031;;045-942-104-775-903;;001-779-867-387-972;;013-142-717-038-23X;;027-477-313-726-928,10.1006/jmbi.1996.0548;;8876650;;12218124;;10.4049/jimmunol.169.6.3076;;12850000;;10.1016/s0006-291x(03)01131-8;;10.1006/jmbi.1999.3192;;10543973;;10556035;;10.1006/jmbi.1999.3141;;10.1073/pnas.79.6.1979;;pmc346105;;6804947,MacCallum et al. (1996). J. Mol. Biol. 262:732-745.;;De Pascalis et al. (2002). Journal of Immunology. 169:3076-3084.;;Casset et al. (2003). Biochemical and Biophysical Reseaerch Communications. 307:198-205.;;Chen et al. (1999). J. Mol. biol. 293:865-881.;;Wu et al. (1999). J. Mol. Biol. 294:151-162.;;Rudikoff et al. (1982). PNAS. 79:1979-1983.,ACTIVE
76,WO,A1,WO 2013/044215 A1,034-711-150-654-881,2013-03-28,2013,US 2012/0056886 W,2012-09-24,US 201261597409 P;;US 201161538454 P;;US 201261692978 P,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/034-711-150-654-881,Patent Application,yes,11,19,76,82,80,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;C07K16/00;;C12P21/08,,5,2,108-821-214-937-013;;042-041-573-268-106,10.1038/nature05355;;17183313;;19664991;;10.1016/j.stem.2009.05.019,"NOGUERA-TROISE ET AL., NATURE, vol. 444, 2006, pages 1032 - 1037;;HOEY ET AL., CELL STEM CELL, vol. 5, 2009, pages 168 - 177;;POUWELS ET AL.: ""Cloning Vectors: A Laboratory Manual"", 1985, ELSEVIER;;LUCKOW; SUMMERS, BIOLTECHNOLOGY, vol. 6, 1988, pages 47;;See also references of EP 2758073A4",PENDING
77,IN,A,IN 871KON2014 A,063-173-239-103-599,2015-08-21,2015,IN 871KON2014 A,2014-04-21,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/063-173-239-103-599,Patent Application,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;C12P21/08,,0,0,,,,PENDING
78,US,A1,US 2021/0061903 A1,058-484-555-310-298,2021-03-04,2021,US 202016928452 A,2020-07-14,US 202016928452 A;;US 201715847335 A;;US 201715401543 A;;US 201615163301 A;;US 201414476582 A;;US 201213625417 A;;US 201261692978 P;;US 201261597409 P;;US 201161538454 P,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,MEREO BIOPHARMA 5 INC (2012-12-11),https://lens.org/058-484-555-310-298,Patent Application,yes,0,0,76,82,80,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,C07K16/28;;A61K31/4745;;A61K31/7068;;A61K39/00;;A61K39/395;;A61K45/00;;A61K45/06;;C07K16/18;;C07K16/22;;C07K16/30,,0,0,,,,ACTIVE
79,HR,T1,HR P20230078 T1,087-227-146-915-880,2023-05-12,2023,HR P20230078 T,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;EP 18197338 A,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,,MEREO BIOPHARMA 5 INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/087-227-146-915-880,Granted Patent,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/08,,0,0,,,,ACTIVE
80,CN,A,CN 107722122 A,109-911-760-349-329,2018-02-23,2018,CN 201710584230 A,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;CN 201280056471 A;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 binding agents and uses thereof,"- 125 The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The presentinvention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent orantibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/109-911-760-349-329,Patent Application,no,10,2,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,C07K16/22;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K45/06;;A61P35/00;;A61P35/02;;C07K16/28;;C12N15/13,,0,0,,,,ACTIVE
81,RS,B1,RS 63965 B1,187-852-629-636-068,2023-03-31,2023,RS P20230110 A,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;EP 18197338 A,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,,MEREO BIOPHARMA 5 INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/187-852-629-636-068,Granted Patent,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/08,,0,0,,,,ACTIVE
82,MX,A,MX 2014003558 A,014-912-811-215-241,2014-06-23,2014,MX 2014003558 A,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF.,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/014-912-811-215-241,Patent Application,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;C07K16/00;;C12P21/08,,0,0,,,,ACTIVE
83,US,B2,US 10730940 B2,062-848-354-937-704,2020-08-04,2020,US 201715847335 A,2017-12-19,US 201715847335 A;;US 201715401543 A;;US 201615163301 A;;US 201414476582 A;;US 201213625417 A;;US 201261692978 P;;US 201261597409 P;;US 201161538454 P,2011-09-23,VEGF/DLL4 binding agents and uses thereof,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,MEREO BIOPHARMA 5 INC (2012-12-11),https://lens.org/062-848-354-937-704,Granted Patent,yes,321,1,76,82,80,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/395;;A61K31/4745;;A61K31/7068;;A61K39/00;;A61K45/00;;A61K45/06;;C07K16/18;;C07K16/22;;C07K16/28;;C07K16/30;;C07K16/46,,349,262,045-942-104-775-903;;014-113-432-888-031;;084-085-138-348-898;;006-049-213-810-548;;042-535-804-056-355;;164-216-761-918-204;;070-614-370-694-544;;016-251-721-517-200;;021-197-916-777-658;;115-778-640-766-918;;020-327-681-254-735;;000-913-948-188-914;;015-807-813-009-849;;126-923-418-365-467;;043-293-799-149-190;;003-984-734-905-938;;037-480-189-672-490;;018-597-551-636-944;;059-703-624-598-226;;005-112-559-456-657;;053-851-713-620-401;;006-553-734-546-212;;003-849-961-384-35X;;105-316-874-895-908;;031-901-495-166-515;;061-397-752-245-555;;004-522-738-863-341;;016-291-551-264-744;;001-779-867-387-972;;032-443-032-575-719;;049-134-753-209-354;;061-518-684-585-221;;099-532-412-433-785;;034-331-211-704-877;;078-200-031-570-847;;100-371-416-663-157;;029-611-134-469-353;;027-845-339-272-06X;;133-610-790-984-99X;;016-270-419-085-156;;079-109-121-457-433;;025-070-183-573-259;;015-506-336-131-104;;037-809-048-883-498;;048-319-205-023-297;;007-837-250-546-989;;027-519-986-651-310;;018-320-647-455-556;;056-188-962-943-86X;;101-575-504-070-651;;073-702-812-203-896;;091-232-484-240-784;;138-876-315-756-795;;054-283-410-011-338;;060-684-120-299-26X;;112-241-917-646-013;;009-062-652-854-847;;090-306-007-122-585;;095-500-970-877-346;;027-306-913-195-466;;068-271-687-772-412;;129-005-046-068-395;;106-254-156-307-214;;032-048-398-057-385;;002-209-250-502-039;;003-711-275-433-72X;;035-232-534-898-963;;149-834-701-635-194;;035-067-471-486-809;;038-442-198-715-21X;;110-500-797-458-579;;072-351-640-594-174;;068-352-608-171-550;;065-608-090-342-50X;;005-119-615-003-591;;067-111-531-425-423;;065-542-021-501-547;;061-958-083-948-364;;164-451-236-197-939;;042-041-573-268-106;;016-512-212-388-570;;087-726-883-167-698;;008-498-336-394-659;;031-100-076-670-370;;032-071-991-081-664;;087-191-128-287-209;;089-486-878-211-546;;075-221-017-149-582;;077-495-150-106-187;;092-634-627-505-478;;089-633-612-001-004;;136-835-589-937-16X;;002-723-775-902-029;;017-328-222-500-841;;085-727-974-637-837;;023-378-335-265-81X;;033-368-627-556-233;;008-844-599-921-544;;099-964-134-794-845;;030-922-427-128-310;;021-745-342-029-670;;129-973-531-805-684;;006-574-964-805-278;;046-013-436-890-449;;015-623-518-697-144;;068-238-957-669-243;;106-753-778-592-300;;014-119-439-143-988;;104-212-297-137-759;;054-531-591-081-65X;;022-883-652-460-089;;085-528-415-223-353;;056-502-337-160-838;;014-785-980-334-859;;004-425-043-791-551;;029-657-616-636-736;;004-602-847-993-84X;;056-289-930-116-029;;054-277-945-870-664;;044-312-778-204-450;;024-810-152-282-074;;085-249-110-169-470;;128-376-920-124-813;;066-699-026-742-579;;086-164-247-322-732;;043-453-890-807-326;;024-298-462-228-882;;095-334-545-560-259;;024-561-324-817-879;;062-547-748-254-237;;010-916-105-450-247;;020-855-322-534-259;;024-042-571-208-910;;032-607-776-688-407;;030-630-100-818-462;;113-146-142-749-076;;041-945-536-319-424;;113-146-142-749-076;;108-327-398-058-238;;052-515-652-666-158;;092-881-815-515-655;;020-636-405-917-503;;048-208-171-994-922;;117-775-899-628-564;;039-118-196-658-356;;058-205-097-704-518;;018-709-667-787-457;;096-836-261-967-31X;;077-108-010-423-006;;030-607-398-087-475;;006-454-751-452-062;;071-717-719-996-536;;108-821-214-937-013;;011-745-980-251-775;;048-103-697-044-146;;127-754-934-722-768;;085-593-346-327-896;;033-658-808-499-907;;006-798-173-804-888;;000-185-481-899-567;;008-268-944-751-345;;000-935-046-673-192;;008-151-002-104-508;;033-073-320-277-143;;065-287-969-992-103;;028-156-483-654-882;;015-239-659-590-870;;069-144-826-896-138;;027-020-473-411-693;;024-779-467-240-124;;102-675-067-390-626;;016-014-793-014-160;;041-596-561-800-698;;100-984-968-676-329;;020-564-002-939-564;;042-204-626-457-327;;018-414-301-058-606;;089-635-536-661-885;;027-477-313-726-928;;094-311-434-287-343;;090-714-216-170-949;;081-098-206-476-749;;026-048-786-530-595;;049-192-915-761-746;;072-064-906-772-096;;061-751-917-222-159;;043-558-136-070-327;;107-303-389-554-878;;064-792-093-706-002;;058-211-492-859-131;;091-347-675-692-644;;093-067-181-692-392;;063-640-832-834-034;;000-438-864-132-323;;036-379-137-455-723;;000-438-864-132-323;;175-243-588-850-607;;080-191-903-791-47X;;013-642-802-665-79X;;047-364-936-221-939;;085-729-060-237-502;;016-658-224-490-240;;037-711-371-585-567;;047-025-555-564-763;;011-910-096-463-060;;026-145-110-279-358;;008-266-889-199-914;;006-257-463-053-048;;125-269-916-334-305;;002-219-259-764-94X;;031-063-853-127-197;;022-375-749-274-329;;051-940-176-386-905;;067-279-783-581-616;;008-479-069-316-491;;049-991-770-424-933;;091-582-771-406-994;;053-665-131-053-807;;045-094-249-115-990;;069-495-502-499-501;;091-114-424-339-46X;;016-314-653-579-682;;052-795-433-555-537;;009-188-067-200-010;;037-589-218-577-038;;083-606-989-843-197;;047-462-962-275-331;;119-515-479-159-88X;;008-411-420-307-533;;013-142-717-038-23X;;006-124-137-496-346;;003-711-929-171-854;;049-491-181-937-297;;025-046-032-214-179;;035-236-318-471-090;;060-472-079-666-376;;028-960-308-516-850;;066-407-919-450-381;;150-651-615-448-193;;078-077-493-330-521;;091-051-926-686-546;;018-146-170-889-398;;064-048-827-826-930;;035-275-453-395-352;;012-005-224-634-423;;059-212-558-154-670;;132-484-526-820-872;;020-239-636-647-054;;022-648-069-840-113;;155-710-259-787-090;;025-331-205-864-51X;;000-740-232-876-831;;028-960-308-516-850;;022-983-639-581-992;;026-365-124-273-808;;014-158-096-594-681;;049-666-882-297-378;;059-476-065-054-670;;082-593-540-788-849;;015-283-465-647-996;;032-117-626-844-978;;022-560-800-296-262,12850000;;10.1016/s0006-291x(03)01131-8;;12218124;;10.4049/jimmunol.169.6.3076;;10.1073/pnas.0530291100;;pmc153034;;12629218;;12496471;;10.4161/cbt.1.5.159;;10.1200/jco.2007.14.7116;;18316791;;10.1126/science.284.5415.770;;10221902;;15288256;;10.1016/j.semcancer.2004.04.010;;10.1073/pnas.91.9.3809;;pmc43671;;8170992;;15549094;;10.1038/nature03100;;17363584;;10.1158/0008-5472.can-06-4158;;pmc2118717;;10.1084/jem.20061442;;17261636;;10.1158/1538-7445.am2012-lb-196;;10.1158/1538-7445.am2011-2834;;10.1158/1538-7445.am2013-4330;;9041643;;pmc2143633;;10.1002/pro.5560060217;;10.4049/jimmunol.147.1.86;;2051030;;9212098;;10.1038/nm0797-730;;10.1038/nrm2009;;16921404;;pmc154142;;10.1186/bcr559;;12631384;;10.1126/science.3925553;;3925553;;10586066;;10.4049/jimmunol.163.12.6694;;8424945;;10.1021/bi00055a024;;1699952;;pmc2116333;;10.1083/jcb.111.5.2129;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;10.1023/a:1009512414430;;11467450;;11905803;;10.1038/35101072;;19436303;;10.1038/sj.bjc.6605061;;pmc2695695;;1512548;;10.1084/jem.176.3.855;;pmc2119366;;10.1006/jmbi.1999.3192;;10543973;;pmc4790121;;19487335;;10.1634/theoncologist.2008-0272;;10.1016/0022-2836(87)90412-8;;3681981;;10.1016/0022-2836(85)90137-8;;4093982;;10385321;;10.1038/9872;;10.1038/352624a0;;1907718;;10.1158/0008-5472.can-06-3126;;16990346;;10.1016/j.modgep.2004.05.004;;15533827;;7516563;;10.1016/s0923-2494(94)80039-1;;10.1158/1535-7163.targ-13-b78;;10.1073/pnas.0703478104;;pmc1891215;;17548814;;15790776;;10.1634/stemcells.2004-0205;;10.2210/pdb1fc1/pdb;;7236608;;10.2210/pdb1fc2/pdb;;10.1021/bi00512a001;;20046569;;pmc2715180;;10.4161/mabs.1.1.7347;;pmc1064073;;10.1186/bcr920;;15535842;;10.1182/blood.v100.6.2046.h81802002046_2046_2055;;12200365;;2045660;;10.1016/0022-1759(91)90189-m;;15466159;;pmc529534;;10.1101/gad.1239004;;10.1093/annonc/mdv050.18;;1831692;;10.1016/0092-8674(91)90111-b;;pmc2671578;;10.1038/nm1712;;18297084;;pmc397852;;10.1073/pnas.82.11.3688;;3159018;;10.1007/s12015-007-0023-5;;17873349;;17440163;;10.1093/jnci/djk133;;10.1158/0008-5472.can-10-2817;;21193546;;17709001;;10.1016/s0962-8924(97)01161-6;;15959516;;10.1038/nature03589;;17533181;;10.1161/circulationaha.106.675462;;10.1073/pnas.040337597;;pmc15970;;10688880;;10.1073/pnas.0407290101;;15520367;;pmc524697;;3023699;;pmc255246;;10.1128/jvi.61.1.218-220.1987;;8620493;;10.1093/jnci/djm148;;17728207;;10.1200/jco.2014.32.3_suppl.279;;10.1007/s10555-005-5865-1;;15785879;;10.1073/pnas.101138098;;pmc33218;;11344278;;17611219;;10.1242/dev.004184;;10.1200/jco.2008.20.9114;;19433683;;10.4049/jimmunol.152.11.5368;;8189055;;pmc3177777;;10.1186/2045-824x-3-18;;21831306;;10.1158/0008-5472.can-05-4226;;16951162;;15520185;;10.1158/0008-5472.can-04-1813;;10.1182/blood.v95.5.1616.005k31_1616_1625;;10688816;;14986825;;10.1046/j.1399-0004.2003.00194.x;;10.1016/j.mvr.2007.06.006;;17692341;;8654676;;10.1042/bst0231035;;10.1016/0022-2836(92)90639-2;;1507232;;17259973;;10.1038/nature05571;;10.1016/j.exphem.2007.05.014;;17637499;;3044339;;10.1016/s0959-8049(14)70292-8;;19664991;;10.1016/j.stem.2009.05.019;;17556669;;10.1161/01.res.0000266408.42939.e4;;16770536;;10.1007/s10555-006-8504-6;;12177445;;10.1073/pnas.172398299;;pmc123267;;16989900;;10.1016/j.molimm.2006.08.001;;10.1016/0022-2836(92)90894-p;;1404359;;15170211;;10.1038/ni1080;;pmc2361628;;10.1038/sj.bjc.6602719;;16136053;;10.1016/s0022-1759(97)00172-5;;9461335;;10.1016/0958-1669(94)90053-1;;7765176;;10.1158/1078-0432.ccr-08-2740;;19509175;;6933450;;pmc349762;;10.1073/pnas.77.7.4030;;15563463;;10.1074/jbc.m406788200;;12615665;;10.1161/01.atv.0000060892.81529.8f;;10.1093/annonc/mdn713;;19150949;;7897213;;10.4049/jimmunol.154.7.3310;;10.1126/science.1222879;;pmc3577348;;22653731;;10.1016/s0161-5890(98)00095-9;;10199394;;7566092;;10.1038/377355a0;;10805736;;pmc85741;;10.1128/mcb.20.11.3928-3941.2000;;12568441;;10.3322/canjclin.53.1.5;;10.1101/gad.6.3.345;;1372276;;10.1200/jco.2013.31.15_suppl.2502;;10.1038/321522a0;;3713831;;10.1073/pnas.172398399;;pmc123268;;12177446;;389741;;10.1016/0378-1119(79)90029-5;;10556249;;10.1093/protein/12.10.879;;1172191;;10.1038/256495a0;;10.1007/bf02893458;;15188021;;10.4049/jimmunol.148.5.1547;;1531669;;pmc529533;;10.1101/gad.1239204;;15466160;;10837027;;pmc316662;;10.1101/gad.14.11.1343;;10.1073/pnas.081615298;;11274374;;pmc31881;;7509044;;10.1038/367645a0;;10.1038/sj.leu.2403288;;14990974;;10.1016/s0161-5890(98)00109-6;;10369421;;10.1038/sj.onc.1203703;;10918578;;16291593;;10.1182/blood-2005-08-3329;;16023591;;10.1016/j.ccr.2005.06.013;;10.1038/nm.2021;;19855400;;pmc2780347;;10.1158/0008-5472.can-06-0191;;16618717;;10.1161/01.res.0000258174.77370.2c;;17234965;;10.1186/bcr1021;;15987436;;pmc1143566;;10.1096/fj.05-4880fje;;16571776;;12482957;;pmc140667;;10.1128/mcb.23.1.14-25.2003;;10.1073/pnas.0611206104;;pmc1805530;;17296940;;23750318;;10.2217/cns.12.36;;pmc3673744;;25700513;;10.1126/science.1261093;;pmc4445638;;10.1006/jmbi.1996.0548;;8876650;;1873503;;10.3233/hab-1991-2302;;10.1046/j.1432-0436.2001.690207.x;;11798067;;10.1038/nbt0792-779;;1368267;;1748994;;10.1016/0022-2836(91)90498-u;;10.1210/en.2007-0477;;17916635;;pmc2734500;;pmc3491453;;23019585;;10.1073/pnas.1206400109;;10.1038/348552a0;;2247164;;10.1016/s0959-8049(12)72395-x;;10.1158/1535-7163.targ-13-a71;;10.1016/s0959-8049(12)72395-x;;10.1200/jco.2014.32.15_suppl.2544;;10.1038/nbt0798-677;;9661204;;10528225;;10.1002/(sici)1097-4652(199912)181:3<393::aid-jcp3>3.0.co;2-6;;16489059;;10.1158/1078-0432.ccr-05-2570;;15319485;;10.1093/toxsci/kfh254;;10.1038/305537a0;;6137772;;1560176;;10.1016/0165-022x(92)90051-b;;10.1016/s0952-7915(97)80138-0;;9099790;;9039255;;10.1016/s0092-8674(00)81867-x;;10.1146/annurev.cb.11.110195.000343;;10.1146/annurev.cellbio.11.1.35;;8689561;;10.1353/dem.2000.0009;;11086575;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;12133727;;10.1016/s1367-5931(02)00346-0;;10.1038/sj.onc.1206758;;14528285;;10.1038/nature05355;;17183313;;10.1073/pnas.051624498;;pmc30615;;11248040;;pmc390431;;10.1073/pnas.82.14.4592;;3927286;;pmc1698634;;17028337;;10.1534/genetics.106.061630;;10.3892/ijmm.14.5.779;;15492845;;10.1158/0008-5472.can-05-1208;;16204037;;10.1097/01.moh.0000143965.90813.70;;15548998;;8642337;;10.1084/jem.183.5.2283;;pmc2192581;;19154719;;pmc8114544;;10.1016/j.devcel.2008.12.009;;10.1093/glycob/cwi007;;15496501;;pmc3608722;;10.4049/jimmunol.1202820;;23440416;;17605027;;10.1007/s00418-007-0306-6;;10.3109/14017431.2010.511256;;20799913;;15288259;;10.1016/j.semcancer.2004.04.013;;10.4049/jimmunol.150.3.880;;8423344;;8360482;;10.4049/jimmunol.151.5.2623;;15781650;;10.1158/0008-5472.can-04-1890;;16409162;;10.1146/annurev.med.57.121304.131240;;11072240;;10.1002/1097-0215(20001201)88:5<726::aid-ijc7>3.0.co;2-h;;10.1006/excr.2000.5034;;11035934;;16697642;;10.1016/j.tcb.2006.04.003;;10.1038/35102167;;11689955;;10.1038/nature05313;;17183323;;3127726;;10.1038/332323a0;;18758481;;10.1038/onc.2008.226;;8898201;;10.1016/s0092-8674(00)81368-9;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;17822956;;10.1016/j.molmed.2007.07.002;;pmc1134670;;15330757;;10.1042/bj20041022;;10.1182/blood-2006-12-063933;;pmc1885521;;17311993;;10.1016/0378-1119(95)00821-7;;8647439;;18392005;;10.1038/nbt0408-366c;;pmc2119072;;10.1084/jem.175.1.217;;1346155;;12814948;;10.1111/j.1749-6632.2003.tb03219.x;;10.1073/pnas.95.11.6157;;pmc27609;;9600934;;17308088;;10.1158/0008-5472.can-06-3311;;10837024;;10.1101/gad.14.11.1313;;pmc316657;;17259972;;10.1038/nature05577;;10.1093/jnci/djp280;;pmc2758310;;19738166;;7688398;;10.4049/jimmunol.151.4.2296;;10631780;;10.1016/s0167-7799(99)01398-0;;10.1016/s1359-6349(10)71927-3;;25324140;;10.1158/1078-0432.ccr-14-1373;;10.1016/s1359-6349(10)71927-3;;7544153;;10.1002/(sici)1097-0215(20000601)86:5<652::aid-ijc8>3.3.co;2-m;;10797286;;10.1002/(sici)1097-0215(20000601)86:5<652::aid-ijc8>3.0.co;2-v;;10.1158/1538-7445.am2015-255;;388229;;10.1038/282039a0;;10.1016/j.exphem.2005.12.016;;16569589;;pmc2394258;;12865906;;10.1038/sj.bjc.6601107;;10.1016/0076-6879(86)21019-8;;3724461;;10.3892/ijo.17.6.1131;;11078798;;8747303;;10.1291/hypres.18.259;;8139658;;10.1038/368150a0;;0008139658;;10.1186/1471-5945-2-7;;pmc111189;;11978185;;15293563;;10.1532/ijh97.04065;;17457300;;10.1038/nrc2130;;14754405;;10.2174/1381612043453603;;pmc453097;;1834458;;10.1002/j.1460-2075.1991.tb04932.x;;1675655;;10.4049/jimmunol.147.1.60;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;9576833;;10.1006/dbio.1998.8863;;10.1016/j.molmed.2005.09.008;;16214417;;11107116;;10.1002/1096-911x(20001201)35:6<554::aid-mpo13>3.0.co;2-r;;10.1016/s1081-1206(10)62794-9;;9723555;;9630891;;10.1038/nbt0396-309;;10.1126/science.2451287;;2451287;;10.1007/978-1-61779-968-6_2;;22886243;;9166828;;10.1182/blood.v89.11.3919;;10.1016/s1054-3589(08)60931-x;;8504061;;10.1038/nm754;;12185362;;10.1126/science.1102160;;15472075;;12509463;;10.1128/mcb.23.2.655-664.2003;;pmc151540;;10.1182/blood-2005-03-1000;;16219802;;pmc1895896;;10.1016/j.febslet.2006.03.024;;16574107;;10.1016/s1359-6349(08)72532-1;;17934452;;10.1038/nbt1345;;10556035;;10.1006/jmbi.1999.3141;;10.1074/jbc.m505569200;;15994325;;10.1038/nature08751;;20147986;;10.1182/blood.v98.13.3793;;11739188;;10.4049/jimmunol.155.4.1994;;7636250;;10.1158/0008-5472.sabcs-09-5071;;10.1158/1538-7445.am2013-3725;;22952347;;10.1158/1078-0432.ccr-12-0736;;10.1158/1538-7445.am2014-207;;10.1158/1538-7445.am2012-3357;;10.1158/1538-7445.am2014-1898;;10.1093/oxfordjournals.jbchem.a002832;;11134954;;10.1073/pnas.92.14.6414;;pmc41528;;7604005;;10.1038/nrd984;;12509759;;10.1016/s0022-1759(00)00339-2;;11223065;;10.1093/protein/gzn047;;18790793;;pmc2759461;;10.1016/j.tibtech.2004.03.006;;10.1016/s0167-7799(04)00080-0;;15109810;;pmc1302257;;10.1016/s0006-3495(02)73929-5;;12202384;;21803743;;10.1158/0008-5472.can-11-1704;;10.1074/jbc.m500815200;;15757893;;10.1016/j.coi.2008.06.012;;18656541;;15680154;;10.1016/j.jim.2004.11.005;;10835110;;10.1093/protein/13.5.361;;22952347;;10.1158/1078-0432.ccr-12-0736;;16527339;;10.1016/j.ygyno.2006.01.030;;20624122;;10.2217/fon.10.62;;10.1182/blood-2010-08-302067;;21498671;;10.1038/scibx.2011.151;;pmc2570514;;18827808;;10.1038/sj.bjc.6604484;;21824400;;pmc3170613;;10.1186/2045-824x-3-17;;10.1158/1078-0432.ccr-07-1393;;18094402;;pmc3174342;;10.1158/0008-5472.can-10-2719;;21795478;;22679110;;10.1158/1535-7163.mct-11-1027,"Casset et al. (2003). Biochem. and Biophys. Res. Comm. 307:198-205.;;De Pascalis et al. (2002). J. Immunol. 169:3076-3084.;;Al-Hajj, M., et al., “Prospective Identification of Tumorigenic Breast Cancer Cells,” Proceedings of the National Academy of Sciences 100(7):3983-3988, The National Academy of Sciences, United States (2003).;;Allenspach, E.J., et al., “Notch Signaling in Cancer,” Cancer Biology Therapy 1(5):466-476, Landes Biosience, United Kingdom (2002).;;Amado, R.G., et al., “Wild-Type KRAS is Required for Panitumumab Efficacy in Patients with Metastatic Colorectal Cancer,” Journal of Clinical Oncology 26(10):1626-1634, American Society of Clinical Oncology, United States (2008).;;Artavanis-Tsakonas, S., et al., “Notch Signaling: Cell Fate Control and Signal Integration in Development,” Science 284(5415):770-776, American Association for the Advancement of Science, United States (1999).;;Axelson, H., “Notch Signaling and Cancer: Emerging Complexity,” Seminars in Cancer Biology 14(5):317-319, Academic Press, England (2004).;;Barbas, C.F. 3rd., et al., “In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity,” Proceedings of the National Academy of Sciences 91(9):3809-3813, National Academy of Sciences, United States (1994).;;Beachy, P.A., et al., “Tissue Repair and Stem Cell Renewal in Carcinogenesis,” Nature 432(7015):324-331, Nature Publishing Group, England (2004).;;Bellavia, D., et al., “Constitutive Activation of NF-κB and T-cell Leukemia/lymphoma in Notch3 Transgenic Mice,” The EMBO Journal 19(13):3337-3348, European Molecular Biology Organization, Germany (2000).;;Benvenuti, S., et al., “Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies,” Cancer Research 67(6):2643-2648, American Association for Cancer Research, United States (2007).;;Besseyrias, V., et al., “Hierarchy of Notch-Delta interactions promoting T cell lineage commitment and maturation,” The Journal of Experimental Medicine 204(2):331-343, The Rockefeller University Press, United States (2007).;;Beviglia, L., et al., “Anti-DLL4 reduces tumor growth and tumorigenicity in B-RAF V600E melanomas including those with acquired resistance to B-RAF inhibitors,” AACR 103rd Annual Meeting 2012, Mar. 31-Apr. 4, Abstract LB-196, 1 page (2012).;;Beviglia, L., et al., “Anti-DLL4 Treatment Inhibits Melanoma Tumor Growth, Recurrence, Metastases and Reduces Frequency of Cancer Stem Cells in a Clinically Relevant Tumor Model in NOD/SCID Mice,” Cancer Research 71(8 Suppl.):Abstract 2834, AACR 102nd Annual Meeting 2011, Apr. 2-6, 2011.;;Beviglia, L., et al., “In vivo evaluation of anti-tumor activity by an anti-VEGF and anti-DLL4 bispecific antibody in a humanized model of skin graft,” AACR 104th Annual Meeting 2013, Abstract 4330, Apr. 6-10, 1 page (2013).;;Bloom, J,W., et al., “Intrachain Disulfide Bond in the Core Hinge Region of Human IgG4,” Protein Science 6(2):407-415, John Wiley & Sons, Inc., United States (Feb. 1997).;;Boerner, P., et al., “Production of Antigen-specific Human Monoclonal Antibodies from in Vitro-primed Human Splenocytes,” Journal of Immunology 147(1):86-95, The American Association of Immunologists, United States (1991).;;Bonnet, D. and Dick, J.E., “Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell,” Nature Medicine 3(7):730-737, Nature Publishing Company, United States (1997).;;Bray, S.J., “Notch signalling: a simple pathway becomes complex,” Nature Reviews Molecular Cell Biology 7(9):678-689, Nature Publishing Group, United States (2006).;;Brennan, K. and Brown, A.M., “Is there a Role for Notch Signalling in Human Breast Cancer?,” Breast Cancer Research 5(2):69-75, BioMed Central Ltd., United Kingdom (2003).;;Brennan, M., et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments,” Science 229(4708):81-83, American Association for the Advancement of Science, United States (Jul. 1985).;;Brorson, K., et al., “Mutational Analysis of Avidity and Fine Specificity of Anti-Levan Antibodies,” Journal of Immunology 163(12):6694-6701, American Association of Immunologists, United States (1999).;;Brummell, D.A., et al., “Probing the Combining Site of an Anti-Carbohydrate Antibody by Saturation-Mutagenesis: Role of the Heavy-Chain CDR3 Residues,” Biochemistry 32(4):1180-1187, American Chemical Society, United States (1993).;;Burgess, W.H., et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,” The Journal of Cell Biology 111(5Pt1):2129-2138, The Rockefeller University Press, United States (Nov. 1990).;;Burks, E.A., et al., “In vitro Scanning Saturation Mutagenesis of an Antibody Binding Pocket,” Proceedings of the National Academy of Sciences USA 94(2):412-417, Plenum Publishing Corporation , United States (1997).;;Callahan, R. and Raafat, A., “Notch Signaling in Mammary Gland Tumorigenesis,” Journal of Mammary Gland Biology and Neoplasia 6(1):23-36, Kluwer Academic/Plenum Publishers, United States (2001).;;Carter, P., “Improving the efficacy of antibody-based cancer therapies,” Nature Reviews Cancer 1(2):118-129, Nature Publishing Group, United States (2001).;;Chartier, C., et al., “The Hippo Signaling Pathway Mediates BMP Inhibition of Cancer Stem Cells,” 2015 AACR Annual meeting, Apr. 18-22, Abstract 2322, 1 page (2015).;;Chau, I. and Cunningham, D., “Treatment in advanced colorectal cancer: what, when and how?,” British Journal of Cancer 100(11)1 704-1719, Nature Publishing Group, United States (2009).;;Chen, C., et al., “Generation and Analysis of Random Point Mutations in an Antibody CDR2 Sequence: Many Mutated Antibodies Lose their Ability to Bind Antigen,” The Journal of Experimental Medicine 176(3):855-866, Rockefeller University Press, United States (1992).;;Chen, Y., et al,, “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen,” Journal of Molecular Biology 293(4):865-881, Academic Press, England (Nov. 1999).;;Chi, A.S., et al., “Angiogenesis as a Therapeutic Target in Malignant Gliomas,” Oncologist 14(6):621-636, AlphaMed Press, United States (2009).;;Chothia, C. and Lesk, A.M., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” Journal of Molecular Biology 196(4):901-917, Elsevier Science, United States (Aug. 1987).;;Chothia, C., et al, “Domain association in immunoglobulin molecules. The packing of variable domains,” Journal of Molecular Biology 186(3):651-663, Elsevier Science, England (1985).;;Chowdhury, P.S. and Pastan, I., “Improving Antibody Affinity by Mimicking Somatic Hypermutation in Vitro,” Nature Biotechnology 17(6):568-572, Nature Publishing Group, United States (Jun. 1999).;;Clackson, T., et al., “Making Antibody Fragments using Phage Display Libraries,” Nature 352(6336):624-628, Nature Publishing Group, England (Aug. 1991).;;Clarke, M.F., et al., “Cancer stern cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells,” Cancer Research 66(19):9339-9344, American Association for Cancer Research, United States (2006).;;Claxton, S. and Fruttiger, M., “Periodic Delta-like 4 expression in developing retinal arteries,” Gene Expression Pattern 5:123-127, Elsevier B.V., Netherlands (2004).;;Cole, S.P.C., et al., “The EBV-Hybridoma Technique and Its Application to Human Lung Cancer,” in Monoclonal Antibodies and Cancer Therapy, Reisfeld, R.A. and Sell, S., eds., pp. 77-96, Alan R. Liss, Inc., United States (1985).;;Colman, P.M., “Effects of Amino Acid Sequence Changes on Antibody-antigen Interactions,” Research in Immunology 145(1):33-36, Elsevier, France (Jan. 1994).;;Cubillo, A., et al., “A Ph1b Study of Derncizurnab (DEM, anti-DLL4) with Gemcitabine (GEM) in Patients with 1st Line Locally Advanced or Metastatic Pancreatic Cancer,” AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 19-23, 2013, Poster (2013), 8 pages.;;Cubillo, A., et al., “A Phase Ib study of demcizumab (DEM, anti-DLL4) with gemcitabine (GEM) in patients with first line locally advanced or metastatic pancreatic cancer,” Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 19-23, 2013, Abstract B78, 2 pages (2013).;;Dalerba, P., et al., “Phenotypic characterization of human colorectal cancer stem cells,” Proceedings of the National Academy of Sciences 104(24):10158-10163, National Academy of Sciences, United States (2007).;;Dando, J.S., et al., “Notch/Delta4 interaction in human embryonic liver CD34+ CD38− cells: positive influence on BFU-E production and LTC-IC potential maintenance,” Stem Cells 23(4):550-560, John Wiley & Sons, Inc., United States (2005).;;Deisenhofer, J., “Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein a from Staphylococcus aureus at 2.9- and 2.8-A resolution,” Biochemistry 20(9):2361-2370, American Chemical Society, United States (1981).;;Deonarain, M.P., et al., “Antibodies Targeting Cancer Stem Cells: A New Paradigm in Immunotherapy?,” mAbs 1(1):12-25,Taylor & Francis, United States (2009).;;Dixit, R., “Cardiovascular Safety of Biologics: Challenges and Opportunities,” Medimmune, Safety Pharmacology Society, Annular Meeting Speakers Presentations (Oct. 3, 2012).;;Dontu, G., et al., “Role of Notch Signaling in Cell-Fate Determination of Human Mammary Stem/progenitor Cells,” Breast Cancer Research 6(6):R605-R615, BioMed Central, England (2004).;;Dorsch, M. et al., “Ectopic expression of Delta4 impairs hematopoietic development and leads to lymphoproliferative disease,” Blood 100(6):2046-2055, American Society of Hematology, United States (2002).;;Dreher, M.L., et al., “Colony assays for antibody fragments expressed in bacteria,” Journal of Immunological Methods 139(2):197-205, Elsevier Science, United States (1991).;;Duarte, A., et al., “Dosage-sensitive requirement for mouse Dll4 in artery development,” Genes & Development 18(20):2474-2478, Cold Spring Harbor Laboratory Press, United States (2004).;;Dupont, J. “Anti-Angiogenic Agents and Cardiovascular Effects: Implications for Clinical Development in Cancer,” presentation given in Barcelona, Spain on Nov. 4, 2011, 16 pages.;;Dupont, J., et al., “A Phase 1b Study of Anti-DLL4 (Delta-Like Ligand 4) Antibody Demcizumab (DEM) with Pemetrexed (PEM) and Carboplatin (CARBO) in Patients with 1st-Line Non-Squamous NSCLC,” 2015 European Lung Cancer Conference (ELCC), Geneva, Switzerland, Apr. 15-18, Abstract 114, 2 pages (2015).;;Ellisen, L.W., et al., “TAN-1, the Human Homolog of the Drosophila Notch Gene is Broken by Chromosomal Translocations in T Lymphoblastic neoplasm,” Cell 66(4):649-661, Cell Press, United States (1991).;;Engin,F., et al., “Dimorphic effects of Notch signaling in bone homeostasis,” Nature Medicine 14(3):299-305, Nature Publishing Group, United States (2008).;;English language translation of Oishi, H., et al., “Novel therapeutic strategy for pancreatic cancer targeting Notch signaling pathway,” Proceedings of the Japanese Cancer Association 65:311-312, Japan (2006).;;English language translation of “Tumor-angiogenesis suppression therapy targeting the Notch signaling pathway,” Suizo (Pancreas) 21(3):249, Japan (2006).;;Eppstein, D.A., et al., “Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor,” Proceedings of the National Academy of Sciences 82(11):3688-3692, National Academy of Sciences, United States (1985).;;European Search Report for EP Application No. EP10824244.7, Munich, Germany, dated Feb. 18, 2013, 6 pages.;;Farnie, G. and Clarke, R.B., “Mammary stem cells and breast cancer—role of Notch signalling,” Stem Cell Reviews and Reports 3(2):169-175, Humana Press, United States (2007).;;Farnie, G., et al., “Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways,” Journal of the National Cancer institute 99(8):616-627, Oxford University Press, United Kingdom (2007).;;Fischer, M., et al., “Anti-DLL4 Inhibits Growth and Reduces Tumor-Initiating Cell Frequency in Colorectal Tumors with Oncogenic KRAS Mutations,” Cancer Research 71(5):1520-1525, American Association for Cancer Research, United States (2011).;;Fleming, R.J., et al., “The NOTCH receptor and its ligands,” Trends in Cell Biology 7(11):437-441, Elsevier Science Ltd., The Netherlands (1997).;;Fre, S., et al., “Notch Signals Control the Fate of Immature Progenitor Cells in the Intestine,” Nature 435(7044):964-968, Nature Publishing Group, United States (2005).;;Fung, E., et al., “Delta-like 4 induces notch signaling in macrophages: implications for inflammation,” Circulation 115(23):2948-2956, American Heart Association, Inc., United States (2007).;;Gagnon, M.L., et al., “Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity,” Proceedings of the National Academy of Sciences 97(6):2573-2578, National Academy of Sciences, United States (2000).;;Gale, N.W., et al., “Haploinsufficiency of Delta-like 4 Ligand Results in Embryonic Lethality due to Major Defects in arterial and Vascular Development,” Proceedings of the National Academy of Sciences 101(45):15949-15954, National Academy of Sciences, United States (2004).;;Gallahan, D., et al., “A new common integration region (int-3) for mouse mammary tumor virus on mouse chromosome 17,” Journal of Virology 61(1):218-220, American Society for Microbiology, United States (1987).;;Gallahan, D., et al., “Expression of a Truncated Int3 Gene in Developing Secretory Mammary Epithelium Specifically Retards Lobular Differentiation Resulting in Tumorigenesis,” Cancer Research 56(8):1775-1785, American Association for Cancer Research, United States (1996).;;Garber, K., “Notch Emerges as New Cancer Drug Target,” Journal of the national Cancer Institute 99(17):1284-1285, Oxford University Press, United States (2007).;;Goding, J.W., “Production of Monoclonal Antibodies,” in Monoclonal Antibodies: Principles and Practice, 2nd ed., pp. 59-103, Academic Press Inc., London (1986).;;Gracian, A.C., et al., “A phase 1b study of the anticancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) with or without paclitaxel protein bound particles (nab-paclitaxel) in patients with pancreatic cancer,” 2014 Gastrointestinal Cancers Symposium, Abstract 279, 2 pages (2014).;;Gray-Schopfer, V.C., et al., “The Role of B-RAF in Melanoma,” Cancer Metastasis Reviews 24(1):165-183, Springer Science + Business Media, Inc., Netherlands (2005).;;Gridley, T., “Notch Signaling During Vascular Development,” Proceedings of the National Academy of Sciences 98(10):5377-5378, National Academy of Sciences, United States (2001).;;Gridley, T. “Notch signaling in vascular development and physiology,” Development 134(15):2709-2718, (2007).;;Gronberg, B.H., et al., “Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared with Gemcitabine Plus Carboplatin as First-line Chemotherapy in Advanced Non-small-cell Lung Cancer,” Journal of Clinical Oncology 27(19):3217-3224, American Society of Clinical Oncology, United States (2009).;;Gruber, M., et al., “Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed in Escherichia coli,” The Journal of Immunology 152(11):5368-5374, The American Association of Immunologists, Inc., United States (1994).;;Gurney, A. and Hoey, T., “Anti-DLL4, a Cancer Therapeutic with Multiple Mechanisms of Action,” Vascular Cell 3, 4 pages, BioMed Central, United States (2011).;;Hainaud, P., et al., “The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions,” Cancer Research 66(17):8501-8510, American Association for Cancer Research, United States (2006).;;Hallahan, A.R., et al., “The SmoA1 Mouse Model Reveals that Notch Signaling is Critical for the Growth and Survival of Sonic Hedgehog-Induced Medulloblastomas,” Cancer Research 64(21):7794-7800, American Association for Cancer Research, United States (2004).;;Han, W., et al., “A soluble form of human Delta-like-1 inhibits differentiation of hematopoietic progenitor cells,” Blood 95(5):1616-1625, The American Society of Hematology, United States (2000).;;Harlow, E. and Lane, D., eds., “Immunoassays,” in Antibodies: A Laboratory Manual, 14:553-612, Cold Spring Harbor Laboratory, United States (1988).;;Harper, J.A., et al., “Notch Signaling in Development and Disease,” Clinical Genetics 64(6):461-472, Blackwell Publishing, United States (2003).;;Harrington, L.S., et al., “Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells,” Microvascular Research 75(2):144-154, Elsevier Science, United States (2008).;;Harris, W.J., “Production of Humanized Monoclonal Antibodies for in vivo Imaging and Therapy,” Biochemical Society Transactions 23(4):1035-1038, Portland Press on the Behalf of the Biochemical Society, England (1995).;;Hawkins, R.E., et al., “Selection of phage antibodies by binding affinity. Mimicking affinity maturation,” Journal of Molecular Biology 226(3):889-896, Elsevier Science, United States (1992).;;Hellström, M., et al., “Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis,” Nature 445(7129):776-780, Nature Publishing Group, United States (2007).;;Henning, K., et al., “mNotch1 signaling and erythropoietin cooperate in erythroid differentiation of multipotent progenitor cells and upregulate beta-globin,” Experimental Hematology 35(9):1321-1332, Elsevier Science, United States (2007).;;Hermentin, P. and Seiler, F.R., “Investigations with Monoclonal Antibody Drug (Anthracycline) Conjugates,” Behring Institute Research Communications 82:197-215, Behringwerke Ag, Germany (1988).;;Hidalgo, M., et al., “A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxvel in Patients with Pancreatic Cancer,” European Society for Medical Oncology 2014 Congress, Sep. 17 and Sep. 28, Poster 616PD, 1 page (2014).;;Hidalgo, M., et al., “A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, Anti-DLL4) and Gemcitabine (GEM) with or without Paclitaxel Protein Bound Particles (Nab-Paclitaxel) in pts with Pancreatic Cancer,” 2015 ASCO Annual Meeting, Abstract 4118, 3 pages (2015).;;Hidalgo, M., et al., “Pre-Clinical and Clinical Activity of Anti-DLL4 (Demcizumab) in Combination with Gemcitabine Plus nab-Paclitaxel in Pancreatic Cancer,” 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Preclinical Models Poster Session, Abstract 166, 2 pages (Nov. 2014).;;Hoey, T., et al., “DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency,”Cell Stem Cell 5(2):168-177, Elsevier Science, United States (2009).;;Hofmann, J.J. and Iruela-Arispe, M.L., “Notch signaling in blood vessels: who is talking to whom about what?,” Circulation Research 100(11):1556-1568, American Heart Association, Inc., United States (2007).;;Holash, J., et al., “Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents,” Cancer Metastasis Rev 25:243-252, Dordrecht, Netherlands (2006).;;Holash, J., et al., “VEGF-Trap: A VEGF Blocker with Potent Antitumor Effects,” Proceedings of the National Academy of Sciences USA 99(17):11393-11398, National Academy of Sciences, United States (2002).;;Holm, P., et al., “Functional Mapping and Single Chain Construction of the Anti-cytokeratin 8 Monoclonal Antibody TS1,” Molecular Immunology 44(6):1075-1084, Pergamon Press, England (Feb. 2007).;;Hoogenboom, H.R. and Winter, G., “By-Passing Immunisation. Human Antibodies from Synthetic Repertoires of Germline VH Gene Segments Rearranged in vitro,” Journal of Molecular Biology 227(2):381-388, Elsevier, England (1992).;;Hope, K.J., et al., “Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in selfrenewal capacity,” Nature Immunology 5(7):738-743, Nature Publishing Group,United States (2004).;;Hopfer, O., et al., “The Notch Pathway in Ovarian Carcinomas and Adenomas,” British Journal of Cancer 93(6):709-718, Nature Publishing Group on behalf of Cancer Research UK, England (2005).;;Humphreys, D.P., et al., “Formation of dimeric Fabs in Escherichia coli: effect of hinge size and isotype, presence of interchain disulphide bond, Fab′ expression levels, tail piece sequences and growth conditions,” Journal of Immunological Methods 209(2):193-202, Elsevier Science, Netherlands (1997).;;Hurle, M.R. and Gross, M., “Protein engineering techniques for antibody humanization,” Current Opinion in Biotechnology 5(4):428-433, (1994).;;Hurwitz, H.I., et al., “Phase I Trial of Pazopanib in Patients with Advanced Cancer,” Clinical Cancer Research 15(12):4220-4227, American Association for Cancer Research, United States (2009).;;Hwang, K.J., et al., “Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study,” Proceedings of the National Academy of Sciences 77(7):4030-4034, National Academy of Sciences, United States (1980).;;International Preliminary Report on Patentability and Written Opinion for International Application No. PCT/US2010/53064, International Searching Authority, dated Feb. 14, 2011, 7 pages.;;International Preliminary Report on Patentability for Application No. PCT/US2016/053316, International Searching Authority, dated Apr. 5, 2018, 11 pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2013/065015, The International Bureau of WIPO, Switzerland, dated Apr. 22, 2014, 17 pages.;;International Search Report for International Application No. PCT/US16/53316, ISA/US, Alexandria, Virginia, dated Feb. 21, 2017, 7 pages.;;International Search Report for International Application No. PCT/US2010/53064, dated Feb. 14, 2011, 3 Pages.;;International Search Report for International Application No. PCT/US2015/024251, ISA/US, Alexandria, Virginia, United States, dated Jul. 16, 2015, 4 pages.;;International Search Report for International Patent Application No. PCT/US11/60773, International Searching Authority, Alexandria, Virginia, United States, dated Mar. 26, 2012, 3 pages.;;International Search Report for International Patent Application No. PCT/US2007/020889, United States Patent and Trademark Office, United States, dated Apr. 9, 2008, 5 pages.;;International Search Report with the Written Opinion of the International Searching Authority for International application No. PCT/US10/32625, United States Patent and Trademark Office, United States, dated Dec. 17, 2010, 11 pages.;;International Search Report with the Written Opinion of the International Searching Authority for International application No. PCT/US12/56886, United States Patent and Trademark Office, United States, dated Feb. 28, 2013, 8 pages.;;International Search Report with the Written Opinion of the International Searching Authority for International application No. PCT/US15/58327, United States Patent and Trademark Office, United States, dated May 19, 2016, 12 pages.;;International Search Report with Written Opinion for International Application No. PCT/US2010/58511, International Searching Authority, United States, dated Mar. 3, 2011, 9 pages.;;Ishiko, E., et al., “Notch signals inhibit the development of erythroid/megakaryocytic cells by suppressing GATA-1 activity through the induction of HES1,” The Journal of Biological Chemistry 280(6):4929-4939, American Society for Biochemistry and Molecular Biology, United States (2005).;;Iso, T., et al., “Notch Signaling in Vascular Development,” Arteriosclerosis, Thrombosis, and Vascular Biology 23(4):543-553, American Heart Association, Inc., United States (2003).;;Izzedine, H., et al., “Management of Hypertension in Angiogenesis Inhibitor-Treated Patients,” Annals of Oncology 20(5):807-815, Oxford University Press, England (2009).;;Jackson, J.R., et al., “In vitro antibody maturation. Improvement of a high affinity, neutralizing antibody against IL-1 beta,” The Journal of Immunology 154(7):3310-3319, The American Association of Immunologists, Inc., United States (1995).;;Janda, C.Y., “Structural Basis of Wnt Recognition by Frizzled,” Science 337(6090):59-64, American Association for the Advancement of Science, United States (2012).;;Janeway, Jr., et al., “Immunobiology, The Immune System in Health and Disease,” Edition 4:579-581, Current Biology Publications (1999).;;Jang, Y.-J., et al., “The Structural Basis for DNA Binding by an Anti-DNA Autoantibody,” Molecular Immunology 35(18):1207-1217, Pergamon Press, England (1998).;;Jarriault, S., et al., “Signalling Downstream of Activated Mammalian Notch,” Nature 377(6547):355-358, Nature Publishing Group, United States (1995).;;Jeffries, S. and Capobianco, A.J., “Neoplastic transformation by Notch requires nuclear localization,” Molecular and Cellular Biology 20(11):3928-3941, American Society for Microbiology, United States (2000).;;Jemal, A., et al., “Cancer Statistics, 2003,” CA—A Cancer Journal for Clinicians 53(1):05-26, American Cancer Society, United States (2003).;;Jhappan, C., et al., “Expression of an Activated Notch-Related int-3 Transgene Interferes with Cell Differentiation and Induces Neoplastic Transformation in Mammary and Salivary Glands,” Genes & Development 6(3):345-355, Cold Spring Harbor Laboratory Press, United States (1992).;;Jimeno, A., et al., “Phase 1 study of REGN421 (R)/SAR153192, a fully-human delta-like ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumors,” ASCO University 2013 ASCO Annual Meeting accessed at http://meetinglibrary.asco.org/content/113836-132, 2 pages.;;Jones, P.T., et al., “Replacing the Complementarity-determining Regions in a Human Antibody with those from a Mouse,” Nature 321(6069):522-525, Nature Publishing Group, England (May 1986).;;Kim, E.S., et al., “Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma,” Proceedings of the National Academy of Sciences 99(17):11399-11404, National Academy of Sciences, United States (2002).;;Kingsman, A.J., et al., “Replication in Saccharomyces cerevisiae of Plasmid pBR313 Carrying DNA from the Yeast TrpI Region,” Gene 7(2):141-152, Elsevier/North-Holland Biomedical Press, Netherlands (Oct. 1979).;;Kobayashi, H., et al., “Tryptophan H33 Plays an Important Role in Pyrimidine (6-4) Pyrimidone Photoproduct Binding by a High-Affinity Antibody,” Protein Engineering Design and Selection 12(10):879-884, Oxford University Press, United States (1999).;;Kohler, G. and Milstein, C., “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,” Nature 256(5517):495-497, Macmillan Journals Ltd., England (Aug. 1975).;;Kopper, L. and Hajdu, M., “Tumor Stem Cells,” Pathology Oncology Research 10(2):69-73, Aranyl Lajos Foundation, Hungary (2004).;;Kostelny, S.A., et al., “Formation of a Bispecific Antibody by the Use of Leucine Zippers,” The Journal of Immunology 148(5):1547-1553, American Association of Immunologists, United States (Mar. 1992).;;Krebs, L.T., et al., “Haploinsufficient Lethality and Formation of Arteriovenous Malformations in Notch Pathway Mutants,” Genes & Development 18(20):2469-2473, Cold Spring Harbor Laboratory Press, United States (2004).;;Krebs, L.T., et al., “Notch Signaling is Essential for Vascular Morphogenesis in Mice,” Genes & Development 14(11):1343-1352, Cold Spring Harbor Laboratory Press, United States (2000).;;Kuo, C.J., et al., “Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer,” Proceedings of the National Academy of Sciences 98(8):4605-4610, National Academy of Sciences, United States (2001).;;Lapidot, T., et al., “A Cell Initiating Human Acute Myeloid Leukaemia After Transplantation Into SCID Mice,” Nature 367(6464):645-648, Nature Publishing Group, United States (1994).;;Lauret, E., et al., “Membrane-Bound Delta-4 Notch Ligand Reduces the Proliferative Activity of Primitive Human Hematopoietic CD34+CD38low Cells while Maintaining their LTC-IC Potential,” Leukemia 18(4):788-797, Nature Publishing Group, United States (2006).;;Lazar, E., et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,” Molecular and Cellular Biology 8(3):1247-1252, American Society for Microbiology, United States (Mar. 1988).;;Lee, H.S., et al., “Generation and Characterization of a Novel Single-gene-encoded Single-chain Immunoglobulin Molecule with Antigen Binding Activity and Effector Functions,” Molecular Immunology 36(1):61-71, Elsevier Science Ltd., Netherlands (Jan. 1999).;;Leethanakul, C., et al., “Distinct Pattern of Expression of Differentiation and Growth-Related Genes in Squamous Cell Carcinomas of the Head and Neck Revealed by the Use of Laser Capture Microdissection and cDNA Arrays,” Oncogene 19(28):3220-3224, Nature Publishing Group, United States (2000).;;Lenihan, D.J., “How is cardiac toxicity defined and what impact does this have on cancer outcome or drug development,” PowerPoint Presentation from the DIA Meeting, 42 slides (2011).;;Leong, K.G. and Karsan, A., “Recent Insights into the Role of Notch Signaling in Tumorigenesis,” Blood 107(6):2223-2233, The American Society of Hematology, United States (2006).;;Li, J.L. and Harris A.L., “Notch Signaling from Tumor Cells: A New Mechanism of Angiogenesis,” Cancer Cell 8(1):pp. 1-3, Cell Press, United States (2005).;;Li, X., et al., “Notch3 Signaling is Required for the Development of Pulmonary Arterial Hypertension,” Nature Medicine 15(11):1289-1297, Nature Publishing Company, United States (2009).;;Lievre, A., et al., “KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer,” Cancer Research 66(8):3992-3995, American Association for Cancer Research, United States (2006).;;Limbourg, A., et al., “Notch ligand Delta-like 1 is essential for postnatal arteriogenesis,” Circulation Research 100(3):363-371, American Heart Association, Inc., United States (2007).;;Liu, S., et al., “Mammary stem cells, self-renewal pathways, and carcinogenesis,” Breast Cancer Research 7(3):86-95, BioMed Central, England (2005).;;Liu, Z.J., et al., “Inhibition of endothelial cell proliferation by Notch 1 signaling is mediated by represessing MAPK and P14K/Akt pathways and requires MAML1,” Federation of American Societies for Experimental Biology 20:E201-E210, American Society for Experimental Biology, United States (2006).;;Liu, Z.J., et al., “Regulation of Notchl and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis,” Molecular and Cellular Biology 23(1):14-25, American Society for Microbiology, United States (2003).;;Lobov, I.B., et al., “Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting,” Proceedings of the National Academy of Sciences 104(9):3219-3224, National Academy of Sciences, United States (2007).;;Lu, K.V., and Bergers, G., “Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma,” CNS Oncology 2(1):49-65, Future Medicine, Inc., United States (2013).;;Luca, V.C., et al., “Structural basis for Notch1 engagement of Delta-like 4,” Science, 347(6224):847-853, American Association for the Advancement of Science, United States (2015). et al.",ACTIVE
84,ES,T3,ES 2938628 T3,064-273-141-619-532,2023-04-13,2023,ES 18197338 T,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,Agentes de unión a VEGF/DLL4 y usos de los mismos,"La presente invención se refiere a agentes de unión a VEGF, agentes de unión a DLL4, agentes de unión biespecíficos de VEGF/DLL4 y métodos de uso de los agentes para tratar enfermedades tales como el cáncer. La presente invención proporciona anticuerpos que se unen específicamente a VEGF humano, anticuerpos que se unen específicamente a DLL4 humana y anticuerpos biespecíficos que se unen específicamente a VEGF humano y/o DLL4 humana. La presente invención proporciona además métodos para usar los agentes para inhibir el crecimiento tumoral. También se describen métodos para tratar el cáncer que comprenden administrar una cantidad con efecto terapéutico de un agente o anticuerpo de la presente invención a un paciente que tiene un tumor o cáncer. (Traducción automática con Google Translate, sin valor legal)",MEREO BIOPHARMA 5 INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/064-273-141-619-532,Granted Patent,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/08,,0,0,,,,ACTIVE
85,AU,B2,AU 2017/210673 B2,146-017-847-487-201,2019-03-28,2019,AU 2017/210673 A,2017-08-07,AU 2017/210673 A;;AU 2015/268749 A;;AU 2013/201095 A;;US 201261692978 P;;US 201161538454 P;;US 201261597409 P;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 binding agents and uses thereof,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/146-017-847-487-201,Granted Patent,no,2,0,4,82,0,,C07K16/00;;A61K39/00;;C12P21/08,,0,0,,,,ACTIVE
86,HU,T2,HU E042192 T2,163-620-885-772-348,2019-06-28,2019,HU E12833767 A,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,,ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/163-620-885-772-348,Amended Patent,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/08,,0,0,,,,PENDING
87,FI,T3,FI 3485903 T3,007-168-973-549-096,2023-01-31,2023,FI 18197338 T,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,,,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/007-168-973-549-096,Unknown,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/08,,0,0,,,,PENDING
88,US,B2,US 10159782 B2,062-261-268-594-618,2018-12-25,2018,US 201314429592 A,2013-09-18,US 201314429592 A;;US 201261703191 P;;US 201361874741 P;;US 2013/0060404 W,2012-09-19,Method and system for enhanced imaging visualization of deep brain anatomy using infusion,"Provided is a method and system for delivering a diagnostic agent to a site in the brain of a subject for imaging at least a portion of the brain site on a medical imaging system. The method and system includes a catheter device with associated lumens having diagnostic agent ports for delivering the diagnostic agent (e.g., infusate) through the lumens and advancing the diagnostic agent so as to exit out from the lumens to at least a portion of the brain site and while sealing a portion of the brain site thereby preventing the exited diagnostic agent from travelling proximally beyond the sealing location, and at the same time imaging at least a portion of the brain site during at least a portion of the sealing duration so that the brain site can be visualized on a medical imaging system. The diagnostic agent (infusate) is able to highlight borders and internal patterns of the deep structures of the brain thereby enabling direct targeting. Ultimately this leads to reduced complications, enhanced therapy, and the elimination of the need for awake surgery. The method and system provides the capability heretofore not possible to visualize the small, often indistinct regions, which will greatly improve clinical outcomes with therapeutic interventions.",ELIAS WILLIAM J;;BOND AARON E;;GILLIES GEORGE T;;UNIV VIRGINIA PATENT FOUNDATION,ELIAS WILLIAM J;;BOND AARON E;;GILLIES GEORGE T,UNIVERSITY OF VIRGINIA PATENT FOUNDATION (2013-12-03);;UNIVERSITY OF VIRGINIA (2013-10-13),https://lens.org/062-261-268-594-618,Granted Patent,yes,85,4,5,5,0,A61M25/10;;A61B5/0042;;A61B5/055;;A61M25/007;;A61M25/0127;;A61M25/1002;;A61M31/005;;A61M2025/0042;;A61M2025/105;;A61M2025/1052;;A61M2025/1093;;G01R33/285;;A61B6/032;;A61B6/12;;A61B6/481;;A61B6/501;;A61M25/10;;A61B5/0042;;A61B5/055;;A61M25/007;;A61M25/0127;;A61M25/1002;;A61M31/005;;A61M2025/0042;;A61M2025/105;;A61M2025/1052;;A61M2025/1093;;G01R33/285;;A61B6/032;;A61B6/12;;A61B6/481;;A61B6/501;;A61M5/007;;A61M25/0026;;A61M2025/0037;;A61N1/36139,A61B5/055;;A61B5/00;;A61B6/00;;A61B6/03;;A61B6/12;;A61M5/00;;A61M25/00;;A61M25/01;;A61M25/10;;A61M31/00;;A61N1/36;;G01R33/28,,48,44,025-436-075-770-54X;;019-837-589-695-401;;002-154-516-131-453;;017-864-558-610-576;;018-211-497-893-135;;010-318-113-512-823;;037-315-113-227-826;;166-982-437-010-515;;023-042-472-834-936;;123-261-250-568-05X;;005-824-206-707-479;;012-898-797-523-967;;025-076-573-169-961;;033-498-203-758-54X;;070-767-623-822-485;;005-672-609-080-164;;026-698-144-036-485;;027-390-894-379-503;;034-857-530-497-541;;036-272-578-633-724;;046-792-685-913-66X;;020-300-680-711-842;;086-731-007-693-09X;;002-024-637-029-038;;055-384-190-448-931;;054-182-351-237-210;;088-421-309-373-832;;000-975-142-042-477;;001-148-148-771-555;;077-336-525-929-166;;087-568-570-461-481;;078-687-047-868-776;;008-082-006-772-347;;069-559-717-258-908;;001-447-676-601-242;;013-269-517-688-762;;002-678-405-898-317;;037-666-099-701-791;;003-528-760-802-669;;069-263-694-910-12X;;038-147-649-040-062;;154-753-776-781-061;;089-330-668-020-118;;038-585-674-487-966,10.1063/1.3077262;;10.1088/0957-4484/15/1/018;;10.1109/68.752527;;10.1109/68.720261;;10.1049/el:19961529;;10.1109/leos.2005.1548202;;26848911;;10.3171/2015.10.jns151154;;10.1109/2944.788420;;10.1063/1.121709;;10.1016/j.wneu.2010.06.008;;21299996;;10.3171/2012.1.peds11391;;22462711;;19782522;;10.1016/j.jvs.2009.07.072;;10.1109/leos.1998.737802;;10.1109/68.669218;;10.3171/jns.2004.101.2.0314;;15309925;;10.1023/b:neon.0000041874.02554.b3;;15527083;;10.1002/mds.22080;;18442130;;17977271;;10.3171/jns-07/11/0983;;10.3171/2008.7.17625;;18821828;;10.1016/j.neuroimage.2011.10.049;;22036683;;10.1088/0967-3334/33/12/2003;;23151433;;10.1371/journal.pone.0056266;;pmc3574132;;23457542;;10.1109/lpt.2005.856400;;10.1109/lpt.2005.849975;;10.1212/01.wnl.0000194272.79084.7e;;16434672;;18824788;;10.1088/1478-3975/5/3/036010;;23215793;;10.3109/08941939.2012.677967;;16055972;;10.3233/thc-2005-13403;;20488320;;10.1016/j.jvs.2010.01.033;;10.1159/000331269;;22104373;;10.1063/1.3626469;;16429411;;10.1002/ana.20737;;22791029;;pmc4104674;;10.1227/neu.0b013e3182672ac9;;21548744;;10.3171/2011.4.jns102075;;10.3171/2011.7.jns11250;;21854118;;17557455;;16703895;;10.3171/jns.2006.104.5.845;;10.3171/jns-07/11/0998;;17977273;;10.3109/03091902.2011.645943;;22316101;;10.1007/s10544-012-9684-1;;22892642;;10.1213/ane.0b013e31824cb835;;22451591;;19272871;;10.1109/tbme.2008.2009527;;pmc2995881;;20861152;;10.1093/brain/awq239;;22120376;;10.1016/j.wneu.2011.05.051,"Allison, S.W. et al., “Temperature-dependent fluorescence decay lifetimes of the phosphor Y3(Al0.5Ga0.5)5O12:Ce 1%”, Journal of Applied Physics, 2009), pp. 036105-1-036105-3, vol. 105, Issue 3, Published by AIP Publishing, United States.;;Bauman, M.A. et al., “Physical Characterization of Neurocatheter Performance in a Brain Phantom Gelatin with Nanoscale Porosity: Stead-State and Oscillatory Flows,” Nanotechnology, 2004, pp. 92-97, vol. 15, Published by IOP Publishing Ltd, UK.;;Bond, A.E. et al., “43 GHz Modulation Bandwidth Packaged InGaAsP MQW EA Modulators with Integrated Mode Converters”, Proceedings of ECOC'99, 25th European Conference on Optical Communication, Sep. 26-30, 1999, Nice, France, pp. 14-15 (2 pages) Suppl., Published by OSA Publishing, United States.;;Bond, A.E. et al., “Aperture Dependent Loss Analysis in Vertical-Cavity Surface-Emitting Lasers”, IEEE Photonics Technology Letters, Apr. 1999, pp. 397-399, vol. 11, No. 4, Published by IEEE Publications, United States.;;Bond, A.E. et al., “Aperture Placement Effects in Oxide-Defined Vertical-Cavity Surface-Emitting Lasers”, IEEE Photonics Technology Letters, Oct. 1998, pp. 1362-1364, vol. 10, No. 10, Published by IEEE Publications, United States.;;Bond, A.E. et al., “Backgating reduction in MESFETs using an AIAs native oxide buffer layer”, Electronics Letters, Nov. 21, 1996, pp. 2271-2273, vol. 32, No. 24, Published by the Institution of Engineering and Technology, UK.;;Bond, A. et al., “Challenges in Optoelectronic Component Packaging for Next Generation Pluggable Modules”, IEEE conference Publications, 2005 IEEE LEOS Annual Meeting Conference Proceedings, Lasers and Electro-Optics Society 18th Annual Meeting Sydney, Australia, Oct. 2005, pp. 706-707, Published by IEEE Publications, United States.;;Bond, A.E. et al., “Convection-enhanced delivery improves MRI visualization of basal ganglia for stereotactic surgery”, Journal of Neurosurgery, 2016, pp. 1080-1086, vol. 125, Issue 5, Published by the American Association of Neurological Surgeons, United States.;;Bond, A.E. et al., “Design of Low-Loss Single-Mode Vertical-Cavity Surface-Emitting Lasers”, IEEE Journal of Selected Topics in Quantum Electronics, May/Jun. 1999, pp. 574-581, vol. 5, No. 3, Published by IEEE Publications, United States.;;Bond, A.E. et al., “Monolithically integrated surface and substrate emitting vertical cavity lasers for smart pixels”, Applied Physics Letters, Jul. 6, 1998, pp. 19-21, vol. 73, No. 1, Published by AIP Publishing, United States.;;Bond, A.E. et al., “Operative Strategies for Minimizing Hearing Loss and other major Complications Associated with Microvascular Decompression for Trigeminal Neuralgia”, World Neurosurgery, Jul. 2010, pp. 172-177, vol. 74, No. 1, Published by Elsevier, Amsterdam, Netherlands.;;Bond, A.E. et al., “Spinal arachnoid cysts in the pediatric population: report of 31 cases and a review of the literature”, Journal of Neurosurgery: Pediatrics, Apr. 2012, pp. 432-441, vol. 9, No. 4, Published by the American Association of Neurological Surgeons, United States.;;Bond, A.E. et al., “The Influence of Stents on the Performance of an Ultrasonic Navigation System for Endovascular Procedures,” Journal of Vascular Surgery, Nov. 2009, pp. 1143-1148, vol. 50, No. 5, Published by Elsevier, Amsterdam, Netherlands.;;Bond, A.E., “Ultralow threshold monolithically integrated surface and substrate emitting vertical cavity surface emitting lasers with properties controlled by oxide aperture placement,” Conference Proceedings Publications, Lasers and Electro-Optics Society Annual Meeting, IEEE Lasers and Electro-Optics Society 1998 Annual Meetings, Dec. 1-4, 1998, pp. 208-209, vol. 1, Orlando, FL, USA, Published by IEEE Publications, United States.;;Bond, A.E. et al., “Vertical-Cavity Surface-Emitting Lasers with Spatially Adjustable DBR Reflectivity to Enable Free-Space Photonic Repeaters”, IEEE Photonics Technology Letters, May 1998, pp. 636-638, vol. 10, No. 5, Published by IEEE Publications, United States.;;Chen, M.Y. et al., “Intratumoral Administration and Convection-Enhanced Delivery,” in Newton, H., ed., Handbook of Brain Tumor Chemotherapy, 2006, Chap. 20, pp. 295-304, Academic Press, New York, USA.;;Chen, Z., et al., “A realistic brain tissue phantom for intraparenchymal infusion studies”, Journal of Neurosurgery, 2004, pp. 314-322, vol. 101, Issue 2, Published by the American Association of Neurological Surgeons, United States.;;Chiocca, E.A et al., “Neurosurgical Delivery of Chemotherapeutics, Targeted Toxins, Genetic and Viral Therapies in Neuro-Oncology,” Journal of Neuro-Oncology, 2004, pp. 101-117, vol. 69, Published by Springer Science+Business Media, Germany.;;Elias, W.J. et al., “Dexmedetomidine and arousal affect subthalamic neurons”, Movement Disorders, 2008, pp. 1317-1320, vol. 23, No. 9, Published by Wiley-Liss, United States.;;Elias, W.J. et al., “Cortical and subcortical brain shift during stereotactic procedures”, Journal of Neurosurgery, 2007, pp. 983-988, vol. 107, Issue 5, Published by the American Association of Neurological Surgeons, United States.;;Elias, W.J. et al., “Focused ultrasound surgery”, Neurosurg Focus, Jan. 2012, Introduction (1 page), vol. 32, Issue 1, Published by the American Association of Neurological Surgeons, United States.;;Elias, W.J. et al., “Sulcal and ventricular trajectories in stereotactic surgery”, Journal of Neurosurgery, Feb. 2009, pp. 201-207, vol. 110, Issue 2, Published by the American Association of Neurological Surgeons, United States.;;Elias, W.J. et al., “Validation of connectivity-based thalamic segmentation with direct electrophysiologic recordings from human sensory thalamus”, Neuroimage, 2012, pp. 2025-2034, vol. 59, Issue 3, Published by Elsevier, Amsterdam, Netherlands.;;Flouty, O. et al., “A New Device Concept for Directly Modulating Spinal Cord Pathways: Initial in vivo Experimental Results,” Physiological Measurement, 2012, pp. 2003-2015, vol. 33, No. 12, Published by IOP Publishing Ltd, UK.;;Flouty, O.E. et al., “Intracranial Somatosensory Responses with Direct Spinal Cord Stimulation in Anesthetized Sheep,” PLOS ONE, Feb. 2013, e56266 (11 pgs.), vol. 8, Issue 2, Published by Public Library of Science, United States.;;Foulk, H. et al., “Broad Temperature Operation and Widely Tunable High Dynamic Range High-Speed Amplified Electroabsorption Modulator”, IEEE Photonics Technology Letters, Oct. 2005, pp. 2191-2193, vol. 17, No. 10, Published by IEEE Publications, United States.;;Frateschi, N.C. et al., “Uncooled Performance of 10-Gb/s Laser Modules With InGaAlAs—InP and InGaAsP—InP MQW Electroabsorption Modulators Integrated With Semiconductor Amplifiers”, IEEE Photonics Technology Letters, Jul. 2005, pp. 1378-1380, vol. 17, No. 7, Published by IEEE Publications, United States.;;Frysinger, R.C., et al., “Bipolar Deep Brain Stimulation Permits Routine EKG, EEG, and Polysomnography”, Neurology, Jan. 2006, pp. 268-270, vol. 66, No. 2, Published by the American Academy of Neurology, United States.;;Gevertz, J.L. et al., “Simulating Tumor Growth in Confined Heterogeneous Environments” Physical Biology, 2008, 036010 (10 pgs.), vol. 5, No. 3, Published by IOP Publishing Ltd, UK.;;Gibson-Corley, K.N. et al., “Ovine Tests of a Novel Spinal Cord Neuromodulator and Dentate Ligament Fixation Method,” Journal of Investigative Surgery, 2012, pp. 366-374, vol. 25, No. 6, Published by Informa Healthcare, United States.;;Gillies, G.T. et al., “Positive Pressure Infusion of Therapeutic Agents into Brain Tissues: Mathematical and Experimental Simulations,” Technology and Health Care, 2005, pp. 235-243, vol. 13, Published by IOS Press, Amsterdam, Netherlands.;;Han, S. et al., “Comparison of Ultrasound and CT Scan Determined AAA Diameters Following Endovascular AAA Repair,” Society for Clinical Vascular Surgery 37th Annual Symposium, Mar. 18-21, 2009, Ft. Lauderdale, FL, USA, Published by the Society for Clinical Vascular Surgery.;;Han, S.M. et al., “Ultrasound-determined diameter measurements are more accurate than axial computed tomography after endovascular aortic aneurysm repair”, Journal of Vascular Surgery, Jun. 2010, pp. 1381-1389, vol. 51, No. 6, Published by Elsevier, Amsterdam, Netherlands.;;Hilliard, J.D. et al., “Effective Subthalamic Nucleus Deep Brain Stimulation Sites May Differ for Tremor, Bradykinesia and Gait Disturbances in Parkinson's Disease”, Stereotactic and Functional Neurosurgery, 2011, pp. 357-364, vol. 89, No. 6, Published by Karger Publishing, Basel, Switzerland.;;Howard III, M.A. et al., “Intradural Approach to Selective Stimulation in the Spinal Cord for Treatment of Intractable Pain: Design Principles and Wireless Protocol” Journal of Applied Physics, 2011, pp. 044702-01-044702-12, vol. 110, Issue 2, Published by AIP Publishing, United States.;;Lang, A.E., et al., “Randomized Controlled Trial of Intraputamenal Glial Cell Line-Derived Neurotrophic Factor Infusion in Parkinson Disease”, Ann Neurol, 2006, pp. 459-466, vol. 59, Published by John Wiley & Sons, United States.;;Medel, R. et al., “Magnetic Resonance-Guided Focused Ultrasound Surgery: Part 2: A Review of Current and Future Applications”, Neurosurgery, Oct. 2012, pp. 755-763, vol. 71, No. 4, Published by Oxford University Press, Oxford, England, UK.;;Pouratian, N. et al., “Comprehensive analysis of risk factors for seizures after deep brain stimulation surgery”, Journal of Neurosurgery, Aug. 2011, pp. 310-315, vol. 115, Issue 2, Published by the American Association of Neurological Surgeons, United States.;;Pouratian, N. et al., “Multi-institutional evaluation of deep brain stimulation targeting using probabilistic connectivity-based thalamic segmentation”, Journal of Neurosurgery, Nov. 2011, pp. 995-1004, vol. 115, Issue 5, Published by the American Association of Neurological Surgeons, United States.;;Quigg, M. et al., “Acute Insomnia Following Surgery of the Ventralis Intermedius Nucleus of the Thalamus for Tremor”, Journal of Clinical Sleep Medicine, 2007, pp. 58-59, vol. 3, No. 1, Published by the American Academy of Sleep Medicine, United States.;;Quigg, M. et al., “Conduction aphasia as a function of the dominant posterior perisylvian cortex”, Journal of Neurosurgery, May 2006, pp. 845-848, vol. 104, Issue 5, Published by the American Association of Neurological Surgeons, United States.;;Sansur, C.A. et al., “Incidence of symptomatic hemorrhage after stereotactic electrode placement”, Journal of Neurosurgery, Nov. 2007, pp. 998-1003, vol. 107, Issue 5, Published by the American Association of Neurological Surgeons, United States.;;Song, S.-H. et al., “Inductively Coupled Microfluidic Pressure Meter for in vivo Monitoring of Cerebrospinal Fluid Shunt Function”, Journal of Medical Engineering & Technology, 2012, pp. 156-162, vol. 36, Issue 3, Published by Informa Healthcare, United States.;;Song, S.-H. et al., “Power and Signal Transmission Protocol for a Contactless Subdural Spinal Cord Stimulation Device”, Biomedical Microdevices, 2013, pp. 27-36, vol. 15, Published by Kluwer Academic Publishers, Boston.;;Thiele, R.H. et al., “Manipulation of Hyperbaric Lidocaine Using a Weak Magnetic Field: A Pilot Study”, Anesthesia & Analgesia, Jun. 2012, pp. 1365-1367, vol. 114, No. 6, Published by Lippincott Williams & Wilkins, Netherlands.;;Tucker-Schwartz, J.M. et al., “Pressure-Frequency Sensing Subxiphoid Access System for Use in Percutaneous Cardiac Electrophysiology: Prototype Design and Pilot Study Results”, IEEE Transactions on Biomedical Engineering, Apr. 2009, pp. 1160-1168, vol. 56, No. 4, Published by IEEE Publications, United States.;;Wylie, S.A. et al, “Subthalamic nucleus stimulation influences expression and suppression of impulsive behaviour in Parkinson's disease”, Brain A Journal of Neurology, 2010, pp. 3611-3624, vol. 133, Published by Oxford University Press, Oxford, England, UK.;;Zada, G. et al., “Incidence Trends in the Anatomic Location of Primary Malignant Brain Tumors in the United States: 1992-2006”, World Neurosurgery, Mar. 2012, pp. 518-524, vol. 77, No. 3, Published by Elsevier, Amsterdam, Netherlands.",ACTIVE
89,LT,T,LT 2758073 T,080-469-938-299-438,2019-01-10,2019,LT 12833767 T,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,,ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/080-469-938-299-438,Unknown,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/08,,0,0,,,,PENDING
90,CA,C,CA 2849562 C,124-240-597-274-601,2020-07-21,2020,CA 2849562 A,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/124-240-597-274-601,Granted Patent,no,0,0,76,82,80,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,C07K16/28;;A61K39/00;;C07K16/22;;C07K16/46;;C12N15/13,,0,0,,,,ACTIVE
91,AU,C1,AU 2013/201095 C1,139-359-476-045-362,2019-12-05,2019,AU 2013/201095 A,2012-09-24,US 201261692978 P;;US 201161538454 P;;US 201261597409 P;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 binding agents and uses thereof,"- 125 The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/139-359-476-045-362,Amended Patent,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,C07K16/00;;A61K39/00;;C12P21/08,,0,0,,,,ACTIVE
92,ES,T3,ES 2707580 T3,036-425-469-483-055,2019-04-04,2019,ES 12833767 T,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;US 2012/0056886 W,2011-09-23,Agentes de unión a VEGF/DLL4 y usos de los mismos,"Un anticuerpo biespecífico que comprende: a) un primer sitio de unión a antígeno que se une específicamente al factor de crecimiento endotelial 5 vascular humano (VEGF), y b) un segundo sitio de unión a antígeno que se une específicamente al ligando análogo a delta 4 humano (DLL4), en el que el primer sitio de unión a antígeno comprende una CDR1 de cadena pesada que comprende NYWMH (SEQ ID NO: 17), una CDR2 de cadena pesada que comprende DINPSNGRTSYKEKFKR (SEQ ID NO:18), y una CDR3 de cadena pesada que comprende HYDDKYYPLMDY (SEQ ID NO:19); en el que el segundo sitio de unión a antígeno comprende TAYYIH (SEQ ID NO:13) o AYYIH (SEQ ID NO:79), una CDR2 de cadena pesada que comprende YIX1X2YX3X4ATNYNQKFKG (SEQ ID NO:80), en donde X1 es serina o alanina, X2 es serina, asparagina o glicina, X3 es asparagina o lisina y X4 es glicina, arginina o ácido aspártico, y una CDR3 de cadena pesada que comprende RDYDYDVGMDY (SEQ ID NO:16); y en donde tanto el primero como el segundo sitios de unión a antígeno comprenden una CDR1 de cadena ligera que comprende RASESVDNYGISFMK (SEQ ID NO:20), una CDR2 de cadena ligera que comprende AASNQGS (SEQ ID NO:21) y una CDR3 de cadena ligera que comprende QQSKEVPWTFGG (SEQ ID NO:22).",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/036-425-469-483-055,Granted Patent,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/08,,0,0,,,,ACTIVE
93,CR,A,CR 20140172 A,054-463-561-608-914,2014-06-19,2014,CR 20140172 A,2014-04-10,US 201261597409 P;;US 201161538454 P;;US 201261692978 P,2011-09-23,AGENTES DE LIGACIÓN AL FACTOR DE CRECIMIENTO ENDOTELIAL VASCULAR/LIGANDO 4 SIMILAR A DELTA (VEGF/DLL4) Y USOS DE LOS MISMOS,"La presente invención se refiere a agentes de ligación a VEGF, agentes de ligación bioespecíficos a VEGF/DLL4.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/054-463-561-608-914,Patent Application,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;C07K16/00;;C12P21/08,,0,0,,,,PENDING
94,US,B2,US 9376488 B2,067-444-164-975-735,2016-06-28,2016,US 201414476582 A,2014-09-03,US 201414476582 A;;US 201213625417 A;;US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,VEGF binding antibodies,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,MEREO BIOPHARMA 5 INC (2012-12-11),https://lens.org/067-444-164-975-735,Granted Patent,yes,99,12,76,82,80,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,C07K16/22;;A61K31/4745;;A61K31/7068;;A61K39/00;;A61K39/395;;A61K45/00;;A61K45/06;;C07K16/18;;C07K16/28,,99,48,042-535-804-056-355;;000-913-948-188-914;;015-807-813-009-849;;126-923-418-365-467;;053-851-713-620-401;;006-553-734-546-212;;105-316-874-895-908;;032-443-032-575-719;;100-371-416-663-157;;027-845-339-272-06X;;025-070-183-573-259;;138-876-315-756-795;;009-062-652-854-847;;129-005-046-068-395;;106-254-156-307-214;;032-048-398-057-385;;003-711-275-433-72X;;087-726-883-167-698;;008-498-336-394-659;;031-100-076-670-370;;017-328-222-500-841;;033-368-627-556-233;;046-013-436-890-449;;068-238-957-669-243;;085-528-415-223-353;;054-277-945-870-664;;044-312-778-204-450;;043-453-890-807-326;;024-298-462-228-882;;113-146-142-749-076;;041-945-536-319-424;;113-146-142-749-076;;108-327-398-058-238;;058-205-097-704-518;;071-717-719-996-536;;000-935-046-673-192;;041-596-561-800-698;;107-303-389-554-878;;016-658-224-490-240;;011-910-096-463-060;;006-257-463-053-048;;002-219-259-764-94X;;119-515-479-159-88X;;060-472-079-666-376;;066-407-919-450-381;;150-651-615-448-193;;078-077-493-330-521;;035-236-318-471-090,10.1200/jco.2007.14.7116;;18316791;;10.1158/1538-7445.am2012-lb-196;;10.1158/1538-7445.am2011-2834;;10.1158/1538-7445.am2013-4330;;10586066;;10.4049/jimmunol.163.12.6694;;8424945;;10.1021/bi00055a024;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;pmc4790121;;19487335;;10.1634/theoncologist.2008-0272;;10.1016/j.modgep.2004.05.004;;15533827;;10.1158/1535-7163.targ-13-b78;;20046569;;pmc2715180;;10.4161/mabs.1.1.7347;;10.1158/0008-5472.can-10-2817;;21193546;;10.1073/pnas.040337597;;pmc15970;;10688880;;10.1200/jco.2014.32.3_suppl.279;;10.1007/s10555-005-5865-1;;15785879;;10.1073/pnas.101138098;;pmc33218;;11344278;;10.1200/jco.2008.20.9114;;19433683;;16770536;;10.1007/s10555-006-8504-6;;12177445;;10.1073/pnas.172398299;;pmc123267;;16989900;;10.1016/j.molimm.2006.08.001;;10.1093/annonc/mdn713;;19150949;;10.1016/s0161-5890(98)00095-9;;10199394;;10.1073/pnas.172398399;;pmc123268;;12177446;;10556249;;10.1093/protein/12.10.879;;10.1073/pnas.081615298;;11274374;;pmc31881;;10.1038/nm.2021;;19855400;;pmc2780347;;10.1158/0008-5472.can-06-0191;;16618717;;23750318;;10.2217/cns.12.36;;pmc3673744;;25700513;;10.1126/science.1261093;;pmc4445638;;10.1016/s0959-8049(12)72395-x;;10.1158/1535-7163.targ-13-a71;;10.1016/s0959-8049(12)72395-x;;10.1200/jco.2014.32.15_suppl.2544;;10.1016/s0952-7915(97)80138-0;;9099790;;10.1038/sj.onc.1206758;;14528285;;10.1093/glycob/cwi007;;15496501;;16697642;;10.1016/j.tcb.2006.04.003;;17308088;;10.1158/0008-5472.can-06-3311;;pmc2394258;;12865906;;10.1038/sj.bjc.6601107;;8747303;;10.1291/hypres.18.259;;15293563;;10.1532/ijh97.04065;;14754405;;10.2174/1381612043453603;;10.1016/s1359-6349(08)72532-1;;10.1158/1538-7445.am2013-3725;;10.1158/1538-7445.am2014-207;;10.1158/1538-7445.am2012-3357;;10.1158/1538-7445.am2014-1898;;10.1158/0008-5472.sabcs-09-5071,"Amado, R.G., et al., ""Wild-Type KRAS is Required for Panitumumab Efficacy in Patients with Metastatic Colorectal Cancer,"" Journal of Clinical Oncology 26(10):1626-1634, American Society of Clinical Oncology, United States (2008).;;Beviglia, L., et al., ""Anti-DLL4 reduces tumor growth and tumorigenicity in B-RAF V600E melanomas including those with acquired resistance to B-RAF inhibitors,"" AACR 103rd Annual Meeting, Mar. 31-Apr. 4, 2012, Abstract LB-196, 1 page (2012).;;Beviglia, L., et al., ""Anti-DLL4 Treatment Inhibits Melanoma Tumor Growth, Recurrence, Metastases and Reduces Frequency of Cancer Stem Cells in a Clinically Relevant Tumor Model in NOD/SCID Mice,"" Cancer Research 71(8 Suppl.):Abstract 2834, AACR 102nd Annual Meeting 2011, Apr. 2-6, 2011.;;Beviglia, L., et al., ""In vivo evaluation of anti-tumor activity by an anti-VEGF and anti-DLL4 bispecific antibody in a humanized model of skin graft,"" AACR 104th Annual Meeting 2013, Abstract 4330, Apr. 6-10, 1 page (2013).;;Brorson, K., et al., ""Mutational Analysis of Avidity and Fine Specificity of Anti-Levan Antibodies,"" Journal of Immunology 163(12):6694-6701, American Association of Immunologists, United States (1999).;;Brummell, D.A., et al., ""Probing the Combining Site Role of an Anti-Carbohyrdate Antibody by Saturation-Mutagenesis: Role of the Heavy-Chain CDR3 Residues,"" Biochemistry 32(4):1180-1187, American Chemical Society, United States (1993).;;Burks, E.A., et al., ""In vitro Scanning Saturation Mutagenesis of an Antibody Binding Pocket,"" Proceedings of the National Academy of Sciences of the United States of America 94(2):412-417, National Academy of Sciences, United States (1997).;;Chi, A.S., et al., ""Angiogenesis as a Therapeutic Target in Malignant Gliomas,"" Oncologist 14(6):621-636, AlphaMed Press, United States (2009).;;Claxton, S. and Fruttiger, M., ""Periodic Delta-like 4 expression in developing retinal arteries,"" Gene Expression Pattern 5:123-127, Elsevier B.V., Netherlands (2004).;;Cubillo, A., et al., ""A Ph1b Study of Demcizumab (DEM, anti-DLL4) with Gemcitabine (GEM) in Patients with 1st Line Locally Advanced or Metastatic Pancreatic Cancer,"" AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 19-23, 2013, Poster (2013), 8 pages.;;Cubillo, A., et al., ""A Phase lb study of demcizumab (DEM, anti-DLL4) with gemcitabine (GEM) in patients with first line locally advanced or metastatic pancreatic cancer,"" Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 19-23, 2013, Abstract B78, 2 pages (2013).;;Deonarain, M.P., et al., ""Antibodies Targeting Cancer Stem Cells: A New Paradigm in Immunotherapy?,"" mAbs 1(1):12-25,Taylor & Francis, United States (2009).;;Dupont, J. ""Anti-Angiogenic Agents and Cardiovascular Effects: Implications for Clinical Development in Cancer,"" presentation given in Barcelona, Spain on Nov. 4, 2011, 16 pages.;;English language Abstract of Chinese Patent No. CN 1511850 A, European Patent Office, espacenet database-Worldwide (2004).;;European Search Report for EP Application No. EP10824244.7, Munich, Germany, mailed on Feb. 18, 2013, 6 pages.;;Fischer, M., et al., ""Anti-DLL4 Inhibits Growth and Reduces Tumor-Initiating Cell Frequency in Colorectal Tumors with Oncogenic KRAS Mutations,"" Cancer Research 71(5):1520-1525, American Association for Cancer Research, United States (2011).;;Gagnon, M.L., et al., ""Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression in the antitumor activity,"" Proceedings of the National Academy of Sciences 97(6):2573-2578, National Academy of Sciences, United States (2000).;;Gracian, A.C., et al., ""A phase 1b study of the anticancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) with or without paclitaxel protein bound particles (nab-paclitaxel) in patients with pancreatic cancer,"" 2014 Gastrointestinal Cancers Symposium, Abstract 279, 2 pages (2014).;;Gray-Schopfer, V.C., et al., ""The Role of B-RAF in Melanoma,"" Cancer Metastasis Reviews 24(1):165-183, Springer Science + Business Media, Inc., Netherlands (2005).;;Gridley, T., ""Notch Signaling During Vascular Development,"" Proceedings of the National Academy of Sciences 98(10):5377-5378, National Academy of Sciences, United States (2001).;;Gronberg, B.H., et al., ""Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared with Gemcitabine Plus Carboplatin as First-line Chemotherapy in Advanced Non-small-cell Lung Cancer,"" Journal of Clinical Oncology 27(19):3217-3224, Americal Society of Clinical Oncology, United States (2009).;;Hidalgo, M., et al., ""A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxvel in Patients with Pancreatic Cancer,"" European Society for Medical Oncology 2014 Congress, Sep. 17 and Sep. 28, Poster 616PD, 1 page (2014).;;Holash, J., et al., ""Inhibitors of growth factor receptors, singaling pathways and angiogenesis as therapeutic molecular agents,"" Cancer Metastasis Rev 25:243-252, Dordrecht, Netherlands (2006).;;Holash, J., et al., ""VEGF-Trap: A VEGF Blocker with Potent Antitumor Effects,"" Proceedings of the National Academy of Sciences USA 99(17):11393-11398, National Academy of Sciences, United States (2002).;;Holm, P., et al., ""Functional Mapping and Single Chain Construction of the Anti-Cytokeratin 8 Monoclonal Antibody TS1,"" Molecular Immunology 44(6):1075-1084, Pergamon Press, England (2007).;;International Preliminary Report on Patentability and Written Opinion for International Application No. PCT/US2010/53064, International Searching Authority, mailed on Feb. 14, 2011, 7 pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2013/065015, The International Bureau of WIPO, Switzerland, mailed on Apr. 22, 2014, 17 pages.;;International Search Report for International Application No. PCT/US2010/53064, mailed on Feb. 14, 2011, 3 Pages.;;Izzedine, H., et al., ""Management of Hypertension in Angiogenesis Inhibitor-Treated Patients,"" Annals of Oncology 20(5):807-815, Oxford University Press, England (2009).;;Jang, Y.J., et al., ""The Structural Basis for DNA Binding by an Anti-DNA Autoantibody,"" Molecular Immunology 35(18):1207-1217, Pergamon Press, England (1998).;;Jimeno, A., et al., ""Phase 1 study of REGN421 (R)/SAR153192, a fully-human delta-like ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumors,"" ASCO Annual Meeting accessed at http://meetinglibrary.asco.org/content/113836-132, 2 pages.;;Kim, E.S., et al., ""Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma,"" Proceedings of the National Academy of Sciences 99(17):11399-11404, National Academy of Sciences, United States (2002).;;Kobayashi, H., et al., ""Tryptophan H33 Plays an Important Role in Pyrimidine (6-4) Pyrimidone Photoproduct Binding by a High-Affinity Antibody,"" Protein Engineering Design and Selection 12(10):879-884, Oxford University Press, United States (1999).;;Kuo, C.J., et al., ""Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer,"" Proceedings of the National Academy of Sciences 98(8)4605-4610, National Academy of Sciences, United States (2001).;;Lenihan, D.J., ""How is cardiac toxicity defined and what impact does this have on cancer outcome or drug development,"" PowerPoint Presentation from the DIA Meeting, 42 slides (2011).;;Li, X., et al., ""Notch3 Singaling is Required for the Development of Pulmonary Arterial Hypertension,"" Nature Medicine 15(11):1289-1297, Nature Publishing Company, United States (2009).;;Lievre, A., et al., ""KRAS Mutation Status is Predictive of Response to Cetuximab Therapy in Colorectal Cancer,"" Cancer Research 66(8):3992-3995, American Association for Cancer Research, United States (2006).;;Lu, K.V., and Bergers, G., ""Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma,"" CNS Oncology 2(1):49-65, Future Medicine, Inc., United States (2013).;;Luca, V.C., et al., ""Structural basis for Notch1 engagement of Delta-like 4,"" Science, 347(6224):847-853, American Association for the Advancement of Science, United States (2015).;;McKeage, M., et al., ""A Phase 1b Study of Demcizumab plus Pemetrexed and Carboplatin in Patients with 1st line Non-Squamous Non-Small Cell Lung Cancer (NSCLC),"" 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Nov. 6-9, 2012, Poster (2012), 9 pages.;;McKeage, M., et al., ""A Phase lb study of demcizumab (DEM, anti-DLL4) plus pemetrexed and carboplatin in patients with first line stage IIIB/IV non-squamous non-small cell lung cancer,"" Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 19-23, 2013, Abstract A71, 2 pages (2013).;;McKeage, M., et al., ""Phase 1b Study of Demcizumab plus Pemetrexed and Carboplatin in Patients with 1st line Non-Small Cell Lung Cancer (NSCLC),"" AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 19-23, 2013, Poster (2013), 8 pages.;;McKeage, M.J., et al., ""A phase 1b study of the anticancer stem cell agent demcizumab (DEM), pemetrexed (PEM), and carboplatin (CARBO) in pts with first-line nonsquamous NSCLC,"" 2014 ASCO Annual Meeting, Abstract 2544, 2 pages (2014).;;Morrison, S.J., et al., ""Hematopoietic Stem Cells: Challenges to Expectations,"" Current Opinion in Immunology 9(2):216-221, Elsevier Science, United States (1997).;;NCT01189929, ""A Phase 1b Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer"" as updated on Aug. 26, 2010, ClinicalTrials.gov archive, accessed at https://clinicaltrials.gov/archives/NCT01189929/2010-08-26, accessed on Apr. 20, 2015, 5 pages.;;NCT01189929, ""A Phase 1b Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer"" as updated on Dec. 15, 2011, ClinicalTrials.gov archive, accessed at https://clinicaltrials.gov/archives/NCT01189929/2011-12-15, accessed on Apr. 20, 2015, 5 pages.;;NCT01189968, ""A Phase 1b Study of Carboplatin and Pemetrexed Plus OMP-21M18 as 1st-line Treatment in Subjects with Non-Squamous Non-Small Cell Lung Cancer"" as updated on Aug. 26, 2010, ClinicalTrials.gov archive, accessed at https://clinicaltrials.gov/archive/NTC01189968/2010-08-26, accessed on Apr. 20, 2015, 5 pages.;;NCT01189968, ""A Phase 1b Study of Carboplatin and Pemetrexed Plus OMP-21M18 as 1st-line Treatment in Subjects with Non-Squamous Non-Small Cell Lung Cancer"" as updated on Dec. 15, 2011, ClinicalTrials.gov archive, accessed at https://clinicaltrials.gov/archive/NCT01189968/2011-12-15, accessed on Apr. 20, 2015, 5 pages.;;Nickoloff, B.J., et al., ""Notch Signaling as a Therapeutic Target in Cancer: a New Approach to the Development of Cell Fate Modifying Agents,"" Oncogene 22(42):6598-6608, Nature Publishing Group, England (2003).;;Office Action mailed Mar. 12, 2014, in U.S. Appl. No. 13/625,417, Gurney, A.L., et al., filed Sep. 24, 2012.;;OncoMed Pharmaceuticals, Press Release, ""Clinical Cancer Research Publishes OncoMed Data Demonstrating Anti-Cancer Activity for Anti-DLL4 (Demcizumab) in Pancreatic Cancer,"" Sep. 6, 2012, 2 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed and Lilly Enter Clinical Supply Agreement to Evaluate the Combination of Demcizumab and Alimta(R) (pemetrexed for injection) in Lung Cancer,"" Apr. 2, 2015, 4 pages.;;OncoMed Pharmaceuticals, Press Release, ""OncoMed Announces Abstracts Accepted at the 2014 ASCO Annual Meeting,"" Apr. 23, 2014, 2 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed Announces Abstracts Accepted for Presentation at the 2015 ASCO Annual Meeting,"" Apr. 21, 2015, 2 pages.;;OncoMed Pharmaceuticals, Press Release, ""OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status,"" Mar. 1, 2011, 3 pages.;;OncoMed Pharmaceuticals, Press Release, ""OncoMed's Demcizumab Phase 1b Clinical Trials Show Encouraging Safety and Anti-Tumor Activity at ESMO,"" Sep. 28, 2014, 3 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed Doses First Patient in Phase 1 Clinical Trial of Novel Anti-DLL4/VEGF Bispecific Antibody,"" Jan. 5, 2015, 2 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed Highlights Immuno-Oncology Discoveries During 2015 Research & Development Day,"" Apr. 29, 2015, 3 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed Initiates Dosing in Phase 2 Clinical Trial of Demcizumab for the Treatment of Non-Small Cell Lung Cancer,"" Feb. 4, 2015, 3 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed Initiates Dosing in Randomized Phase 2 Clinical Trial of Demcizumab in Pancreatic Cancer Patients,"" Apr. 22, 2015, 3 pages.;;OncoMed Pharmaceuticals, Press Release, ""OncoMed Pharmaceuticals Announces Presentations of Anti-Notch2/3 and Demcizumab Clinical Data at EORTC-NCI-AACR Meeting,"" Nov. 9, 2012, 3 pages.;;OncoMed Pharmaceuticals, Press Release, ""OncoMed Pharmaceuticals Initiates Phase 1b/2 Clinical Trial of Demcizuman (Anti-DLL4) in Combination with Paclitaxel in Ovarian Cancer,"" Sep. 19, 2013, 3 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed Pharmaceuticals Presents Data From Clinical Trials of Four Novel Anti-Cancer Stem Cell (Anti-CSC) Therapeutics at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Oct. 19-23, 2013,"" Oct. 21, 2013, 4 pages.;;OncoMed Pharmaceuticals, Press Release, ""OncoMed Pharmaceuticals Presents Data From Demcizumab Phase 1b Clinical Study in Pancreatic Cancer at the 2014 Gastrointestinal Cancers Symposium,"" Jan. 17, 2014, 3 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed Pharmaceuticals Recaps New Data Presented at AACR,"" Apr. 3, 2012, 2 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed Pharmaceuticals to Present Data From Clinical Trails of Four Novel Anti-Cancer Stem Cell (Anti-CSC) Therapeutics in Five Posters at the AACR-NCI-EOTRC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Oct. 19-23, 2013,"" Oct. 14, 2013, 4 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed Pharmaceuticals to Present Data From Two Clinical Programs in Advanced Pancreatic Cancer at the 2014 Gastroinestinal Cancers Symposium,"" Jan. 9, 2014, 2 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed Pharmaceuticals to Review Key ASCO Data for Demcizumab and Tarextumab During Conference Call on Tuesday, Jun. 2, 2015,"" May 28, 2015, 2 pages.;;OncoMed Pharmaceuticals, Press Release, ""OncoMed Pharmaceuticals Updates Phase 1b Data for Demcizumab With Pemetrexed and Carboplatin in Patients With First-Line Stage IIIb/IV Non-Small Cell Lung Cancer at the AACR-NCO-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Oct. 19-23, 2013,"" Oct. 20, 2013, 3 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed Pharmaceuticals Presents Data From Phase 1b Trial of Demcizumab in Pancreatic Cancer at the 2015 ASCO Annual Meeting,"" Jun. 1, 2015, 3 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed Presents Data on Clinical and Preclinical Anti-Cancer Stem Cell Programs at American Association for Cancer Research Annual Meeting,"" Apr. 21, 2015, 3 pages.;;OncoMed Pharmaceuticals, Press Release, ""OncoMed Presents Data on Multiple Anti-Cancer Stem Cell Programs at American Association for Cancer Research Annual Meeting,"" Apr. 8, 2014, 4 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed Pharmaceuticals Demcizumab Data From Phase 1b Clinical Trail in Non-Small Cell Lung Cancer Patients at the European Lung Cancer Conference,"" Apr. 16, 2015, 3 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed Presents New Clinical and Biomarker Data From its Tarextumab and Demcizumab Clinical Trials at the EORTC-NCI-AACR Symposium,"" Nov. 21, 2014, 3 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed Presents New Data in Six Anti-Cancer Stem Cell Programs at AACR,"" Apr. 9, 2013, 3 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed Presents Updated Demcizumab Data in Non-Small Cell Lung Cancer at the 2015,"" Jun. 1, 2015, 3 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed to Present Clinical and Preclinical Data at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Meeting,"" Oct. 30, 2014, 2 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed to Present Clinical Data for Demcizumab at the European Lung Cancer Conference,"" Apr. 9, 2015, 2 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed to Presents Data From Three Clinical Studies at the 2014 ASCO Annual Meeting,"" May 14, 2014, 4 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed to Present New and Emerging Data from Demcizumab (anti-DLL4, OMP-21M18) and Tarextumab (anti-Notch2/3, OMP-59R5) Clinical Studies at the European Society for Medical Oncology 2014 Congress,"" Sep. 17, 2014, 2 pages.;;OncoMed Pharmaceuticals Press Release, ""OncoMed to Present New Data in Six Anti-Cancer Stem Cell Programs at AACR,"" Apr. 2, 2013, 2 pages.;;Pisano, C., et al., ""Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist,"" Glycobiology 15(2):1C-6C, Oxford University Press, England (2005).;;Rehman, A.O. and Wang, C-U, ""Notch signaling in the regulation of tumor angiogenesis,"" Trends in Cell Biology 16(6):293-300, Elsevier Ltd., England (2006).;;Shields, J.M., et al., ""Lack of Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase Signaling Shows a New Type of Melanoma,"" Cancer Research 67(4):1502-1512, American Association for Cancer Research, United States (2007).;;Sica, D.A., ""Angiogenesis Inhibitors and Hypertension,"" US Cardiovascular Disease 79-80, Touch Briefings, United States (2007).;;Sullivan, D.C. and Bicknell, R., ""New molecular pathways in angiogenesis,"" British Journal of Cancer 89:228-231, Cancer Research UK, United Kingdom (2003).;;Takeda, T. and Kohno, M., ""Brain Natriuretic Peptide in Hypertension,"" Hypertension Research 18(4):259-266, Nature Publishing Group, England (1995).;;Tavares, M.J., et al., ""Inhibition of Vascular Endothelium by the Notch-Ligand Delta-4 Unveils a Novel Therapeutic Target,"" Abstract#1944, Poster Board Session: 115-11, Blood 102(11):3 pages, American Society of Hematology, United States (2003).;;Thurston, G., and Gale, N.W., ""Vasuclar Endothelial Growth Factor and Other Signaling Pathways in Developmental and Pathologic Angiogenesis,"" International Journal of Hematology 80:7-20, The Japanese Society of Hematology, Japan (2004).;;Ton, N.C. and Jayson, G.C., ""Resistance to Anti-VEGF Agents,"" Current Pharmaceutical Design 10:51-64, Bentham Science Publishers Ltd., Netherlands (2004).;;Wong, O.K., et al., ""Voreloxin (formerly SNS-595) is a potent DNA intercalator and topoisomerase II poison that induces cell cycle dependent DNA damage and rapid apoptosis in cancer cell lines,"" 24th EORTC-NCI-AACR Symposium, Nov. 9, Poster 169, 1 page (2012).;;Yan, Wei., ""Design and Engineering of Fc Heterodimers for the Production of Bispecific Antibodies,"" Symposium Abstract, Keystone Symposia on Molecular and Cellular Biology, Accelerating Life Science Discovery, Mar. 27-Apr. 1, 2009, Whistler, British Columbia.;;Yan, Wei, The Design and Engineering of Fc Heterodimers for the Production of Bispecific Antibodies and Other Heterodirner Fusion Proteins, Symposium Abstract, 20th Annual International Conference, Antibody Engineering, Antibody Engineering and Immunotherapeutics for the 21st Century, Dec. 6-10, 2009, San Diego, California.;;Yan, Wei, ""The Design and Engineering of Fc Heterodimers for the Production of Bispecific Antibodies,"" Symposium Abstract, Eleventh Annual Phage Display of Antibodies and Peptides, Approaches for 2nd Generation Biologics, Apr. 6-Apr. 7, 2009, Boston, Massachusetts.;;Yen, W-C., et al., ""Anti-DLL4 (demcizumab) inhibits tumor growth and reduces cancer stem cell frequency in patient-derived ovarian cancer xenografts,"" AACR 104th Annual Meeting 2013, Abstract 3725, Apr. 6-10, 1 page (2013).;;Yen, W-C., et al., ""Dual targeting of DLL4 and VEGF signaling by a novel bispecific antibody inhibits tumor growth and reduces cancer stem cell frequency,"" AACR Annual Meeting 2014, Apr. 5-9, 2014, Abstract 207, 1 page (2014).;;Yen, W-C., et al., ""Targeting cancer stem cells by an anti-DLL4 antibody inhibits epithelial-to-mesenchymal transition, delays tumor recurrence and overcomes drug resistance in breast and pancreatic cancer,"" AACR 103rd Annual Meeting, Mar. 31-Apr. 4, 2012, Abstract 3357, 1 page (2013).;;Yen, W-C., et al., ""The combination of gemcitabine/nab-paclitaxel and anti-DLL4 (demcizumab) producces synergistic growth inhibition, delays tumor recurrence and reduces tumor initiating cells in pancreatic cancer,"" American Association for Cancer Research Annual Meeting 2014, Abstract 1898, 1 page (2014).;;Yen, W-C., et al., ""Targeting Cancer Stem Cells and Vasculature by a Novel Anti-Delta-Like 4 Ligand (DLL4) Antibody for Treatment of Triple Negative Breast Cancer,"" Cancer Research 69(Suppl.)(24):788s-789s, Abstract 5071, American Association for Cancer Research, United States (2009).",ACTIVE
95,US,B1,US 6249627 B1,071-257-000-828-764,2001-06-19,2001,US 39463499 A,1999-09-13,US 39463499 A,1999-09-13,Arrangement for self-aligning optical fibers to an array of surface emitting lasers,An arrangement for providing attachment and alignment between an array of surface emitting lasers and an array of optical fibers utilizes a first substrate for supporting the laser array and a second substrate for supporting the fibers. The second substrate is formed to including a plurality of apertures that are disposed to self-align with the laser array upon attachment. Alignment fiducials may be formed on both substrates to facilitate the alignment.,LUCENT TECHNOLOGIES INC,BOND AARON EUGENE;;DAUTARTAS MINDAUGAS FERNAND;;PRZYBYLEK GEORGE JOHN,LUCENT TECHNOLOGIES INC (1999-09-08),https://lens.org/071-257-000-828-764,Granted Patent,yes,2,21,1,1,0,G02B6/4232;;G02B6/4232;;G02B6/423;;G02B6/423;;G02B6/4231;;G02B6/4231,G02B6/42,385/49;;385/52;;385/50;;385/131;;372/108,0,0,,,,EXPIRED
96,MX,B,MX 361712 B,121-069-094-055-769,2018-12-14,2018,MX 2014003558 A,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF.,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,AUSTIN L GURNEY;;AARON KEN SATO;;CHRISTOPHER JOHN BOND,,https://lens.org/121-069-094-055-769,Granted Patent,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/395;;A61P35/00;;C07K16/22;;C12P21/08,,0,0,,,,ACTIVE
97,AU,B2,AU 2013/201095 B2,108-288-847-646-432,2015-09-17,2015,AU 2013/201095 A,2012-09-24,US 201261692978 P;;US 201161538454 P;;US 201261597409 P;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 binding agents and uses thereof,"- 125 The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/108-288-847-646-432,Granted Patent,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,C07K16/00;;A61K39/00;;C12P21/08,,0,0,,,,ACTIVE
98,MX,A,MX 2018010331 A,180-318-416-706-822,2020-09-02,2020,MX 2018010331 A,2014-03-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF.,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/180-318-416-706-822,Patent Application,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;C07K16/00;;C12P21/08,,0,0,,,,PENDING
99,EP,A4,EP 2758073 A4,044-451-647-320-726,2015-04-29,2015,EP 12833767 A,2012-09-24,US 201161538454 P;;US 201261597409 P;;US 201261692978 P;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,,ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/044-451-647-320-726,Search Report,no,5,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;A61P35/00;;C07K16/00;;C12P21/08,,2,1,000-438-864-132-323,10.1016/s1359-6349(10)71927-3,"SMITH D C ET AL: ""222 A first-in-human, phase I trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem cells (CSC) in patients with advanced solid tumors"", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 8, no. 7, 1 November 2010 (2010-11-01), pages 73, XP027497910, ISSN: 1359-6349, [retrieved on 20101101], DOI: 10.1016/S1359-6349(10)71927-3;;See also references of WO 2013044215A1",ACTIVE
100,WO,A4,WO 2013/044215 A4,126-750-590-778-332,2013-06-27,2013,US 2012/0056886 W,2012-09-24,US 201261597409 P;;US 201161538454 P;;US 201261692978 P,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/126-750-590-778-332,Patent Application,no,0,0,76,82,80,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;C07K16/00;;C12P21/08,,0,0,,,,PENDING
101,AU,A1,AU 2017/210673 A1,089-874-588-965-918,2017-08-24,2017,AU 2017/210673 A,2017-08-07,AU 2017/210673 A;;AU 2015/268749 A;;AU 2013/201095 A;;US 201261692978 P;;US 201161538454 P;;US 201261597409 P;;US 2012/0056886 W,2011-09-23,VEGF/DLL4 binding agents and uses thereof,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/089-874-588-965-918,Patent Application,no,0,0,4,82,0,,C07K16/00;;A61K39/00;;C12P21/08,,0,0,,,,ACTIVE
102,US,A1,US 2016/0362499 A1,140-685-238-160-671,2016-12-15,2016,US 201615163301 A,2016-05-24,US 201615163301 A;;US 201414476582 A;;US 201213625417 A;;US 201261692978 P;;US 201261597409 P;;US 201161538454 P,2011-09-23,Polynucleotides Encoding VEGF/DLL4 Binding Agents,"The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,MEREO BIOPHARMA 5 INC (2012-12-11),https://lens.org/140-685-238-160-671,Patent Application,yes,0,7,76,82,80,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,C07K16/30;;C07K16/22,,0,0,,,,ACTIVE
103,US,B2,US 6856441 B2,128-138-877-410-131,2005-02-15,2005,US 64748503 A,2003-08-25,US 64748503 A;;US 40555502 P,2002-08-23,Method of tuning wavelength tunable electro-absorption modulators,"A method of tuning an electroabsorption modulator (EAM). A reference average power loss factor for light having a reference peak wavelength that is modulated by the EAM is provided. This loss factor is based on operation of the EAM using a reference bias voltage, a reference temperature, and a reference modulation signal which has a predetermined duty cycle. Input light is coupled into the EAM and modulated using a modulation signal which has the same duty cycle as the reference modulation signal. The input power of the input light and the average output power of light emitted from the EAM are measured. These input and average output powers are used to generate an average power loss factor. The average power loss factor is compared to the reference average power loss factor and the bias voltage and/or the temperature of the EAM are adjusted to reduce differences between these loss factors.",NETWORKS INC T,ZHANG LIYAN;;FRATESCHI NEWTON C;;ZHANG JIAMING;;BOND AARON,CYOPTICS INC (2000-04-18);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-01-06);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2023-02-02);;BROADCOM INTERNATIONAL PTE. LTD (2020-08-26);;CYOPTICS ACQUISITION CORP (2007-04-02);;APOGEE PHOTONICS INC (2005-07-11);;T-NETWORKS INC (2003-08-23),https://lens.org/128-138-877-410-131,Granted Patent,yes,4,31,2,2,0,G02F1/0123;;G02F1/0123;;G02F1/0157;;G02F1/0157,G02F1/01;;G02F1/015,359/245;;359/240,0,0,,,,EXPIRED
104,NZ,A,NZ 623724 A,147-279-228-662-433,2016-09-30,2016,NZ 62372412 A,2012-09-24,US 2012/0056886 W;;US 201261597409 P;;US 201161538454 P;;US 201261692978 P,2011-09-23,Vegf/dll4 binding agents and uses thereof,"Disclosed is a bispecific antibody comprising: a) a first antigen-binding site that specifically binds human vascular endothelial growth factor (VEGF), and b) a second antigen-binding site that specifically binds human delta-like 4 ligand (DLL4), comprising the CDRs of the sequences as defined in the specification. Also disclosed is its use in treating cancer.",ONCOMED PHARM INC,GURNEY AUSTIN L;;SATO AARON KEN;;BOND CHRISTOPHER JOHN,,https://lens.org/147-279-228-662-433,Patent Application,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K39/00;;C07K16/00;;C12P21/08,,0,0,,,,PENDING
105,US,B2,US 6786096 B2,022-003-181-550-492,2004-09-07,2004,US 26301 A,2001-11-28,US 26301 A,2001-11-28,System and technique for detecting the presence of foreign material,"
    A system and technique for detecting the presence of foreign material is presented. An ultrasound transmitter interrogates the bulk material and an array of detectors receives the off angle ultrasound scattering response of the bulk material. The presence of foreign material is determined when the off angle scattering response exceeds a predetermined threshold. The technique is especially suitable for the detection of bone in meat. 
",BATTELLE MEMORIAL INSTITUTE,BOND LEONARD J;;DIAZ AARON A;;PAPPAS RICHARD A;;STEWART TIMOTHY,BATTELLE MEMORIAL INSTITUTE (2002-03-11),https://lens.org/022-003-181-550-492,Granted Patent,yes,31,14,2,11,0,G01N29/11;;G01N29/11;;G01N21/59;;G01N21/59;;G01N29/048;;G01N29/048;;G01N33/12;;G01N33/12;;G01N2291/015;;G01N2291/015;;G01N2291/02475;;G01N2291/02475;;G01N2291/02836;;G01N2291/02836;;G01N2291/048;;G01N2291/048;;G01N2291/103;;G01N2291/103;;G01N2291/105;;G01N2291/105,G01N21/59;;G01N29/02;;G01N29/04;;G01N29/11;;G01N33/02;;G01N33/12;;G06M7/00,73/598;;73/600,4,0,,,"Goebbels, K., ""Structure Analysis by Scattered Ultrasonic Radiation"", Research Technology in NDT, vol. 4, Chapter 4, Shafe. Academic Press.;;Proceedings of the 16<th >International Congress on Acoustics and the 135<th >Meeting of the Acoustical Society of American, Jun. 20-26, 1998, Seattle, WA.;;Bond, L.J. and Saffari, N, ""Mode-conversion Ultrasonic Testing"", Chapter 5; Nondestructive Testing, vol. 7, pp. 146-189, ISBN 0-12-639057-6, 1984, Academic Press, London.;;Lawrie, W.E., ""Ultrasonic Nondestructive Coating Evaluation"", AF Conference Proceedings, pp. 343-371 (1964).",EXPIRED
106,HK,A1,HK 1199209 A1,171-466-752-757-299,2015-06-26,2015,HK 14112776 A,2014-12-22,US 2012/0056886 W;;US 201161538454 P;;US 201261597409 P;;US 201261692978 P,2011-09-23,VEGF/DLL4 BINDING AGENTS AND USES THEREOF VEGF/DLL4,,ONCOMED PHARMACEUTICALSINC,AUSTIN L GURNEY L;;SATO AARON KEN;;CJ CHRISTOPHER JOHN BOND,,https://lens.org/171-466-752-757-299,Patent Application,no,0,0,76,82,0,A61K31/4745;;A61K31/7068;;A61K39/3955;;A61K45/06;;C07K16/22;;C07K16/28;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/00;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K45/06;;A61K31/4745;;A61K31/7068;;C07K16/22;;C07K16/28;;A61P35/00;;A61P35/02;;A61K39/00;;A61K45/06;;A61K31/4745;;A61K31/7068;;A61K39/395;;A61K2039/505;;C07K2317/31;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/22;;C07K16/28;;A61K39/00;;A61K39/3955;;A61K45/00;;C07K16/18;;C07K16/30;;C07K16/303;;C07K16/3046;;C07K2317/56;;C07K2317/565,A61K/;;C07K/;;C12P/,,0,0,,,,PENDING
107,US,A1,US 2003/0098796 A1,167-539-753-655-075,2003-05-29,2003,US 26301 A,2001-11-28,US 26301 A,2001-11-28,System and technique for detecting the presence of foreign material,"
   A system and technique for detecting the presence of foreign material is presented. An ultrasound transmitter interrogates the bulk material and an array of detectors receives the off angle ultrasound scattering response of the bulk material. The presence of foreign material is determined when the off angle scattering response exceeds a predetermined threshold. The technique is especially suitable for the detection of bone in meat. 
",BOND LEONARD J.;;DIAZ AARON A.;;PAPPAS RICHARD A.;;STEWART TIMOTHY,BOND LEONARD J;;DIAZ AARON A;;PAPPAS RICHARD A;;STEWART TIMOTHY,BATTELLE MEMORIAL INSTITUTE (2002-03-11),https://lens.org/167-539-753-655-075,Patent Application,yes,0,6,2,11,0,G01N29/11;;G01N29/11;;G01N21/59;;G01N21/59;;G01N29/048;;G01N29/048;;G01N33/12;;G01N33/12;;G01N2291/015;;G01N2291/015;;G01N2291/02475;;G01N2291/02475;;G01N2291/02836;;G01N2291/02836;;G01N2291/048;;G01N2291/048;;G01N2291/103;;G01N2291/103;;G01N2291/105;;G01N2291/105,G01N21/59;;G01N29/02;;G01N29/04;;G01N29/11;;G01N33/02;;G01N33/12;;G06M7/00,340/627;;367/93;;73/863;;209/509,0,0,,,,EXPIRED
108,US,B1,US 7753390 B1,104-415-837-739-786,2010-07-13,2010,US 42279509 A,2009-04-13,US 42279509 A;;US 36806406 A,2006-03-03,Fifth wheel assembly,"A fifth wheel assembly comprises a fifth wheel having a plurality of journal bearings extending generally downward from its underside, and an “I-shaped” transverse beam member for mounting the assembly to a truck frame. The beam member is dimensioned to span across parallel longitudinal truck frame members and it includes mounting flanges extending generally downward from either lateral side where the mounting flanges have a plurality of apertures for receiving suitable fasteners inserted therein for mounting said beam member to the truck frame members. The transverse member also includes a plurality of pivot bearing pairs to receive the journal bearings of the fifth wheel which is coupled thereto by a trunnion.",FONTAINE FIFTH WHEEL CO,MANN STEVEN WILLIAM;;TERRY JEFF MARCUS;;RHODES JAMES MATTHEW;;BOND CHRISTOPHER AARON,FONTAINE FIFTH WHEEL COMPANY (2009-07-30),https://lens.org/104-415-837-739-786,Granted Patent,yes,8,12,3,3,0,B62D53/0814;;B62D53/0814;;B62D53/08;;B62D53/08;;B62D53/0871;;B62D53/0871,B62D53/08,280/438.1;;280/433;;280/407;;280/441.1,0,0,,,,INACTIVE
109,US,B1,US 7530589 B1,126-901-100-190-604,2009-05-12,2009,US 48236606 A,2006-07-07,US 48236606 A,2006-07-07,Fifth wheel assembly with removable bearing plate,"A fifth wheel with a removable bearing plate includes a load structure comprising frame walls and inner bracing, and including a plurality of flanges, each of said plurality of flanges having an aperture disposed therethrough, said load structure also having at least two pivot bearings; and a bearing plate having a plurality of fasteners extending from an underside of said bearing plate disposed at locations corresponding to the disposition of said apertures configured to permit removable attachment of said bearing plate to said load structure and plurality of ridges disposed upon the underside to form a seat for said frame walls.",FONTAINE INTERNAT,MANN STEVEN WILLIAM;;TERRY JEFF MARCUS;;RHODES JAMES MATTHEW;;BOND CHRISTOPHER AARON,FONTAINE FIFTH WHEEL COMPANY (2009-07-30);;FONTAINE INTERNATIONAL (2006-04-28),https://lens.org/126-901-100-190-604,Granted Patent,yes,9,5,1,1,0,B62D53/0885;;B62D53/0885;;B62D53/0814;;B62D53/0814,B62D53/08,280/433;;384/421,0,0,,,,INACTIVE
110,US,B1,US 7448639 B1,028-232-977-840-038,2008-11-11,2008,US 29692505 A,2005-12-08,US 29692505 A,2005-12-08,Fifth wheel mounting bracket,A fifth wheel mounting bracket is provided. Said mounting bracket allows for the transfer of the load placed on the hitch plate through the mounting pin rather than through its contact surface with the saddle bearing of the hitch plate.,FONTAINE INTERNAT,MANN STEVEN WILLIAM;;TERRY JEFF MARCUS;;RHODES JAMES MATTHEW;;BOND CHRISTOPHER AARON,FONTAINE FIFTH WHEEL COMPANY (2009-07-30);;FONTAINE INTERNATIONAL (2005-11-03),https://lens.org/028-232-977-840-038,Granted Patent,yes,11,7,1,1,0,B62D53/08;;B62D53/08,B62D53/08,280/441.1,0,0,,,,INACTIVE
111,US,B1,US 7516974 B1,011-265-337-451-724,2009-04-14,2009,US 36806406 A,2006-03-03,US 36806406 A,2006-03-03,Fifth wheel assembly,"A fifth wheel assembly comprises a fifth wheel having a plurality of journal bearings extending generally downward from its underside, and a transverse beam member for mounting the assembly to a truck frame. The beam member is dimensioned to span across parallel longitudinal truck frame members and it includes mounting flanges extending generally downward from either lateral side where the mounting flanges have a plurality of apertures for receiving suitable fasteners inserted therein for mounting said beam member to the truck frame members. The transverse member also includes a plurality of pivot bearing pairs to receive the journal bearings of the fifth wheel which is coupled thereto by a trunnion.",FONTAINE INTERNAT,MANN STEVEN WILLIAM;;TERRY JEFF MARCUS;;RHODES JAMES MATTHEW;;BOND CHRISTOPHER AARON,FONTAINE FIFTH WHEEL COMPANY (2009-07-30);;FONTAINE INTERNATIONAL (2006-02-27),https://lens.org/011-265-337-451-724,Granted Patent,yes,8,12,3,3,0,B62D53/0814;;B62D53/0814;;B62D53/08;;B62D53/08;;B62D53/0871;;B62D53/0871,B62D53/06,280/433;;280/407;;280/438.1;;280/441.1;;280/407.1,0,0,,,,INACTIVE
112,US,B1,US 7694992 B1,150-362-461-185-165,2010-04-13,2010,US 42277809 A,2009-04-13,US 42277809 A;;US 36806406 A,2006-03-03,Fifth wheel assembly,"A fifth wheel assembly comprises a fifth wheel having a plurality of journal bearings extending generally downward from its underside, and an “I-shaped” transverse beam member for mounting the assembly to a truck frame. The beam member is dimensioned to span across parallel longitudinal truck frame members and it includes mounting flanges extending generally downward from either lateral side where the mounting flanges have a plurality of apertures for receiving suitable fasteners inserted therein for mounting said beam member to the truck frame members. The transverse member also includes a plurality of pivot bearing pairs to receive the journal bearings of the fifth wheel which is coupled thereto by a trunnion.",FONTAINE FIFTH WHEEL CO,MANN STEVEN WILLIAM;;TERRY JEFF MARCUS;;RHODES JAMES MATTHEW;;BOND CHRISTOPHER AARON,FONTAINE FIFTH WHEEL COMPANY (2009-07-30),https://lens.org/150-362-461-185-165,Granted Patent,yes,11,1,3,3,0,B62D53/0814;;B62D53/0814;;B62D53/08;;B62D53/08;;B62D53/0871;;B62D53/0871,B62D53/08,280/438.1;;280/433;;280/407.1,0,0,,,,INACTIVE
113,WO,A3,WO 2003/046548 A3,019-133-727-343-776,2004-01-15,2004,US 0238006 W,2002-11-27,US 26301 A;;US 22897602 A,2001-11-28,SYSTEM AND TECHNIQUE FOR DETECTING FOREIGN MATERIAL IN MEAT,"Systems and techniques for detecting the presence of foreign material in food utilizing optical backlighting and/or ultrasonic inspection are presented. In optical backlighting, a substantially monochromatic light source optically backlights a food stream with source light having a wavelength between about 500 and 600nm. An image of the food stream is captured and the presence of foreign material is determined when a portion of the detected image exceeds a predetermined threshold. The technique is especially suitable for the detection of bone in chicken meat, and the light source can be a planar array of green LEDs. In ultrasonic inspection, a process stream is interrogated with pulses of ultrasound and the presence of foreign material is determined based on the detected off-angle ultrasound scattering response.",BATTELLE MEMORIAL INSTITUTE;;BOND LEONARD J;;DIAZ AARON A;;PAPPAS RICHARD A;;STEWART TIMOTHY;;MENDOZA ALBERT,BOND LEONARD J;;DIAZ AARON A;;PAPPAS RICHARD A;;STEWART TIMOTHY;;MENDOZA ALBERT,,https://lens.org/019-133-727-343-776,Search Report,yes,9,0,9,11,0,A22C17/008;;A22C21/00;;G01N33/12;;G01N33/12;;G01N21/59;;G01N21/59;;G01N21/85;;G01N21/85;;G01N21/8806;;G01N21/8806;;G01N21/8901;;G01N21/8901;;G01N29/048;;G01N29/048;;G01N29/11;;G01N29/11;;G01N2201/0626;;G01N2201/0626;;G01N2291/015;;G01N2291/015;;G01N2291/02475;;G01N2291/02475;;G01N2291/02836;;G01N2291/02836;;G01N2291/044;;G01N2291/044;;G01N2291/048;;G01N2291/048;;G01N2291/103;;G01N2291/103;;G01N2291/105;;G01N2291/105,G01N21/35;;G01N21/59;;G01N21/88;;G01N21/89;;G01N29/02;;G01N29/04;;G01N29/11;;G01N33/02;;G01N33/12;;G06M7/00,,0,0,,,,PENDING
114,US,B2,US 6992771 B2,131-693-756-933-738,2006-01-31,2006,US 22897602 A,2002-08-27,US 22897602 A;;US 26301 A,2001-11-28,Systems and techniques for detecting the presence of foreign material,"Systems and techniques for detecting the presence of foreign material in food utilizing optical backlighting and/or ultrasonic inspection are presented. In optical backlighting, a substantially monochromatic light source optically backlights a food stream with source light having a wavelength between about 500 and 600 nm. An image of the food stream is captured and the presence of foreign material is determined when a portion of the detected image exceeds a predetermined threshold. The technique is especially suitable for the detection of bone in chicken meat, and the light source can be a planar array of green LEDs. In ultrasonic inspection, a process stream is interrogated with pulses of ultrasound and the presence of foreign material is determined based on the detected off-angle ultrasound scattering response.",BATTELLE MEMORIAL INSTITUTE,BOND LEONARD J;;DIAZ AARON A;;PAPPAS RICHARD A;;STEWART TIMOTHY;;MENDOZA ALBERT,BATTELLE MEMORIAL INSTITUTE (2002-10-17),https://lens.org/131-693-756-933-738,Granted Patent,yes,47,14,9,11,0,A22C17/008;;A22C21/00;;G01N33/12;;G01N33/12;;G01N21/59;;G01N21/59;;G01N21/85;;G01N21/85;;G01N21/8806;;G01N21/8806;;G01N21/8901;;G01N21/8901;;G01N29/048;;G01N29/048;;G01N29/11;;G01N29/11;;G01N2201/0626;;G01N2201/0626;;G01N2291/015;;G01N2291/015;;G01N2291/02475;;G01N2291/02475;;G01N2291/02836;;G01N2291/02836;;G01N2291/044;;G01N2291/044;;G01N2291/048;;G01N2291/048;;G01N2291/103;;G01N2291/103;;G01N2291/105;;G01N2291/105,G01N21/55;;G01N21/35;;G01N21/59;;G01N21/88;;G01N21/89;;G01N29/02;;G01N29/04;;G01N29/11;;G01N33/02;;G01N33/12;;G06M7/00,356/445;;X250223 R;;209/588,4,0,,,"Goebbels, K., ""Structure Analysis by Scattered Ultrasonic Radiation"", Research Technology in NDT, vol. 4, Chapter 4, Shafe. Academic Press.;;Proceedings of the 16<SUP>th </SUP>International Congress on Acoustics and the 135<SUP>th </SUP>Meeting of the Acoustical Society of American, Jun. 20-26, 1998, Seattle, WA.;;Bond, L.J. and Saffari, N, ""Mode-conversion Ultrasonic Testing"", Chapter 5; Nondestructive Testing, vol. 7, pp. 146-189, ISBN 0-12-639057-6, 1984, Academic Press, London.;;Lawrie, W.E., ""Ultrasonic Nondestructive Coating Evaluation"", AF Conference Proceedings, pp. 343-371 (1964).",EXPIRED
115,WO,A2,WO 2003/046548 A2,095-190-282-683-002,2003-06-05,2003,US 0238006 W,2002-11-27,US 26301 A;;US 22897602 A,2001-11-28,SYSTEM AND TECHNIQUE FOR DETECTING THE PRESENCE OF FOREIGN MATERIAL,"Systems and techniques for detecting the presence of foreign material in food utilizing optical backlighting and/or ultrasonic inspection are presented. In optical backlighting, a substantially monochromatic light source optically backlights a food stream with source light having a wavelength between about 500 and 600nm. An image of the food stream is captured and the presence of foreign material is determined when a portion of the detected image exceeds a predetermined threshold. The technique is especially suitable for the detection of bone in chicken meat, and the light source can be a planar array of green LEDs. In ultrasonic inspection, a process stream is interrogated with pulses of ultrasound and the presence of foreign material is determined based on the detected off-angle ultrasound scattering response.",BATTELLE MEMORIAL INSTITUTE;;BOND LEONARD J;;DIAZ AARON A;;PAPPAS RICHARD A;;STEWART TIMOTHY;;MENDOZA ALBERT,BOND LEONARD J;;DIAZ AARON A;;PAPPAS RICHARD A;;STEWART TIMOTHY;;MENDOZA ALBERT,,https://lens.org/095-190-282-683-002,Patent Application,yes,0,0,9,11,0,A22C17/008;;A22C21/00;;G01N33/12;;G01N33/12;;G01N21/59;;G01N21/59;;G01N21/85;;G01N21/85;;G01N21/8806;;G01N21/8806;;G01N21/8901;;G01N21/8901;;G01N29/048;;G01N29/048;;G01N29/11;;G01N29/11;;G01N2201/0626;;G01N2201/0626;;G01N2291/015;;G01N2291/015;;G01N2291/02475;;G01N2291/02475;;G01N2291/02836;;G01N2291/02836;;G01N2291/044;;G01N2291/044;;G01N2291/048;;G01N2291/048;;G01N2291/103;;G01N2291/103;;G01N2291/105;;G01N2291/105,G01N21/35;;G01N21/59;;G01N21/88;;G01N21/89;;G01N29/02;;G01N29/04;;G01N29/11;;G01N33/02;;G01N33/12;;G06M7/00,,0,0,,,,PENDING
116,US,A1,US 2003/0098409 A1,182-406-201-537-147,2003-05-29,2003,US 22897602 A,2002-08-27,US 22897602 A;;US 26301 A,2001-11-28,Systems and techniques for detecting the presence of foreign material,"
   Systems and techniques for detecting the presence of foreign material in food utilizing optical backlighting and/or ultrasonic inspection are presented. In optical backlighting, a substantially monochromatic light source optically backlights a food stream with source light having a wavelength between about 500 and 600 nm. An image of the food stream is captured and the presence of foreign material is determined when a portion of the detected image exceeds a predetermined threshold. The technique is especially suitable for the detection of bone in chicken meat, and the light source can be a planar array of green LEDs. In ultrasonic inspection, a process stream is interrogated with pulses of ultrasound and the presence of foreign material is determined based on the detected off-angle ultrasound scattering response. 
",BOND LEONARD J.;;DIAZ AARON A.;;PAPPAS RICHARD A.;;STEWART TIMOTHY;;MENDOZA ALBERT,BOND LEONARD J;;DIAZ AARON A;;PAPPAS RICHARD A;;STEWART TIMOTHY;;MENDOZA ALBERT,BATTELLE MEMORIAL INSTITUTE (2002-10-17),https://lens.org/182-406-201-537-147,Patent Application,yes,41,33,9,11,0,A22C17/008;;A22C21/00;;G01N33/12;;G01N33/12;;G01N21/59;;G01N21/59;;G01N21/85;;G01N21/85;;G01N21/8806;;G01N21/8806;;G01N21/8901;;G01N21/8901;;G01N29/048;;G01N29/048;;G01N29/11;;G01N29/11;;G01N2201/0626;;G01N2201/0626;;G01N2291/015;;G01N2291/015;;G01N2291/02475;;G01N2291/02475;;G01N2291/02836;;G01N2291/02836;;G01N2291/044;;G01N2291/044;;G01N2291/048;;G01N2291/048;;G01N2291/103;;G01N2291/103;;G01N2291/105;;G01N2291/105,G01N21/35;;G01N21/59;;G01N21/88;;G01N21/89;;G01N29/02;;G01N29/04;;G01N29/11;;G01N33/02;;G01N33/12;;G06M7/00,250/223;;209/588;;209/938;;209/939,0,0,,,,EXPIRED
117,AU,A1,AU 2002/348255 A1,064-094-149-424-867,2003-06-10,2003,AU 2002/348255 A,2002-11-27,US 26301 A;;US 22897602 A;;US 0238006 W,2001-11-28,SYSTEM AND TECHNIQUE FOR DETECTING THE PRESENCE OF FOREIGN MATERIAL,,BATTELLE MEMORIAL INSTITUTE,BOND LEONARD J;;DIAZ AARON A;;PAPPAS RICHARD A;;STEWART TIMOTHY;;MENDOZA ALBERT,,https://lens.org/064-094-149-424-867,Patent Application,no,0,0,9,11,0,A22C17/008;;A22C21/00;;G01N33/12;;G01N33/12;;G01N21/59;;G01N21/59;;G01N21/85;;G01N21/85;;G01N21/8806;;G01N21/8806;;G01N21/8901;;G01N21/8901;;G01N29/048;;G01N29/048;;G01N29/11;;G01N29/11;;G01N2201/0626;;G01N2201/0626;;G01N2291/015;;G01N2291/015;;G01N2291/02475;;G01N2291/02475;;G01N2291/02836;;G01N2291/02836;;G01N2291/044;;G01N2291/044;;G01N2291/048;;G01N2291/048;;G01N2291/103;;G01N2291/103;;G01N2291/105;;G01N2291/105,G01N21/35;;G01N21/59;;G01N21/88;;G01N21/89;;G01N29/02;;G01N29/04;;G01N29/11;;G01N33/02;;G01N33/12;;G06M7/00,,0,0,,,,DISCONTINUED
118,AU,A8,AU 2002/348255 A8,051-144-179-265-386,2003-06-10,2003,AU 2002/348255 A,2002-11-27,US 26301 A;;US 22897602 A;;US 0238006 W,2001-11-28,System and technique for detecting foreign material in meat,,BATTELLE MEMORIAL INSTITUTE,DIAZ AARON A;;PAPPAS RICHARD A;;BOND LEONARD J;;MENDOZA ALBERT;;STEWART TIMOTHY,,https://lens.org/051-144-179-265-386,Patent Application,no,0,0,9,11,0,A22C17/008;;A22C21/00;;G01N33/12;;G01N33/12;;G01N21/59;;G01N21/59;;G01N21/85;;G01N21/85;;G01N21/8806;;G01N21/8806;;G01N21/8901;;G01N21/8901;;G01N29/048;;G01N29/048;;G01N29/11;;G01N29/11;;G01N2201/0626;;G01N2201/0626;;G01N2291/015;;G01N2291/015;;G01N2291/02475;;G01N2291/02475;;G01N2291/02836;;G01N2291/02836;;G01N2291/044;;G01N2291/044;;G01N2291/048;;G01N2291/048;;G01N2291/103;;G01N2291/103;;G01N2291/105;;G01N2291/105,G01N21/35;;G01N21/59;;G01N21/88;;G01N21/89;;G01N29/02;;G01N29/04;;G01N29/11;;G01N33/02;;G01N33/12;;G06M7/00,,0,0,,,,DISCONTINUED
119,WO,B1,WO 2003/046548 B1,039-950-537-953-966,2004-03-18,2004,US 0238006 W,2002-11-27,US 26301 A;;US 22897602 A,2001-11-28,SYSTEM AND TECHNIQUE FOR DETECTING FOREIGN MATERIAL IN MEAT,"Systems and techniques for detecting the presence of foreign material in food utilizing optical backlighting and/or ultrasonic inspection are presented. In optical backlighting, a substantially monochromatic light source optically backlights a food stream with source light having a wavelength between about 500 and 600nm. An image of the food stream is captured and the presence of foreign material is determined when a portion of the detected image exceeds a predetermined threshold. The technique is especially suitable for the detection of bone in chicken meat, and the light source can be a planar array of green LEDs. In ultrasonic inspection, a process stream is interrogated with pulses of ultrasound and the presence of foreign material is determined based on the detected off-angle ultrasound scattering response.",BATTELLE MEMORIAL INSTITUTE;;BOND LEONARD J;;DIAZ AARON A;;PAPPAS RICHARD A;;STEWART TIMOTHY;;MENDOZA ALBERT,BOND LEONARD J;;DIAZ AARON A;;PAPPAS RICHARD A;;STEWART TIMOTHY;;MENDOZA ALBERT,,https://lens.org/039-950-537-953-966,Patent Application,no,0,0,9,11,0,A22C17/008;;A22C21/00;;G01N33/12;;G01N33/12;;G01N21/59;;G01N21/59;;G01N21/85;;G01N21/85;;G01N21/8806;;G01N21/8806;;G01N21/8901;;G01N21/8901;;G01N29/048;;G01N29/048;;G01N29/11;;G01N29/11;;G01N2201/0626;;G01N2201/0626;;G01N2291/015;;G01N2291/015;;G01N2291/02475;;G01N2291/02475;;G01N2291/02836;;G01N2291/02836;;G01N2291/044;;G01N2291/044;;G01N2291/048;;G01N2291/048;;G01N2291/103;;G01N2291/103;;G01N2291/105;;G01N2291/105,G01N21/35;;G01N21/59;;G01N21/88;;G01N21/89;;G01N29/02;;G01N29/04;;G01N29/11;;G01N33/02;;G01N33/12;;G06M7/00,,0,0,,,,PENDING
120,US,B2,US 7363817 B2,118-572-600-622-413,2008-04-29,2008,US 49674404 A,2004-10-12,US 49674404 A;;US 26301 A;;US 22897602 A;;US 0238006 W,2001-11-28,System and technique for detecting the presence of foreign material,"Systems and techniques for detecting the presence of foreign material in food utilizing optical backlighting and/or ultrasonic inspection are presented. In optical backlighting, a substantially monochromatic light source optically backlights a food stream with source light having a wavelength between about 500 and 600 nm. An image of the food stream is captured and the presence of foreign material is determined when a portion of the detected image exceeds a predetermined threshold. The technique is especially suitable for the detection of bone in chicken meat, and the light source can be a planar array of green LEDs. In ultrasonic inspection, a process stream is interrogated with pulses of ultrasound and the presence of foreign material is determined based on the detected off-angle ultrasound scattering response.",BATTELLE MEMORIAL INSTITUTE,BOND LEONARD J;;DIAZ AARON A;;PAPPAS RICHARD A;;STEWART TIMOTHY L;;MENDOZA ALBERT,BATTELLE MEMORIAL INSTITUTE (2004-08-16),https://lens.org/118-572-600-622-413,Granted Patent,yes,45,18,9,11,0,A22C17/008;;A22C21/00;;G01N33/12;;G01N33/12;;G01N21/59;;G01N21/59;;G01N21/85;;G01N21/85;;G01N21/8806;;G01N21/8806;;G01N21/8901;;G01N21/8901;;G01N29/048;;G01N29/048;;G01N29/11;;G01N29/11;;G01N2201/0626;;G01N2201/0626;;G01N2291/015;;G01N2291/015;;G01N2291/02475;;G01N2291/02475;;G01N2291/02836;;G01N2291/02836;;G01N2291/044;;G01N2291/044;;G01N2291/048;;G01N2291/048;;G01N2291/103;;G01N2291/103;;G01N2291/105;;G01N2291/105,G01N29/04;;G01N21/35;;G01N21/55;;G01N21/59;;G01N21/88;;G01N21/89;;G01N29/02;;G01N29/11;;G01N33/02;;G01N33/12;;G06M7/00,73/598;;73/602;;356/445;;X250223 R,5,0,,,"PCT/US02/38006 International Preliminary Examination Report dated Apr. 18, 2006,;;Goebbels, K., ""Structure Analysis by Scattered Ultrasonic Radiation"", Research Technology in NDT, vol. 4, Chapter 4, Shafe. Academic Press.;;Proceedings of the 16<SUP>th </SUP>International Congress on Acoustics and the 135<SUP>th </SUP> Meeting of the Acoustical Society of American, Jun. 20-26, 1998, Seattle, WA.;;Bond, L.J. and Saffari, N, ""Mode-conversion Ultrasonic Testing"", Chapter 5; Nondestructive Testing, vol. 7, pp. 146-189, ISBN 0-12-639057-6, 1984, Academic Press, London.;;Lawrie, W.E., ""Ultrasonic Nondestructive Coating Evaluation"", AF Conference Proceedings, pp. 343-371 (1964).",EXPIRED
121,US,A1,US 2005/0068535 A1,131-911-625-217-320,2005-03-31,2005,US 49674404 A,2004-10-12,US 49674404 A;;US 26301 A;;US 22897602 A;;US 0238006 W,2001-11-28,System and technique for detecting the presence of foreign material,"Systems and techniques for detecting the presence of foreign material in food utilizing optical backlighting and/or ultrasonic inspection are presented. In optical backlighting, a substantially monochromatic light source optically backlights a food stream with source light having a wavelength between about 500 and 600 nm. An image of the food stream is captured and the presence of foreign material is determined when a portion of the detected image exceeds a predetermined threshold. The technique is especially suitable for the detection of bone in chicken meat, and the light source can be a planar array of green LEDs. In ultrasonic inspection, a process stream is interrogated with pulses of ultrasound and the presence of foreign material is determined based on the detected off-angle ultrasound scattering response.",BATTELLE MEMORIAL INSTITUTE,BOND LEONARD J;;DIAZ AARON A;;PAPPAS RICHARD A;;STEWART TIMOTHY L;;MENDOZA ALBERT,BATTELLE MEMORIAL INSTITUTE (2004-08-16),https://lens.org/131-911-625-217-320,Patent Application,yes,37,15,9,11,0,A22C17/008;;A22C21/00;;G01N33/12;;G01N33/12;;G01N21/59;;G01N21/59;;G01N21/85;;G01N21/85;;G01N21/8806;;G01N21/8806;;G01N21/8901;;G01N21/8901;;G01N29/048;;G01N29/048;;G01N29/11;;G01N29/11;;G01N2201/0626;;G01N2201/0626;;G01N2291/015;;G01N2291/015;;G01N2291/02475;;G01N2291/02475;;G01N2291/02836;;G01N2291/02836;;G01N2291/044;;G01N2291/044;;G01N2291/048;;G01N2291/048;;G01N2291/103;;G01N2291/103;;G01N2291/105;;G01N2291/105,G01N21/35;;G01N21/59;;G01N21/88;;G01N21/89;;G01N29/02;;G01N29/04;;G01N29/11;;G01N33/02;;G01N33/12;;G06M7/00,356/433,0,0,,,,EXPIRED
122,US,A1,US 2012/0001033 A1,189-739-087-579-721,2012-01-05,2012,US 97705610 A,2010-12-22,US 97705610 A;;US 28470809 P,2009-12-24,EQUIPMENT MOUNTING APPARATUS AND METHOD,An apparatus and method for mounting electronic equipment onto a pole are disclosed.,WILDE GARY P;;BILLINGSLEY BRYAN;;SOVIC MATTHEW;;BOND DEAN;;FOSTER JOHN;;DESMOND AARON;;WILDE JOSHUA,WILDE GARY P;;BILLINGSLEY BRYAN;;SOVIC MATTHEW;;BOND DEAN;;FOSTER JOHN;;DESMOND AARON;;WILDE JOSHUA,GLOBAL CONTROLS AND ELECTRIC (2010-12-21),https://lens.org/189-739-087-579-721,Patent Application,yes,13,1,1,1,0,F16M13/02;;F16M13/02;;Y10T29/49826;;Y10T29/49826,H05K7/00;;B23P11/00;;F16M13/02,248/73;;29/428,0,0,,,,DISCONTINUED
123,US,A1,US 2021/0039966 A1,043-860-067-945-261,2021-02-11,2021,US 202016944886 A,2020-07-31,US 202016944886 A;;US 201962883550 P,2019-08-06,WATER PURIFICATION,"Production of decontaminated water from contaminated water using a vessel, an inlet to the vessel wherein the contaminated water is introduced into the vessel, an outlet to the vessel wherein the decontaminated water is removed from the vessel, a plasmonic-photocatalyst membrane connected to the vessel, plasmonic nanoparticles or nanostructures connected to the plasmonic-photocatalyst membrane, and a source of ultraviolet light that directs ultraviolet light onto the vessel, the plasmonic-photocatalyst membrane, the plasmonic nanoparticles or nanostructures, and the contaminated water to produce the decontaminated water from the contaminated water.",L LIVERMORE NAT SECURITY LLC,BRISBIN RYAN P;;ZHOU JENNY;;CHANG ALLAN S;;BOND TIZIANA C;;SIMON AARON J;;VOSS LARS,LAWRENCE LIVERMORE NATIONAL SECURITY LLC (2020-01-16),https://lens.org/043-860-067-945-261,Patent Application,yes,0,0,2,2,0,B01J21/063;;C02F1/725;;C02F1/32;;C02F2101/40;;C02F2305/08;;C02F2305/10;;B01J35/59;;B01J35/23;;B01J35/39;;C02F1/325;;C02F1/725;;B01J21/063;;C02F2101/40;;C02F2305/08;;C02F2305/10;;B01J35/39;;B01J35/56;;B01J35/59,C02F1/32;;B01J21/06;;B01J35/00;;B01J35/04;;B01J35/06;;C02F1/72,,0,0,,,,ACTIVE
124,US,B2,US 11358880 B2,099-465-179-024-303,2022-06-14,2022,US 202016944886 A,2020-07-31,US 202016944886 A;;US 201962883550 P,2019-08-06,Water purification,"Production of decontaminated water from contaminated water using a vessel, an inlet to the vessel wherein the contaminated water is introduced into the vessel, an outlet to the vessel wherein the decontaminated water is removed from the vessel, a plasmonic-photocatalyst membrane connected to the vessel, plasmonic nanoparticles or nanostructures connected to the plasmonic-photocatalyst membrane, and a source of ultraviolet light that directs ultraviolet light onto the vessel, the plasmonic-photocatalyst membrane, the plasmonic nanoparticles or nanostructures, and the contaminated water to produce the decontaminated water from the contaminated water.",L LIVERMORE NAT SECURITY LLC,BRISBIN RYAN P;;ZHOU JENNY;;CHANG ALLAN S;;BOND TIZIANA C;;SIMON AARON J;;VOSS LARS,LAWRENCE LIVERMORE NATIONAL SECURITY LLC (2020-01-16),https://lens.org/099-465-179-024-303,Granted Patent,yes,3,0,2,2,0,B01J21/063;;C02F1/725;;C02F1/32;;C02F2101/40;;C02F2305/08;;C02F2305/10;;B01J35/59;;B01J35/23;;B01J35/39;;C02F1/325;;C02F1/725;;B01J21/063;;C02F2101/40;;C02F2305/08;;C02F2305/10;;B01J35/39;;B01J35/56;;B01J35/59,C02F1/32;;B01J21/06;;B01J35/00;;B01J35/04;;B01J35/06;;C02F1/72,,17,16,008-534-672-345-405;;047-013-799-615-733;;004-587-425-245-718;;093-776-774-703-327;;111-622-287-262-113;;065-579-238-424-529;;113-463-706-727-585;;113-150-467-502-364;;080-597-207-691-889;;171-927-826-823-674;;016-649-504-224-41X;;007-804-626-777-689;;051-770-355-747-623;;036-879-565-640-782;;054-512-648-069-974;;015-455-338-615-244,10.1021/acsanm.9b00485;;10.1016/1010-6030(94)03804-x;;10.1021/ja305603t;;22891916;;17588640;;10.1016/j.chemosphere.2007.05.021;;10.1016/s1010-6030(02)00374-x;;10.1002/adma.201201075;;22821738;;26497411;;pmc4620498;;10.1038/srep15288;;10.1088/0022-3727/48/18/184006;;10.1016/j.jcat.2010.11.001;;10.1016/j.jece.2019.103233;;10.1016/j.jiec.2013.07.012;;16503343;;10.1016/j.watres.2005.12.042;;10.1002/smll.201200564;;22961930;;18650009;;10.1016/j.jhazmat.2008.05.162;;22200297;;10.1021/es00003a037;;16570988;;10.1021/jp060082z,"Asapu, et al., “W. Electron Transfer and Near-Field Mechanisms in Plasmonic Gold-Nanoparticle-Modified TiO2 Photocatalytic Systems,” ACS Appl. Nano Mater., 2019, 2 (7), pp. 4067-4074.;;Brezová, et al., “Photocatalytic Degradation of P-Toluenesulphonic Acid in Aqueous Systems Containing Powdered and Immobilized Titanium Dioxide,” J. Photochem. Photobiol. A Chem., 1994, 83 (1), pp. 69-75.;;Cushing, et al., Photocatalytic Activity Enhanced by Plasmonic Resonant Energy Transfer from Metal to Semiconductor. J. Am Chem. Soc. 2012, 134 (36), pp. 15033-15041.;;Dai, et al., “Photocatalytic Degradation of Methyl Orange in Aqueous Suspension of Mesoporous Titania Nanoparticles,” Chemosphere, 2007, 69 (9), pp. 1361-1367.;;Gomes da Silva, et al., “Photochemical and Photocatalytic Degradation of an Azo Dye in Aqueous Solution by UV Irradiation,” J Photochem. Photobiol. A Chem., 2003, 155 (1-3), pp. 133-143.;;Guo, et al., “Direct Growth of TiO2 Nanosheet Arrays on Carbon Fibers for Highly Efficient Photocatalytic Degradation of Methyl Orange,” Adv. Mater. 2012, 24 (35), pp. 4761-4764.;;Hao, et al, “Aluminum Plasmonic Photocatalysis,” Sci. Rep., 2015, 5, pp. 1-7.;;Honda, et al., “Efficient UV Photocatalysis Assisted by Densely Distributed Aluminum Nanoparticles.” J. Phys. D. Appl. Phys. 2015, 48 (18), 184006, pp. 1-6.;;Hou, et al., “Plasmonic Enhancement of Photocatalytic Decomposition of Methyl Orange under Visible Light,” J. Catal. 2011, 277 (2), pp. 149-153.;;Jani, et al., “Understanding the Effect of Plasmonic Enhancement on Photocatalytic Activity of TiO2 Nanotube Arrays,” Mater. Charact. 2017, 128 (Nov. 2016), pp. 134-141.;;Khatun, et al., “Plasmonic Enhanced Au Decorated TiO2 Nanotube Arrays as a Visible Light Active Catalyst towards Photocatalytic CO2 Conversion to CH4” J. Environ. Chem. Eng., 2019, 7 (6), 103233, pp. 1-10.;;Lee, et al., “TiO2 Photocatalyst for Water Treatment Applications,” J. Ind. Eng. Chem. 2013, 19 (6), pp. 1761-1769.;;Li, et al., “Photocatalytic Degradation of Methyl Orange by TiO2-Coated Activated Carbon and Kinetic Study,” Water Res., 2006, 40 (6), pp. 1119-1126.;;Paramasivam, et al., “A Review of Photocatalysis Using Self-Organized TiO 2 Nanotubes and Other Ordered Oxide Nanostructures,” Small 2012, 8 (20), pp. 3073-3103.;;Tasaki, et al., “Degradation of Methyl Orange Using Short-Wavelength UV Irradiation with Oxygen Microbubbles,” J. Hazard. Mater., 2009, 162 (2-3), pp. 1103-1110.;;Vinodgopal, et al., “Enhanced Rates of Photocatalytic Degradation of an Azo Dye Using SnO2/TiO2 Coupled Semiconductor Thin Films,” Environ. Sci. Technol., 1995, 29 (3), pp. 841-845.;;Wang, et al., “Wavelength-Sensitive Photocatalytic Degradation of Methyl Orange in Aqueous Suspension over Iron(III)-Doped TiO2 Nanopowders under UV and Visible Light Irradiation,” J. Phys. Chem. B, 2006, 110 (13), pp. 6804-6809.",ACTIVE
125,US,A1,US 2003/0026576 A1,030-500-529-444-410,2003-02-06,2003,US 92289101 A,2001-08-06,US 92289101 A,2001-08-06,Reducing optical loss in semiconductor opto-electronic devices by hydrogen passivation of dopants,"
   A method for reducing optical loss in opto-electronic devices includes passivating P-type dopant impurities formed within various cladding and contact layer films. The passivating species is atomic hydrogen produced by a hydrogen containing plasma. The atomic hydrogen complexes with P-type dopant impurities to form electrically neutral pairs which are void of free carriers. Absorption, and loss, of the optical wave is therefore suppressed as it propagates through the P-doped layers because of the reduced free carrier concentration in the P-doped layers. 
",ASOUS WALEED A.;;BOND AARON EUGENE;;HARTMAN ROBERT LOUIS;;PARAYANTHAL PADMAN;;PRZYBYLEK GEORGE JOHN;;SHTENGEL GLEB E.,ASOUS WALEED A;;BOND AARON EUGENE;;HARTMAN ROBERT LOUIS;;PARAYANTHAL PADMAN;;PRZYBYLEK GEORGE JOHN;;SHTENGEL GLEB E,AGERE SYSTEMS OPTOELECTRONICS GUARDIAN CORP (2001-06-10),https://lens.org/030-500-529-444-410,Patent Application,yes,0,4,1,1,0,H01S5/106;;H01S5/164;;H01S5/168;;H01S2301/176;;H01S5/164;;H01S5/106;;H01S2301/176;;H01S5/168,H01S5/10;;H01S5/16,385/131;;385/142;;X43851,0,0,,,,DISCONTINUED
126,US,A1,US 2009/0038932 A1,034-256-068-220-556,2009-02-12,2009,US 83585407 A,2007-08-08,US 83585407 A,2007-08-08,DEVICE AND METHOD FOR NONINVASIVE ULTRASONIC TREATMENT OF FLUIDS AND MATERIALS IN CONDUITS AND CYLINDRICAL CONTAINERS,"A system, method, and device are described for ultrasonic treatment of viscous fluids, including, e.g., crude oils that provide a variety of desired modifications. The invention includes a container having a circumvolving outer wall configured to allow passage of a quantity of a material within a passageway therein and ultrasonic transducers that attach to and circumvolve the outer wall of the container. The ultrasonic transducers transmit ultrasonic energy into material within the container at preselected frequencies thereby achieving desired effects.",BATTELLE MEMORIAL INSTITUTE,DENSLOW KAYTE M;;POSAKONY GERALD J;;BOND LEONARD J;;DIAZ AARON A;;ALNAJJAR MIKHAIL S;;FRANZ JAMES A,BATTELLE MEMORIAL INSTITUTE (2007-08-07),https://lens.org/034-256-068-220-556,Patent Application,yes,32,46,3,3,0,B01J19/10;;C10G33/06;;B01F25/50;;B01F31/84;;B01F31/86;;B01J19/10;;C10G33/06;;B01F25/50;;B01F31/84;;B01F31/86,C07C1/00;;B01J19/12,204/157.15;;204/193,0,0,,,,DISCONTINUED
127,MX,A,MX 2008005970 A,020-517-706-450-706,2009-03-03,2009,MX 2008005970 A,2008-05-08,US 83585407 A,2007-08-08,DEVICE AND METHOD FOR NONINVASIVE ULTRASONIC TREATMENT OF FLUIDS AND MATERIALS IN CONDUITS AND CYLINDRICAL CONTAINERS.,"A system, method, and device are described for ultrasonic treatment of viscous fluids, including, e.g., crude oils that provide a variety of desired modifications. The invention includes a container having a circumvolving outer wall configured to allow passage of a quantity of a material within a passageway therein and ultrasonic transducers that attach to and circumvolve the outer wall of the container. The ultrasonic transducers transmit ultrasonic energy into material within the container at preselected frequencies thereby achieving desired effects.",BATTELLE MEMORIAL INSTITUTE,DENSLOW KAYTE M;;POSAKONY GERALD J;;BOND LEONARD J;;DIAZ AARON A;;ALNAJJAR MIKHAIL S;;FRANZ JAMES A,,https://lens.org/020-517-706-450-706,Patent Application,no,0,0,3,3,0,B01J19/10;;C10G33/06;;B01F25/50;;B01F31/84;;B01F31/86;;B01J19/10;;C10G33/06;;B01F25/50;;B01F31/84;;B01F31/86,C10G15/08;;B01J19/00;;C10G31/00,,0,0,,,,DISCONTINUED
128,CA,A1,CA 2629985 A1,008-482-916-813-956,2009-02-08,2009,CA 2629985 A,2008-04-25,US 83585407 A,2007-08-08,DEVICE AND METHOD FOR NONINVASIVE ULTRASONIC TREATMENT OF FLUIDS AND MATERIALS IN CONDUITS AND CYLINDRICAL CONTAINERS,"A system, method, and device are described for ultrasonic treatment of visco us fluids, including, e.g., crude oils that provide a variety of desired modifications. The invention includes a container having a circumvolving outer wall configured to allow passage of a quantity of a material within a passageway therein and ultrasonic transducers that attach to and circumvolve the outer wall of the container. The ultrasonic transducers transmit ultrasonic energy into materi al within the container at preselected frequencies thereby achieving desired effects.",BATTELLE MEMORIAL INSTITUTE,POSAKONY GERALD J;;DENSLOW KAYTE M;;FRANZ JAMES A;;ALNAJJAR MIKHAIL S;;DIAZ AARON A;;BOND LEONARD J,,https://lens.org/008-482-916-813-956,Patent Application,no,0,0,3,3,0,B01J19/10;;C10G33/06;;B01F25/50;;B01F31/84;;B01F31/86;;B01J19/10;;C10G33/06;;B01F25/50;;B01F31/84;;B01F31/86,B01J19/10;;C10G15/08;;C10G31/00,,0,0,,,,DISCONTINUED
129,US,A1,US 2004/0195231 A1,053-961-397-437-468,2004-10-07,2004,US 40699303 A,2003-04-03,US 40699303 A,2003-04-03,System and technique for ultrasonic determination of degree of cooking,"
   A method and apparatus are described for determining the doneness of food during a cooking process. Ultrasonic signal are passed through the food during cooking. The change in transmission characteristics of the ultrasonic signal during the cooking process is measured to determine the point at which the food has been cooked to the proper level. In one aspect, a heated fluid cooks the food, and the transmission characteristics along a fluid-only ultrasonic path provides a reference for comparison with the transmission characteristics for a food-fluid ultrasonic path. 
",BOND LEONARD J.;;DIAZ AARON A.;;JUDD KAYTE M.;;PAPPAS RICHARD A.;;CLIFF WILLIAM C.;;PFUND DAVID M.;;MORGEN GERALD P.,BOND LEONARD J;;DIAZ AARON A;;JUDD KAYTE M;;PAPPAS RICHARD A;;CLIFF WILLIAM C;;PFUND DAVID M;;MORGEN GERALD P,BATTELLE MEMORIAL INSTITUTE (2003-06-17),https://lens.org/053-961-397-437-468,Patent Application,yes,27,17,3,3,0,F24C7/08;;F24C7/08;;H05B6/687;;H05B6/687,F24C7/08;;H05B1/02;;H05B6/68,2194,0,0,,,,EXPIRED
130,AU,B2,AU 2015/289475 B2,031-066-753-613-810,2018-05-17,2018,AU 2015/289475 A,2015-07-17,US 201562180987 P;;US 201562190089 P;;US 201514752030 A;;US 201562190999 P;;US 201462026449 P;;US 2015/0040965 W,2014-07-18,Method and system for identifying and sampling hydrocarbons with buoys,"Method and system is described for hydrocarbon exploration and development. The method and system include one or more remote devices, such as buoys, which are utilized to identify and collect samples of target materials. The buoys include measurement components, sampling components and storage components to manage the obtained samples.",EXXONMOBIL UPSTREAM RES CO,CORBETT KEVIN;;BOND WILLIAM;;HORNBOSTEL SCOTT;;LEVIEN LOUISE;;POTTORF ROBERT;;MEURER WILLIAM;;HIESHIMA GLENN;;N'GUESSAN A LUCIE;;NEDWED TIMOTHY;;REGBERG AARON,,https://lens.org/031-066-753-613-810,Granted Patent,no,1,0,12,25,0,G01V9/007;;G01N33/241,G01V9/00;;G01N33/24,,1,0,,,"Joshua Leighton ET AL, ""System Design of an Unmanned Aerial Vehicle (UAV) for Marine Environmental Sensing"", (2013-02-01), URL: http://www.dtic.mil/docs/citations/ADA573151",ACTIVE
131,WO,A1,WO 2005/022144 A1,059-683-036-354-369,2005-03-10,2005,US 2004/0009875 W,2004-03-30,US 40699303 A,2003-04-03,SYSTEM AND TECHNIQUE FOR ULTRASONIC DETERMINATION OF DEGREE OF COOKING,"A method and apparatus are described for determining the doneness of food during a cooking process. Ultrasonic signals (24) are passed through the food (16) during cooking. The change in transmission characteristics of the ultrasonic signal (24) during the cooking process is measured to determine the point at which the food (16) has been cooked to the proper level. In one aspect, a heated fluid (14) cooks the food, and the transmission characteristics along a fluid-only ultrasonic path provides a reference for comparison with the transmission characteristics for a food-fluid ultrasonic path.",BATTELLE MEMORIAL INSTITUTE;;BOND LEONARD J;;DIAZ AARON A;;JUDD KAYTE M;;PAPPAS RICHARD A;;CLIFF WILLIAM C;;PFUND DAVID M;;MORGEN GERALD P,BOND LEONARD J;;DIAZ AARON A;;JUDD KAYTE M;;PAPPAS RICHARD A;;CLIFF WILLIAM C;;PFUND DAVID M;;MORGEN GERALD P,,https://lens.org/059-683-036-354-369,Patent Application,yes,2,2,3,3,0,F24C7/08;;F24C7/08;;H05B6/687;;H05B6/687,F24C7/08;;H05B1/02;;H05B6/68,,1,1,137-658-250-676-37X,10.1016/0041-624x(90)90093-4,"MCCLEMENTS D J ET AL: ""ULTRASONIC CHARACTERIZATION OF A FOOD EMULSION"", ULTRASONICS, IPC SCIENCE AND TECHNOLOGY PRESS LTD. GUILDFORD, GB, vol. 28, no. 4, 1 July 1990 (1990-07-01), pages 266 - 272, XP000143013, ISSN: 0041-624X",PENDING
132,AU,A1,AU 2015/289475 A1,099-146-827-983-476,2017-02-02,2017,AU 2015/289475 A,2015-07-17,US 201562180987 P;;US 201562190089 P;;US 201514752030 A;;US 201562190999 P;;US 201462026449 P;;US 2015/0040965 W,2014-07-18,Method and system for identifying and sampling hydrocarbons with buoys,"Method and system is described for hydrocarbon exploration and development. The method and system include one or more remote devices, such as buoys, which are utilized to identify and collect samples of target materials. The buoys include measurement components, sampling components and storage components to manage the obtained samples.",EXXONMOBIL UPSTREAM RES CO,CORBETT KEVIN;;BOND WILLIAM;;HORNBOSTEL SCOTT;;LEVIEN LOUISE;;POTTORF ROBERT;;MEURER WILLIAM;;HIESHIMA GLENN;;N'GUESSAN A LUCIE;;NEDWED TIMOTHY;;REGBERG AARON,,https://lens.org/099-146-827-983-476,Patent Application,no,0,0,12,25,0,G01V9/007;;G01N33/241,G01V9/00;;G01N33/24,,0,0,,,,ACTIVE
133,US,B2,US 7191698 B2,056-821-360-557-786,2007-03-20,2007,US 40699303 A,2003-04-03,US 40699303 A,2003-04-03,System and technique for ultrasonic determination of degree of cooking,"A method and apparatus are described for determining the doneness of food during a cooking process. Ultrasonic signal are passed through the food during cooking. The change in transmission characteristics of the ultrasonic signal during the cooking process is measured to determine the point at which the food has been cooked to the proper level. In one aspect, a heated fluid cooks the food, and the transmission characteristics along a fluid-only ultrasonic path provides a reference for comparison with the transmission characteristics for a food-fluid ultrasonic path.",BATTELLE MEMORIAL INSTITUTE,BOND LEONARD J;;DIAZ AARON A;;JUDD KAYTE M;;PAPPAS RICHARD A;;CLIFF WILLIAM C;;PFUND DAVID M;;MORGEN GERALD P,BATTELLE MEMORIAL INSTITUTE (2003-06-17),https://lens.org/056-821-360-557-786,Granted Patent,yes,28,41,3,3,0,F24C7/08;;F24C7/08;;H05B6/687;;H05B6/687,A23L1/00;;F24C7/08;;H05B1/02;;H05B6/68,99/330;;99/451,17,9,017-097-136-736-836;;029-152-957-646-592;;034-877-633-130-521;;118-251-406-323-658;;170-180-222-618-013;;004-199-743-738-636;;096-005-104-351-178;;009-788-695-914-312;;128-157-885-169-29X,10.1533/9781845696177.75;;10.1016/s1385-8947(97)00066-1;;10.1111/j.1365-2621.1997.tb12237.x;;10.1016/s0260-8774(99)00038-2;;10.1016/s0925-5214(00)00138-1;;10.1081/fri-120014354;;10.1016/s0260-8774(01)00166-2;;10.1016/s0260-8774(01)00122-4;;10.1016/s0041-624x(02)00085-9;;12159930,"Jewish Cooking. Feb. 24, 1999. http://web.archive.org/web/19990224050147/http://www.jewfaq.org/food.htm.;;Arielle's Recipe Archive. Dec. 21, 2001. http://web.archive.org/web/20011221224208/http://www.fortunecity.com/meltingpot/belgium/1029/frieddough.html.;;David Julian McClements, ""Ultrasonic Characterization of a Food Emulsion"" Ultrasonics, IPC Science and Technology Press Ltd, vol. 28, No. 4, Jul. 1, 2990, pp. 266-272.;;David Julian McClements, ""Ultrasonic NDT of Foods and Drinks"" International Advances in NDT, vol. 17, pp. 63-83.;;Soong et al. ""Ultrasonic Characterization of Slurries in an Autoclave Reactor at Elevated Temperatures"" U.S. Department of Energy, 1996.;;Wilbur A. Gould, Ph. D., ""Unit Operations for the Food Industries"" CTI Publications, Feb. 1996, pp. 75-78.;;Soong et al. ""Ultrasonic measurement of solids concentration in an autoclave reactor at high temperature"" Chemical Engineering Journal, 1997, pp. 175-180.;;Schultz et al. ""Ultrasonic propagation in metal power-viscous liquid suspensions"" Acoustical Society of America, 1997, pp. 1361-1369.;;Nielsen et al. ""Low Frequency Ultrasonics for Texture Measurements in Cooked Carrots (Daucus carota L.)"" Journal of Food Service, 1997. pp. 1167-1175.;;Heldman et al. ""Principles of Food Processing"" Chapman & Hull, 1997, pp. 39-42.;;Soong et al. ""Ultrasonic Characterizations of Slurries in a Bubble Column Reactor"" American Chemical Society, 1999, pp. 2137-2143.;;Mizrach et al. ""Nondestructive ultrasonic detemination of avocado softening process"" Journal of Food Engineering, 1999, pp. 139-144.;;Flitsanov et al. ""Measurement of avocado softening at various temperatures using ultrasound"" Postharvest Biology and Technology, 2000, pp. 279-286.;;Mulet et al. ""Noninvasive Ultrasonic Measurements in the Food Industry"" Food Reviews International, vol. 18, 2002, pp. 123-133.;;Llull et al. ""Evaluation of textural properties of a meat-based product (sobrassada) using ultrasonic techniques"" Journal of Food Engineering, 2002, pp. 279-285.;;Llull et al. ""The use of ultrasound velocity measurement to evaluate the textural properties of sobrassada from Mallorca"" Journal of Food Engineering, 2002, pp. 323-330.;;Benedito et al. ""Application of low intensity ultrasonics to cheese manufacturing processes"" Ultrasonics, 2002, pp. 19-23.",INACTIVE
134,AU,A1,AU 2013/273865 A1,006-736-200-869-713,2015-01-22,2015,AU 2013/273865 A,2013-06-05,US 201213494464 A;;CA 2013000552 W,2012-06-12,Method of applying a thin spray-on liner and robotic applicator therefor,"A method and system for applying a liner material to a contoured surface, such as an exposed rock face in an underground hard rock mine, is disclosed. Locations of a plurality of spatially distributed surface grid points on the contoured surface may be detected so as to generate a representative topographical profile of the contoured surface. Based on the plurality of surface grid points, a spray path for a liner application device configured to emit a spray of the liner material may be determined. In some cases, the spray path may have a trajectory that follows the topographical profile of the contoured surface offset therefrom within a spray range of the liner application device. Liner material may then be sprayed onto the contoured surface while controlling the liner application device to undertake at least one pass of the spray path.",ABB INC,BOND BRIAN J;;ELIAS ABEL J;;ELLIOTT AARON J;;GALIPEAU SETH;;GREAVES MARK;;KELLY STEPHEN M;;MCDONALD NICK;;RICHARDSON BRIAN W;;SIMPSON STEVEN F,,https://lens.org/006-736-200-869-713,Patent Application,no,0,0,11,11,0,B05B15/70;;B05D1/02;;E21D11/10;;E21D11/10;;E21D11/381;;E21D11/10;;Y10S901/43;;Y10S901/43,E21D11/00;;B05B15/10;;E21D11/40,,0,0,,,,INACTIVE
135,SE,C2,SE 542775 C2,116-633-157-024-550,2020-07-07,2020,SE 1451530 A,2013-06-05,US 201213494464 A;;CA 2013000552 W,2012-06-12,Method of applying a thin spray-on liner and robotic applicator therefor,"A method and system for applying a liner material to a contoured surface, such as an exposed rock face in an underground hard rock mine, is disclosed. Locations of a plurality of spatially distributed surface grid points on the contoured surface may be detected so as to generate a representative topographical profile of the contoured surface. Based on the plurality of surface grid points, a spray path for a liner application device configured to emit a spray of the liner material may be determined. In some cases, the spray path may have a trajectory that follows the topographical profile of the contoured surface offset therefrom within a spray range of the liner application device. Liner material may then be sprayed onto the contoured surface while controlling the liner application device to undertake at least one pass of the spray path.",ABB INC,ELLIOTT AARON J;;ELIAS ABEL J;;BOND BRIAN J;;RICHARDSON BRIAN W;;GREAVES MARK;;MCDONALD NICK;;GALIPEAU SETH;;KELLY STEPHEN M;;SIMPSON STEVEN F,,https://lens.org/116-633-157-024-550,Granted Patent,no,0,0,11,11,0,B05B15/70;;B05D1/02;;E21D11/10;;E21D11/10;;E21D11/381;;E21D11/10;;Y10S901/43;;Y10S901/43,E21D11/10;;B05B15/70;;E21D11/40,,0,0,,,,ACTIVE
136,US,A1,US 2013/0330467 A1,033-781-425-022-873,2013-12-12,2013,US 201213494464 A,2012-06-12,US 201213494464 A,2012-06-12,METHOD OF APPLYING A THIN SPRAY-ON LINER AND ROBOTIC APPLICATOR THEREFOR,"A method and system for applying a liner material to a contoured surface, such as an exposed rock face in an underground hard rock mine, is disclosed. Locations of a plurality of spatially distributed surface grid points on the contoured surface may be detected so as to generate a representative topographical profile of the contoured surface. Based on the plurality of surface grid points, a spray path for a liner application device configured to emit a spray of the liner material may be determined. In some cases, the spray path may have a trajectory that follows the topographical profile of the contoured surface offset therefrom within a spray range of the liner application device. Liner material may then be sprayed onto the contoured surface while controlling the liner application device to undertake at least one pass of the spray path.",BOND BRIAN J;;ELIAS ABEL J;;ELLIOTT AARON J;;GALIPEAU SETH;;GREAVES MARK;;KELLY STEPHEN M;;MCDONALD NICK;;RICHARDSON BRIAN W;;SIMPSON STEVE F;;ABB INC,BOND BRIAN J;;ELIAS ABEL J;;ELLIOTT AARON J;;GALIPEAU SETH;;GREAVES MARK;;KELLY STEPHEN M;;MCDONALD NICK;;RICHARDSON BRIAN W;;SIMPSON STEVE F,ABB INC (2012-06-05),https://lens.org/033-781-425-022-873,Patent Application,yes,2,16,11,11,0,B05B15/70;;B05D1/02;;E21D11/10;;E21D11/10;;E21D11/381;;E21D11/10;;Y10S901/43;;Y10S901/43,C23C16/52,427/8;;118/695,0,0,,,,DISCONTINUED
137,CA,A1,CA 2877324 A1,184-716-437-766-102,2013-12-19,2013,CA 2877324 A,2013-06-05,US 201213494464 A;;CA 2013000552 W,2012-06-12,METHOD OF APPLYING A THIN SPRAY-ON LINER AND ROBOTIC APPLICATOR THEREFOR,"A method and system for applying a liner material to a contoured surface, such as an exposed rock face in an underground hard rock mine, is disclosed. Locations of a plurality of spatially distributed surface grid points on the contoured surface may be detected so as to generate a representative topographical profile of the contoured surface. Based on the plurality of surface grid points, a spray path for a liner application device configured to emit a spray of the liner material may be determined. In some cases, the spray path may have a trajectory that follows the topographical profile of the contoured surface offset therefrom within a spray range of the liner application device. Liner material may then be sprayed onto the contoured surface while controlling the liner application device to undertake at least one pass of the spray path.",ABB INC,BOND BRIAN J;;ELIAS ABEL J;;ELLIOTT AARON J;;GALIPEAU SETH;;GREAVES MARK;;KELLY STEPHEN M;;MCDONALD NICK;;RICHARDSON BRIAN W;;SIMPSON STEVEN F,,https://lens.org/184-716-437-766-102,Patent Application,no,0,0,11,11,0,B05B15/70;;B05D1/02;;E21D11/10;;E21D11/10;;E21D11/381;;E21D11/10;;Y10S901/43;;Y10S901/43,E21D11/00;;B05B15/10;;E21D11/40,,0,0,,,,ACTIVE
138,CA,C,CA 2877324 C,156-178-175-860-279,2020-04-14,2020,CA 2877324 A,2013-06-05,US 201213494464 A;;CA 2013000552 W,2012-06-12,METHOD OF APPLYING A THIN SPRAY-ON LINER AND ROBOTIC APPLICATOR THEREFOR,"A method and system for applying a liner material to a contoured surface, such as an exposed rock face in an underground hard rock mine, is disclosed. Locations of a plurality of spatially distributed surface grid points on the contoured surface may be detected so as to generate a representative topographical profile of the contoured surface. Based on the plurality of surface grid points, a spray path for a liner application device configured to emit a spray of the liner material may be determined. In some cases, the spray path may have a trajectory that follows the topographical profile of the contoured surface offset therefrom within a spray range of the liner application device. Liner material may then be sprayed onto the contoured surface while controlling the liner application device to undertake at least one pass of the spray path.",ABB INC,BOND BRIAN J;;ELIAS ABEL J;;ELLIOTT AARON J;;GALIPEAU SETH;;GREAVES MARK;;KELLY STEPHEN M;;MCDONALD NICK;;RICHARDSON BRIAN W;;SIMPSON STEVEN F,,https://lens.org/156-178-175-860-279,Granted Patent,no,0,0,11,11,0,E21D11/10;;Y10S901/43;;B05B15/70;;E21D11/10;;E21D11/10;;B05D1/02;;E21D11/381;;Y10S901/43,E21D11/00;;B05B12/00;;E21D11/40,,0,0,,,,ACTIVE
139,AU,B2,AU 2013/273865 B2,024-917-043-531-908,2017-06-08,2017,AU 2013/273865 A,2013-06-05,US 201213494464 A;;CA 2013000552 W,2012-06-12,Method of applying a thin spray-on liner and robotic applicator therefor,"A method and system for applying a liner material to a contoured surface, such as an exposed rock face in an underground hard rock mine, is disclosed. Locations of a plurality of spatially distributed surface grid points on the contoured surface may be detected so as to generate a representative topographical profile of the contoured surface. Based on the plurality of surface grid points, a spray path for a liner application device configured to emit a spray of the liner material may be determined. In some cases, the spray path may have a trajectory that follows the topographical profile of the contoured surface offset therefrom within a spray range of the liner application device. Liner material may then be sprayed onto the contoured surface while controlling the liner application device to undertake at least one pass of the spray path.",ABB INC,BOND BRIAN J;;ELIAS ABEL J;;ELLIOTT AARON J;;GALIPEAU SETH;;GREAVES MARK;;KELLY STEPHEN M;;MCDONALD NICK;;RICHARDSON BRIAN W;;SIMPSON STEVEN F,,https://lens.org/024-917-043-531-908,Granted Patent,no,2,0,11,11,0,B05B15/70;;B05D1/02;;E21D11/10;;E21D11/10;;E21D11/381;;E21D11/10;;Y10S901/43;;Y10S901/43,E21D11/00;;B05B15/10;;E21D11/40,,0,0,,,,INACTIVE
140,WO,A1,WO 2013/185206 A1,146-704-187-444-525,2013-12-19,2013,CA 2013000552 W,2013-06-05,US 201213494464 A,2012-06-12,METHOD OF APPLYING A THIN SPRAY-ON LINER AND ROBOTIC APPLICATOR THEREFOR,"A method and system for applying a liner material to a contoured surface, such as an exposed rock face in an underground hard rock mine, is disclosed. Locations of a plurality of spatially distributed surface grid points on the contoured surface may be detected so as to generate a representative topographical profile of the contoured surface. Based on the plurality of surface grid points, a spray path for a liner application device configured to emit a spray of the liner material may be determined. In some cases, the spray path may have a trajectory that follows the topographical profile of the contoured surface offset therefrom within a spray range of the liner application device. Liner material may then be sprayed onto the contoured surface while controlling the liner application device to undertake at least one pass of the spray path.",ABB INC,BOND BRIAN J;;ELIAS ABEL J;;ELLIOTT AARON J;;GALIPEAU SETH;;GREAVES MARK;;KELLY STEPHEN M;;MCDONALD NICK;;RICHARDSON BRIAN W;;SIMPSON STEVEN F,,https://lens.org/146-704-187-444-525,Patent Application,yes,3,1,11,11,0,B05B15/70;;B05D1/02;;E21D11/10;;E21D11/10;;E21D11/381;;E21D11/10;;Y10S901/43;;Y10S901/43,E21D11/00;;B05B15/10;;E21D11/40,,3,0,,,"TOLLINKSY, N.: ""Research consortium tests spray-on liner."", SUDBURY MINING SOLUTIONS JOURNAL, 1 June 2012 (2012-06-01), Retrieved from the Internet <URL:http://www.sudbun.niiningsolutions.con1/research-consortiuni-tests-spraj.-0n-liner.html> [retrieved on 20130807];;RISPIN, M.: ""Is Computerized Shotcreting a Possibility? ... It's a Reality"", 14 October 2004 (2004-10-14), Retrieved from the Internet <URL:http:/A\T.\T.v.basf-cc.ae/en/Literatures/Technicalpaper/I)ocuments/ASA%20Logica%20Article.pdf> [retrieved on 20130807];;EFNARC: ""Specification and Guidelines on Thin Spray-on Liners for Mining and Tunnelling"", 25 July 2008 (2008-07-25), Retrieved from the Internet <URL:http://www.efnarc.org/pdf/ENC%20250TSL%20v7.2%2025-07-08rl.pdf> [retrieved on 20130807]",PENDING
141,BR,A2,BR 112014031172 A2,134-306-864-390-650,2017-06-27,2017,BR 112014031172 A,2013-06-05,CA 2013000552 W;;US 201213494464 A,2012-06-12,método para aplicar um forro fino por aspersão e aplicador robótico para tal,"abstract: (en)a method and system for applying a liner material to a contoured surface, such as an exposed rock face in an underground hard rock mine, is disclosed. locations of a plurality of spatially distributed surface grid points on the contoured surface may be detected so as to generate a representative topographical profile of the contoured surface. based on the plurality of surface grid points, a spray path for a liner application device configured to emit a spray of the liner material may be determined. in some cases, the spray path may have a trajectory that follows the topographical profile of the contoured surface offset therefrom within a spray range of the liner application device. liner material may then be sprayed onto the contoured surface while controlling the liner application device to undertake at least one pass of the spray path tradução do resumo resumo patente de invenção: “método para aplicar um forro fino por aspersão e aplicador robótico para tal” trata-se de um método e sistema para aplicar um material de forro em uma superfície contornada, como uma face de rocha exposta em uma mina de rocha dura subterrânea. localizações de uma pluralidade de pontos de grade de superfície na superfície contornada espacialmente distribuídos podem ser detectadas de modo a gerar um perfil topográfico representativo da superfície contornada. com base na pluralidade de pontos de grade de superfície, um trajeto de aspersão para um dispositivo de aplicação de forro configurado para emitir uma aspersão do material de forro pode ser determinado. em alguns casos, o trajeto de aspersão pode ter uma trajetória que segue o perfil topográfico do desvio de superfície contornada a partir do mesmo dentro de uma faixa de aspersão do dispositivo de aplicação de forro. o material de forro pode ser então aspergido sobre a superfície contornada ao mesmo tempo em que controla o dispositivo de aplicação de forro para ser submetido a pelo menos uma passagem do trajeto de aspersão.",ABB INC,AARON J ELLIOTT;;ABEL J ELIAS;;BRIAN J BOND;;BRIAN W RICHARDSON;;MARK GREAVES;;NICK MCDONALD;;SETH GALIPEAU;;STEPHEN M KELLY;;STEVEN F SIMPSON,,https://lens.org/134-306-864-390-650,Patent Application,no,0,0,11,11,0,B05B15/70;;B05D1/02;;E21D11/10;;E21D11/10;;E21D11/381;;E21D11/10;;Y10S901/43;;Y10S901/43,E21D11/00;;E21D11/40,,0,0,,,,DISCONTINUED
142,US,A1,US 2015/0198041 A1,061-051-900-733-625,2015-07-16,2015,US 201514670527 A,2015-03-27,US 201514670527 A;;US 201213494464 A,2012-06-12,METHOD OF APPLYING A THIN SPRAY-ON LINER AND ROBOTIC APPLICATOR THEREFOR,"A method and system for applying a liner material to a contoured surface, such as an exposed rock face in an underground hard rock mine, is disclosed. Locations of a plurality of spatially distributed surface grid points on the contoured surface may be detected so as to generate a representative topographical profile of the contoured surface. Based on the plurality of surface grid points, a spray path for a liner application device configured to emit a spray of the liner material may be determined. In some cases, the spray path may have a trajectory that follows the topographical profile of the contoured surface offset therefrom within a spray range of the liner application device. Liner material may then be sprayed onto the contoured surface while controlling the liner application device to undertake at least one pass of the spray path.",BOND BRIAN J;;ELIAS ABEL J;;ELLIOTT AARON J;;GALIPEAU SETH;;GREAVES MARK;;KELLY STEPHEN M;;RICHARDSON BRIAN W;;SIMPSON STEVEN F;;MCDONALD NICK;;ABB INC,BOND BRIAN J;;ELIAS ABEL J;;ELLIOTT AARON J;;GALIPEAU SETH;;GREAVES MARK;;KELLY STEPHEN M;;RICHARDSON BRIAN W;;SIMPSON STEVEN F;;MCDONALD NICK,ABB INC (2012-06-05),https://lens.org/061-051-900-733-625,Patent Application,yes,2,8,11,11,0,B05B15/70;;B05D1/02;;E21D11/10;;E21D11/10;;E21D11/381;;E21D11/10;;Y10S901/43;;Y10S901/43,E21D11/38;;B05D1/02,,0,0,,,,ACTIVE
143,SE,A1,SE 1451530 A1,133-451-777-921-462,2014-12-12,2014,SE 1451530 A,2013-06-05,US 201213494464 A;;CA 2013000552 W,2012-06-12,Method of applying a thin spray-on liner and robotic applicator therefor,"A method and system for applying a liner material to a contoured surface, such as an exposed rock face in an underground hard rock mine, is disclosed. Locations of a plurality of spatially distributed surface grid points on the contoured surface may be detected so as to generate a representative topographical profile of the contoured surface. Based on the plurality of surface grid points, a spray path for a liner application device configured to emit a spray of the liner material may be determined. In some cases, the spray path may have a trajectory that follows the topographical profile of the contoured surface offset therefrom within a spray range of the liner application device. Liner material may then be sprayed onto the contoured surface while controlling the liner application device to undertake at least one pass of the spray path.",ABB INC,BOND BRIAN J;;ELIAS ABEL J;;ELLIOTT AARON J;;GALIPEAU SETH;;GREAVES MARK;;KELLY STEPHEN M;;MCDONALD NICK;;RICHARDSON BRIAN W;;SIMPSON STEVEN F,,https://lens.org/133-451-777-921-462,Patent Application,no,0,0,11,11,0,B05B15/70;;B05D1/02;;E21D11/10;;E21D11/10;;E21D11/381;;E21D11/10;;Y10S901/43;;Y10S901/43,E21D11/10;;B05B15/10;;E21D11/40,,0,0,,,,ACTIVE
144,US,B2,US 10012078 B2,142-027-295-863-056,2018-07-03,2018,US 201514670527 A,2015-03-27,US 201514670527 A;;US 201213494464 A,2012-06-12,Method of applying a thin spray-on liner and robotic applicator therefor,"A method and system for applying a liner material to a contoured surface, such as an exposed rock face in an underground hard rock mine, is disclosed. Locations of a plurality of spatially distributed surface grid points on the contoured surface may be detected so as to generate a representative topographical profile of the contoured surface. Based on the plurality of surface grid points, a spray path for a liner application device configured to emit a spray of the liner material may be determined. In some cases, the spray path may have a trajectory that follows the topographical profile of the contoured surface offset therefrom within a spray range of the liner application device. Liner material may then be sprayed onto the contoured surface while controlling the liner application device to undertake at least one pass of the spray path.",BOND BRIAN J;;ELIAS ABEL J;;ELLIOTT AARON J;;GALIPEAU SETH;;GREAVES MARK;;KELLY STEPHEN M;;RICHARDSON BRIAN W;;SIMPSON STEVEN F;;MCDONALD NICK;;ABB INC,BOND BRIAN J;;ELIAS ABEL J;;ELLIOTT AARON J;;GALIPEAU SETH;;GREAVES MARK;;KELLY STEPHEN M;;RICHARDSON BRIAN W;;SIMPSON STEVEN F;;MCDONALD NICK,ABB INC (2012-06-05),https://lens.org/142-027-295-863-056,Granted Patent,yes,8,0,11,11,0,B05B15/70;;B05D1/02;;E21D11/10;;E21D11/10;;E21D11/381;;E21D11/10;;Y10S901/43;;Y10S901/43,B05D1/02;;E21D11/10;;E21D11/38,,1,0,,,"Australian Patent Examination Report No. 1, dated Sep. 22, 2016.",ACTIVE
145,CA,A1,CA 2950441 A1,009-412-920-517-36X,2016-01-21,2016,CA 2950441 A,2015-07-17,US 201462026449 P;;US 201562180987 P;;US 201514752030 A;;US 201562190089 P;;US 201562190999 P;;US 2015/0040959 W,2014-07-18,METHOD AND SYSTEM FOR PERFORMING SURVEYING AND SAMPLING IN A BODY OF WATER,"Method and system is described for marine surveying. The method involves operations for exploring and developing hydrocarbons with one or more unmanned vehicles. The unmanned vehicles are used to perform marine surveying and to obtain one or more samples that may be used to identify chemical, hydrocarbon and/or biologic information, which may be used for environmental monitoring of bodies of water.",EXXONMOBIL UPSTREAM RES CO,LEVIEN LOUISE;;ROBINSON AMELIA C;;POTTORF ROBERT J;;BOND WILLIAM E;;REGBERG AARON B;;N'GUESSAN A LUCIE;;CORBETT KEVIN T;;HORNBOSTEL SCOTT C;;MEURER WILLIAM P,,https://lens.org/009-412-920-517-36X,Patent Application,no,0,0,12,25,0,G01V9/007;;G01N33/241,G01N1/02;;G01N1/14;;G01N21/25;;G01N33/24,,0,0,,,,ACTIVE
146,AU,A1,AU 2015/289472 A1,092-042-502-078-960,2017-02-02,2017,AU 2015/289472 A,2015-07-17,US 201562190999 P;;US 201562190089 P;;US 201562180987 P;;US 201514752030 A;;US 201462026449 P;;US 2015/0040959 W,2014-07-18,Method and system for performing surveying and sampling in a body of water,"Method and system is described for marine surveying. The method involves operations for exploring and developing hydrocarbons with one or more unmanned vehicles. The unmanned vehicles are used to perform marine surveying and to obtain one or more samples that may be used to identify chemical, hydrocarbon and/or biologic information, which may be used for environmental monitoring of bodies of water.",EXXONMOBIL UPSTREAM RES CO,LEVIEN LOUISE;;ROBINSON AMELIA C;;POTTORF ROBERT J;;BOND WILLIAM E;;REGBERG AARON B;;N'GUESSAN A LUCIE;;CORBETT KEVIN T;;HORNBOSTEL SCOTT C;;MEURER WILLIAM P,,https://lens.org/092-042-502-078-960,Patent Application,no,0,0,12,25,0,G01V9/007;;G01N33/241,G01V9/00;;G01N33/24,,0,0,,,,ACTIVE
147,EP,A1,EP 3170035 A1,171-702-330-902-662,2017-05-24,2017,EP 15747876 A,2015-07-17,US 201462026449 P;;US 201562180987 P;;US 201514752030 A;;US 201562190089 P;;US 201562190999 P;;US 2015/0040959 W,2014-07-18,METHOD AND SYSTEM FOR PERFORMING SURVEYING AND SAMPLING IN A BODY OF WATER,,EXXONMOBIL UPSTREAM RES CO,LEVIEN LOUISE;;ROBINSON AMELIA C;;POTTORF ROBERT J;;BOND WILLIAM E;;REGBERG AARON B;;N'GUESSAN A LUCIE;;CORBETT KEVIN T;;HORNBOSTEL SCOTT C;;MEURER WILLIAM P,EXXONMOBIL TECHNOLOGY AND ENGINEERING COMPANY (2023-02-01);;EXXONMOBIL UPSTREAM RESEARCH COMPANY (2021-01-06),https://lens.org/171-702-330-902-662,Patent Application,yes,0,2,12,25,0,G01V9/007;;G01N33/241,G01V9/00;;G01N33/24,,0,0,,,,PENDING
148,AU,B2,AU 2015/289472 B2,161-294-716-221-277,2018-03-01,2018,AU 2015/289472 A,2015-07-17,US 201562190999 P;;US 201562190089 P;;US 201562180987 P;;US 201514752030 A;;US 201462026449 P;;US 2015/0040959 W,2014-07-18,Method and system for performing surveying and sampling in a body of water,"Method and system is described for marine surveying. The method involves operations for exploring and developing hydrocarbons with one or more unmanned vehicles. The unmanned vehicles are used to perform marine surveying and to obtain one or more samples that may be used to identify chemical, hydrocarbon and/or biologic information, which may be used for environmental monitoring of bodies of water.",EXXONMOBIL UPSTREAM RES CO,LEVIEN LOUISE;;ROBINSON AMELIA C;;POTTORF ROBERT J;;BOND WILLIAM E;;REGBERG AARON B;;NGUESSAN A LUCIE;;CORBETT KEVIN T;;HORNBOSTEL SCOTT C;;MEURER WILLIAM P,,https://lens.org/161-294-716-221-277,Granted Patent,no,0,0,12,25,0,G01V9/007;;G01N33/241,G01V9/00;;G01N33/24,,1,0,,,"FRIES D ET AL, ""Solar robotic material sampler system for chemical, biological and physical ocean observations"", OCEANS 2011, IEEE, (2011-09-19), ISBN 978-1-4577-1427-6, pages 1 - 5",ACTIVE
149,US,B2,US 9638828 B2,048-366-944-643-678,2017-05-02,2017,US 201514802768 A,2015-07-17,US 201514802768 A;;US 201514752030 A;;US 201562190999 P;;US 201562190089 P;;US 201562180987 P;;US 201462026449 P,2014-07-18,Method and system for performing surveying and sampling in a body of water,"Method and system is described for marine surveying. The method involves operations for exploring and developing hydrocarbons with one or more unmanned vehicles. The unmanned vehicles are used to perform marine surveying and to obtain one or more samples that may be used to identify chemical, hydrocarbon and/or biologic information, which may be used for environmental monitoring of bodies of water.",LEVIEN LOUISE;;ROBINSON AMELIA C;;POTTORF ROBERT J;;BOND WILLIAM E;;REGBERG AARON B;;N'GUESSAN A LUCIE;;CORBETT KEVIN T;;HORNBOSTEL SCOTT C;;MEURER WILLIAM P;;EXXONMOBIL UPSTREAM RES CO,LEVIEN LOUISE;;ROBINSON AMELIA C;;POTTORF ROBERT J;;BOND WILLIAM E;;REGBERG AARON B;;N'GUESSAN A LUCIE;;CORBETT KEVIN T;;HORNBOSTEL SCOTT C;;MEURER WILLIAM P,EXXONMOBIL UPSTREAM RESEARCH COMPANY (2015-10-27),https://lens.org/048-366-944-643-678,Granted Patent,yes,36,6,2,25,0,G01N33/241;;G01V9/007;;G01N33/1833;;Y02A20/20;;B63B35/00;;B64U2101/30;;B64U2101/64;;G01V8/02;;B64C39/024;;B63B35/00;;B63B2035/008;;G01N33/241;;G01V9/007;;G01N33/1833;;Y02A20/20;;B64U2101/00,G01V8/02;;B63B35/00;;B64C39/02;;G01N33/18;;G01N33/24;;G01V9/00,,59,34,044-635-428-816-488;;063-808-335-357-472;;118-846-522-432-651;;137-303-946-637-990;;129-166-413-431-908;;035-509-387-245-450;;019-400-253-631-621;;096-445-787-532-929;;088-642-051-882-443;;135-661-255-448-688;;031-305-975-388-853;;104-168-432-829-315;;121-060-312-600-147;;032-297-172-513-648;;027-207-751-966-606;;040-195-112-256-654;;053-226-302-483-760;;167-019-023-603-151;;080-757-968-847-809;;023-373-350-964-35X;;169-611-765-088-713;;128-627-335-496-556;;020-459-656-890-398;;030-952-603-608-733;;067-156-046-543-054;;034-576-906-625-900;;108-172-709-940-700;;108-829-751-072-074;;065-633-303-499-59X;;070-003-918-828-497;;004-552-425-477-906;;018-632-693-525-044;;072-872-134-536-143;;062-584-408-126-186,10.1109/mra.2005.1511873;;10.23919/oceans.2011.6107141;;10890441;;10.1038/35016542;;10.1515/9781501509056-014;;10.1016/0012-821x(91)90133-3;;10.1016/0016-7037(95)00439-4;;10.1021/es070905d;;18186347;;10.1016/0012-821x(88)90021-0;;10.1021/es803717d;;19673300;;10.1109/oceans.2007.4449412;;10.1126/science.1195223;;20724584;;10.1016/0009-2541(88)90108-8;;10.1190/1.2781533;;10.1016/0022-1694(81)90070-6;;12907798;;10.1126/science.1085116;;10.2516/ogst:2003015;;10.1109/iros.2011.6048757;;10.1016/0883-2927(88)90001-7;;10.1109/iros.2011.6048700;;10.21236/ada390519;;10.1144/gsl.sp.1995.086.01.02;;10.1007/s11430-007-0091-z;;10.1046/j.1468-8123.2002.00023.x;;10.1126/science.1121756;;16456080;;10.1016/j.margeo.2010.05.007;;10.1306/ad4616d3-16f7-11d7-8645000102c1865d;;10.1016/0016-7037(95)00213-j;;10.2516/ogst:2003018;;10.5670/oceanog.2009.19;;10.1016/0375-6742(77)90083-8;;10.1038/ngeo848;;10.1130/0091-7613(1990)018<0072:ngampf>2.3.co;2;;10.1029/jz066i001p00277;;10.1002/rob.20399,"Abrams, M.A., et al., (2010), “Geochemical Evaluation of Ocean Surface Slick Methods to Ground Truth Satellite Seepage Anomalies for Seepage Detection”, AAPG Convention, Search and Discovery Article #40604, pp. 1-18.;;ASTM International, (2011), “Standard Practices for Sampling of Waterborne Oils”, pp. D4489-D4495.;;Autonomous Surface Vehicles Limited, (2015), ASV Global, Retrieved Oct. 9, 2015, from C-Cat 5 Datasheet: http://www.asvglobal.com, pp. 1-4.;;Caccia, M., et al., (2005), “Sampling Sea Surfaces with SESAMO”, IEEE Robotics & Automation Magazine, pp. 95-105.;;Chase, C.R., et al., (2010), “Real-Time Monitoring of Oil Using Ultraviolet Filter Fluorometry”, Sea Technology, pp. 1-9.;;Chelsea Technologies Group, Ltd., (2015), “UV AquaTracka Fluorometer”, Retrieved Oct. 9, 2015 from http://www.chelsea.co.uk/allproduct/marine/fluorometers/uv-aquatracka-fluorometer, 2 pages.;;CSafe Global (2015), AcuTemp AX56L, Retrieved Oct. 9, 2015 from http://www.acutemp.com/products-AcuTemp-AX56L, 1 page.;;Dalgleish, F. R., et al., (2013), “Towards Persistent Real-Time Autonomous Surveillance and Mapping of Surface Hydrocarbons”, OTC 24241, Houston: Offshore Technology Conference, pp. 1-18.;;Engineering Toolbox, The, (2015) “The Engineering Toolbox—Liquids—Densities”, Retrieved Oct. 9, 2015 from the Engineering Toolbox: http://www.engineeringtoolbox.com/liquids-densities-d—743.html, 8 pages.;;National Oceanic and Atmospheric Administration, (2012), “Open Water Oil Identification Job Aid”, Seattle: US Dept. of Commerce, pp. 1-52.;;Caccia, M. et al., “Design and Exploitation of an Autonomous Surface Vessel for the Study of Sea-Air Interactions,” Proceedings of the 2005 IEEE, Barcelona, Spain, pp. 3582-3587 (Apr. 2005).;;Camilli, R. et al., “Integrating In-situ Chemical Sampling with AUV Control Systems,” 2004 MTTS/IEEE Techno-Ocean Conf., Piscataway, NJ, pp. 101-109 (Nov. 9-12, 2004).;;BRIAN ROBINSON: ""A GUIDE TO THE SAMPLING AND ANALYSIS OF WATERS, WASTEWATERS, SOILS AND WASTES"", ENVIRONMENT PROTECTION AUTHORITY STATE GOVERNMENT OF VICTORIA, 1 March 2000 (2000-03-01), XP055216718, Retrieved from the Internet <URL:http://www.monitor2manage.com.au/userdata/downloads/p_/Victorian EPA A guide to the sampling and analysis of waters.pdf> [retrieved on 20150928];;D. FRIES ; G. BARTON ; G. HENDRICK ; B. GREGSON ; L. HOTALING ; JOHN PAUL ; A. SANDERSON ; R. BLIDBERG: ""Solar robotic material sampler system for chemical, biological and physical ocean observations"", OCEANS 2011, IEEE, 19 September 2011 (2011-09-19), pages 1 - 5, XP032075878, ISBN: 978-1-4577-1427-6;;JOSHUA LEIGHTON, S B: ""System Design of an Unmanned Aerial Vehicle (UAV) for Marine Environmental Sensing"", 1 February 2013 (2013-02-01), XP055217103, Retrieved from the Internet <URL:http://www.dtic.mil/docs/citations/ADA573151>;;Robinson, B., “A Guide to the Sampling and Analysis of Waters, Wastewaters, Soils and Wastes,” Environment Protection Authority, State Government of Victoria, 54 pgs. (Mar. 2000).;;Aeschbach-Hertig, W., et al., (2000), “Palaeotemperature Reconstruction From Noble Gases in Ground Water Taking Into Account Equilibration With Entrapped Air”, Nature, vol. 405, pp. 1040-1044.;;Ballentine, C.J., et al., (2002), “Production, Release and Transport of Noble Gases in the Continental Crust”, GeoScienceWorld, pp. 481-538.;;Ballentine, C.J., et al., (1991), “Rare Gas Constraints on Hydrocarbon Accumulation, Crustal Degassing and Groundwater Flow in the Pannonian Basin”, Earth and Planetary Science Letters, vol. 105, pp. 229-246.;;Ballentine, C.J., et al., (1996), “A Magnus Opus: Helium, Neon, and Argon Isotopes in a North Sea Oilfield”, Geochimica et Cosmochimica Acta., vol. 60, No. 5., pp. 831-849.;;Balletine, C.J., et al., (2002), “Tracing Fluid Origin, Transport and Interaction in the Crust”, GeoScienceWorld, pp. 539-614.;;Battani, A., et al., (2010), “Trinidad Mud Volcanoes: The Origin of the Gas”, AAPG Memoir 93, pp. 225-238.;;Bell, R.J., et al., (2007), “Calibration of an In Situ Membrane Inlet Mass Spectrometer for Measurements of Dissolved Gases and Volatile Organics in Seawater”, Environ. Sci. Technol., vol. 41, pp. 8123-8128.;;Bosch, A., et al., (1988), “Natural Gas Association With Water and Oil As Depicted by Atmospheric Noble Gases: Case Studies From the Southeastern Mediterranean Coastal Plain”, Earth and Planetary Science Letters, vol. 87, pp. 338-346.;;Camilli, R., et al., (2009), “Characterizing Spatial and Temporal Variability of Dissolved Gases in Aquatic Environments With In Situ Mass Spectrometry”, Environ. Sci. Technol., vol. 43, pp. 5014-5021.;;Camilli, R., et al., (2007), “Characterizing Marine Hydrocarbons With In-Situ Mass Spectrometry”, MTS, 7 pages.;;Camilli, R., et al., (2010), “Tracking Hydrocarbon Plume Transport and Biodegradation At Deepwater Horizon”, Science, vol. 330, pp. 201-204.;;Chung, H.M., et al., (1988), “Origin of Gaseous Hydrocarbons in Subsurface Environments: Theoretical Considerations of Carbon Isotope Distribution”, Chemical Geology, vol. 71, pp. 97-103.;;Crovetto, R., et al., (1982), “Solubilities of Inert Gases and Methane in H2O and in D2 O in the Temperature Range of 300 to 600 K”, J. Chem. Phys., vol. 78(2), pp. 1077-1086.;;Dunn-Norman, S., et al., (2004), “Reliability of Pressure Signals in Offshore Pipeline Leak Detection”, Dept. of the Interior, MMS TA&R Program, pp. 1-86.;;Fomel, S., et al., (2007), “Poststack Velocity Analysis by Separation and Imaging of Seismic Diffractions”, Geophysics, vol. 72(6), pp. U89-U94.;;Heaton, T.H.E., et al., (1981), “Excess Air in Groundwater”, J. Hydrol., vol. 50, pp. 201-216.;;Hohl, D., et al., (2010), “Energy, Environment and Climate Directorate White Paper”, DCO Energy, Environment and Climate Workshop, 38 pages.;;Holbrook, W.S., et al., (2003), “Thermohaline Fine Structure in an Oceanographic Front From Seismic Reflection Profiling”, Science, vol. 301, pp. 821-824.;;Huc, A.Y., (2003), “Petroleum Geochemistry At the Dawn of the 21st Century”, Oil & Gas Science and Technology, vol. 58(2), pp. 233-241.;;IP.com, (2012), “Detection of Underwater Hydrocarbon and Related Fluid Seeps Using Reflection Seismic Data”, 3 pages.;;Jakuba, M.V., et al., (2011), “Toward Automatic Classification of Chemical Sensor Data From Autonomous Underwater Vehicles”, IEEE/RSJ International Conference on Intelligent Robots and Systems, pp. 4722-4727.;;Kharaka, Y.K., et al., (1988), “The Solubility of Noble Gases in Crude Oil at 25-100 C”, Applied Geochemistry, vol. 3, pp. 137-144.;;Kinsey, J.C., et al., (2011), “Assessing the Deepwater Horizon Oil Spill With the Sentry Autonomous Underwater Vehicle”, IEEE/RSJ International Conference on Intelligent Robots and Systems, pp. 261-267.;;Lamontagne, R.A., et al., (2001), “Response of METS Sensor to Methane Concentrations Found on the Texas-Louisiana Shelf in the Gulf of Mexico”, Navel Research Laboratory, 14 pages.;;Larter, S.R., et al., (1995), “Reservoir Geochemistry: Methods, Applications and Opportunities”, The Geochemistry of Reservoir, Geological Society Special Publication No. 86, pp. 5-32.;;Liu, W., et al., (2007), “Ternary Geochemical-Tracing System in Natural Gas Accumulation”, Science in China Series D: Earth Sciences, vol. 50(10), pp. 1494-1503.;;Macdonald, I.R., et al., (2002), “Transfer of Hydrocarbons From Natural Seeps to the Water Column and Atmosphere”, Geofluids, vol. 2, pp. 95-107.;;Makris, N.C., (2006), “Fish Population and Behavior Revealed by Instantaneous Continental Shelf-Scale Imaging”, Science, vol. 311, pp. 660-663.;;Mangelsdorf, K., et al., (2011), “Microbial Lipid Markers Within and Adjacent to Challenger Mound in the Belgica Carbonate Mound Province, Porcupine Basin, Offshore Ireland (IODP Expedition 307)”, Marine Geology, vol. 282, pp. 91-101.;;Narr, W., et al., (1984), “Origin of Reservoir Fractures in Little Knife Field, North Dakota”, The American Association of Petroleum Geologists Bulletin, vol. 68(9), pp. 1087-1100.;;Ozgul, E., (2002), “Geochemical Assessment of Gaseous Hydrocarbons: Mixing of Bacterial and Thermogenic Methane in the Deep Subsurface Petroleum System, Gulf of Mexico Continental Slope”, Texas A&M University, Thesis, pp. 1-167.;;Pinti, D.L., et al., (1995), “Noble Gases in Crude Oils From the Paris Basin, France: Implications for the Origin of Fluids and Constraints on Oil-Water-Gas Interactions”, Geochimica et Cosmochimica Acta, vol. 59(16), pp. 3389-3404.;;Prinzhofer, A., et al., (2003), “Gas Isotopes Tracing: An Important Tool for Hydrocarbons Exploration”, Oil & Gas Science and Technology, vol. 58(2), pp. 299-311.;;Ruddick, B., et al., (2009), “Waer Column Seismic Images as Maps of Temperature Gradient”, Oceanography, vol. 22(1), pp. 192-205.;;Sackett, W.M., (1977), “Use of Hydrocarbon Sniffing in Offshore Exploration”, Journal of Geochemical Exploration, vol. 7, pp. 243-254.;;Smith, S.P.. et al., (1985), “Noble Gas Solubility in Water At High Temperature”, GCA, vol. 46, p. 397.;;Valentine, D.L., et al., (2010), “Asphalt Volcanoes as a Potential Source of Methane to Late Pleistocene Coastal Waters”, Nature Geoscience, vol. 3, pp. 345-348.;;Zaikowski, A., et al., (2010), “Noble Gas and Methane Partitioning From Ground Water: An Aid to Natural Gas Exploration and Reservoir Evaluation”, Geology, vol. 18, pp. 72-74.;;Zartman, R.E., et al., (1961), “Helium, Argon, and Carbon in Some Natural Gases”, Journal of Geophysical Research, vol. 66, No. 1, pp. 277-306.;;Zhang, Y., et al., (2011), “A Peak-Capture Algorithm Used on an Autonomous Underwater Vehicle in the 2010 Gulf of Mexico Oil Spill Response Scientific Survey”, Journal of Field Robotics, vol. 28(4), pp. 484-496.;;Dalgleish, F.R., et al., (2013), “Towards Persistent Real-Time Autonomous Surveillance and Mapping of Surface Hydrocarbons”, OCT 24241, pp. 1-18.;;Chase, C., et al., (2010), “Real-Time Monitoring of Oil Using Ultraviolet Filter Fluorometry”, Sea Technology, pp. 45-50.;;ASTM International (2011), “Standard Practices for Sampling of Waterborne Oils”, Designation: D4489-95 (Reapproved 2011), pp. 1-4.",ACTIVE
150,CA,C,CA 2950441 C,051-954-712-395-74X,2021-02-16,2021,CA 2950441 A,2015-07-17,US 201462026449 P;;US 201562180987 P;;US 201514752030 A;;US 201562190089 P;;US 201562190999 P;;US 2015/0040959 W,2014-07-18,METHOD AND SYSTEM FOR PERFORMING SURVEYING AND SAMPLING IN A BODY OF WATER,"Method and system is described for marine surveying. The method involves operations for exploring and developing hydrocarbons with one or more unmanned vehicles. The unmanned vehicles are used to perform marine surveying and to obtain one or more samples that may be used to identify chemical, hydrocarbon and/or biologic information, which may be used for environmental monitoring of bodies of water.",EXXONMOBIL UPSTREAM RES CO,LEVIEN LOUISE;;ROBINSON AMELIA C;;POTTORF ROBERT J;;BOND WILLIAM E;;REGBERG AARON B;;N'GUESSAN A LUCIE;;CORBETT KEVIN T;;HORNBOSTEL SCOTT C;;MEURER WILLIAM P,,https://lens.org/051-954-712-395-74X,Granted Patent,no,0,0,12,25,0,G01V9/007;;G01N33/241,G01N1/02;;G01N1/14;;G01N21/25,,0,0,,,,ACTIVE
151,WO,A1,WO 2016/011385 A1,155-398-462-189-746,2016-01-21,2016,US 2015/0040959 W,2015-07-17,US 201562180987 P;;US 201462026449 P;;US 201514752030 A;;US 201562190089 P;;US 201562190999 P,2014-07-18,METHOD AND SYSTEM FOR PERFORMING SURVEYING AND SAMPLING IN A BODY OF WATER,"Method and system is described for marine surveying. The method involves operations for exploring and developing hydrocarbons with one or more unmanned vehicles. The unmanned vehicles are used to perform marine surveying and to obtain one or more samples that may be used to identify chemical, hydrocarbon and/or biologic information, which may be used for environmental monitoring of bodies of water.",EXXONMOBIL UPSTREAM RES CO;;LEVIEN LOUISE;;ROBINSON AMELIA C;;POTTORF ROBERT J;;BOND WILLIAM E;;REGBERG AARON B;;N GUESSAN A LUCIE;;CORBETT KEVIN T;;HORNBOSTEL SCOTT C;;MEURER WILLIAM P,LEVIEN LOUISE;;ROBINSON AMELIA C;;POTTORF ROBERT J;;BOND WILLIAM E;;REGBERG AARON B;;N GUESSAN A LUCIE;;CORBETT KEVIN T;;HORNBOSTEL SCOTT C;;MEURER WILLIAM P,,https://lens.org/155-398-462-189-746,Patent Application,yes,0,9,12,25,0,G01V9/007;;G01N33/241,G01V9/00;;G01N33/24,,2,1,063-808-335-357-472,10.23919/oceans.2011.6107141,"FRIES D ET AL: ""Solar robotic material sampler system for chemical, biological and physical ocean observations"", OCEANS 2011, IEEE, 19 September 2011 (2011-09-19), pages 1 - 5, XP032075878, ISBN: 978-1-4577-1427-6;;JOSHUA LEIGHTON ET AL: ""System Design of an Unmanned Aerial Vehicle (UAV) for Marine Environmental Sensing"", 1 February 2013 (2013-02-01), XP055217103, Retrieved from the Internet <URL:http://www.dtic.mil/docs/citations/ADA573151>",PENDING
152,US,A1,US 2016/0018559 A1,146-269-717-931-520,2016-01-21,2016,US 201514802768 A,2015-07-17,US 201514802768 A;;US 201514752030 A;;US 201562190999 P;;US 201562190089 P;;US 201562180987 P;;US 201462026449 P,2014-07-18,Method And System For Performing Surveying And Sampling In A Body Of Water,"Method and system is described for marine surveying. The method involves operations for exploring and developing hydrocarbons with one or more unmanned vehicles. The unmanned vehicles are used to perform marine surveying and to obtain one or more samples that may be used to identify chemical, hydrocarbon and/or biologic information, which may be used for environmental monitoring of bodies of water.",LEVIEN LOUISE;;ROBINSON AMELIA C;;POTTORF ROBERT J;;BOND WILLIAM E;;REGBERG AARON B;;N GUESSAN A LUCIE;;CORBETT KEVIN T;;HORNBOSTEL SCOTT C;;MEURER WILLIAM P,LEVIEN LOUISE;;ROBINSON AMELIA C;;POTTORF ROBERT J;;BOND WILLIAM E;;REGBERG AARON B;;N GUESSAN A LUCIE;;CORBETT KEVIN T;;HORNBOSTEL SCOTT C;;MEURER WILLIAM P,EXXONMOBIL UPSTREAM RESEARCH COMPANY (2015-10-27),https://lens.org/146-269-717-931-520,Patent Application,yes,5,12,2,25,0,G01N33/241;;G01V9/007;;G01N33/1833;;Y02A20/20;;B63B35/00;;B64U2101/30;;B64U2101/64;;G01V8/02;;B64C39/024;;B63B35/00;;B63B2035/008;;G01N33/241;;G01V9/007;;G01N33/1833;;Y02A20/20;;B64U2101/00,G01V8/02;;B63B35/00;;B64C39/02,,0,0,,,,ACTIVE
153,CN,B,CN 101229798 B,134-521-266-391-25X,2012-06-20,2012,CN 200810009017 A,2008-01-25,US 62689707 A,2007-01-25,Vehicle mounting and alignment bracket,"A bracket for attaching and aligning a forward-looking radar (FLR) having a front face is disclosed according to one embodiment. The bracket includes a bracket frame having an attachment feature for attaching the FLR to the bracket frame. The bracket also includes a first mounting feature extending from the bracket frame for coupling the bracket face and the first mounting surface of the conveyance to define a first mounting surface angle. The bracket also includes a bracket member extending from the bracket frame. The bracket member includes an end portion disposed proximate to the bracket face and a distal end portion, which includes a second mounting feature for coupling the bracket member and the second mounting surface thereby defining a second mounting surface angle and aligning theFLR front face to an alignment angle.",FORD MOTOR CO,AARON MILLS;;JOHN WILDS;;KURT PETERSON;;HARISH DUTT;;PAUL SCHMITT;;BOND JOHN V;;JOHN WUERTH;;JOHN JURONOC;;STANKO PAUL L;;JOSEPH CIARAVINO;;ALAN HARTLEY JEFFREY;;MICHAEL CZARNECKI,,https://lens.org/134-521-266-391-25X,Granted Patent,no,0,0,6,6,0,B60R19/483;;Y10T29/49899;;Y10T29/49902;;G01S2013/93271;;Y10T29/49899;;Y10T29/49902;;B60R19/483,B60R16/02;;H01Q1/32,,0,0,,,,ACTIVE
154,US,A1,US 2008/0179900 A1,169-754-142-811-256,2008-07-31,2008,US 62689707 A,2007-01-25,US 62689707 A,2007-01-25,VEHICLE MOUNTING AND ALIGNMENT BRACKET,"A bracket for attaching and aligning a forward-looking radar (FLR) having a front face is disclosed according to one embodiment. The bracket includes a bracket frame having an attachment feature for attaching the FLR to the bracket frame. The bracket also includes a first mounting feature extending from the bracket frame for coupling the bracket face and the first mounting surface of the conveyance to define a first mounting surface angle. The bracket also includes a bracket member extending from the bracket frame. The bracket member includes an end portion disposed proximate to the bracket face and a distal end portion, which includes a second mounting feature for coupling the bracket member and the second mounting surface thereby defining a second mounting surface angle and aligning the FLR front face to an alignment angle.",FORD MOTOR CO,HARTLEY JEFFREY ALAN;;SCHMITT PAUL;;BOND JOHN V;;WUERTH JOHN;;CZARNECKI MICHAEL;;CIARAVINO JOSEPH;;JURONOC JOHN;;MILLS AARON;;PETERSON KURT;;STANKO PAUL L;;WILDS JOHN;;DUTT HARISH,FORD MOTOR COMPANY (2007-01-16),https://lens.org/169-754-142-811-256,Patent Application,yes,14,15,6,6,0,B60R19/483;;Y10T29/49899;;Y10T29/49902;;G01S2013/93271;;Y10T29/49899;;Y10T29/49902;;B60R19/483,B60R19/48,293/117,0,0,,,,ACTIVE
155,US,B2,US 8511727 B2,143-627-959-583-782,2013-08-20,2013,US 201113168204 A,2011-06-24,US 201113168204 A;;US 62689707 A,2007-01-25,Vehicle mounting and alignment bracket,"A bracket for attaching and aligning a forward-looking radar (FLR) having a front face is disclosed according to one embodiment. The bracket includes a bracket frame having an attachment feature for attaching the FLR to the bracket frame. The bracket also includes a first mounting feature extending from the bracket frame for coupling the bracket face and the first mounting surface of the conveyance to define a first mounting surface angle. The bracket also includes a bracket member extending from the bracket frame. The bracket member includes an end portion disposed proximate to the bracket face and a distal end portion, which includes a second mounting feature for coupling the bracket member and the second mounting surface thereby defining a second mounting surface angle and aligning the FLR front face to an alignment angle.",HARTLEY JEFFREY ALAN;;SCHMITT PAUL;;BOND III JOHN V;;WUERTH JOHN;;CZARNECKI MICHAEL;;CIARAVINO JOSEPH;;JURONOC JOHN;;MILLS AARON;;PETERSON KURT;;STANKO PAUL L;;WILDS SR JOHN;;DUTT HARISH;;FORD MOTOR CO,HARTLEY JEFFREY ALAN;;SCHMITT PAUL;;BOND III JOHN V;;WUERTH JOHN;;CZARNECKI MICHAEL;;CIARAVINO JOSEPH;;JURONOC JOHN;;MILLS AARON;;PETERSON KURT;;STANKO PAUL L;;WILDS SR JOHN;;DUTT HARISH,,https://lens.org/143-627-959-583-782,Granted Patent,yes,21,3,6,6,0,B60R19/483;;Y10T29/49899;;Y10T29/49902;;G01S2013/93271;;Y10T29/49899;;Y10T29/49902;;B60R19/483,B60R19/48,293/117;;293/155;;296/30;;343/713,0,0,,,,ACTIVE
156,US,A1,US 2011/0247194 A1,189-624-120-159-439,2011-10-13,2011,US 201113168204 A,2011-06-24,US 201113168204 A;;US 62689707 A,2007-01-25,VEHICLE MOUNTING AND ALIGNMENT BRACKET,"A bracket for attaching and aligning a forward-looking radar (FLR) having a front face is disclosed according to one embodiment. The bracket includes a bracket frame having an attachment feature for attaching the FLR to the bracket frame. The bracket also includes a first mounting feature extending from the bracket frame for coupling the bracket face and the first mounting surface of the conveyance to define a first mounting surface angle. The bracket also includes a bracket member extending from the bracket frame. The bracket member includes an end portion disposed proximate to the bracket face and a distal end portion, which includes a second mounting feature for coupling the bracket member and the second mounting surface thereby defining a second mounting surface angle and aligning the FLR front face to an alignment angle.",FORD MOTOR CO,HARTLEY JEFFREY ALAN;;SCHMITT PAUL;;BOND III JOHN V;;WUERTH JOHN;;CZARNECKI MICHAEL;;CIARAVINO JOSEPH;;JURONOC JOHN;;MILLS AARON;;PETERSON KURT;;STANKO PAUL L;;WILDS SR JOHN;;DUTT HARISH,,https://lens.org/189-624-120-159-439,Patent Application,yes,6,4,6,6,0,B60R19/483;;Y10T29/49899;;Y10T29/49902;;G01S2013/93271;;Y10T29/49899;;Y10T29/49902;;B60R19/483,B23P17/00;;B23P11/00,29/466;;29/468,0,0,,,,ACTIVE
157,US,B2,US 9453828 B2,195-673-150-826-19X,2016-09-27,2016,US 201514802754 A,2015-07-17,US 201514802754 A;;US 201514752030 A;;US 201562190999 P;;US 201562190089 P;;US 201562180987 P;;US 201462026449 P,2014-07-18,Method and system for identifying and sampling hydrocarbons with buoys,"Method and system is described for hydrocarbon exploration and development. The method and system include one or more remote devices, such as buoys, which are utilized to identify and collect samples of target materials. The buoys include measurement components, sampling components and storage components to manage the obtained samples.",CORBETT KEVIN T;;BOND WILLIAM E;;POTTORF ROBERT J;;REGBERG AARON B;;N'GUESSAN A LUCIE;;HORNBOSTEL SCOTT C;;MEURER WILLIAM P;;LEVIEN LOUISE;;HIESHIMA GLENN B;;NEDWED TIMOTHY J;;EXXONMOBIL UPSTREAM RES CO,CORBETT KEVIN T;;BOND WILLIAM E;;POTTORF ROBERT J;;REGBERG AARON B;;N'GUESSAN A LUCIE;;HORNBOSTEL SCOTT C;;MEURER WILLIAM P;;LEVIEN LOUISE;;HIESHIMA GLENN B;;NEDWED TIMOTHY J,,https://lens.org/195-673-150-826-19X,Granted Patent,yes,31,8,2,25,0,B63B22/24;;B63B22/24;;B63B27/30;;B63B2022/006;;B63B2022/006;;G01N33/1886;;G01N33/1886;;Y10S901/01;;Y10S901/01,G01V5/00;;B63B22/00;;B63B22/24;;B63B27/30;;G01N33/18,,59,36,118-846-522-432-651;;137-303-946-637-990;;129-166-413-431-908;;035-509-387-245-450;;036-127-222-840-334;;019-400-253-631-621;;096-445-787-532-929;;088-642-051-882-443;;135-661-255-448-688;;031-305-975-388-853;;104-168-432-829-315;;046-228-701-203-565;;121-060-312-600-147;;032-297-172-513-648;;027-207-751-966-606;;040-195-112-256-654;;053-226-302-483-760;;167-019-023-603-151;;009-720-563-663-178;;023-373-350-964-35X;;169-611-765-088-713;;128-627-335-496-556;;020-459-656-890-398;;030-952-603-608-733;;067-156-046-543-054;;034-576-906-625-900;;108-172-709-940-700;;108-829-751-072-074;;065-633-303-499-59X;;070-003-918-828-497;;004-552-425-477-906;;018-632-693-525-044;;072-872-134-536-143;;062-584-408-126-186;;156-447-915-452-100;;044-635-428-816-488,10890441;;10.1038/35016542;;10.1515/9781501509056-014;;10.1016/0012-821x(91)90133-3;;10.1016/0016-7037(95)00439-4;;10.1515/9781501509056-015;;10.1021/es070905d;;18186347;;10.1016/0012-821x(88)90021-0;;10.1021/es803717d;;19673300;;10.1109/oceans.2007.4449412;;10.1126/science.1195223;;20724584;;10.1016/0009-2541(88)90108-8;;10.1063/1.443074;;10.1190/1.2781533;;10.1016/0022-1694(81)90070-6;;12907798;;10.1126/science.1085116;;10.2516/ogst:2003015;;10.1109/iros.2011.6048757;;10.1016/0883-2927(88)90001-7;;10.1109/iros.2011.6095008;;10.21236/ada390519;;10.1144/gsl.sp.1995.086.01.02;;10.1007/s11430-007-0091-z;;10.1046/j.1468-8123.2002.00023.x;;10.1126/science.1121756;;16456080;;10.1016/j.margeo.2010.05.007;;10.1306/ad4616d3-16f7-11d7-8645000102c1865d;;10.1016/0016-7037(95)00213-j;;10.2516/ogst:2003018;;10.5670/oceanog.2009.19;;10.1016/0375-6742(77)90083-8;;10.1038/ngeo848;;10.1130/0091-7613(1990)018<0072:ngampf>2.3.co;2;;10.1029/jz066i001p00277;;10.1002/rob.20399;;10.4043/1984-ms;;10.1109/mra.2005.1511873,"Aeschbach-Hertig, W., et al., (2000), ""Palaeotemperature Reconstruction From Noble Gases In Ground Water Taking Into Account Equillibration With Entrapped Air"", Nature, vol. 405, pp. 1040-1044.;;Ballentine, C.J., et al., (2002), ""Production, Release and Transport of Noble Gases In The Continental Crust"", GeoScienceWorld, pp. 481-538.;;Ballentine, C.J., et al., (1991), ""Rare Gas Constraints On Hydrocarbon Accumulation, Crustial Degassing and Groundwater Flow In The Pannonian Basin"", Earth and Planetary Science Letters, vol. 105, pp. 229-246.;;Ballentine, C.J., et al., (1996), ""A Magnus Opus: Helium, Neon, and Argon Isotopes In A North Sea Oilfield"", Geochimica et Cosmochimica Acta., vol. 60, No. 5., pp. 831-849.;;Ballentine, C.J., et al., (2002), ""Tracing Fluid Origin, Transport and Interaction In The Crust"", GeoScienceWorld, pp. 539-614.;;Battani, A., et al., (2010), ""Trinidad Mud Volcanoes: The Origin of The Gas"", AAPG Memoir 93, pp. 225-238.;;Bell, R.J., et al., (2007), ""Calibration of An In Situ Membrane Inlet Mass Spectrometer For Measurements of Dissolved Gases and Volatile Organics In Seawater"", Environ. Sci. Technol., vol. 41, pp. 8123-8126.;;Bosch, A., et al., (1988), ""Natural Gas Association With Water and Oil As Depicted By Atmospheric Noble Gases: Case Studies From The Southeastern Mediterranean Costal Plan"", Earth and Planetary Science Letters, vol. 87, pp. 338-346.;;Camilli, R., et al., (2009), ""Characterizing Spatial and Temporal Variability of Dissolved Gases in Aquatic Environments With In Situ Mass Spectrometry"", Environ. Sci. Technol., vol. 43, pp. 5014-5021.;;Camilli, R., et al., (2007), ""Characterizing Marine Hydrocarbons With In-Situ Mass Spectrometry"", MTS, 7 pages.;;Camilli, R., et al., (2010), ""Tracking Hydrocarbon Plume Transport and Biodegradation At Deepwater Horizon"", Science, vol. 330, pp. 201-204.;;Chung, H.M., et al., (1988), ""Origin of Gaseous Hydrocarbons in Subsurface Environments: Theoretical Considerations of Carbon Isotope Distribution"", Chemical Geology, vol. 71, pp. 97-103.;;Crovetto, R., et al., (1982), ""Solubilities of inert Gases and Methane in H2O and in D2O In The Temperature Range of 300 to 600 K"", J. Chem. Phys., vol. 78(2), pp. 1077-1086.;;Dunn-Norman, S., et al., (2004), ""Reliability of Pressure Signals In Offshore Pipeline Leak Detection"", Dept. of The Interior, MMS TA&R Program, pp. 1-86.;;Fomel, S., et ale (2007), ""Poststack Velocity Analysis by Separation and Imaging of Seismic Diffractions"", Geophysics, vol. 72(6), pp. U89-U94.;;Heaton, T.H.E., et al., (1981), ""Excess Air"" in Groundwater, J. Hydrol., vol. 50, pp. 201-216.;;Hohl, D., et al., (2010), ""Energy, Environment and Climate Directorate White Paper"", DCO Energy, Environment and Climate Workshop, 38 pages.;;Holbrook, W.S., et al., (2003), ""Thermohaline Fine Structure in an Oceanographic Front From Seismic Reflection Profiling"", Science, vol. 301, pp. 821-824.;;Huc, A.Y., (2003), ""Petroleum Geochemistry At The Dawn of The 21st Century"", Oil & Gas Science and Technology, vol. 58(2), pp. 233-241.;;IP.com, (2012), ""Detection of Underwater Hydrocarbon and Related Fluid Seeps Using Reflection Seismic Data"", 3 pages.;;Jakuba, M.V., et al., (2011), ""Toward Automatic Classification of Chemical Sensor Data From Autonomous Underwater Vehicles"", IEEE/RSJ International Conference on Intelligent Robots and Systems, pp. 4722-4727.;;Kharaka, Y.K., et al., (1988), ""The Solubility of Noble Gases in Crude Oil at 25-100 C"", Applied Geochemistry, vol. 3, pp. 137-144.;;Kinsey, J.C., et al., (2011), ""Assessing the Deepwater Horizon Oil Spill With the Sentry Autonomous Undetwater Vehicle"", IEEE/RSJ International Conference on Intelligent Robots and Systems, pp. 261-267.;;Lamontagne, R.A., et al., (2001), ""Response of METS Sensor To Methane Concentrations Found On The Texas-Louisiana Shelf In The Gulf of Mexico"", Navel Research Laboratory, 14 pages.;;Larter, S.R., et al., (1995), ""Reservoir Geochemistry: Methods, Applications and Opportunities"", The Geochemistry of Reservoir, Geological Society Special Publication No. 86, pp. 5-32.;;Liu, W., et al., (2007), ""Ternary Geochemical-Tracing System In Natural Gas Accumulation"", Science In China Series D: Earth Sciences, vol. 50(10), pp. 1494-1503.;;Macdonald, I.R., et al., (2002), ""Transfer of Hydrocarbons From Natural Seeps To The Water Column and Atmosphere"", Geofluids, vol. 2, pp. 95-107.;;Makris, N.C., (2006), ""Fish Population and Behavior Revealed By Instantaneous Continental Shelf-Scale Imaging"", Science, vol. 311, pp. 660-663.;;Mangelsdorf, K., et al., (2011), ""Microbial Lipid Markers Within and Adjacent To Challenger Mound In The Beigica Carbonate Mound Province, Porcupine Basin, Offshore Ireland (IODP Expedition 307)"", Marine Geology, vol. 282, pp. 91-101.;;Narr, W., et al., (1984), ""Origin of Reservoir Fractures In Little Knife Field, North Dakota"", The American Association of Petroleum Geologists Bulletin, vol. 68(9), pp. 1087-1100.;;Ozgul, E., (2002), ""Geochemical Assessment of Gaseous Hydrocarbons: Mixing of Bacterial and Thermogenic Methane In The Deep Subsutface Petroleum System, Gulf of Mexico Continental Slope"", Texas A&M University, Thesis, pp. 1-167.;;Pinti, D.L., et al., (1995), ""Noble Gases In Crude Oils From The Paris Basin, France: Implications For The Origin of Fluids and Constraints On Oil-Water-Gas Interactions"", Geochimica et Cosmochimica Acta, vol. 59(16), pp. 3389-3404.;;Prinzhofer, A., et al., (2003), ""Gas Isotopes Tracing: An Important Tool For Hydrocarbons Exploration"", Oil & Gas Science and Technology, vol. 58(2), pp. 299-311.;;Ruddick, B., et al., (2009), ""Wear Column Seismic Images As Maps of Temperature Gradient"", Oceanography, vol. 22(1), pp. 192-205.;;Sackett, W.M., (1977), ""Use of Hydrocarbon Sniffing In Offshore Exploration"", Journal of Geochemical Exploration, vol. 7, pp. 243-254.;;Smith, S.P., et al., (1985), ""Noble Gas Solubility in Water At High Temperature"", GCA, vol. 46, p. 397.;;Valentine, D.L., et al., (2010), ""Asphalt Volcanoes As A Potential Source of Methane To Late Pleistocene Coastal Waters"", Nature Geoscience, vol. 3, pp. 345-348.;;Zaikowski, A., et al., (2010), ""Noble Gas and Methane Partitioning From Ground Water: An Aid To Natural Gasa Exploration and Reservoir Evaluation"", Geology, vol. 18, pp. 72-74.;;Zartman, R.E., et al., (1961), ""Helium, Argon, and Carbon In Some Natural Gases"", Journal of Geophysical Research, vol. 66, No. 1, pp. 277-306.;;Zhang, Y., et al., (2011), ""A Peak-Capture Algorithm Used On An Autonomous Underwater Vehicle In The 2010 Gulf of Mexico Oil Spit Response Scientific Survey"", Journal of Field Robotics, vol. 28(4), pp. 484-496.;;Dalgleish, F.R., et al., (2013), ""Towards Persistent Real-Time Autonomous Surveillance and Mapping of Surface Hydrocarbons"", OCT 24241, pp. 1-18.;;Chase, C., et al., (2010), ""Real-Time Monitoring of Oil Using Ultraviolet Filter Fluorometry"", Sea Technology, pp. 45-50.;;ASTM International (2011), ""Standard Practices for Sampling of Waterborne Oils"", Designation: D4489-95 (Reapproved 2011), pp. 1-4.;;Caccia, M. et al., ""Design and Exploitation of an Autonomous Surface Vessel for the Study of Sea-Air Interactions,"" Proceedings of the 2005 IEEE, Barcelona, Spain, pp. 3582-3587 (Apr. 2005).;;Camilli, R. et al., ""Integrating In-situ Chemical Sampling with AUV Control Systems,"" 2004 MTTS/IEEE Techno-Ocean Conf., Piscataway, NJ, pp. 101-109 (Nov. 9-12, 2004).;;Chang, W.J. et al., ""Evaluation of Boat Deployable Thin Film Oil Samplers,"" XP055216718, Offshore Technology Conf., Dallas, TX, 20 pgs. (1984).;;Fries, D. et al., ""Solar Robotic Material Sampler System for Chemical, Biological and Physical Ocean Observations,""XP032075878, IEEE, 5 pgs. (Sep. 19, 2011).;;Leighton, J., ""System Design of an Unmanned Aerial Vehicle (UAV) for Marine Environmental Sensing,"" XP055217103, S.B., http://www.dtic.mil/docs/citations/ADA573151, Massachusetts of Technology, 70 pgs. (Feb. 2013).;;Robinson, B., ""A Guide to the Sampling and Analysis of Waters, Wastewaters, Soils and Wastes,"" Environment Protection Authority, State Government of Victoria, 54 pgs. (Mar. 2000).;;Abrams, M.A., et al., (2010), ""Geochemical Evaluation of Ocean Surface Slick Methods to Ground Truth Satellite Seepage Anomalies For Seepage Detection"", AAPG Convention, Search and Discovery Article #40604, pp. 1-18.;;ASTM International, (2011), ""Standard Practices for Sampling of Waterborne Oils"", pp. D4489-95.;;Autonomous Surface Vehicles Limited, (2015), ASV Global, Retrieved Oct. 9, 2015, from C-Cat 5 Datasheet: http://www.asvglobal.com, pp. 1-4.;;Caccia, M., et al., (2005), ""Sampling Sea Surfaces with SESAMO"", IEEE Robotics & Automation Magazine, pp. 95-105.;;Chase, C.R., et al., (2010), ""Real-Time Monitoring of Oil Using Ultraviolet Filter Fluorometry"", Sea Technology, pp. 1-9.;;Chelsea Technologies Group, Ltd., (2015), ""UV AquaTracka Fluorometer"", Retrieved Oct. 9, 2015 from http://www.chelsea.co.uk/allproduct/marine/fluorometers/uv-aquatracka-fluorometer, 2 pages.;;CSafe Global (2015), AcuTemp AX56L, Retrieved Oct. 9, 2015 from http://www.acutemp.com/products-AcuTemp-AX56L, 1 page.;;Dalgleish, F. R., et al., (2013), ""Towards Persistent Real-Time Autonomous Surveillance and Mapping of Surface Hydrocarbons"", OTC 24241, Houston: Offshore Technology Conference, pp. 1-18.;;Engineering Toolbox, The, (2015) ""The Engineering Toolbox-Liquids-Densities"", Retrieved Oct. 9, 2015 from The Engineering Toolbox: http://www.engineeringtoolbox.com/liquids-densities-d-743.html, 8 pages.;;National Oceanic and Atmospheric Administration, (2012), ""Open Water Oil Identification Job Aid"", Seattle: US Dept. of Commerce, pp. 1-52.",ACTIVE
158,CA,C,CA 2951281 C,114-353-677-696-335,2019-01-15,2019,CA 2951281 A,2015-07-17,US 201462026449 P;;US 201562180987 P;;US 201514752030 A;;US 201562190089 P;;US 201562190999 P;;US 2015/0040965 W,2014-07-18,METHOD AND SYSTEM FOR IDENTIFYING AND SAMPLING HYDROCARBONS WITH BUOYS,"Method and system is described for hydrocarbon exploration and development. The method and system include one or more remote devices, such as buoys, which are utilized to identify and collect samples of target materials. The buoys include measurement components, sampling components and storage components to manage the obtained samples.",EXXONMOBIL UPSTREAM RES CO,CORBETT KEVIN T;;BOND WILLIAM E;;HORNBOSTEL SCOTT C;;LEVIEN LOUISE;;POTTORF ROBERT J;;MEURER WILLIAM P;;HIESHIMA GLENN B;;N'GUESSAN A LUCIE;;NEDWED TIMOTHY J;;REGBERG AARON B,,https://lens.org/114-353-677-696-335,Granted Patent,no,0,2,12,25,0,G01V9/007;;G01N33/241,G01N1/10;;G01N1/14;;G01N21/64;;G01N27/00,,0,0,,,,ACTIVE
159,EP,A1,EP 3170034 A1,061-346-198-073-572,2017-05-24,2017,EP 15745668 A,2015-07-17,US 201462026449 P;;US 201562180987 P;;US 201514752030 A;;US 201562190089 P;;US 201562190999 P;;US 2015/0040965 W,2014-07-18,METHOD AND SYSTEM FOR IDENTIFYING AND SAMPLING HYDROCARBONS WITH BUOYS,,EXXONMOBIL UPSTREAM RES CO,CORBETT KEVIN T;;BOND WILLIAM E;;HORNBOSTEL SCOTT C;;LEVIEN LOUISE;;POTTORF ROBERT J;;MEURER WILLIAM P;;HIESHIMA GLENN B;;N'GUESSAN A LUCIE;;NEDWED TIMOTHY J;;REGBERG AARON B,EXXONMOBIL TECHNOLOGY AND ENGINEERING COMPANY (2023-02-01);;EXXONMOBIL UPSTREAM RESEARCH COMPANY (2021-01-06),https://lens.org/061-346-198-073-572,Patent Application,yes,0,0,12,25,0,G01V9/007;;G01N33/241,G01V9/00;;G01N33/24,,0,0,,,,PENDING
160,CA,A1,CA 2951281 A1,123-495-079-064-40X,2016-01-21,2016,CA 2951281 A,2015-07-17,US 201462026449 P;;US 201562180987 P;;US 201514752030 A;;US 201562190089 P;;US 201562190999 P;;US 2015/0040965 W,2014-07-18,METHOD AND SYSTEM FOR IDENTIFYING AND SAMPLING HYDROCARBONS WITH BUOYS,"Method and system is described for hydrocarbon exploration and development. The method and system include one or more remote devices, such as buoys, which are utilized to identify and collect samples of target materials. The buoys include measurement components, sampling components and storage components to manage the obtained samples.",EXXONMOBIL UPSTREAM RES CO,CORBETT KEVIN T;;BOND WILLIAM E;;HORNBOSTEL SCOTT C;;LEVIEN LOUISE;;POTTORF ROBERT J;;MEURER WILLIAM P;;HIESHIMA GLENN B;;N'GUESSAN A LUCIE;;NEDWED TIMOTHY J;;REGBERG AARON B,,https://lens.org/123-495-079-064-40X,Patent Application,no,0,2,12,25,0,G01V9/007;;G01N33/241,G01N1/10;;G01N1/14;;G01N21/64;;G01N27/00;;G01N33/24,,0,0,,,,ACTIVE
161,US,B2,US 7988212 B2,141-897-090-158-962,2011-08-02,2011,US 62689707 A,2007-01-25,US 62689707 A,2007-01-25,Vehicle mounting and alignment bracket,"A bracket for attaching and aligning a forward-looking radar (FLR) having a front face is disclosed according to one embodiment. The bracket includes a bracket frame having an attachment feature for attaching the FLR to the bracket frame. The bracket also includes a first mounting feature extending from the bracket frame for coupling the bracket face and the first mounting surface of the conveyance to define a first mounting surface angle. The bracket also includes a bracket member extending from the bracket frame. The bracket member includes an end portion disposed proximate to the bracket face and a distal end portion, which includes a second mounting feature for coupling the bracket member and the second mounting surface thereby defining a second mounting surface angle and aligning the FLR front face to an alignment angle.",FORD MOTOR CO,HARTLEY JEFFREY ALAN;;SCHMITT PAUL;;BOND III JOHN V;;WUERTH JOHN;;CZARNECKI MICHAEL;;CIARAVINO JOSEPH;;JURONOC JOHN;;MILLS AARON;;PETERSON KURT;;STANKO PAUL L;;WILDS SR JOHN;;DUTT HARISH,FORD MOTOR COMPANY (2007-01-16),https://lens.org/141-897-090-158-962,Granted Patent,yes,15,15,6,6,0,B60R19/483;;Y10T29/49899;;Y10T29/49902;;G01S2013/93271;;Y10T29/49899;;Y10T29/49902;;B60R19/483,B60R19/48,293/117;;293/155;;296/30;;343/713,0,0,,,,ACTIVE
162,WO,A1,WO 2016/011388 A1,021-734-692-994-581,2016-01-21,2016,US 2015/0040965 W,2015-07-17,US 201562180987 P;;US 201462026449 P;;US 201514752030 A;;US 201562190089 P;;US 201562190999 P,2014-07-18,METHOD AND SYSTEM FOR IDENTIFYING AND SAMPLING HYDROCARBONS WITH BUOYS,"Method and system is described for hydrocarbon exploration and development. The method and system include one or more remote devices, such as buoys, which are utilized to identify and collect samples of target materials. The buoys include measurement components, sampling components and storage components to manage the obtained samples.",EXXONMOBIL UPSTREAM RES CO;;CORBETT KEVIN T;;BOND WILLIAM E;;HORNBOSTEL SCOTT C;;LEVIEN LOUISE;;POTTORF ROBERT J;;MEURER WILLIAM P;;HIESHIMA GLENN B;;N GUESSAN A LUCIE;;NEDWED TIMOTHY J;;REGBERG AARON B,CORBETT KEVIN T;;BOND WILLIAM E;;HORNBOSTEL SCOTT C;;LEVIEN LOUISE;;POTTORF ROBERT J;;MEURER WILLIAM P;;HIESHIMA GLENN B;;N GUESSAN A LUCIE;;NEDWED TIMOTHY J;;REGBERG AARON B,,https://lens.org/021-734-692-994-581,Patent Application,yes,5,5,12,25,0,G01V9/007;;G01N33/241,G01V9/00;;G01N33/24,,3,2,063-808-335-357-472;;156-447-915-452-100,10.23919/oceans.2011.6107141;;10.4043/1984-ms,"BRIAN ROBINSON: ""A GUIDE TO THE SAMPLING AND ANALYSIS OF WATERS, WASTEWATERS, SOILS AND WASTES"", 1 March 2000 (2000-03-01), XP055216718, Retrieved from the Internet <URL:http://www.monitor2manage.com.au/userdata/downloads/p_/Victorian EPA A guide to the sampling and analysis of waters.pdf> [retrieved on 20150928];;FRIES D ET AL: ""Solar robotic material sampler system for chemical, biological and physical ocean observations"", OCEANS 2011, IEEE, 19 September 2011 (2011-09-19), pages 1 - 5, XP032075878, ISBN: 978-1-4577-1427-6;;WILLIAM J. CHANG ET AL: ""Evaluation of Boat Deployable Thin Film OiI Samplers"", OFFSHORE TECHNOLOGY CONFERENCE, 1 October 1984 (1984-10-01), XP055216746, Retrieved from the Internet <URL:https://www.onepetro.org/download/conference-paper/OTC-1984-MS?id=conference-paper/OTC-1984-MS> [retrieved on 20150928]",PENDING
163,US,A1,US 2016/0018377 A1,010-214-029-084-866,2016-01-21,2016,US 201514802754 A,2015-07-17,US 201514802754 A;;US 201514752030 A;;US 201562190999 P;;US 201562190089 P;;US 201562180987 P;;US 201462026449 P,2014-07-18,Method and System For Identifying And Sampling Hydrocarbons With Buoys,"Method and system is described for hydrocarbon exploration and development. The method and system include one or more remote devices, such as buoys, which are utilized to identify and collect samples of target materials. The buoys include measurement components, sampling components and storage components to manage the obtained samples.",CORBETT KEVIN T;;BOND WILLIAM E;;POTTORF ROBERT J;;REGBERG AARON B;;N GUESSAN A LUCIE;;HORNBOSTEL SCOTT C;;MEURER WILLIAM P;;LEVIEN LOUISE;;HIESHIMA GLENN B;;NEDWED TIMOTHY J,CORBETT KEVIN T;;BOND WILLIAM E;;POTTORF ROBERT J;;REGBERG AARON B;;N GUESSAN A LUCIE;;HORNBOSTEL SCOTT C;;MEURER WILLIAM P;;LEVIEN LOUISE;;HIESHIMA GLENN B;;NEDWED TIMOTHY J,,https://lens.org/010-214-029-084-866,Patent Application,yes,4,14,2,25,0,B63B22/24;;B63B22/24;;B63B27/30;;B63B2022/006;;B63B2022/006;;G01N33/1886;;G01N33/1886;;Y10S901/01;;Y10S901/01,G01N33/18;;B63B22/24;;B63B27/30,,0,0,,,,ACTIVE
164,EP,A4,EP 2776873 A4,126-932-963-056-98X,2015-11-04,2015,EP 12848243 A,2012-11-09,US 201161558822 P;;US 201261595394 P;;US 201261616813 P;;US 2012/0052542 W;;US 2012/0064548 W,2011-11-11,EXPLORATION METHOD AND SYSTEM FOR DETECTION OF HYDROCARBONS,,EXXONMOBIL UPSTREAM RES CO,POTTORF ROBERT J;;LAWSON MICHAEL;;MAY STEVEN R;;DREYFUS SÉBASTIEN L;;RAMAN SUMATHY;;SRNKA LEONARD J;;MEURER WILLIAM P;;POWELL WILLIAM G;;RUDOLPH KURT W;;VANDEWATER CHRISTOPHER;;CHERNEY DANIEL;;ERTAS MEHMET D;;ROBINSON AMELIA;;REGBERG AARON B;;N GUESSAN A LUCIE;;BOND WILLIAM,EXXONMOBIL UPSTREAM RESEARCH COMPANY (2021-01-06),https://lens.org/126-932-963-056-98X,Search Report,no,10,0,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,B63G8/00;;C12Q1/64;;E21B49/00;;G01N1/00;;G01N29/14;;G01N33/24;;G01V3/08;;G01V5/00;;G01V8/00;;G01V8/02;;G01V9/00;;G01V11/00;;G06F19/00,,3,2,121-746-515-171-561;;019-574-676-632-693,10.1029/1999jb900049;;10.1117/1.2822611,"JAMES R COCHRAN ET AL: ""Continuous near-bottom gravity measurements made with a BGM-3 gravimeter in DSV Alvin on the East Pacific Rise crest near 9°31'N and 9°50'N"", 1 January 1999 (1999-01-01), pages 841 - 10, XP055194323, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/doi/10.1029/1999JB900049/pdf> [retrieved on 20150608];;ZSOLT VOLENT ET AL: ""Kelp forest mapping by use of airborne hyperspectral imager"", JOURNAL OF APPLIED REMOTE SENSING, 26 December 2007 (2007-12-26), pages 11503, XP055194571, Retrieved from the Internet <URL:http://dx.doi.org/10.1117/1.2822611> [retrieved on 20150610], DOI: 10.1117/1.2822611;;See also references of WO 2013071185A1",ACTIVE
165,AU,B2,AU 2012/335021 B2,152-416-578-121-919,2015-08-20,2015,AU 2012/335021 A,2012-11-09,US 201261616813 P;;US 201161558822 P;;US 2012/0052542 W;;US 201261595394 P;;US 2012/0064548 W,2011-11-11,Exploration method and system for detection of hydrocarbons,"A method for detecting hydrocarbons is described. The method includes performing a remote sensing survey of a survey location to identify a target location. Then, an underwater vehicle (UV) is deployed into a body of water and directed to the target location. The UV collects measurement data within the body of water at the target location, which is then analyzed to determine whether hydrocarbons are present at the target location.",EXXONMOBIL UPSTREAM RES CO,POTTORF ROBERT J;;LAWSON MICHAEL;;MAY STEVEN R;;DREYFUS SEBASTIEN L;;RAMAN SUMATHY;;BOND WILLIAM;;SRNKA LEONARD J;;MEURER WILLIAM P;;POWELL WILLIAM G;;RUDOLPH KURT W;;VANDEWATER CHRISTOPHER;;CHERNEY DANIEL;;ERTAS MEHMET D;;ROBINSON AMELIA;;REGBERG AARON B;;N GUESSAN A LUCIE,,https://lens.org/152-416-578-121-919,Granted Patent,no,3,0,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,G01V11/00,,0,0,,,,ACTIVE
166,EP,A1,EP 2776873 A1,186-105-400-026-397,2014-09-17,2014,EP 12848243 A,2012-11-09,US 201161558822 P;;US 201261595394 P;;US 201261616813 P;;US 2012/0052542 W;;US 2012/0064548 W,2011-11-11,EXPLORATION METHOD AND SYSTEM FOR DETECTION OF HYDROCARBONS,,EXXONMOBIL UPSTREAM RES CO,POTTORF ROBERT J;;LAWSON MICHAEL;;MAY STEVEN R;;DREYFUS SÉBASTIEN L;;RAMAN SUMATHY;;SRNKA LEONARD J;;MEURER WILLIAM P;;POWELL WILLIAM G;;RUDOLPH KURT W;;VANDEWATER CHRISTOPHER;;CHERNEY DANIEL;;ERTAS MEHMET D;;ROBINSON AMELIA;;REGBERG AARON B;;N GUESSAN A LUCIE;;BOND WILLIAM,EXXONMOBIL UPSTREAM RESEARCH COMPANY (2021-01-06),https://lens.org/186-105-400-026-397,Patent Application,yes,0,1,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,B63G8/00;;C12Q1/64;;E21B49/00;;G01N1/00;;G01N29/14;;G01N33/24;;G01V3/08;;G01V5/00;;G01V8/00;;G01V8/02;;G01V9/00;;G01V11/00;;G06F19/00,,0,0,,,,ACTIVE
167,RU,C2,RU 2593438 C2,081-919-293-018-193,2016-08-10,2016,RU 2014123721 A,2012-11-09,US 201161558822 P;;US 201261595394 P;;US 201261616813 P;;US 2012/0052542 W;;US 2012/0064548 W,2011-11-11,SURVEY METHOD AND SYSTEM FOR DETECTION OF HYDROCARBONS,"FIELD: data processing.SUBSTANCE: invention relates to geophysics and can be used to search for hydrocarbon deposits in a sea area. Method includes performance of remote seismic investigations of a search site to identify the target site. Then the underwater device (UD) is deployed in the water mass and directed to the target site. In the water mass at the target site measurement data is collected with the help of the underwater device; the data is then analysed to determine whether hydrocarbons are present on the target site.EFFECT: higher accuracy and reliability of survey results.12 cl, 5 dwg",EKSONMOBIL APSTRIM RISERCH KOMPANI,POTTORF ROBERT DZH;;LOUSON MAJKL;;MEJ STIVEN R;;DREJFUS SEBASTEN L;;RAMAN SUMATKHI;;BOND UILLYAM;;SRNKA LEONARD DZH;;MYURER UILLYAM P;;PAUELL UILLYAM G;;RUDOLF KURT U;;VANDEUOTER KRISTOFER;;CHERNI DENIEL;;ERTAS MEKHMET D;;ROBINSON AMELIYA;;REGBERG AARON B;;N'GESSAN A LYUSI,,https://lens.org/081-919-293-018-193,Granted Patent,no,0,1,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,G01V1/38;;B63G8/00;;G01V8/02;;G01V11/00,,0,0,,,,ACTIVE
168,WO,A1,WO 2013/071185 A1,152-872-353-948-332,2013-05-16,2013,US 2012/0064548 W,2012-11-09,US 2012/0052542 W;;US 201161558822 P;;US 201261616813 P;;US 201261595394 P,2011-11-11,EXPLORATION METHOD AND SYSTEM FOR DETECTION OF HYDROCARBONS,"A method for detecting hydrocarbons is described. The method includes performing a remote sensing survey of a survey location to identify a target location. Then, an underwater vehicle (UV) is deployed into a body of water and directed to the target location. The UV collects measurement data within the body of water at the target location, which is then analyzed to determine whether hydrocarbons are present at the target location.",EXXONMOBIL UPSTREAM RES CO;;POTTORF ROBERT J;;LAWSON MICHAEL;;MAY STEVEN R;;DREYFUS SEBASTIEN L;;RAMAN SUMATHY;;BOND WILLIAM;;SRNKA LEONARD J;;MEURER WILLIAM P;;POWELL WILLIAM G;;RUDOLPH KURT W;;VANDEWATER CHRISTOPHER;;CHERNEY DANIEL;;ERTAS MEHMET D;;ROBINSON AMELIA;;REGBERG AARON B;;N GUESSAN A LUCIE,POTTORF ROBERT J;;LAWSON MICHAEL;;MAY STEVEN R;;DREYFUS SEBASTIEN L;;RAMAN SUMATHY;;BOND WILLIAM;;SRNKA LEONARD J;;MEURER WILLIAM P;;POWELL WILLIAM G;;RUDOLPH KURT W;;VANDEWATER CHRISTOPHER;;CHERNEY DANIEL;;ERTAS MEHMET D;;ROBINSON AMELIA;;REGBERG AARON B;;N GUESSAN A LUCIE,,https://lens.org/152-872-353-948-332,Patent Application,yes,7,27,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,G01V11/00,,1,0,,,See also references of EP 2776873A4,PENDING
169,CA,A1,CA 2853284 A1,063-536-502-806-292,2013-05-16,2013,CA 2853284 A,2012-11-09,US 201161558822 P;;US 201261595394 P;;US 201261616813 P;;US 2012/0052542 W;;US 2012/0064548 W,2011-11-11,EXPLORATION METHOD AND SYSTEM FOR DETECTION OF HYDROCARBONS,"A method for detecting hydrocarbons is described. The method includes performing a remote sensing survey of a survey location to identify a target location. Then, an underwater vehicle (UV) is deployed into a body of water and directed to the target location. The UV collects measurement data within the body of water at the target location, which is then analyzed to determine whether hydrocarbons are present at the target location.",EXXONMOBIL UPSTREAM RES CO,POTTORF ROBERT J;;LAWSON MICHAEL;;MAY STEVEN R;;DREYFUS SEBASTIEN L;;RAMAN SUMATHY;;BOND WILLIAM;;SRNKA LEONARD J;;MEURER WILLIAM P;;POWELL WILLIAM G;;RUDOLPH KURT W;;VANDEWATER CHRISTOPHER;;CHERNEY DANIEL;;ERTAS MEHMET D;;ROBINSON AMELIA;;REGBERG AARON B;;N GUESSAN A LUCIE,,https://lens.org/063-536-502-806-292,Patent Application,no,0,1,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,G01V9/00;;G01V1/38;;G01V3/08;;G01V7/00,,0,0,,,,ACTIVE
170,EP,B1,EP 2776873 B1,079-711-110-339-02X,2021-03-10,2021,EP 12848243 A,2012-11-09,US 201161558822 P;;US 201261595394 P;;US 201261616813 P;;US 2012/0052542 W;;US 2012/0064548 W,2011-11-11,EXPLORATION METHOD FOR DETECTION OF HYDROCARBONS,,EXXONMOBIL UPSTREAM RES CO,POTTORF ROBERT J;;LAWSON MICHAEL;;MAY STEVEN R;;DREYFUS SÉBASTIEN L;;RAMAN SUMATHY;;SRNKA LEONARD J;;MEURER WILLIAM P;;POWELL WILLIAM G;;RUDOLPH KURT W;;VANDEWATER CHRISTOPHER;;CHERNEY DANIEL;;ERTAS MEHMET D;;ROBINSON AMELIA;;REGBERG AARON B;;N'GUESSAN A LUCIE;;BOND WILLIAM,EXXONMOBIL UPSTREAM RESEARCH COMPANY (2021-01-06),https://lens.org/079-711-110-339-02X,Granted Patent,yes,1,0,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,B63G8/00;;C12Q1/64;;E21B49/00;;G01N1/00;;G01N29/14;;G01N33/24;;G01V3/08;;G01V5/00;;G01V8/00;;G01V8/02;;G01V9/00;;G01V11/00,,1,1,007-491-492-068-830,10.1016/j.epsl.2007.08.020,"EILER ET AL: ""''Clumped-isotope'' geochemistry-The study of naturally-occurring, multiply-substituted isotopologues"", EARTH AND PLANETARY SCIENCE LETTERS, NORTH HOLLAND PUBL., CO, NL, vol. 262, no. 3-4, 12 October 2007 (2007-10-12), pages 309 - 327, XP022532839, ISSN: 0012-821X, DOI: 10.1016/J.EPSL.2007.08.020",ACTIVE
171,CA,C,CA 2853284 C,137-887-906-550-18X,2018-08-28,2018,CA 2853284 A,2012-11-09,US 201161558822 P;;US 201261595394 P;;US 201261616813 P;;US 2012/0052542 W;;US 2012/0064548 W,2011-11-11,EXPLORATION METHOD AND SYSTEM FOR DETECTION OF HYDROCARBONS,"A method for detecting hydrocarbons is described. The method includes performing a remote sensing survey of a survey location to identify a target location. Then, an underwater vehicle (UV) is deployed into a body of water and directed to the target location. The UV collects measurement data within the body of water at the target location, which is then analyzed to determine whether hydrocarbons are present at the target location.",EXXONMOBIL UPSTREAM RES CO,POTTORF ROBERT J;;LAWSON MICHAEL;;MAY STEVEN R;;DREYFUS SEBASTIEN L;;RAMAN SUMATHY;;BOND WILLIAM;;SRNKA LEONARD J;;MEURER WILLIAM P;;POWELL WILLIAM G;;RUDOLPH KURT W;;VANDEWATER CHRISTOPHER;;CHERNEY DANIEL;;ERTAS MEHMET D;;ROBINSON AMELIA;;REGBERG AARON B;;N'GUESSAN A LUCIE,,https://lens.org/137-887-906-550-18X,Granted Patent,no,0,6,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,G01V9/00;;G01V1/38;;G01V3/08;;G01V7/00,,0,0,,,,ACTIVE
172,AU,A1,AU 2012/335021 A1,183-643-539-231-132,2014-05-29,2014,AU 2012/335021 A,2012-11-09,US 201261616813 P;;US 201161558822 P;;US 2012/0052542 W;;US 201261595394 P;;US 2012/0064548 W,2011-11-11,Exploration method and system for detection of hydrocarbons,"A method for detecting hydrocarbons is described. The method includes performing a remote sensing survey of a survey location to identify a target location. Then, an underwater vehicle (UV) is deployed into a body of water and directed to the target location. The UV collects measurement data within the body of water at the target location, which is then analyzed to determine whether hydrocarbons are present at the target location.",EXXONMOBIL UPSTREAM RES CO,POTTORF ROBERT J;;LAWSON MICHAEL;;MAY STEVEN R;;DREYFUS SEBASTIEN L;;RAMAN SUMATHY;;BOND WILLIAM;;SRNKA LEONARD J;;MEURER WILLIAM P;;POWELL WILLIAM G;;RUDOLPH KURT W;;VANDEWATER CHRISTOPHER;;CHERNEY DANIEL;;ERTAS MEHMET D;;ROBINSON AMELIA;;REGBERG AARON B;;N GUESSAN A LUCIE,,https://lens.org/183-643-539-231-132,Patent Application,no,0,0,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,G01V11/00,,0,0,,,,ACTIVE
173,US,A1,US 2004/0015566 A1,062-226-964-259-860,2004-01-22,2004,US 19995002 A,2002-07-19,US 19995002 A,2002-07-19,Electronic item management and archival system and method of operating the same,"
   An electronic item management and archival system for managing and archiving items. Each item includes at least one of image data, audio data, and video data. The system includes a server configured to receive items, archive at least one of the received items to an archive, and retrieve at least one of the archived items from the archive. In some embodiments, the server also includes architecture that supports a pool of threads promoting multiple, independent archive and retrieve operations concurrently. 
",ANDERSON MATTHEW;;BALWALLI KRISHNA;;BENSON LAURIE;;BOND BRUCE;;BROWN PORTIA;;CAI YING;;DA SILVA DOMINIC;;EDWARDS KEAY;;FIGUEIREDO HARRING;;FIORENTINO MARK;;HAETTICH ERIC;;HELLER GARY;;KAVIANI SAEED;;LEWANDOWSKI KEITH;;MCLAUGHLIN ELLEN;;MUDD JOHN;;MUKHERJEE KUNAL;;MYLES ZARINA;;NASKOV ZORAN;;PHILLIPS AARON;;SAVRDA STEVEN;;WILSON ROBERT,ANDERSON MATTHEW;;BALWALLI KRISHNA;;BENSON LAURIE;;BOND BRUCE;;BROWN PORTIA;;CAI YING;;DA SILVA DOMINIC;;EDWARDS KEAY;;FIGUEIREDO HARRING;;FIORENTINO MARK;;HAETTICH ERIC;;HELLER GARY;;KAVIANI SAEED;;LEWANDOWSKI KEITH;;MCLAUGHLIN ELLEN;;MUDD JOHN;;MUKHERJEE KUNAL;;MYLES ZARINA;;NASKOV ZORAN;;PHILLIPS AARON;;SAVRDA STEVEN;;WILSON ROBERT,FISERV INCORPORATED (2002-10-17),https://lens.org/062-226-964-259-860,Patent Application,yes,60,130,5,5,0,G06Q20/00;;G06Q20/042;;G06Q20/102;;G06Q20/108;;G06Q40/123;;G06F16/185;;G06Q40/123;;G06Q20/042;;G06Q20/00;;G06Q20/102;;G06Q20/108;;Y10S707/99934;;Y10S707/99936;;Y10S707/99933;;G06F16/185,G06F17/30,709/219,0,0,,,,EXPIRED
174,US,A1,US 2008/0168439 A1,041-453-910-876-212,2008-07-10,2008,US 5292508 A,2008-03-21,US 5292508 A;;US 19995002 A,2002-07-19,ELECTRONIC ITEM MANAGEMENT AND ARCHIVAL SYSTEM AND METHOD OF OPERATING THE SAME,"An electronic item management and archival system for managing and archiving items. Each item includes at least one of image data, audio data, and video data. The system includes a server configured to receive items, archive at least one of the received items to an archive, and retrieve at least one of the archived items from the archive. In some embodiments, the server also includes architecture that supports a pool of threads promoting multiple, independent archive and retrieve operations concurrently.",ANDERSON MATTHEW;;BALWALLI KRISHNA;;BENSON LAURIE;;BOND BRUCE;;BROWN PORTIA;;CAI YING;;DA SILVA DOMINIC;;EDWARDS KEAY;;FIGUEIREDO HARRING;;FIORENTINO MARK;;HAETTICH ERIC;;HELLER GARY;;KAVIANI SAEED;;LEWANDOWSKI KEITH;;MCLAUGHLIN ELLEN;;MUDD JOHN;;MUKHERJEE KUNAL;;MYLES ZARINA;;NASKOV ZORAN;;PHILLIPS AARON;;SAVRDA STEVEN;;WILSON ROBERT,ANDERSON MATTHEW;;BALWALLI KRISHNA;;BENSON LAURIE;;BOND BRUCE;;BROWN PORTIA;;CAI YING;;DA SILVA DOMINIC;;EDWARDS KEAY;;FIGUEIREDO HARRING;;FIORENTINO MARK;;HAETTICH ERIC;;HELLER GARY;;KAVIANI SAEED;;LEWANDOWSKI KEITH;;MCLAUGHLIN ELLEN;;MUDD JOHN;;MUKHERJEE KUNAL;;MYLES ZARINA;;NASKOV ZORAN;;PHILLIPS AARON;;SAVRDA STEVEN;;WILSON ROBERT,FISERV INC (2002-10-17),https://lens.org/041-453-910-876-212,Patent Application,yes,56,17,5,5,0,G06Q20/00;;G06Q20/042;;G06Q20/102;;G06Q20/108;;G06Q40/123;;G06F16/185;;G06Q40/123;;G06Q20/042;;G06Q20/00;;G06Q20/102;;G06Q20/108;;Y10S707/99934;;Y10S707/99936;;Y10S707/99933;;G06F16/185,G06F9/455;;G06F17/30,718/1,0,0,,,,EXPIRED
175,RU,C2,RU 2608344 C2,074-629-382-669-423,2017-01-17,2017,RU 2014123655 A,2012-11-09,US 201161558822 P;;US 201261595394 P;;US 201261616813 P;;US 2012/0052542 W;;US 2012/0064549 W,2011-11-11,METHOD OF SURVEYING AND SYSTEM FOR DETECTION OF HYDROCARBONS USING UNDERWATER VEHICLE,"FIELD: geology.SUBSTANCE: invention relates to geology and can be used when searching for hydrocarbon accumulations. Disclosed is method of detecting hydrocarbons using underwater vehicle, equipped with one or more measuring components. Method includes navigation of underwater vehicle in water area; monitoring of water body with measuring components, connected with underwater vehicle to collect measurement data. At that, measuring components comprise mass spectrometer and fluorometer to determine chemical components concentrations by mass-spectrometer and fluorometer. Collected data from underwater vehicle is used to determine, presence of hydrocarbons, and their location.EFFECT: high accuracy of obtained data.30 cl, 5 dwg",EKSONMOBIL APSTRIM RISERCH KOMPANI,POTTORF ROBERT DZH;;LOUSON MAJKL;;MEJ STIVEN R;;DREJFUS SEBASTEN L;;RAMAN SUMATKHI;;BOND UILLYAM;;SRNKA LEONARD DZH;;MYURER UILLYAM P;;PAUELL UILLYAM G;;RUDOLF KURT U;;VANDEUOTER KRISTOFER DZH;;CHERNI DENIEL;;ERTAS MEKHMET D;;ROBINSON AMELIYA K;;REGBERG AARON B;;N'GESSAN A LYUSI,,https://lens.org/074-629-382-669-423,Granted Patent,no,9,0,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,G01V1/38;;B63G8/00;;G01J3/42;;G01N21/31;;G01N21/3504;;G01N21/64;;G01V8/02,,0,0,,,,ACTIVE
176,EP,A1,EP 2776872 A1,098-441-533-997-587,2014-09-17,2014,EP 12847005 A,2012-11-09,US 201161558822 P;;US 201261595394 P;;US 201261616813 P;;US 2012/0052542 W;;US 2012/0064549 W,2011-11-11,EXPLORATION METHOD AND SYSTEM FOR DETECTION OF HYDROCARBONS WITH AN UNDERWATER VEHICLE,,EXXONMOBIL UPSTREAM RES CO,POTTORF ROBERT J;;LAWSON MICHAEL;;MAY STEVEN R;;DREYFUS SEBASTIEN L;;RAMAN SUMATHY;;BOND WILLIAM;;SRNKA LEONARD J;;MEURER WILLIAM P;;POWELL WILLIAM G;;RUDOLPH KURT W;;VANDEWATER CHRISTOPHER J;;CHERNEY DANIEL;;ERTAS MEHMET D;;ROBINSON AMELIA C;;REGBERG AARON B;;N'GUESSAN LUCIE A,EXXONMOBIL UPSTREAM RESEARCH COMPANY (2015-12-09),https://lens.org/098-441-533-997-587,Patent Application,yes,0,0,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,G01V9/00;;B63G8/00;;G01N33/24;;G01V5/00;;G01V11/00,,0,0,,,,ACTIVE
177,EP,A4,EP 2776872 A4,196-905-837-582-79X,2015-07-29,2015,EP 12847005 A,2012-11-09,US 201161558822 P;;US 201261595394 P;;US 201261616813 P;;US 2012/0052542 W;;US 2012/0064549 W,2011-11-11,EXPLORATION METHOD AND SYSTEM FOR DETECTION OF HYDROCARBONS WITH AN UNDERWATER VEHICLE,,EXXONMOBIL UPSTREAM RES CO,POTTORF ROBERT J;;LAWSON MICHAEL;;MAY STEVEN R;;DREYFUS SEBASTIEN L;;RAMAN SUMATHY;;BOND WILLIAM;;SRNKA LEONARD J;;MEURER WILLIAM P;;POWELL WILLIAM G;;RUDOLPH KURT W;;VANDEWATER CHRISTOPHER J;;CHERNEY DANIEL;;ERTAS MEHMET D;;ROBINSON AMELIA C;;REGBERG AARON B;;N GUESSAN LUCIE A,EXXONMOBIL UPSTREAM RESEARCH COMPANY (2015-12-09),https://lens.org/196-905-837-582-79X,Search Report,no,4,0,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,G01V11/00;;G01N1/00;;G01N29/14;;G01N33/24;;G01V3/08;;G01V5/00;;G01V8/00;;G01V8/02;;G01V9/00;;G06F19/00,,5,4,130-351-261-978-006;;063-808-335-357-472;;044-520-651-913-985;;005-763-831-961-468,10.1109/oceans.2004.1402902;;10.23919/oceans.2011.6107141;;10.1016/j.marpolbul.2009.10.018;;19948348;;19540535;;10.1016/j.marpolbul.2009.05.016,"CAMILLI R ET AL: ""Integrating in-situ chemical sampling with auv control systems"", OCEANS '04. MTTS/IEEE TECHNO-OCEAN '04 KOBE, JAPAN NOV. 9-12, 2004, PISCATAWAY, NJ, USA,IEEE, vol. 1, 9 November 2004 (2004-11-09), pages 101 - 109, XP010775989, ISBN: 978-0-7803-8669-3, DOI: 10.1109/OCEANS.2004.1402902;;FRIES D ET AL: ""Solar robotic material sampler system for chemical, biological and physical ocean observations"", OCEANS 2011, IEEE, 19 September 2011 (2011-09-19), pages 1 - 5, XP032075878, ISBN: 978-1-4577-1427-6;;TEDETTI M ET AL: ""Utilization of a submersible UV fluorometer for monitoring anthropogenic inputs in the Mediterranean coastal waters"", MARINE POLLUTION BULLETIN, OXFORD, GB, vol. 60, no. 3, 1 March 2010 (2010-03-01), pages 350 - 362, XP026954321, ISSN: 0025-326X, [retrieved on 20091130];;CAMILLI R ET AL: ""Method for rapid localization of seafloor petroleum contamination using concurrent mass spectrometry and acoustic positioning"", MARINE POLLUTION BULLETIN, OXFORD, GB, vol. 58, no. 10, 1 October 2009 (2009-10-01), pages 1505 - 1513, XP026644134, ISSN: 0025-326X, [retrieved on 20090621], DOI: 10.1016/J.MARPOLBUL.2009.05.016;;See also references of WO 2013071186A1",ACTIVE
178,AU,A8,AU 2012/335022 A8,187-537-564-638-862,2016-04-21,2016,AU 2012/335022 A,2012-11-09,US 201261616813 P;;US 2012/0052542 W;;US 201161558822 P;;US 201261595394 P;;US 2012/0064549 W,2011-11-11,Exploration method and system for detection of hydrocarbons with an underwater vehicle,A method for detecting hydrocarbons with an underwater vehicle equipped with one or more measurement components is described. The method includes navigating the UV within the body of water; monitoring the body of water with measurement components associated with the UV to collect measurement data. The collected data from the UV is used to determine whether hydrocarbons are present and at the location.,EXXONMOBIL UPSTREAM RES CO,POTTORF ROBERT J;;LAWSON MICHAEL;;MAY STEVEN R;;DREYFUS SEBASTIEN L;;RAMAN SUMATHY;;BOND WILLIAM;;SRNKA LEONARD J;;MEURER WILLIAM P;;POWELL WILLIAM G;;RUDOLPH KURT W;;VANDEWATER CHRISTOPHER J;;CHERNEY DANIEL;;ERTAS MEHMET D;;ROBINSON AMELIA C;;REGBERG AARON;;N GUESSAN A LUCIE,,https://lens.org/187-537-564-638-862,Patent Application,no,2,0,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,G01V11/00,,0,0,,,,ACTIVE
179,AU,A1,AU 2012/335022 A1,015-339-399-547-005,2014-05-29,2014,AU 2012/335022 A,2012-11-09,US 201261616813 P;;US 2012/0052542 W;;US 201161558822 P;;US 201261595394 P;;US 2012/0064549 W,2011-11-11,Exploration method and system for detection of hydrocarbons with an underwater vehicle,A method for detecting hydrocarbons with an underwater vehicle equipped with one or more measurement components is described. The method includes navigating the UV within the body of water; monitoring the body of water with measurement components associated with the UV to collect measurement data. The collected data from the UV is used to determine whether hydrocarbons are present and at the location.,EXXONMOBIL UPSTREAM RES CO,POTTORF ROBERT J;;LAWSON MICHAEL;;MAY STEVEN R;;DREYFUS SEBASTIEN L;;RAMAN SUMATHY;;BOND WILLIAM;;SRNKA LEONARD J;;MEURER WILLAIM P;;POWELL WILLIAM G;;RUDOLPH KURT W;;VANDEWATER CHRISTOPHER J;;CHERNEY DANIEL;;ERTAS MEHMET D;;ROBINSON AMELIA C;;REGBERG AARON;;N GUESSAN A LUCIE,,https://lens.org/015-339-399-547-005,Patent Application,no,0,0,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,G01V11/00,,0,0,,,,ACTIVE
180,CA,A1,CA 2853286 A1,028-599-994-607-431,2013-05-16,2013,CA 2853286 A,2012-11-09,US 201161558822 P;;US 201261595394 P;;US 201261616813 P;;US 2012/0052542 W;;US 2012/0064549 W,2011-11-11,EXPLORATION METHOD AND SYSTEM FOR DETECTION OF HYDROCARBONS WITH AN UNDERWATER VEHICLE,A method for detecting hydrocarbons with an underwater vehicle equipped with one or more measurement components is described. The method includes navigating the UV within the body of water; monitoring the body of water with measurement components associated with the UV to collect measurement data. The collected data from the UV is used to determine whether hydrocarbons are present and at the location.,EXXONMOBIL UPSTREAM RES CO,POTTORF ROBERT J;;LAWSON MICHAEL;;MAY STEVEN R;;DREYFUS SEBASTIEN L;;RAMAN SUMATHY;;BOND WILLIAM;;SRNKA LEONARD J;;MEURER WILLIAM P;;POWELL WILLIAM G;;RUDOLPH KURT W;;VANDEWATER CHRISTOPHER J;;CHERNEY DANIEL;;ERTAS MEHMET D;;ROBINSON AMELIA C;;REGBERG AARON B;;N GUESSAN A LUCIE,,https://lens.org/028-599-994-607-431,Patent Application,no,0,0,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,G01V11/00;;G01N21/64;;G01N27/00,,0,0,,,,ACTIVE
181,BR,A2,BR 112014007824 A2,028-575-128-893-869,2017-04-18,2017,BR 112014007824 A,2012-11-09,US 2012/0064548 W;;US 201161558822 P;;US 201261595394 P;;US 201261616813 P;;US 2012/0052542 W,2011-11-11,método e sistema de exploração para detecção de hidrocarbonetos,"1/1 resumo método e sistema de exploração para detecção de hidrocarbonetos é descrito um método para detecção de hidrocarbonetos. o método inclui realizar um levantamento de leitura remoto de um local de pesquisa para identificar um local alvo. em seguida, um veículo submarino (uv) é posicionado em um corpo dágua e dirigido ao local alvo. o uv coleta dados de medição dentro do corpo dágua no local alvo, que são então analisados para determinar se hidrocarbonetos estão presentes no local alvo.",EXXONMOBIL UPSTREAM RES CO,A LUCIE N'GUESSAN;;AARON B REGBERG;;AMELIA C ROBINSON;;CHRISTOPHER J VANDEWATER;;DANIEL CHERNEY;;KURT W RUDOLPH;;LEONARD J SRNKA;;MEHMET D ERTAS;;MICHAEL LAWSON;;ROBERT J POTTORF;;SEBASTIEN L DREYFUS;;STEVEN R MAY;;SUMATHY RAMAN;;WILLIAM BOND;;WILLIAM G POWELL;;WILLIAM P MEURER,,https://lens.org/028-575-128-893-869,Patent Application,no,0,0,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,G01V11/00,,0,0,,,,ACTIVE
182,BR,A2,BR 112014007827 A2,153-531-587-618-687,2017-04-18,2017,BR 112014007827 A,2012-11-09,US 2012/0064549 W;;US 201161558822 P;;US 201261595394 P;;US 201261616813 P;;US 2012/0052542 W,2011-11-11,método e sistema de exploração para detecção de hidrocarbonetos com um veículo submarino,1/1 resumo método e sistema de exploração para detecção de hidrocarbonetos com um veículo submarino é descrito um método para detecção de hidrocarbonetos com um veículo submarino equipado com um ou mais componentes de medição. o método inclui navegar o uv dentro do corpo dágua; monitorar o corpo dágua com componentes de medição associados com o uv para coletar dados de medição. os dados coletados pelo uv são usados para determinar se hidrocarbonetos estão presentes e a localização.,EXXONMOBIL UPSTREAM RES CO,A LUCIE N'GUESSAN;;AARON B REGBERG;;AMELIA C ROBINSON;;CHRISTOPHER J VANDEWATER;;DANIEL CHERNEY;;KURT W RUDOLPH;;LEONARD J SRNKA;;MEHMET D ERTAS;;MICHAEL LAWSON;;ROBERT J POTTORF;;SEBASTIEN L DREYFUS;;STEVEN R MAY;;SUMATHY RAMAN;;WILLIAM BOND;;WILLIAM G POWELL;;WILLIAM P MEURER,,https://lens.org/153-531-587-618-687,Patent Application,no,0,0,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,G01V11/00,,0,0,,,,ACTIVE
183,US,B2,US 9612231 B2,048-090-789-517-238,2017-04-04,2017,US 201214350773 A,2012-11-09,US 201214350773 A;;US 2012/0052542 W;;US 201161558822 P;;US 201261595394 P;;US 201261616813 P;;US 2012/0064548 W,2011-11-11,Exploration method and system for detection of hydrocarbons,"A method for detecting hydrocarbons is described. The method includes performing a remote sensing survey of a survey location to identify a target location. Then, an underwater vehicle (UV) is deployed into a body of water and directed to the target location. The UV collects measurement data within the body of water at the target location, which is then analyzed to determine whether hydrocarbons are present at the target location.",POTTORF ROBERT J;;SRNKA LEONARD J;;BOND WILLIAM;;DREYFUS SEBASTIEN L;;LAWSON MICHAEL;;MEURER WILLIAM P;;CHERNEY DANIEL P;;MAY STEVEN R;;POWELL WILLIAM G;;VANDEWATER CHRISTOPER J;;ERTAS MEHMET D;;RAMAN SUMATHY;;REGBERG AARON B;;N'GUESSAN A LUCIE;;ROBINSON AMELIA C;;RUDOLPH KURT W;;EXXONMOBIL UPSTREAM RES CO,POTTORF ROBERT J;;SRNKA LEONARD J;;BOND WILLIAM;;DREYFUS SEBASTIEN L;;LAWSON MICHAEL;;MEURER WILLIAM P;;CHERNEY DANIEL P;;MAY STEVEN R;;POWELL WILLIAM G;;VANDEWATER CHRISTOPER J;;ERTAS MEHMET D;;RAMAN SUMATHY;;REGBERG AARON B;;N'GUESSAN A LUCIE;;ROBINSON AMELIA C;;RUDOLPH KURT W,KNIGHT BRENT R (2012-12-18),https://lens.org/048-090-789-517-238,Granted Patent,yes,90,18,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,G01N31/16;;B63G8/00;;G01N1/00;;G01N29/14;;G01N33/24;;G01V1/38;;G01V3/08;;G01V5/00;;G01V8/00;;G01V8/02;;G01V9/00;;G01V11/00;;G06F19/00,,38,33,118-846-522-432-651;;042-560-303-822-095;;081-134-032-010-759;;035-509-387-245-450;;129-166-413-431-908;;019-400-253-631-621;;096-445-787-532-929;;031-305-975-388-853;;088-642-051-882-443;;135-661-255-448-688;;104-168-432-829-315;;046-228-701-203-565;;032-297-172-513-648;;027-207-751-966-606;;040-195-112-256-654;;167-019-023-603-151;;009-720-563-663-178;;053-226-302-483-760;;023-373-350-964-35X;;169-611-765-088-713;;128-627-335-496-556;;030-952-603-608-733;;067-156-046-543-054;;034-576-906-625-900;;108-172-709-940-700;;108-829-751-072-074;;070-003-918-828-497;;004-552-425-477-906;;018-632-693-525-044;;072-872-134-536-143;;062-584-408-126-186;;121-746-515-171-561;;019-574-676-632-693,10890441;;10.1038/35016542;;10.2138/rmg.2002.47.12;;10.2138/rmg.2002.47.13;;10.1016/0016-7037(95)00439-4;;10.1016/0012-821x(91)90133-3;;10.1021/es070905d;;18186347;;10.1016/0012-821x(88)90021-0;;10.1126/science.1195223;;20724584;;10.1021/es803717d;;19673300;;10.1109/oceans.2007.4449412;;10.1016/0009-2541(88)90108-8;;10.1063/1.443074;;10.1016/0022-1694(81)90070-6;;12907798;;10.1126/science.1085116;;10.2516/ogst:2003015;;10.1016/0883-2927(88)90001-7;;10.1109/iros.2011.6095008;;10.1109/iros.2011.6048757;;10.21236/ada390519;;10.1144/gsl.sp.1995.086.01.02;;10.1007/s11430-007-0091-z;;10.1126/science.1121756;;16456080;;10.1016/j.margeo.2010.05.007;;10.1306/ad4616d3-16f7-11d7-8645000102c1865d;;10.1016/0016-7037(95)00213-j;;10.2516/ogst:2003018;;10.1016/0375-6742(77)90083-8;;10.1038/ngeo848;;10.1130/0091-7613(1990)018<0072:ngampf>2.3.co;2;;10.1029/jz066i001p00277;;10.1002/rob.20399;;10.1029/1999jb900049;;10.1117/1.2822611,"Aeschbach-Hertig, W., et al., (2000), “Palaeotemperature reconstruction from noble gases in ground water taking into account equilibrium with entrapped air”, Nature, 405, pp. 1040-1044.;;Ballentine, C. J., et al., (2002), “Production, release and transport of noble gases in the continental crust”, Reviews in Mineralogy and Geochemistry, 47, pp. 481-538.;;Ballentine, C.J., et al., (2002), “Tracing Fluid Origin, Transport and Interaction in the Crust”, Reviews in Mineralogy and Geochemistry, 47, pp. 539-614.;;Ballentine, C.J., et al., (1996), “A Magnus Opus: Helium, neon, and argon isotopes in a North Sea oilfield”, Geochemica et Cosmochimica Acta, 60(5), 831-849.;;Ballentine, C.J., et al., (1991), “Rare Gas Constraints on Hydrocarbon Accumulation, Crustal Degassing and Groundwater Flow in the Pannonian Basin”, Earth and Planetary Science Letters, 105, pp. 229-246.;;Battani, A., et al., (2010), “Trinidad Mud Volcanoes: The origin of the gas”, Shale Tectonics: AAPG Bulletin Memoir, 93, pp. 225-238.;;Bell, R. J., et al., (2007), “Calibration of an in situ membrane inlet mass spectrometer for measurements of dissolved gases and volatile organics in seawater”, Environ. Sci. Technol. 41, pp. 8123-8128.;;Bosch, A., et al., (1988), “Natural Gas Association with water and oil as depicted by atmospheric noble gases: case studies from the southeastern Mediterranean Coastal Plain”, Earth and Planetary Science Letters, 87, 338-346.;;Camilli, R., et al., (2010), “Tracking Hydrocarbon Plume Transport and Biodegradation at Deepwater Horizon”, Science 330, pp. 201-204.;;Camilli. R.C., et al., (2009), “Characterizing Spatial and Temporal Variability of Dissolved Gases in Aquatic Environments with in situ Mass Spectrometry”, Environmental Science and Technology 43(13), pp. 5014-5021.;;Camilli, R., et al. (2007), “Characterizing Marine Hydrocarbons With In-Situ Mass Spectrometry”, IEEE/MTS Oceans (IEEE/MTS, Vancouver, Canada, 2007), pp. 1-7.;;Chung, H.M., et al., (1988), “Origin of gaseous hydrocarbons in subsurface environments: theoretical considerations of carbon isotope distribution in M. Schoell (Ed.)”, Origins of Methane in the Earth. Chem. Geol., 71, pp. 97-103.;;Crovetto, R., et al., (1982), “Solubilities of inert gases and methane in H2O and D2O in the temperature range of 300 to 600K”, Journal of Chemical Physics 76(2), pp. 1077-1086.;;Dunn-Norman, S., et al, (2004), “Reliability of Pressure Signals in Offshore Pipeline Leak Detection”, Final Report to Dept. of the Interior, MMS TA&R Program SOL 1435-01-00-RP-31077.;;Heaton, T.H.E., et al., (1981), “‘Excess air’ in groundwater”, Journal of Hydrology, 50, pp. 201-216.;;Hohl, D, et al., (2010), “Energy, Environment and Climate Directorate White Paper”, DCO Energy, Environment and Climate Workshop, pp. 1-38.;;Holbrook,W.S., et al., (2003), “Thermohaline fine structure in an oceanographic front from seismic reflection profiling”, Science, v. 301, pp. 821-824.;;Huc, A., (2003), “Petroleum Geochemistry At the Dawn of the 21st Century”, Oil & Gas Science and Technology—Rev. Ifp, vol. 58, No. 2, pp. 233-241.;;Kharaka, Y.K., et al., (1988), “The solubility of noble gases in crude oil at 25-100° C.”, Applied Geochemistry, 3, pp. 137-144.;;Kinsey, J.C., et al., (2011), “Assessing the deepwater horizon oil spill with the sentry autonomous underwater vehicle”, IROS'11—2011 IEEE/RSJ International Conference on Intelligent Robots and Systems: Celebrating 50 Years of Robotics. IEEE International Conference on Intelligent Robots and Systems, pp. 261-267.;;Jakuba, M.V., et al., (2011), “Toward automatic classification of chemical sensor data from autonomous underwater vehicles”, AIROS'11—2011 IEEE/RSJ International Conference on Intelligent Robots and Systems: Celebrating 50 Years of Robotics. IEEE International Conference on Intelligent Robots and Systems, pp. 4722-4727.;;Lamontagne, R.A., et al., (2001), “Response of METS Sensor to Methane Concentrations Found on the Texas-Louisiana Shelf in the Gulf of Mexico”, Naval Research Laboratory report NRL/MR/6110—01-8584, pp. 1-13.;;Larter, S.R., et al., (1995), “Reservoir geochemistry: methods, applications and opportunities”, Geological Society of London Special Publication, 86, pp. 5-32.;;Liu, W., et al. (2007), “Ternary Geochemical-Tracing System in Natural Gas Accumulation”, Science in China Series D—Earth Sciences, vol. 50, No. 10, pp. 1494-1503.;;Makris NC, et al. (2006), “Fish Population and Behavior Revealed by Instantaneous Continental Shelf-Scale Imaging”, Science, 311, pp. 660-663.;;Mangelsdorf, K., et al., (2011), “Microbial Lipid Markers Within and Adjacent to Challenger Mound in the Belgica Carbonate Mound Province, Porcupine Basin, Offshore Ireland (IODP Expedition 307)”, Marine Geology 282, pp. 91-101.;;Narr, W.M., et al., (1984), “Origin of reservoir fractures in Little Knife Field, North Dakota”, American Association of Petroleum Geologists Bulletin, 68, pp. 1087-1100.;;Ozgul, E., (2002), “Geochemical Assessment of Gaseous Hydrocarbons: Mixing of Bacterial and Thermogenic Methane in the Deep Subsurface Petroleum System, Gulf of Mexico Continental Slope”, Thesis, Texas A&M University, pp. 1-167.;;Pinti, D.L., et al., (1995), “Noble gases in crude oils from the Paris Basin: Implications for the origin of fluids and constraints on oil-was-gas-interactions”, Geochemica et Cosmochimica Acta, 59(16), pp. 3389-3404.;;Prinzhofer, A., et al. (2003), “Gas Isotopes Tracing: An Important Tool for Hydrocarbons Exploration”, Oil & Gas Science and Technology—Rev. Ifp, vol. 58, No. 2, pp. 299-311.;;Sackett, WM, (1977), “Use of Hydrocarbon Sniffing in Offshore Exploration”, Journal of Geochemical Exploration 7, pp. 243-254.;;Smith, S.P., (1985), “Noble gas solubility in water at high temperature”, EOS Transactions of the American Geophysical Union, 66, pp. 397.;;Valentine, D.L, et al., (2010), “Asphalt Volcanoes as a Potential Source of Methane to Late Pleistocene Coastal Waters”, Nature Geoscience Letters, DOI: 10.1038/NGEO848, pp. 345-348.;;Zaikowski, A., et al., (1990), “Noble gas and methane partitioning from ground water: An aid to natural gas exploration and reservoir evaluation”, Geology, 18, pp. 72-74.;;Zartman, R.E., et al., (1961), “Helium, argon, and carbon in some natural gases”, Journal of geophysical research, 66(1), pp. 227-306.;;Zhang, Y., et al., (2011), “A peak-capture algorithm used on an autonomous underwater vehicle in the 2010 Gulf of Mexico oil spill response scientific survey”, Journal of Field Robotics, vol. 28, No. 4, pp. 484-496.;;Cochran, J. R., et al., (1999), “Continuous Near-Bottom Gravity Measurements Made With a BGM-3 Gravimeter in DSV Alvin on the East Pacific Rise Crest Near 9°31′N and 9°50′N”, Journal of Geophysical Research, vol. 104, No. B5, pp. 10,841-10,861.;;Volent, Z., et al., (2007), “Kelp Forest Mapping by Use of Airborne Hyperspectral Imager”, Journal of Applied Remote Sensing, vol. 1,011503, pp. 1-22.",ACTIVE
184,US,B2,US 7752286 B2,063-703-124-144-337,2010-07-06,2010,US 5292508 A,2008-03-21,US 5292508 A;;US 19995002 A,2002-07-19,Electronic item management and archival system and method of operating the same,"An electronic item management and archival system for managing and archiving items. Each item includes at least one of image data, audio data, and video data. The system includes a server configured to receive items, archive at least one of the received items to an archive, and retrieve at least one of the archived items from the archive. In some embodiments, the server also includes architecture that supports a pool of threads promoting multiple, independent archive and retrieve operations concurrently.",FISERV INC,ANDERSON MATTHEW;;BALWALLI KRISHNA;;BENSON LAURIE;;BOND BRUCE;;BROWN PORTIA;;CAI YING;;DA SILVA DOMINIC;;EDWARDS KEAY;;FIGUEIREDO HARRING;;FIORENTINO MARK;;HAETTICH ERIC;;HELLER GARY;;KAVIANI SAEED;;LEWANDOWSKI KEITH;;MCLAUGHLIN ELLEN;;MUDD JOHN;;MUKHERJEE KUNAL;;MYLES ZARINA;;NASKOV ZORAN;;PHILLIPS AARON;;SAVRDA STEVEN;;WILSON ROBERT,FISERV INC (2002-10-17),https://lens.org/063-703-124-144-337,Granted Patent,yes,68,96,5,5,0,G06Q20/00;;G06Q20/042;;G06Q20/102;;G06Q20/108;;G06Q40/123;;G06F16/185;;G06Q40/123;;G06Q20/042;;G06Q20/00;;G06Q20/102;;G06Q20/108;;Y10S707/99934;;Y10S707/99936;;Y10S707/99933;;G06F16/185,G06F15/16;;G06F17/30,709/219;;709/217;;705/31;;705/40;;705/42;;705/50;;705/45;;705/32;;705/102;;705/53;;707/204;;718/1;;718/100;;718/101;;718/106,5,1,124-307-709-458-135,10.17487/rfc0793,"Symphony: An Infrastructure for Managing Virtual Servers, Roy Friedman, Elibiham, Ayal Itzkovitz, and Assaf Schuster; Department of Computer Science, The Technion, Haifa 32000, Isreal, 2001.;;Disclosure under § 1.56.;;Chen. ""Link down, TCP connection down and session?"" from the MPLS WG Archive, May 2001.;;Postel, :RFC-793-Transmission Control Protocol, Sep. 9, 2001.;;Final Office Action mailed Apr. 9, 2008 for U.S. Appl. No. 10/859,619, filed Jun. 2, 2004, which is a continuation-in-part of related U.S. Appl. No. 10/199,950.",EXPIRED
185,WO,A1,WO 2013/071186 A1,038-698-239-463-354,2013-05-16,2013,US 2012/0064549 W,2012-11-09,US 201261595394 P;;US 201161558822 P;;US 2012/0052542 W;;US 201261616813 P,2011-11-11,EXPLORATION METHOD AND SYSTEM FOR DETECTION OF HYDROCARBONS WITH AN UNDERWATER VEHICLE,A method for detecting hydrocarbons with an underwater vehicle equipped with one or more measurement components is described. The method includes navigating the UV within the body of water; monitoring the body of water with measurement components associated with the UV to collect measurement data. The collected data from the UV is used to determine whether hydrocarbons are present and at the location.,EXXONMOBIL UPSTREAM RES CO;;POTTORF ROBERT J;;LAWSON MICHAEL;;MAY STEVEN R;;DREYFUS SEBASTIEN L;;RAMAN SUMATHY;;BOND WILLIAM;;SRNKA LEONARD J;;MEURER WILLIAM P;;POWELL WILLIAM G;;RUDOLPH KURT W;;VANDEWATER CHRISTOPHER J;;CHERNEY DANIEL;;ERTAS MEHMET D;;ROBINSON AMELIA C;;REGBERG AARON B;;N GUESSAN A LUCIE,POTTORF ROBERT J;;LAWSON MICHAEL;;MAY STEVEN R;;DREYFUS SEBASTIEN L;;RAMAN SUMATHY;;BOND WILLIAM;;SRNKA LEONARD J;;MEURER WILLIAM P;;POWELL WILLIAM G;;RUDOLPH KURT W;;VANDEWATER CHRISTOPHER J;;CHERNEY DANIEL;;ERTAS MEHMET D;;ROBINSON AMELIA C;;REGBERG AARON B;;N GUESSAN A LUCIE,,https://lens.org/038-698-239-463-354,Patent Application,yes,8,4,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,G01V11/00,,0,0,,,,PENDING
186,AU,B2,AU 2012/335022 B2,117-161-420-003-479,2015-11-26,2015,AU 2012/335022 A,2012-11-09,US 201261616813 P;;US 2012/0052542 W;;US 201161558822 P;;US 201261595394 P;;US 2012/0064549 W,2011-11-11,Exploration method and system for detection of hydrocarbons with an underwater vehicle,A method for detecting hydrocarbons with an underwater vehicle equipped with one or more measurement components is described. The method includes navigating the UV within the body of water; monitoring the body of water with measurement components associated with the UV to collect measurement data. The collected data from the UV is used to determine whether hydrocarbons are present and at the location.,EXXONMOBIL UPSTREAM RES CO,POTTORF ROBERT J;;LAWSON MICHAEL;;MAY STEVEN R;;DREYFUS SEBASTIEN L;;RAMAN SUMATHY;;BOND WILLIAM;;SRNKA LEONARD J;;MEURER WILLAIM P;;POWELL WILLIAM G;;RUDOLPH KURT W;;VANDEWATER CHRISTOPHER J;;CHERNEY DANIEL;;ERTAS MEHMET D;;ROBINSON AMELIA C;;REGBERG AARON;;N GUESSAN A LUCIE,,https://lens.org/117-161-420-003-479,Granted Patent,no,2,0,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,G01V11/00,,0,0,,,,ACTIVE
187,EP,B1,EP 2776872 B1,044-955-571-345-79X,2020-01-08,2020,EP 12847005 A,2012-11-09,US 201161558822 P;;US 201261595394 P;;US 201261616813 P;;US 2012/0052542 W;;US 2012/0064549 W,2011-11-11,EXPLORATION METHOD AND SYSTEM FOR DETECTION OF HYDROCARBONS WITH AN UNDERWATER VEHICLE,,EXXONMOBIL UPSTREAM RES CO,POTTORF ROBERT J;;LAWSON MICHAEL;;MAY STEVEN R;;DREYFUS SEBASTIEN L;;RAMAN SUMATHY;;BOND WILLIAM;;SRNKA LEONARD J;;MEURER WILLIAM P;;POWELL WILLIAM G;;RUDOLPH KURT W;;VANDEWATER CHRISTOPHER J;;CHERNEY DANIEL;;ERTAS MEHMET D;;ROBINSON AMELIA C;;REGBERG AARON B;;N'GUESSAN LUCIE A,EXXONMOBIL UPSTREAM RESEARCH COMPANY (2015-12-09),https://lens.org/044-955-571-345-79X,Granted Patent,yes,12,0,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,G01V9/00;;B63G8/00;;G01N33/24;;G01V5/00;;G01V11/00,,4,0,,,"CAMILLI R ET AL: ""Integrating in-situ chemical sampling with auv control systems"", OCEANS '04. MTTS/IEEE TECHNO-OCEAN '04 KOBE, JAPAN NOV. 9-12, 2004, PISCATAWAY, NJ, USA,IEEE, vol. 1, 9 November 2004 (2004-11-09), pages 101-109, XP010775989, DOI: 10.1109/OCEANS.2004.1402902 ISBN: 978-0-7803-8669-3;;FRIES D ET AL: ""Solar robotic material sampler system for chemical, biological and physical ocean observations"", OCEANS 2011, IEEE, 19 September 2011 (2011-09-19), pages 1-5, XP032075878, ISBN: 978-1-4577-1427-6;;TEDETTI M ET AL: ""Utilization of a submersible UV fluorometer for monitoring anthropogenic inputs in the Mediterranean coastal waters"", MARINE POLLUTION BULLETIN, OXFORD, GB, vol. 60, no. 3, 1 March 2010 (2010-03-01), pages 350-362, XP026954321, ISSN: 0025-326X [retrieved on 2009-11-30];;CAMILLI R ET AL: ""Method for rapid localization of seafloor petroleum contamination using concurrent mass spectrometry and acoustic positioning"", MARINE POLLUTION BULLETIN, OXFORD, GB, vol. 58, no. 10, 1 October 2009 (2009-10-01), pages 1505-1513, XP026644134, ISSN: 0025-326X, DOI: 10.1016/J.MARPOLBUL.2009.05.016 [retrieved on 2009-06-21]",ACTIVE
188,CA,C,CA 2853286 C,167-056-095-124-881,2019-01-08,2019,CA 2853286 A,2012-11-09,US 201161558822 P;;US 201261595394 P;;US 201261616813 P;;US 2012/0052542 W;;US 2012/0064549 W,2011-11-11,EXPLORATION METHOD AND SYSTEM FOR DETECTION OF HYDROCARBONS WITH AN UNDERWATER VEHICLE,"A method for detecting hydrocarbons with an underwater vehicle equipped with one or more measurement components. The method includes navigating the UV within a body of water; monitoring the body of water with measurement components associated with the UV to collect measurement data, wherein the measurement components include a mass spectrometer and fluorometer; using the measurement components to measure molecular and isotopic signatures of non-hydrocarbon gases and hydrocarbons in the body of water; and determining the concentrations of chemical components with the mass spectrometer and fluorometer. The collected data from the UV is used to determine whether hydrocarbons are present and, if present, the location of such hydrocarbons.",EXXONMOBIL UPSTREAM RES CO,POTTORF ROBERT J;;LAWSON MICHAEL;;MAY STEVEN R;;DREYFUS SEBASTIEN L;;RAMAN SUMATHY;;BOND WILLIAM;;SRNKA LEONARD J;;MEURER WILLIAM P;;POWELL WILLIAM G;;RUDOLPH KURT W;;VANDEWATER CHRISTOPHER J;;CHERNEY DANIEL;;ERTAS MEHMET D;;ROBINSON AMELIA C;;REGBERG AARON B;;N'GUESSAN A LUCIE,,https://lens.org/167-056-095-124-881,Granted Patent,no,0,0,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,G01V11/00;;G01N21/64;;G01N27/00,,0,0,,,,ACTIVE
189,US,A1,US 2010/0268690 A1,114-105-473-296-10X,2010-10-21,2010,US 78612110 A,2010-05-24,US 78612110 A;;US 5292508 A;;US 19995002 A,2002-07-19,Electronic Item Management and Archival System and Method of Operating the Same,"An electronic item management and archival system for managing and archiving items. Each item includes at least one of image data, audio data, and video data. The system includes a server configured to receive items, archive at least one of the received items to an archive, and retrieve at least one of the archived items from the archive. In some embodiments, the server also includes architecture that supports a pool of threads promoting multiple, independent archive and retrieve operations concurrently.",FISERV INC,ANDERSON MATTHEW;;BALWALLI KRISHNA;;BENSON LAURIE;;BOND BRUCE;;BROWN PORTIA;;CAI YING;;DA SILVA DOMINIC;;EDWARDS KEAY;;FIGUEIREDO HARRING;;FIORENTINO MARK;;HAETTICH ERIC;;HELLER GARY;;KAVIANI SAEED;;LEWANDOWSKI KEITH;;MCLAUGHLIN ELLEN;;MUDD JOHN;;MUKHERJEE KUNAL;;MYLES ZARINA;;NASKOV ZORAN;;PHILLIPS AARON;;SAVRDA STEVEN;;WILSON ROBERT,,https://lens.org/114-105-473-296-10X,Patent Application,yes,0,32,5,5,0,G06Q20/00;;G06Q20/042;;G06Q20/102;;G06Q20/108;;G06Q40/123;;G06F16/185;;G06Q40/123;;G06Q20/042;;G06Q20/00;;G06Q20/102;;G06Q20/108;;Y10S707/99934;;Y10S707/99936;;Y10S707/99933;;G06F16/185,G06F12/16;;G06F17/30,707/661;;X707E17005;;X707E17009,0,0,,,,DISCONTINUED
190,US,B2,US 7379978 B2,041-622-848-453-95X,2008-05-27,2008,US 19995002 A,2002-07-19,US 19995002 A,2002-07-19,Electronic item management and archival system and method of operating the same,"An electronic item management and archival system for managing and archiving items. Each item includes at least one of image data, audio data, and video data. The system includes a server configured to receive items, archive at least one of the received items to an archive, and retrieve at least one of the archived items from the archive. In some embodiments, the server also includes architecture that supports a pool of threads promoting multiple, independent archive and retrieve operations concurrently.",FISERV INC,ANDERSON MATTHEW;;BALWALLI KRISHNA;;BENSON LAURIE;;BOND BRUCE;;BROWN PORTIA;;CAI YING;;DA SILVA DOMINIC;;EDWARDS KEAY;;FIGUEIREDO HARRING;;FIORENTINO MARK;;HAETTICH ERIC;;HELLER GARY;;KAVIANI SAEED;;LEWANDOWSKI KEITH;;MCLAUGHLIN ELLEN;;MUDD JOHN;;MUKHERJEE KUNAL;;MYLES ZARINA;;NASKOV ZORAN;;PHILLIPS AARON;;SAVRDA STEVEN;;WILSON ROBERT,FISERV INCORPORATED (2002-10-17),https://lens.org/041-622-848-453-95X,Granted Patent,yes,60,278,5,5,0,G06Q20/00;;G06Q20/042;;G06Q20/102;;G06Q20/108;;G06Q40/123;;G06F16/185;;G06Q40/123;;G06Q20/042;;G06Q20/00;;G06Q20/102;;G06Q20/108;;Y10S707/99934;;Y10S707/99936;;Y10S707/99933;;G06F16/185,G06F15/16;;G06F17/30,709/219;;709/217;;707/6;;707/3;;707/4;;705/45;;705/42;;705/40;;705/31,0,0,,,,EXPIRED
191,US,B2,US 9146225 B2,109-868-089-265-944,2015-09-29,2015,US 201214350774 A,2012-11-09,US 201214350774 A;;US 2012/0052542 W;;US 201161558822 P;;US 201261595394 P;;US 201261616813 P;;US 2012/0064549 W,2011-11-11,Exploration method and system for detection of hydrocarbons with an underwater vehicle,A method for detecting hydrocarbons with an underwater vehicle equipped with one or more measurement components is described. The method includes navigating the UV within the body of water; monitoring the body of water with measurement components associated with the UV to collect measurement data. The collected data from the UV is used to determine whether hydrocarbons are present and at the location.,POTTORF ROBERT J;;SRNKA LEONARD J;;BOND WILLIAM;;DREYFUS SEBASTIEN L;;LAWSON MICHAEL;;MEURER WILLIAM P;;CHERNEY DANIEL P;;MAY STEVEN R;;POWELL WILLIAM G;;VANDEWATER CHRISTOPHER J;;ERTAS MEHMET D;;RUDOLPH KURT W;;RAMAN SUMATHY;;REGBERG AARON B;;N GUESSAN A LUCIE;;ROBINSON AMELIA C;;EXXONMOBIL UPSTREAM RES CO,POTTORF ROBERT J;;SRNKA LEONARD J;;BOND WILLIAM;;DREYFUS SEBASTIEN L;;LAWSON MICHAEL;;MEURER WILLIAM P;;CHERNEY DANIEL P;;MAY STEVEN R;;POWELL WILLIAM G;;VANDEWATER CHRISTOPHER J;;ERTAS MEHMET D;;RUDOLPH KURT W;;RAMAN SUMATHY;;REGBERG AARON B;;N GUESSAN A LUCIE;;ROBINSON AMELIA C,KNIGHT BRENT R (2012-12-18),https://lens.org/109-868-089-265-944,Granted Patent,yes,89,18,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,B63G8/00;;G01N1/00;;G01N29/14;;G01N33/24;;G01V1/38;;G01V3/08;;G01V5/00;;G01V8/00;;G01V8/02;;G01V9/00;;G06F19/00,,40,33,118-846-522-432-651;;042-560-303-822-095;;081-134-032-010-759;;035-509-387-245-450;;129-166-413-431-908;;019-400-253-631-621;;096-445-787-532-929;;031-305-975-388-853;;088-642-051-882-443;;135-661-255-448-688;;104-168-432-829-315;;046-228-701-203-565;;032-297-172-513-648;;027-207-751-966-606;;040-195-112-256-654;;167-019-023-603-151;;009-720-563-663-178;;053-226-302-483-760;;023-373-350-964-35X;;169-611-765-088-713;;128-627-335-496-556;;030-952-603-608-733;;067-156-046-543-054;;034-576-906-625-900;;108-172-709-940-700;;108-829-751-072-074;;070-003-918-828-497;;004-552-425-477-906;;018-632-693-525-044;;072-872-134-536-143;;062-584-408-126-186;;005-763-831-961-468;;044-520-651-913-985,10890441;;10.1038/35016542;;10.2138/rmg.2002.47.12;;10.2138/rmg.2002.47.13;;10.1016/0016-7037(95)00439-4;;10.1016/0012-821x(91)90133-3;;10.1021/es070905d;;18186347;;10.1016/0012-821x(88)90021-0;;10.1126/science.1195223;;20724584;;10.1021/es803717d;;19673300;;10.1109/oceans.2007.4449412;;10.1016/0009-2541(88)90108-8;;10.1063/1.443074;;10.1016/0022-1694(81)90070-6;;12907798;;10.1126/science.1085116;;10.2516/ogst:2003015;;10.1016/0883-2927(88)90001-7;;10.1109/iros.2011.6095008;;10.1109/iros.2011.6048757;;10.21236/ada390519;;10.1144/gsl.sp.1995.086.01.02;;10.1007/s11430-007-0091-z;;10.1126/science.1121756;;16456080;;10.1016/j.margeo.2010.05.007;;10.1306/ad4616d3-16f7-11d7-8645000102c1865d;;10.1016/0016-7037(95)00213-j;;10.2516/ogst:2003018;;10.1016/0375-6742(77)90083-8;;10.1038/ngeo848;;10.1130/0091-7613(1990)018<0072:ngampf>2.3.co;2;;10.1029/jz066i001p00277;;10.1002/rob.20399;;19540535;;10.1016/j.marpolbul.2009.05.016;;10.1016/j.marpolbul.2009.10.018;;19948348,"Aeschbach-Hertig, W., et al., (2000), ""Palaeotemperature reconstruction from noble gases in ground water taking into account equilibrium with entrapped air"", Nature, 405, pp. 1040-1044.;;Ballentine, C. J., et al., (2002), ""Production, release and transport of noble gases in the continental crust"", Reviews in Mineralogy and Geochemistry, 47, pp. 481-538.;;Ballentine, C.J., et al., (2002), ""Tracing Fluid Origin, Transport and Interaction in the Crust"", Reviews in Mineralogy and Geochemistry, 47, pp. 539-614.;;Ballentine, C.J., et al., (1996), ""A Magnus Opus: Helium, neon, and argon isotopes in a North Sea oilfield"", Geochemica et Cosmochimica Acta, 60(5), 831-849.;;Ballentine, C.J., et al., (1991), ""Rare Gas Constraints on Hydrocarbon Accumulation, Crustal Degassing and Groundwater Flow in the Pannonian Basin"", Earth and Planetary Science Letters, 105, pp. 229-246.;;Battani, A., et al., (2010), ""Trinidad Mud Volcanoes: The origin of the gas"", Shale Tectonics: AAPG Bulletin Memoir, 93, pp. 225-238.;;Bell, R. J., et al., (2007), ""Calibration of an in situ membrane inlet mass spectrometer for measurements of dissolved gases and volatile organics in seawater"", Environ. Sci. Technol. 41, pp. 8123-8128.;;Bosch, A., et al., (1988), ""Natural Gas Association with water and oil as depicted by atmospheric noble gases: case studies from the southeastern Mediterranean Coastal Plain"", Earth and Planetary Science Letters, 87, 338-346.;;Camilli, R., et al., (2010), ""Tracking Hydrocarbon Plume Transport and Biodegradation at Deepwater Horizon"", Science 330, pp. 201-204.;;Camilli. R.C., et al., (2009), ""Characterizing Spatial and Temporal Variability of Dissolved Gases in Aquatic Environments with in situ Mass Spectrometry"", Environmental Science and Technology 43(13), pp. 5014-5021.;;Camilli, R., et al. (2007), ""Characterizing Marine Hydrocarbons With In-Situ Mass Spectrometry"", IEEE/MTS Oceans (IEEE/MTS, Vancouver, Canada, 2007), pp. 1-7.;;Chung, H.M., et al., (1988), ""Origin of gaseous hydrocarbons in subsurface environments: theoretical considerations of carbon isotope distribution in M. Schoell (Ed.)"", Origins of Methane in the Earth. Chem. Geol., 71, pp. 97-103.;;Crovetto, R., et al., (1982), ""Solubilities of inert gases and methane in H2O and D2O in the temperature range of 300 to 600K"", Journal of Chemical Physics 76(2), pp. 1077-1086.;;Dunn-Norman, S., et al, (2004), ""Reliability of Pressure Signals in Offshore Pipeline Leak Detection"", Final Report to Dept. of the Interior, MMS TA&R Program SOL 1435-01-00-RP-31077.;;Heaton, T.H.E., et al., (1981), ""'Excess air' in groundwater"", Journal of Hydrology, 50, pp. 201-216.;;Hohl, D, et al., (2010), ""Energy, Environment and Climate Directorate White Paper"", DCO Energy, Environment and Climate Workshop, pp. 1-38.;;Holbrook,W.S., et al., (2003), ""Thermohaline fine structure in an oceanographic front from seismic reflection profiling"", Science, v. 301, pp. 821-824.;;Huc, A., (2003), ""Petroleum Geochemistry at the Dawn of the 21st Century"", Oil & Gas Science and Technology-Rev. Ifp, vol. 58, No. 2, pp. 233-241.;;Kharaka, Y.K., et al., (1988), ""The solubility of noble gases in crude oil at 25-100° C."", Applied Geochemistry, 3, pp. 137-144.;;Kinsey, J.C., et al., (2011), ""Assessing the deepwater horizon oil spill with the sentry autonomous underwater vehicle"", IROS'11-2011 IEEE/RSJ International Conference on Intelligent Robots and Systems: Celebrating 50 Years of Robotics. IEEE International Conference on Intelligent Robots and Systems, pp. 261-267.;;Jakuba, M.V., et al., (2011), ""Toward automatic classification of chemical sensor data from autonomous underwater vehicles"", AIROS'11-2011 IEEE/RSJ International Conference on Intelligent Robots and Systems: Celebrating 50 Years of Robotics. IEEE International Conference on Intelligent Robots and Systems, pp. 4722-4727.;;Lamontagne, R.A., et al., (2001), ""Response of METS Sensor to Methane Concentrations Found on the Texas-Louisiana Shelf in the Gulf of Mexico"", Naval Research Laboratory report NRL/MR/6110-01-8584, pp. 1-13.;;Larter, S.R., et al., (1995), ""Reservoir geochemistry: methods, applications and opportunities"", Geological Society of London Special Publication, 86, pp. 5-32.;;Liu, W., et al. (2007), ""Ternary Geochemical-Tracing System in Natural Gas Accumulation"", Science in China Series D-Earth Sciences, vol. 50, No. 10, pp. 1494-1503.;;Makris NC, et al. (2006), ""Fish Population and Behavior Revealed by Instantaneous Continental Shelf-Scale Imaging"", Science, 311, pp. 660-663.;;Mangelsdorf, K., et al., (2011), ""Microbial Lipid Markers Within and Adjacent to Challenger Mound in the Belgica Carbonate Mound Province, Porcupine Basin, Offshore Ireland (IODP Expedition 307)"", Marine Geology 282, pp. 91-101.;;Narr, W.M., et al., (1984), ""Origin of reservoir fractures in Little Knife Field, North Dakota"", American Association of Petroleum Geologists Bulletin, 68, pp. 1087-1100.;;Ozgul, E., (2002), ""Geochemical Assessment of Gaseous Hydrocarbons: Mixing of Bacterial and Thermogenic Methane in the Deep Subsurface Petroleum System, Gulf of Mexico Continental Slope"", Thesis, Texas A&M University, pp. 1-167.;;Pinti, D.L., et al., (1995), ""Noble gases in crude oils from the Paris Basin: Implications for the origin of fluids and constraints on oil-was-gas-interactions"", Geochemica et Cosmochimica Acta, 59(16), pp. 3389-3404.;;Prinzhofer, A., et al. (2003), ""Gas Isotopes Tracing: An Important Tool for Hydrocarbons Exploration"", Oil & Gas Science and Technology-Rev. Ifp, vol. 58, No. 2, pp. 299-311.;;Sackett, WM, (1977), ""Use of Hydrocarbon Sniffing in Offshore Exploration"", Journal of Geochemical Exploration 7, pp. 243-254.;;Smith, S.P., (1985), ""Noble gas solubility in water at high temperature"", EOS Transactions of the American Geophysical Union, 66, pp. 397.;;Valentine, D.L, et al., (2010), ""Asphalt Volcanoes as a Potential Source of Methane to Late Pleistocene Coastal Waters"", Nature Geoscience Letters, DOI: 10.1038/NGEO848, pp. 345-348.;;Zaikowski, A., et al., (1990), ""Noble gas and methane partitioning from ground water: An aid to natural gas exploration and reservoir evaluation"", Geology, 18, pp. 72-74.;;Zartman, R.E., et al., (1961), ""Helium, argon, and carbon in some natural gases"", Journal of geophysical research, 66(1), pp. 227-306.;;Zhang, Y., et al., (2011), ""A peak-capture algorithm used on an autonomous underwater vehicle in the 2010 Gulf of Mexico oil spill response scientific survey"", Journal of Field Robotics, vol. 28, No. 4, pp. 484-496.;;Camilli, R. et al., ""Integrating In-situ Chemical Sampling with AUV Control Systems,"" IEEE, pp. 101-109, 2004.;;Camilli, R. et al., ""Method for rapid localization of seafloor petroleum contamination using concurrent mass spectrometry and acoustic positioning,"" Marine Pollution Bulletin 58, pp. 1505-1513, 2009.;;Fries, D. et al., ""Solar Robotic Material Sampler System for Chemical, Biological and Physical Ocean Observations,"" University of South Florida, Marine Sciences, 6 pgs., 2011.;;Tedetti, M. et al., ""Utilization of a submersible UV fluorometer for monitoring anthropogenic inputs in the Mediterranean coastal waters,"" Marine Pollution Bulletin 60, pp. 350-362, 2010.",ACTIVE
192,US,A1,US 2014/0284465 A1,038-516-108-136-150,2014-09-25,2014,US 201214350774 A,2012-11-09,US 201214350774 A;;US 2012/0052542 W;;US 201161558822 P;;US 201261595394 P;;US 201261616813 P;;US 2012/0064549 W,2011-11-11,EXPLORATION METHOD AND SYSTEM FOR DETECTION OF HYDROCARBONS WITH AN UNDERWATER VEHICLE,A method for detecting hydrocarbons with an underwater vehicle equipped with one or more measurement components is described. The method includes navigating the UV within the body of water; monitoring the body of water with measurement components associated with the UV to collect measurement data. The collected data from the UV is used to determine whether hydrocarbons are present and at the location.,EXXONMOBIL UPSTREAM RES CO,POTTORF ROBERT J;;SRNKA LEONARD J;;BOND WILLIAM;;DREYFUS SEBASTIEN L;;LAWSON MICHAEL;;MEURER WILLIAM P;;CHERNEY DANIEL P;;MAY STEVEN R;;POWELL WILLIAM G;;VANDEWATER CHRISTOPHER J;;ERTAS MEHMET D;;RUDOLPH KURT W;;RAMAN SUMATHY;;REGBERG AARON B;;N GUESSAN A LUCIE;;ROBINSON AMELIA C,,https://lens.org/038-516-108-136-150,Patent Application,yes,3,19,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,G01V5/00;;G01V8/02,250/253,0,0,,,,ACTIVE
193,US,A1,US 2014/0256055 A1,141-557-458-781-787,2014-09-11,2014,US 201214350773 A,2012-11-09,US 201214350773 A;;US 2012/0052542 W;;US 201161558822 P;;US 201261595394 P;;US 201261616813 P;;US 2012/0064548 W,2011-11-11,EXPLORATION METHOD AND SYSTEM FOR DETECTION OF HYDROCARBONS,"A method for detecting hydrocarbons is described. The method includes performing a remote sensing survey of a survey location to identify a target location. Then, an underwater vehicle (UV) is deployed into a body of water and directed to the target location. The UV collects measurement data within the body of water at the target location, which is then analyzed to determine whether hydrocarbons are present at the target location.",EXXONMOBIL UPSTREAM RES CO,POTTORF ROBERT J;;SRNKA LEONARD J;;BOND WILLIAM;;DREYFUS SEBASTIEN L;;LAWSON MICHAEL;;MEURER WILLIAM P;;CHERNEY DANIEL P;;MAY STEVEN R;;POWELL WILLIAM G;;VANDEWATER CHRISTOPER J;;ERTAS MEHMET D;;RAMAN SUMATHY;;REGBERG AARON B;;N GUESSAN A LUCIE;;ROBINSON AMELIA C;;RUDOLPH KURT W,,https://lens.org/141-557-458-781-787,Patent Application,yes,4,28,47,82,0,B63G8/001;;G01V11/00;;G01V5/00;;G01N33/241;;G01V9/007;;B63G8/001;;G01J3/0289;;G01N21/3103;;G01N21/3504;;G01N21/645;;G01V1/38;;G01V8/00;;B63G8/001;;G01V11/00;;G01V9/007;;G01N1/00;;G01N29/14;;G01V1/38;;G01V3/08;;G01V8/02;;G01V9/005;;G01V5/00;;G01N33/241;;G01V8/00;;G01V3/081,G01N1/00;;G01V1/38;;G01N29/14;;G01V3/08;;G01V8/02;;G01V9/00,436/163;;73/584;;356/72;;324/345;;374/45;;73/863;;367/15;;367/7,0,0,,,,ACTIVE
